0000919956-21-000046.txt : 20210511 0000919956-21-000046.hdr.sgml : 20210511 20210511160854 ACCESSION NUMBER: 0000919956-21-000046 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 66 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210511 DATE AS OF CHANGE: 20210511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Diversicare Healthcare Services, Inc. CENTRAL INDEX KEY: 0000919956 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SKILLED NURSING CARE FACILITIES [8051] IRS NUMBER: 621559667 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12996 FILM NUMBER: 21911346 BUSINESS ADDRESS: STREET 1: 1621 GALLERIA BLVD. CITY: BRENTWOOD STATE: TN ZIP: 37027 BUSINESS PHONE: 6157717575 MAIL ADDRESS: STREET 1: 1621 GALLERIA BLVD. CITY: BRENTWOOD STATE: TN ZIP: 37027 FORMER COMPANY: FORMER CONFORMED NAME: ADVOCAT INC DATE OF NAME CHANGE: 19940309 10-Q 1 dvcr-20210331.htm 10-Q dvcr-20210331
0000919956false2021Q112/31P1Y33.3333.3333.3300009199562021-01-012021-03-31xbrli:shares00009199562021-05-05iso4217:USD00009199562021-03-3100009199562020-12-31iso4217:USDxbrli:shares00009199562020-01-012020-03-310000919956us-gaap:CommonStockMember2019-12-310000919956us-gaap:TreasuryStockMember2019-12-310000919956us-gaap:AdditionalPaidInCapitalMember2019-12-310000919956us-gaap:RetainedEarningsMember2019-12-310000919956us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-3100009199562019-12-310000919956us-gaap:RetainedEarningsMember2020-01-012020-03-310000919956us-gaap:CommonStockMember2020-01-012020-03-310000919956us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310000919956us-gaap:InterestRateSwapMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310000919956us-gaap:InterestRateSwapMember2020-01-012020-03-310000919956us-gaap:CommonStockMember2020-03-310000919956us-gaap:TreasuryStockMember2020-03-310000919956us-gaap:AdditionalPaidInCapitalMember2020-03-310000919956us-gaap:RetainedEarningsMember2020-03-310000919956us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-3100009199562020-03-310000919956us-gaap:CommonStockMember2020-12-310000919956us-gaap:TreasuryStockMember2020-12-310000919956us-gaap:AdditionalPaidInCapitalMember2020-12-310000919956us-gaap:RetainedEarningsMember2020-12-310000919956us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000919956us-gaap:RetainedEarningsMember2021-01-012021-03-310000919956us-gaap:CommonStockMember2021-01-012021-03-310000919956us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310000919956us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310000919956us-gaap:CommonStockMember2021-03-310000919956us-gaap:TreasuryStockMember2021-03-310000919956us-gaap:AdditionalPaidInCapitalMember2021-03-310000919956us-gaap:RetainedEarningsMember2021-03-310000919956us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-31dvcr:statedvcr:nursing_centerdvcr:nursing_bed0000919956srt:MinimumMember2021-03-310000919956srt:MaximumMember2021-03-310000919956us-gaap:OtherOperatingIncomeExpenseMember2021-01-012021-03-310000919956dvcr:MedicaidMember2021-01-012021-03-31xbrli:pure0000919956dvcr:MedicaidMember2020-01-012020-03-310000919956dvcr:MedicareMember2021-01-012021-03-310000919956dvcr:MedicareMember2020-01-012020-03-310000919956dvcr:ManagedCareMember2021-01-012021-03-310000919956dvcr:ManagedCareMember2020-01-012020-03-310000919956dvcr:PrivatePayAndOtherMember2021-01-012021-03-310000919956dvcr:PrivatePayAndOtherMember2020-01-012020-03-310000919956dvcr:MedicaidMember2021-03-310000919956dvcr:MedicaidMember2020-12-310000919956dvcr:MedicareMember2021-03-310000919956dvcr:MedicareMember2020-12-310000919956dvcr:ManagedCareMember2021-03-310000919956dvcr:ManagedCareMember2020-12-310000919956dvcr:PrivatePayAndOtherMember2021-03-310000919956dvcr:PrivatePayAndOtherMember2020-12-310000919956us-gaap:MortgagesMember2019-12-310000919956dvcr:AcquisitionLoanMember2019-12-310000919956us-gaap:RevolvingCreditFacilityMember2019-12-310000919956dvcr:AffiliatedRevolvingCreditAgreementMember2019-12-310000919956us-gaap:MortgagesMemberdvcr:AmendedAndRestatedCreditAgreementMember2020-10-140000919956us-gaap:RevolvingCreditFacilityMemberdvcr:MortgageLoanMember2020-10-140000919956us-gaap:RevolvingCreditFacilityMemberdvcr:AmendedAndRestatedCreditAgreementMember2020-10-140000919956us-gaap:RevolvingCreditFacilityMemberdvcr:AmendedAndRestatedCreditAgreementMember2020-10-142020-10-140000919956us-gaap:MortgagesMemberdvcr:AmendedAndRestatedCreditAgreementMember2020-10-142020-10-140000919956us-gaap:LondonInterbankOfferedRateLIBORMemberdvcr:MortgageTermLoanMemberdvcr:AmendedAndRestatedCreditAgreementMember2020-10-142020-10-140000919956dvcr:MortgageTermLoanMemberus-gaap:BaseRateMemberdvcr:AmendedAndRestatedCreditAgreementMember2020-10-142020-10-140000919956dvcr:MortgageLoanMemberus-gaap:LoansPayableMember2021-03-310000919956us-gaap:MortgagesMemberdvcr:MortgageTermLoanMemberdvcr:AmendedAndRestatedCreditAgreementMember2021-01-012021-03-310000919956dvcr:AmendedAndRestatedCreditAgreementMember2020-10-140000919956us-gaap:RevolvingCreditFacilityMemberdvcr:AffiliatedRevolvingCreditAgreementMember2021-03-310000919956us-gaap:RevolvingCreditFacilityMemberdvcr:AffiliatedRevolvingCreditAgreementMember2020-12-310000919956us-gaap:RevolvingCreditFacilityMemberdvcr:AmendedAndRestatedCreditAgreementMember2021-01-012021-03-310000919956dvcr:AmendedAndRestatedCreditAgreementMemberus-gaap:LetterOfCreditMember2021-01-012021-03-31dvcr:letter_of_credit0000919956dvcr:AmendedAndRestatedCreditAgreementMember2021-03-310000919956us-gaap:RevolvingCreditFacilityMemberdvcr:AmendedAndRestatedCreditAgreementMember2021-03-310000919956us-gaap:InterestRateCapMemberus-gaap:CashFlowHedgingMember2021-03-310000919956us-gaap:OtherNoncurrentAssetsMemberus-gaap:InterestRateCapMember2021-03-310000919956us-gaap:InterestRateSwapMember2020-10-012020-10-310000919956us-gaap:InterestRateSwapMember2021-01-012021-03-310000919956us-gaap:OtherNoncurrentAssetsMemberus-gaap:InterestRateSwapMember2021-03-310000919956us-gaap:OtherNoncurrentAssetsMemberus-gaap:InterestRateSwapMember2020-12-310000919956us-gaap:InterestRateSwapMemberus-gaap:OtherNoncurrentLiabilitiesMember2021-03-310000919956us-gaap:InterestRateSwapMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-12-310000919956us-gaap:OtherNoncurrentAssetsMemberus-gaap:InterestRateCapMember2020-12-310000919956us-gaap:InterestRateCapMemberus-gaap:OtherNoncurrentLiabilitiesMember2021-03-310000919956us-gaap:InterestRateCapMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-12-310000919956us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2021-01-012021-03-310000919956us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2020-01-012020-03-310000919956us-gaap:InterestRateCapMember2021-01-012021-03-310000919956us-gaap:InterestRateCapMember2020-01-012020-03-310000919956us-gaap:InterestRateCapMemberus-gaap:InterestExpenseMember2021-01-012021-03-310000919956us-gaap:InterestRateCapMemberus-gaap:InterestExpenseMember2020-01-012020-03-310000919956us-gaap:ProfessionalMalpracticeLiabilityMemberdvcr:SHCRiskCarriersIncMember2021-01-012021-03-310000919956us-gaap:ProfessionalMalpracticeLiabilityMember2021-03-310000919956us-gaap:ProfessionalMalpracticeLiabilityMember2020-12-31dvcr:lawsuit0000919956dvcr:TrialOrArbitrationScheduleTimeframeMember2021-03-310000919956dvcr:SelfInsuranceReceivableCurrentMember2021-03-310000919956dvcr:SelfInsuranceReceivableCurrentMember2020-12-310000919956dvcr:CivilInvestigativeDemandMember2021-01-012021-03-310000919956dvcr:CivilInvestigativeDemandMember2020-01-012020-03-310000919956dvcr:CivilInvestigativeDemandMember2021-03-310000919956dvcr:CivilInvestigativeDemandMember2020-12-310000919956dvcr:PrefundedDeductiblePolicyMember2021-01-012021-03-310000919956dvcr:PrefundedDeductiblePolicyMember2021-03-310000919956dvcr:PrefundedDeductiblePolicyMember2020-12-310000919956dvcr:TwoThousandAndEightStockPurchasePlanMember2008-06-012008-06-300000919956dvcr:TwoThousandAndEightStockPurchasePlanMember2016-05-310000919956dvcr:TwoThousandAndEightStockPurchasePlanMember2016-06-300000919956dvcr:TwoThousandAndTenLongTermIncentivePlanMember2017-05-310000919956dvcr:TwoThousandAndTenLongTermIncentivePlanMember2017-06-300000919956us-gaap:RestrictedStockMember2021-01-012021-03-310000919956us-gaap:RestrictedStockMember2020-01-012020-03-310000919956srt:ChiefExecutiveOfficerMember2020-03-132020-03-130000919956dvcr:StockOptionsAndStockAppreciationRightsSARsMember2020-12-310000919956dvcr:StockOptionsAndStockAppreciationRightsSARsMember2021-01-012021-03-310000919956dvcr:StockOptionsAndStockAppreciationRightsSARsMember2021-03-310000919956us-gaap:RestrictedStockMember2020-12-310000919956us-gaap:RestrictedStockMember2021-03-310000919956us-gaap:RestrictedStockUnitsRSUMember2020-12-310000919956us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310000919956us-gaap:RestrictedStockUnitsRSUMember2021-03-310000919956dvcr:StockOptionsExercisePriceRangeOneMemberdvcr:StockOptionsAndStockAppreciationRightsSARsMember2021-01-012021-03-310000919956dvcr:StockOptionsExercisePriceRangeOneMemberdvcr:StockOptionsAndStockAppreciationRightsSARsMember2021-03-310000919956dvcr:StockOptionsExercisePriceRangeTwoMemberdvcr:StockOptionsAndStockAppreciationRightsSARsMember2021-01-012021-03-310000919956dvcr:StockOptionsExercisePriceRangeTwoMemberdvcr:StockOptionsAndStockAppreciationRightsSARsMember2021-03-310000919956us-gaap:ShareBasedCompensationAwardTrancheOneMemberus-gaap:RestrictedStockMember2020-01-012020-03-310000919956us-gaap:ShareBasedCompensationAwardTrancheTwoMemberus-gaap:RestrictedStockMember2020-01-012020-03-310000919956us-gaap:RestrictedStockMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2020-01-012020-03-3100009199562020-03-272020-03-2700009199562020-11-012020-11-0100009199562020-12-01







UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________ 
FORM 10-Q
________________________________ 
CHECK ONE:
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended: March 31, 2021
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to             .

Commission file No.: 1-12996
________________________________ 
Diversicare Healthcare Services, Inc.
(exact name of registrant as specified in its charter)
 ________________________________
Delaware 62-1559667
(State or other jurisdiction of
incorporation or organization)
 (IRS Employer
Identification No.)
1621 Galleria Boulevard, Brentwood, TN 37027
(Address of principal executive offices) (Zip Code)
(615) 771-7575
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each ClassTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par value per shareDVCROTCQX
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
       If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  
6,952,773
(Outstanding shares of the issuer’s common stock as of May 5, 2021)









Part I. FINANCIAL INFORMATION
ITEM 1 – FINANCIAL STATEMENTS
DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED BALANCE SHEETS
(in thousands)
 
March 31,
2021
December 31,
2020
 (Unaudited) 
CURRENT ASSETS:
Cash $32,437 $30,821 
Accounts receivable49,008 53,691 
Self-insurance receivables1,159 1,025 
Other receivables4,064 4,622 
Prepaid expenses and other current assets4,348 5,356 
Income tax refundable234 1,746 
Total current assets91,250 97,261 
PROPERTY AND EQUIPMENT, at cost135,608 135,234 
Less accumulated depreciation and amortization(93,242)(91,914)
Property and equipment, net42,366 43,320 
OTHER ASSETS:
Operating lease right-of-use assets282,931 290,296 
Acquired leasehold interest, net5,069 5,202 
Other noncurrent assets3,846 3,773 
Total other assets291,846 299,271 
$425,462 $439,852 
The accompanying notes are an integral part of these interim consolidated financial statements.
2








DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED BALANCE SHEETS
(in thousands, except per share amounts)
(continued)
 
March 31,
2021
December 31,
2020
 (Unaudited) 
CURRENT LIABILITIES:
Current portion of long-term debt and finance lease obligations$1,677 $1,660 
Current portion of operating lease liabilities29,429 28,583 
Trade accounts payable16,955 13,901 
Accrued expenses:
Payroll and employee benefits14,420 15,393 
Self-insurance reserves, current portion14,126 12,665 
Deferred income19,505 25,900 
Other current liabilities10,485 14,743 
Total current liabilities106,597 112,845 
NONCURRENT LIABILITIES:
Long-term debt and finance lease obligations, less current portion and deferred financing costs, net58,225 58,526 
Operating lease liabilities, less current portion266,435 274,155 
Self-insurance reserves, less current portion14,081 15,476 
Government settlement accrual7,000 8,000 
Other noncurrent liabilities2,353 2,155 
Total noncurrent liabilities348,094 358,312 
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ DEFICIT:
Common stock, authorized 20,000 shares, $.01 par value, 7,185 and 7,079 shares issued, and 6,953 and 6,847 shares outstanding, respectively
72 71 
Treasury stock at cost, 232 shares of common stock
(2,500)(2,500)
Paid-in capital24,754 24,596 
Accumulated deficit(51,584)(53,510)
Accumulated other comprehensive income29 38 
Total shareholders’ deficit(29,229)(31,305)
$425,462 $439,852 
The accompanying notes are an integral part of these interim consolidated financial statements.
3








DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts, unaudited)
 Three Months Ended March 31,
 20212020
PATIENT REVENUES, NET$113,360 $119,987 
OTHER OPERATING INCOME11,321  
EXPENSES:
Operating96,829 94,859 
Lease and rent expense13,249 13,512 
Professional liability2,083 1,839 
General and administrative6,765 6,758 
Depreciation and amortization2,295 2,288 
Total expenses121,221 119,256 
OPERATING INCOME 3,460 731 
OTHER INCOME (EXPENSE):
Other income39 115 
Interest expense, net(1,022)(1,460)
Total other expense(983)(1,345)
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES2,477 (614)
(PROVISION) BENEFIT FOR INCOME TAXES(343)104 
INCOME (LOSS) FROM CONTINUING OPERATIONS2,134 (510)
LOSS FROM DISCONTINUED OPERATIONS:
Operating loss, net of tax benefit of $72 and $65, respectively
(246)(243)
NET INCOME (LOSS)$1,888 $(753)
NET INCOME (LOSS) PER COMMON SHARE:
Per common share – basic
Continuing operations$0.33 $(0.08)
Discontinued operations(0.04)(0.04)
$0.29 $(0.12)
Per common share – diluted
Continuing operations$0.32 $(0.08)
Discontinued operations(0.04)(0.04)
$0.28 $(0.12)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic6,573 6,506 
Diluted6,741 6,506 
The accompanying notes are an integral part of these interim consolidated financial statements.
4








DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(in thousands and unaudited)
 
 Three Months Ended March 31,
 20212020
NET INCOME (LOSS)$1,888 $(753)
OTHER COMPREHENSIVE INCOME (LOSS):
Change in fair value of cash flow hedges, net of tax(9)(279)
Total other comprehensive loss(9)(279)
COMPREHENSIVE INCOME (LOSS)$1,879 $(1,032)

The accompanying notes are an integral part of these interim consolidated financial statements.
5








DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF SHAREHOLDERS' DEFICIT
(in thousands and unaudited)

Common StockTreasury StockPaid-in CapitalAccumulated DeficitAccumulated
Other
Comprehensive Income (Loss)
Total
Shareholders' Deficit
Shares IssuedAmountSharesAmount
BALANCE, DECEMBER 31, 20196,908 $69 232 $(2,500)$24,026 $(59,079)$568 $(36,916)
Net loss— — — — — (753)— (753)
Issuance of equity grants, net190 1 — — 3 — — 4 
Interest rate cash flow hedge— — — — — — (279)(279)
Stock-based compensation— — — — 338 — — 338 
BALANCE, MARCH 31, 20207,098 $70 232 $(2,500)$24,367 $(59,832)$289 $(37,606)

Common StockTreasury StockPaid-in CapitalAccumulated DeficitAccumulated
Other
Comprehensive Income (Loss)
Total
Shareholders' Deficit
Shares IssuedAmountSharesAmount
BALANCE, DECEMBER 31, 20207,079 $71 232 $(2,500)$24,596 $(53,510)$38 $(31,305)
Net income— — — — — 1,888 — 1,888 
Issuance of equity grants, net106 1 — — 63 — — 64 
Interest rate cash flow hedges— — — — — 38 (9)29 
Stock-based compensation— — — — 95 — — 95 
BALANCE, MARCH 31, 20217,185 $72 232 $(2,500)$24,754 $(51,584)$29 $(29,229)

The accompanying notes are an integral part of these interim consolidated financial statements.
6








DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands and unaudited)
 Three Months Ended March 31,
 20212020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)$1,888 $(753)
Loss from discontinued operations(246)(243)
Income (loss) from continuing operations2,134 (510)
Adjustments to reconcile income (loss) from continuing operations to net cash provided by operating activities:
Depreciation and amortization2,295 2,288 
Provision for self-insured professional liability, net of cash payments474 173 
Amortization of right-of-use assets6,880 5,663 
Stock-based compensation95 338 
Provision for leases in excess of cash payments485 821 
Other93 517 
Changes in assets and liabilities affecting operating activities:
Receivables4,549 246 
Prepaid expenses and other assets1,136 792 
Trade accounts payable and accrued expenses(1,461)(2,021)
Deferred income(6,395) 
Operating lease liabilities(6,874)(5,656)
Net cash provided by continuing operations3,411 2,651 
Discontinued operations(246)(243)
Net cash provided by operating activities3,165 2,408 
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment(1,208)(927)
Purchases of property and equipment with stimulus funds(305) 
Net cash used in continuing operations(1,513)(927)
Discontinued operations  
Net cash used in investing activities(1,513)(927)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of debt and finance lease obligations(377)(2,113)
Proceeds from issuance of debt 2,500 
Proceeds from stimulus funds used to purchase property and equipment305  
Financing costs (419)
Issuance and redemption of employee equity awards, net36 4 
Net cash used in continuing operations(36)(28)
Discontinued operations  
Net cash used in financing activities$(36)$(28)
The accompanying notes are an integral part of these interim consolidated financial statements.
7








DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands and unaudited)
(continued)
 
 Three Months Ended March 31,
 20212020
NET INCREASE IN CASH$1,616 $1,453 
CASH, beginning of period30,821 2,710 
CASH, end of period$32,437 $4,163 
SUPPLEMENTAL INFORMATION:
Cash payments of interest$1,101 $1,599 
Cash (refunds) payments of income taxes$(1,217)$10 
The accompanying notes are an integral part of these interim consolidated financial statements.
8


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2021 AND 2020
(Dollars and shares in thousands, except per share data)
(Unaudited)
1.    BUSINESS
Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare” or the “Company”) provides long-term care services to nursing center patients in eight states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Indiana, Kansas, Mississippi, Missouri, Ohio, Tennessee, and Texas.
As of March 31, 2021, the Company’s continuing operations consist of 61 nursing centers with 7,250 licensed nursing beds. The Company owns 15 and leases 46 of its nursing centers. Our nursing centers range in size from 50 to 320 licensed nursing beds. The licensed nursing bed count does not include 397 licensed assisted and residential living beds.
COVID-19 Pandemic
In January 2020, the Secretary of U.S. Department of Health and Human Services (“HHS”) declared a national public health emergency due to a novel coronavirus. In March 2020, the World Health Organization categorized COVID-19, a disease caused by this coronavirus (“COVID-19”), as a pandemic. According to the Centers for Disease Control and Prevention (“CDC”), older adults and people with certain underlying medical conditions are at higher risk for serious illness from COVID-19. CDC has identified nursing home populations as being at high risk of being affected by pathogens like COVID-19 as a result of the congregate nature of nursing homes and the resident population served.
The Centers for Medicare & Medicaid Services (“CMS”) and the CDC have issued guidance to state and local governments and long-term care facilities to help mitigate the spread of COVID-19. For example, on March 13, 2020, CMS issued a memorandum directing long-term care facilities to significantly restrict visitors and nonessential workers and to restrict communal activities, among other measures. On May 18, 2020, CMS provided “reopening” recommendations for state and local officials to determine the level of mitigation needed to prevent the transmission of COVID-19 in nursing homes, including criteria for relaxing various restrictions. On March 10, 2021, CMS updated its guidance for visitation in nursing homes to account for the availability of COVID-19 vaccines, further relaxing visitation restrictions while emphasizing the importance of maintaining infection prevention practices. To help nursing homes and other providers respond to and contain the spread of COVID-19, CMS has also issued temporary emergency blanket waivers to various government healthcare program requirements. For example, through the end of the public health emergency declaration, CMS is waiving the requirement for a three-day hospital stay prior to Medicare Part A coverage of skilled nursing facility benefits, which allows Medicare beneficiaries that require a new or changed skilled level of care to receive that care under Medicare Part A from a skilled nursing facility without satisfying the hospital stay requirement (sometimes referred to as “skilled in place”). CMS continues to review the need for the waivers and has announced early termination of some waivers as the pandemic and nursing home practices have evolved. In addition, CMS has announced COVID-19 reporting requirements and focused infection control surveys intended to assess long-term care facility compliance with infection control requirements in connection with the COVID-19 pandemic. CDC guidance includes infection prevention and control practices intended to protect both nursing home residents and healthcare personnel.
On March 27, 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) which includes, among other things, modifications to the limitation on business interest expense and net operating loss provisions relative to the payment of Federal income taxes and allows an optional payment deferral of the employer's portion of Social Security taxes that were otherwise due through December 31, 2020. These provisions of the CARES Act were effective after the date of enactment and also include the appropriation of stimulus funds to Medicare and Medicaid providers. The Paycheck Protection Program and Health Care Enhancement Act ("PPPHCE Act"), enacted on April 24, 2020, the Consolidated Appropriations Act, 2021 ("CAA"), enacted December 27, 2020, and American Rescue Plan Act of 2021 ("ARPA"), enacted on March 11, 2021, provide for additional emergency appropriations for COVID-19 response.
Together, the CARES Act and other enacted legislation, authorize funding to healthcare entities to be distributed through the Public Health and Social Services Emergency Fund ("PHSSEF"), also known as the Provider Relief Fund. Payments from PHSSEF, as made to providers through general and targeted distributions, are intended to compensate providers for lost revenues and healthcare-related expenses attributable to the COVID-19 pandemic only. As long as the recipient has sufficient COVID-19 attributable expenses and lost revenues, as defined by the PHSSEF, between January 1, 2020 and June 30, 2021 and complies with certain terms and conditions, these payments are not required to be repaid. The terms and conditions include, among others, requirements to comply with certain reporting requirements, limitations on balance billing and restrictions
9


against using PHSSEF funds to reimburse expenses or losses that have been reimbursed from other sources or that other sources are obligated to reimburse. The CAA provides that targeted distribution payments made to an eligible entity may be allocated by the entity's parent organization among its subsidiary eligible health care providers and the entity receiving the targeted distribution payments remains responsible for reporting obligations. The Company is utilizing the funds it received from the PHSSEF to compensate for COVID-19 attributable lost revenues and pay for permissible expenses, including but are not limited to increased wages and increased costs for personal protective equipment, infection control supplies, and COVID-19 testing.
Additionally, the CARES Act and other enacted legislation authorized additional relief funding to skilled nursing facilities and nursing homes in the form of Nursing Home Infection Control distributions, with a fixed $10,000 distributed for each facility and variable distributions based on number of beds. The legislation also provides for infection control quality incentive payments to skilled nursing facilities and nursing homes based on certain performance measures tied to COVID-19 infections and mortalities. These payments were calculated based on monthly performance periods running from September through December 2020, with the total available bonus payment for each performance period determined in part based on data reported via Certification and Survey Provider Enhanced Reports ("CASPER"). The terms and conditions for this distribution limit use of payments to certain infection control expenses. HHS has not yet published reporting requirements for these distributions and has not yet stipulated a time period by which these funds must be used.
The Company is still evaluating the most recent guidance for amounts distributed under the CARES Act and other enacted legislation; however, the Company currently anticipates, but cannot guarantee, that it will have sufficient COVID-19 attributable expenses and lost revenues to retain the PPSSEF payments it has received to date. The Company will not be able to determine the amount of used funds until the form, process and reporting rules are finalized by the federal government, and the Company knows the full extent of its COVID-19 attributable expenses and lost revenues. There also can be no assurance that the PHSSEF funds will ultimately be enough to reimburse the Company for the full extent of its COVID-19 attributable expenses and losses.
As a result of the COVID-19 pandemic, we have experienced and may continue to experience price increases in equipment, pharmaceuticals, and medical supplies due to increased demand and limited availability for certain items. Staffing, equipment, pharmaceutical and medical supplies and vaccine shortages may impact our ability to admit and treat patients. We have incurred, and may continue to incur, increased expenses arising from the COVID-19 pandemic, particularly in the form of increased labor costs, testing and the increased costs of personal protective equipment, food and infection control supplies. The Company expects such increased expenses to continue and likely increase further into 2021. Refer to Note 4 "COVID-19 Pandemic" for further information.
Since the end of calendar year 2020, there have been additional cases of COVID-19 at certain of our centers. We have experienced and may continue to experience reduced occupancy in our centers, in part due to perceived risks by patients and family members of residential care and their perception of restrictions such as limited visitation policies (which have been relaxed pursuant to CMS guidance), a reduction in patients released to nursing homes from hospitals and other healthcare facilities, and a general reluctance to seek medical care or interface with the healthcare system during the pandemic or for an undetermined period of time. Occupancy may also be affected by the data each nursing home is required to report, including the number of confirmed and suspected cases of COVID-19 and resident deaths related to COVID-19, which is made publicly available through the CDC National Healthcare Safety Network.
2.    CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
The interim consolidated financial statements for the three month periods ended March 31, 2021 and 2020, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at March 31, 2021, the results of operations, changes in shareholders' deficit and cash flows for the three month period ended March 31, 2021 and 2020. The Company’s balance sheet information at December 31, 2020, was derived from its audited consolidated financial statements as of December 31, 2020.
The results of operations for the periods ended March 31, 2021 and 2020 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020.


10


PHSSEF Funds
During the year ended December 31, 2020, the Company implemented certain changes to its accounting policies related to the recognition of stimulus funds through the PHSSEF, which it has applied consistently throughout the period ended March 31, 2021. There is no U.S. GAAP that explicitly covers accounting for government "grants" to for-profit entities with the exception of certain agricultural subsidies. In the absence of authoritative U.S. GAAP guidance, the Company considered the application of other authoritative accounting guidance by analogy and concluded that the guidance outlined in International Accounting Standards 20 - Accounting for Government Grants and Disclosures of Government Assistance ("IAS 20") was the most appropriate analogy for the purpose of recording and classifying the federal and certain state stimulus funds received by the Company. Under IAS 20, once it is reasonably assured that the entity will comply with the conditions of the grant, the grant money should be recognized on a systematic basis over the periods in which the entity recognizes the related expenses or losses for which the grant money is intended to compensate. The Company recognizes grants once both of the following conditions are met: (1) the Company is eligible to receive the grant, and (2) the Company is able to comply with the relevant conditions of the grant. Federal and certain state stimulus funds that are recognized to offset healthcare related expenses and lost revenue attributable to COVID-19 are reflected as "other operating income" on the accompanying interim consolidated statement of operations. Federal stimulus funds received and used toward capital improvements that assist with the response to and prevention and spread of COVID-19 is accounted for as a capital grant. For such an asset acquired with the use of a stimulus funds, the Company will recognize the asset as a net zero asset. Refer to Note 4, "COVID-19 Pandemic" to the interim consolidated financial statements included in this report for additional information.
Additionally, the Company has received Medicaid stimulus funds, which are recognized in accordance with ASC 606. Refer to Note 5, "Revenue Recognition and Accounts Receivable" to the interim consolidated financial statements included in this report for additional information.
3.    RECENT ACCOUNTING GUIDANCE
Accounting Standards Recently Issued But Not Yet Adopted by the Company
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new guidance intends to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for smaller reporting companies for the fiscal year beginning after December 15, 2022 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related disclosures.
In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848). The new guidance contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU No. 2020-04 is optional and may be elected over time as reference rate reform activities occur. During the first quarter of 2020, the Company elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The amendments in the ASU are effective for all entities as of March 12, 2020 through December 31, 2022. The Company continues to evaluate changes in the market and may apply other elections, as applicable, in the future as allowed under ASU No. 2020-04.
4. COVID-19 PANDEMIC
As of March 31, 2021, the Company has received $51,607 from the PHSSEF. The Company recognized $10,534 as income, which is reflected in "other operating income" in the Company's results of operations for the three month period ended March 31, 2021. For the three months ended March 31, 2021, the Company utilized $305 of these stimulus dollars to fund capital improvements to prevent the spread of COVID-19. The remaining stimulus funds of $19,505 as of March 31, 2021 are classified as "deferred income" on the interim consolidated balance sheet, which also includes Nursing Home Infection Control Distributions. The Nursing Home Infection Control Distributions, which also include infection control quality incentive payments, are subject to terms and conditions that require recipients to use the funds for infection control expenses. HHS has not yet published reporting requirements for these distributions and has not yet stipulated a time period by which these funds must be used. The Company recognized $787 of grant funds from states, which is included in "other operating income" in the Company's results of operations for the three month period ended March 31, 2021. Additionally, the Families First Coronavirus Response Act provided states with a temporary increase in the regular federal matching rate, or federal medical assistance percentage, used to determine the federal government's share of the cost of covered services in state Medicaid programs, provided the states agreed to certain conditions such as not imposing cost-sharing requirements for COVID-19-related testing
11


and treatment. The Company recognized $4,056 for the three month period ended March 31, 2021 of Medicaid and Hospice dollars related to this temporary increase in the federal matching rate, which related to patient services rendered and is reflected in "patient revenues, net" in the Company's results of operations for the three month period ended March 31, 2021.
The Company initially elected to participate in the payment deferral of the employer's portion of Social Security taxes. During the third quarter of 2020, the Company ceased the deferral election and paid $3,185. As of March 31, 2021, the Company has no remaining liability related to the payment deferral and does not expect to participate in the payment deferral going forward.
The CARES Act and other stimulus legislation also include other provisions offering financial relief, for example lifting the Medicare sequestration from May 1, 2020 through December 31, 2021, which would have otherwise reduced payments to Medicare providers by 2% as required by the Budget Control Act of 2011 (but also extending sequestration through 2030). For the three month period ended March 31, 2021, the suspension of the Medicare sequestration positively impacted net patient revenues by $751. However, in addition to providing funding for healthcare providers, the ARPA increases the federal budget deficit in a manner that triggers an additional statutorily mandated sequestration under the Pay-As-You-Go Act of 2010 ("PAYGO Act"). As a result, absent congressional action, Medicare spending will be reduced by up to 4 percentage points in FY 2022, in addition to the existing sequestration requirements of the Budget Control Act of 2011.
The Company incurred an additional $8,088 of labor expense and $3,905 for testing and the increased costs of personal protective equipment, food and infection control supplies related to the COVID-19 pandemic for the three month period ended March 31, 2021. These expenses are reflected in "operating expense" in the Company's results of operations for the three month period ended March 31, 2021.
The Company is closely monitoring and evaluating the impact of the COVID-19 pandemic on all aspects of its business. We have identified team members and patients who have tested positive for COVID-19 at all of our centers, and we have incurred an increase in the costs of caring for the team members, patients, and residents in those centers. The Company has also experienced reduced occupancy at its centers and has incurred additional expenditures preparing its centers for potential outbreaks and maintaining the healthcare delivery capacity of its centers. While we have experienced reduced occupancy and increased expenses, we received additional PHSSEF and other stimulus funds during 2020 and the first quarter of 2021, which have been used, and are expected to continue to be used to mitigate the impact of COVID-19 derived lost revenues associated with the reduced occupancy as well as increased expenses, and any cash flow or liquidity impacts therefrom. The Company has an interdisciplinary team monitoring and staying up to date on the latest information about COVID-19. The Company has implemented precautionary measures and response protocols to minimize the spread of COVID-19, following guidance from CMS and the CDC. Nevertheless, the Company expects additional COVID-19 cases will occur at its centers. The Company is continuing to evaluate and consider the potential impact that COVID-19 may have on its liquidity, financial condition and results of operations due to numerous uncertainties. However, given the uncertainty as to the duration of the COVID-19 pandemic and the timing and availability of effective medical treatment and vaccines, it could have a material adverse effect on the Company's future results of operations, financial condition and liquidity.
5. REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE
The Company's revenue is derived from providing quality healthcare services to its patients. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. The promise to provide quality care is accounted for as a single performance obligation satisfied at a point in time, when those services are rendered on a daily basis.
The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans).







12


Disaggregation of Revenue and Accounts Receivable
In accordance with ASC 606, the Company recognized $3,757 and $299 of Medicaid and Hospice stimulus dollars, respectively, for the three month period ended March 31, 2021 that are reflected as patient revenues in the Company's results of operations and in the table below. Refer to Note 4, "COVID-19 Pandemic" for more information. The following table summarizes revenue from contracts with customers by payor source from continuing operations for the periods presented (dollar amounts in thousands):
Three Months Ended March 31,
20212020
Medicaid$49,955 44.1 %$54,330 45.3 %
Medicare24,458 21.6 %20,672 17.2 %
Managed Care13,676 12.1 %12,596 10.5 %
Private Pay and other25,271 22.2 %32,389 27.0 %
Total$113,360 100.0 %$119,987 100.0 %

Accounts receivable from continuing operations as of March 31, 2021 and December 31, 2020 are summarized in the following table:
March 31,December 31,
20212020
Medicaid$17,254 $17,354 
Medicare9,350 14,273 
Managed Care7,861 8,021 
Private Pay and other14,543 14,043 
Total accounts receivable$49,008 $53,691 

6. LONG-TERM DEBT
The Company maintains a credit facility with a syndicate of banks. The Company originally entered into the credit facility in May 2013, and subsequently amended the facility. As of December 31, 2019, the credit facility consisted of a mortgage loan of $67,500, an acquisition loan with a borrowing capacity of $12,500, a revolver with a borrowing capacity of $40,250 and an affiliated revolver with a borrowing capacity of $2,000.
On October 14, 2020, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") with a syndicate of banks, which consists of a $62,000 mortgage loan subsequently amended ("Amended Mortgage Loan"), a $36,000 revolver subsequently amended ("Amended Revolver") and a $2,000 affiliated revolver amended ("Amended Affiliated Revolver"). The Amended Mortgage Loan, Amended Revolver and Amended Affiliated Revolver have a 3-year maturity through September 30, 2023. The Amended Mortgage Loan has a term of 3 years, with principal and interest payable monthly based on a 25-year amortization. Interest on the term loan facility is based on LIBOR plus 4.0% with a 1.0% floor. The Amended Mortgage Loan balance was $60,767 as of March 31, 2021 with an interest rate of 5.0%. The Amended Mortgage Loan consolidated the mortgage and acquisition loans. The Amended Mortgage Loan is secured by 15 owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan, the Amended Revolver and the Amended Affiliated Revolver are cross-collateralized and cross-defaulted. The Company’s Amended Revolver and Amended Affiliated Revolver have an interest rate of LIBOR plus 4.0% and are secured by accounts receivable and are subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.
As of March 31, 2021 and December 31, 2020, the Company had no outstanding borrowings under its revolvers. The interest rate related to the revolvers was 5.0% as of March 31, 2021. Annual fees for letters of credit issued under the Amended Revolver are 3.0% of the amount outstanding. The Company has four letters of credit with a total value of $12,387 outstanding as of March 31, 2021. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the Amended Revolver and the Amended Affiliated Revolver, and the maximum loan amount of $24,377 for these revolvers, the balance available for borrowing under the revolvers was $11,990 at March 31, 2021.
The Company’s debt agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. The Company is in compliance with all such covenants at March 31, 2021.

13


7. DERIVATIVES AND HEDGING ACTIVITIES
In February 2021, the Company entered into an interest rate cap agreement with a member of the bank syndicate as the counterparty. The Company entered into the interest rate cap agreement to mitigate the variable interest rate risk associated with its outstanding mortgage borrowings.
The Company designated the interest rate cap as a cash flow hedge, and the effective portion of the hedge is reflected as a component of other comprehensive income. The interest rate cap has the same maturity date as the Amended Mortgage Loan and has an amortizing notional amount that was $60,767 as of March 31, 2021. The interest rate cap agreement requires the counterparty to pay the Company an amount equal to the applicable notional amount multiplied by the rate by which the LIBOR index exceeds a 1% strike rate during the period.
The Company assesses the effectiveness of the interest rate cap on a quarterly basis and at March 31, 2021, the Company has determined that the interest rate cap was effective. Accordingly, the gain or loss related to the change in fair value of the interest rate cap is recorded in Accumulated Other Comprehensive Income and subsequently reclassified into interest expense in the same period during which the hedged forecasted transaction affects earnings. The fair value of the interest rate cap of $78 at March 31, 2021 was included in other noncurrent assets on the Company's Consolidated Balance Sheets.
In conjunction with the refinancing of its outstanding borrowings during October 2020, the Company terminated its interest rate swap and incurred a loss of $177. Following the termination, $90 was recorded in other comprehensive income and was reclassified as an adjustment to earnings over the remaining term of the original hedge. Of this amount, $38 was recorded as a decrease to retained earnings for the three months ended March 31, 2021.
As of March 31, 2021, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:
Interest Rate DerivativeNumber of InstrumentsNotional
Interest Rate Cap1$60,767 

The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the balance sheets as of March 31, 2021 and December 31, 2020.
Asset DerivativesLiability Derivatives
Fair Value at:Fair Value at:
Balance Sheet ClassificationMarch 31, 2021December 31, 2020Balance Sheet ClassificationMarch 31, 2021December 31, 2020
Interest Rate SwapOther noncurrent assets$ $ Other noncurrent liabilities$ $ 
Interest Rate CapOther noncurrent assets$78 $ Other noncurrent liabilities$ $ 

The table below presents the effect of cash flow hedge accounting on Accumulated Other Comprehensive Income for the three months ended March 31, 2021 and March 31, 2020.
Effect of Derivative Instruments on the Consolidated Statement of Income
Amount of Gain (Loss) Recognized in Other Comprehensive Income on DerivativeLocation of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into IncomeAmount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income
Three months ended March 31, Three months ended March 31,
2021202020212020
Interest Rate Swap$ $(329)
Interest Expense (a)
$(38)$50 
Interest Rate Cap$29 $ 
Interest Expense (a)
$ $ 
Total$29 $(329)$(38)$50 
(a) Total interest expense presented in the consolidated income statements for the three months ended March 31, 2021 and 2020 was $1,022 and $1,460, respectively.

14


8.     LEASES
The Company has operating and finance leases for facilities, corporate offices, and certain equipment. The Company recognizes lease expense for these operating leases on a straight-line basis over the lease term. Leases with an initial term of one year or less are not recorded on the balance sheet. The Company's other leases have original lease terms of one to twelve years, some of which include options to extend the lease for up to twenty years, and some of which include options to terminate the leases within one year. The exercise of lease renewal options is at our sole discretion. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants. Upon adoption of Topic 842, the Company elected the practical expedient to not separate lease and non-lease components for all of its leases as the non-lease components are not significant to the overall lease costs.
ClassificationMarch 31, 2021December 31, 2020
Assets
   Operating lease assetsOperating lease right-of-use assets$282,931 $290,296 
   Finance lease assets
Property and equipment, net (a)
447 508 
Total leased assets$283,378 $290,804 
Liabilities
Current
   OperatingCurrent portion of operating lease liabilities$29,429 $28,583 
   FinanceCurrent portion of long-term debt and finance lease obligations255 251 
Noncurrent
   OperatingOperating lease liabilities, less current portion266,435 274,155 
   FinanceLong-term debt and finance lease obligations, less current portion and deferred financing costs, net
224 280 
Total lease liabilities $296,343 $303,269 
(a) Finance lease assets are recorded net of accumulated amortization of $532 and $471 as of March 31, 2021 and December 31, 2020, respectively.

Lease Cost of Continuing Operations
Three Months Ended March 31,
Classification20212020
Operating lease cost (a)
Lease and rent expense$13,249 $13,512 
Finance lease cost:
   Amortization of finance lease assetsDepreciation and amortization61 61 
   Interest on finance lease liabilitiesInterest expense, net9 9 
Short term lease costOperating expense151 179 
Net lease cost$13,470 $13,761 
(a) Includes variable lease costs, which are immaterial.












15


Maturity of Lease Liabilities
As of March 31, 2021
Operating Leases (a)
Finance Leases (a)
Total
2021$51,408 $283 $51,691 
202252,398 167 52,565 
202353,255 56 53,311 
202453,115 9 53,124 
202554,193  54,193 
After 2025128,178  128,178 
Total lease payments$392,547 $515 $393,062 
Less: Interest(96,683)(36)(96,719)
Present value of lease liabilities$295,864 $479 $296,343 
(a) Operating and finance lease payments exclude option to extend lease terms that are not reasonably certain of being exercised.
The measurement of right-of-use assets and lease liabilities requires the Company to estimate appropriate discount rates. To the extent the rate implicit in the lease is readily determinable, such rate is utilized. However, based on information available at lease commencement for the majority of our leases, the rate implicit in the lease is not known. In these instances, the Company utilizes an incremental borrowing rate, which represents the rate of interest that it would pay to borrow on a collateralized basis over a similar term.

Lease Term and Discount Rate
March 31, 2021December 31, 2020
Weighted-average remaining lease term (years)
   Operating leases7.687.91
   Finance leases2.042.26
Weighted-average discount rate
   Operating leases7.9%7.9%
   Finance leases6.1%6.2%

Other Information
Three Months Ended March 31,
20212020
Cash paid for amounts included in the measurement of lease liabilities
   Operating cash flows for operating leases$12,740 $12,673 
   Operating cash flows for finance leases9 9 
   Financing cash flows for finance leases57 52 

9.    COMMITMENTS AND CONTINGENCIES
Professional Liability and Other Liability Insurance
The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. All of the Company's nursing centers in Tennessee are now covered under the captive insurance policies along with many of the nursing centers in Alabama, Ohio and Texas, as well as those previously operated by the Company in Kentucky and Florida. The insurance coverage provided for these centers under the SHC policy provides coverage limits of at least $1,000 per medical incident with a sublimit per center of $3,000 and total annual aggregate policy limits of $5,000. All other centers within the Company's portfolio are covered through
16


various commercial insurance policies which provide similar coverage limits per medical incident, per location, and on an aggregate basis for covered centers. The deductibles for these policies are covered through the insurance subsidiary.
Reserve for Estimated Self-Insured Professional Liability Claims
Because the Company’s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company’s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of $24,824 and $24,744 as of March 31, 2021 and December 31, 2020, respectively. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.
The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this reserve. Since May 2012, the actuary has assisted management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished as of May 31 and November 30 of each year. The actuary primarily utilizes historical data regarding the frequency and cost of the Company’s past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company’s ultimate professional liability cost for current periods.
On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company’s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator’s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company’s evaluation of the actual claims information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period.
As of March 31, 2021, the Company is engaged in 79 professional liability lawsuits. Twenty-one lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company’s cash expenditures for self-insured professional liability costs were $1,549 and $1,840 for the three months ended March 31, 2021 and 2020, respectively.
The Company follows the accounting guidance in ASC Topic 954 that clarifies that a health care entity should not net insurance recoveries against a related professional liability claim and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the estimated insurance recovery receivables are included within "Self-insurance receivables" on the Consolidated Balance Sheet. As of March 31, 2021 and December 31, 2020 there are estimated insurance recovery receivables of $1,159 and $1,025 in "Self-insurance receivable", respectively.
Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Any potential claims or settlements related to COVID-19 are uncertain at this time. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company’s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company’s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company’s reported earnings and financial position for the period in which the change in accrual is made.
Civil Investigative Demand ("CID")
In February 2020, we entered into a settlement agreement with the U.S. Department of Justice and the State of Tennessee of actions alleging violations of the federal False Claims Act in connection with our provision of therapy and the completion of certain resident admission forms. This settlement resolved an investigation that had begun in 2012 and covers the time period from January 1, 2010 through December 31, 2015. This agreement requires annual payments for a period of five years ending in February 2025 and also requires a contingent payment in the event the Company sells any of its owned facilities during the five-year payment period. Relative to the settlement agreement, the Company paid $1,000 and $500 during the first quarters of 2021 and 2020, respectively. As of March 31, 2021 and December 31, 2020, the Company has $8,000 and $9,000 outstanding related to the settlement agreement, respectively. Of the outstanding balance related to the settlement agreement, $1,000 is reflected as "Other current liabilities" and the remaining $7,000 and $8,000 is reflected as "Government settlement
17


accrual" on the Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020, respectively. Failure to timely make any of these payments could result in rescission of the settlement and result in the government having a very large claim against us, including penalties, and/or make us ineligible to participate in certain government funded healthcare programs, any of which could in turn significantly harm our business and financial condition.
In conjunction with the settlement of the government investigation related to our therapy practices, we entered into a corporate integrity agreement ("CIA") with the Office of the Inspector General of CMS. The CIA has a term of five years and imposes material burdens on the Company, its officers and directors to take actions designed to ensure compliance with applicable healthcare laws, including requirements to maintain specific compliance positions within the Company, to report any non-compliance with the terms of the CIA, to return any overpayments received, to submit annual reports and for an annual audit of submitted claims by an independent review organization. The CIA sets forth penalties for non-compliance by the Company with the terms of the agreement, including possible exclusion from federally funded healthcare programs for material violations of the agreement.
Other Insurance
With respect to workers’ compensation insurance, substantially all of the Company’s employees are covered under either a prefunded deductible policy or state-sponsored programs. The Company has been and remains a non-subscriber to the Texas workers’ compensation system and, therefore, is completely self-insured for employee injuries with respect to its Texas operations. From the period from July 1, 2008 through March 31, 2021, the Company is covered by a prefunded deductible policy. Under this prefunded policy, the Company is self-insured for the first $500 per claim, subject to an aggregate maximum of $3,000. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers’ compensation claims was $1,115 and $1,039 at March 31, 2021 and December 31, 2020, respectively. The Company has a non-current receivable for workers’ compensation policies covering previous years of $2,123 and $2,050 which is included in "other noncurrent assets" on the Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020, respectively. The non-current receivable is a function of payments paid to the Company’s insurance carrier in excess of the estimated level of claims expected to be incurred. Any potential claims or settlements related to COVID-19 are uncertain at this time.
As of March 31, 2021, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to $200 per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims was $2,268 and $2,358 at March 31, 2021 and December 31, 2020, respectively. The differences between actual settlements and reserves are included in expense in the period finalized. Any potential claims or settlements related to COVID-19 are uncertain at this time.
10.    STOCK-BASED COMPENSATION
Overview of Plans
In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (“Stock Purchase Plan”). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers. The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (“RSU's”) at 85% of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally two years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. In June 2016, our shareholders approved an amendment to the Stock Purchase Plan to increase the number of shares of our common stock authorized under the Plan from 150 shares to 350 shares. No grants can be made under the Stock Purchase Plan after April 25, 2028.
In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (“2010 Plan”), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. In June 2017, our shareholders approved an amendment to the 2010 Plan to increase the number of shares of our common stock authorized under the 2010 Plan from 380 shares to 680 shares. No grants can be made under the 2010 Plan after May 31, 2027.
Equity Grants and Valuations
During the three months ended March 31, 2021 and 2020, the Compensation Committee of the Board of Directors approved grants totaling approximately 106 and 198 shares of restricted common stock, respectively, to certain employees and members of the Board of Directors. The fair value of restricted shares is determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest one-third on the first, second and third anniversaries of the
18


grant date. Unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. On March 13, 2020, the Compensation Committee of the Board of Directors approved the grant of 100 shares of common stock to the Company's Chief Executive Officer, as a one-time bonus in lieu of a 2020 salary increase and as recognition for completing the settlement with the Office of the Inspector General and the disposition of all of the Company's facilities in the State of Kentucky. The stock was fully vested on the date of the grant, and the grant date fair value of which was expensed during the quarter ended March 31, 2020.
In computing the fair value estimates for options and stock-only stock appreciation rights ("SOSARs") using the Black-Scholes-Merton valuation method, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.
Upon vesting of equity awards, all restrictions are removed. Our policy is to account for forfeitures of share-based compensation awards as they occur.
Summarized activity of the equity compensation plans is presented below:
Weighted
Options/Average
SOSARsExercise Price
Outstanding, December 31, 202065 $7.92 
Granted  
Exercised  
Expired or cancelled  
Outstanding, March 31, 202165 $7.92 
Exercisable, March 31, 202165 $7.92 
Weighted
Average
RestrictedGrant Date
SharesFair Value
Outstanding, December 31, 2020193 $3.32 
Granted106 4.25 
Vested(88)3.99 
Cancelled  
Outstanding, March 31, 2021211 $3.51 

Summarized activity of the RSU's for the Stock Purchase Plan is as follows:
Weighted
Average
Grant Date
RSU'sFair Value
Outstanding, December 31, 202055 $2.92 
Granted37 4.25 
Vested(26)3.93 
Outstanding, March 31, 202166 $3.27 

19


The SOSARs and Options were valued and recorded in the same manner, and, other than amounts that may be settled pursuant to employment agreements with certain members of management, will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation related to SOSARs and stock options using the Black-Scholes-Merton equity grant valuation model.
The following table summarizes information regarding stock options and SOSAR grants outstanding as of March 31, 2021:
Weighted
Average
Range ofExerciseGrantsGrants
Exercise PricesPricesOutstandingExercisable
$8.14 to $10.21
$8.83 45 45 
$5.86
$5.86 20 20 
65 65 
Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of $95 and $338 in the three month periods ended March 31, 2021 and 2020, respectively.
11. INCOME TAXES
The Company recorded an income tax expense from continuing operations of $343 during the three months ended March 31, 2021 and a benefit of $104 during the three months ended March 31, 2020.
When assessing the recoverability of the Company’s recorded deferred tax assets, the accounting guidance, ASC 740, Income Taxes, requires that all available positive and negative evidence be considered in evaluating the likelihood that the Company will be able to realize the benefit of its deferred tax assets in the future, which is highly judgmental. Such evidence includes, but may not be limited to, scheduled reversals of deferred tax assets and liabilities, projected future taxable income, tax-planning strategies, and the results of recent operations.
As of March 31, 2021, the Company has a valuation allowance in the amount of $18,609. The Company will continue to periodically assess the realizability of its future deferred tax assets.
On March 27, 2020, the CARES Act was enacted and signed into law. Certain provisions of the CARES Act impact the 2019 income tax provision computations of the Company and were reflected in the first quarter of 2020, or the period of enactment. The CARES Act contains modifications on the depreciation of qualified improvement property, as well as the limitation of business interest for tax years beginning in 2019 and 2020. The new life classification of the qualified improvement property, allowing for bonus depreciation to be taken, along with the modification to Section 163(j) to increase the allowable business interest deduction from 30% of adjusted taxable income to 50% of adjusted taxable income significantly increased the allowable deductions of the Company and result in additional taxable losses for the year-ended 2019, resulting in greater net operating losses (“NOL”) to be carried back. The NOL carryback resulted in a tax refund of $321 and an increase to the Work Opportunity Tax Credit (“WOTC”) deferred tax asset, which is offset by a full valuation allowance. These changes pursuant to the CARES Act did not have an impact during the three-month period ended March 31, 2021.
The Company is not currently under examination by any major income tax jurisdiction. During 2021, the statutes of limitations will lapse on the Company's 2017 Federal tax year and certain 2016 and 2017 state tax years. The Company does not believe the Federal or state statute lapses or any other event will significantly impact the balance of unrecognized tax benefits in the next twelve months. The net balance of unrecognized tax benefits was not material to the interim consolidated financial statements for the three months ended March 31, 2021 and 2020.







20


12.    EARNINGS PER COMMON SHARE
Information with respect to basic and diluted net loss per common share is presented below in thousands, except per share:
 
 Three Months Ended March 31,
 20212020
Numerator: Income (loss):
Income (loss) from continuing operations
$2,134 $(510)
Loss from discontinued operations, net of income taxes(246)(243)
Net income (loss)$1,888 $(753)
Denominator: Basic Weighted Average Common Shares Outstanding:6,5736,506
Dilutive effect of stock options, SOSARs, Restricted Shares and Restricted Share Units168  
Adjusted weighted average common shares outstanding6,7416,506
 
 Three Months Ended March 31,
 20212020
Net income (loss) per common share:
Per common share – basic
Income (loss) from continuing operations$0.33 $(0.08)
Loss from discontinued operations
(0.04)(0.04)
Net income (loss) per common share – basic$0.29 $(0.12)
Per common share – diluted
Income (loss) from continuing operations$0.32 $(0.08)
Loss from discontinued operations
(0.04)(0.04)
Net income (loss) per common share – diluted$0.28 $(0.12)
The effects of 65 and 75 SOSARs and options outstanding were excluded from the computation of diluted earnings per common share in the three months ended March 31, 2021 and 2020, respectively, because these securities would have been anti-dilutive.
13.    BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS
Therapy Services
Effective November 1, 2020, the Company entered into agreements with a third party therapy company to outsource the therapy services that were previously provided by the Company through its wholly owned subsidiary Diversicare Therapy Services. The outsourced services include all physical, occupational, and speech therapy provided to patients of the Company’s facilities. The costs associated with these outsourced therapy services are included in Operating Expenses in the Company's Consolidated Statement of Operations. The contracts are for a three-year term, absent termination for cause by either party.
2020 Lease Amendment
On December 1, 2020, the Company entered into an agreement with Omega to transfer operations of a facility located in Florida to another operator. The agreement effectively amended the Omega Master Lease to remove this center, reduce the annual rent expense, and release the Company from any further obligations arising under the Omega Master Lease with respect to the Florida facility. The remaining Lease terms remain unchanged with an initial term of twelve years and two optional 10-year extensions. The annual lease fixed escalator remains at 2.15%.

21


ITEM 2 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Overview
Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare” or the “Company”) provides long-term care services to nursing center patients in eight states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Indiana, Kansas, Mississippi, Missouri, Ohio, Tennessee, and Texas. The Company's operating results also include the results of discontinued operations in the state of Kentucky that have been reclassified on the face of the financial statements to reflect the discontinued status of these operations for all periods presented.
As of March 31, 2021, the Company’s continuing operations consist of 61 nursing centers with 7,250 licensed nursing beds. The Company owns 15 and leases 46 of its nursing centers. Our nursing centers range in size from 50 to 320 licensed nursing beds. The licensed nursing bed count does not include 397 licensed assisted living and residential beds.
Key Performance Metrics
Skilled Mix. Skilled mix represents the number of days our Medicare or Managed Care patients are receiving services at the skilled nursing facilities divided by the total number of days (less days from assisted living patients).
Average rate per day. Average rate per day is the revenue by payor source for a period at the skilled nursing facility divided by actual patient days for the revenue source for a given period.
Average daily skilled nursing census. Average daily skilled nursing census is the average number of patients who are receiving skilled nursing care.
COVID-19 and Federal Relief Legislation
As a result of the COVID-19 pandemic, federal and state governments have passed legislation, promulgated regulations, and taken other administrative actions intended to assist healthcare providers in providing care to COVID-19 and other patients during the public health emergency and to address public health needs. These measures include temporary relaxation of conditions of participation for healthcare providers, relaxation of licensure requirements for healthcare professionals, relaxation of privacy restrictions for telehealth remote communications, promoting use of telehealth by expanding the scope of services for which reimbursement is available, relaxation of certain Medicare reimbursement rules, such as requirement for a three-day hospital stay prior to Medicare Part A coverage of skilled nursing facility benefits, and limited waivers of fraud and abuse laws for activities related to COVID-19 during the public health emergency period. They also include requirements for skilled nursing centers to report to public health authorities, residents and their representatives when residents, and staff are confirmed as having or are being investigated for having COVID-19.
We are working with federal, state, and local health authorities to respond to the COVID-19 pandemic and are taking measures to try to limit the spread of the virus. For example, we have implemented screening protocols for staff, residents, and visitors. CMS requires nursing homes in states with positive testing rates above a certain threshold to test all staff on a weekly basis. Although we are implementing considerable safety measures, caring for COVID-19 patients has associated risks. In addition, we have experienced, and may continue to experience, price increases in equipment, pharmaceuticals, and medical supplies due to increased demand and limited availability for certain items. Staffing, equipment, pharmaceutical and medical supplies and vaccine shortages may impact our ability to admit and treat patients. We have incurred, and may continue to incur, increased expenses arising from the COVID-19 pandemic, particularly in the form of increased labor costs, testing and the increased costs of personal protective equipment, food and infection control supplies. The Company expects such increased expenses to continue and likely increase further into 2021.
Since the end of calendar year 2020, there have been additional cases of COVID-19 at certain of our centers. We have experienced reduced occupancy in our centers, in part due to perceived risks by patients and family members of residential care and their perception of restrictions such as limited visitation policies (which have been relaxed pursuant to CMS guidance), a reduction in patients released to nursing homes from hospitals and other healthcare facilities, and a general reluctance to seek medical care or interface with the healthcare system during the pandemic or for an undetermined period of time. Occupancy may also be affected by the data each nursing home is required to report, including the number of confirmed and suspected cases of COVID-19 and resident deaths related to COVID-19, which is made publicly available through the CDC National Healthcare Safety Network.
The Company is closely monitoring and evaluating the impact of the COVID-19 pandemic on all aspects of its business. We have identified team members and patients who have tested positive for COVID-19 at our centers, and we have incurred increases in the costs of caring for the patients and residents in those centers. The Company incurred an additional $8.1 million of labor expense and $3.9 million for testing and the increased costs of personal protective equipment, food and infection
22


control supplies related to the COVID-19 pandemic for the three month period ended March 31, 2021. The Company has also experienced reduced occupancy at its centers and has incurred additional expenditures preparing our centers for potential outbreaks. The Company has an interdisciplinary team monitoring and keeping apprised of the latest information about the virus and its prevalence. The Company has implemented precautionary measures and response protocols to minimize the spread of the virus, following guidance from the CDC, but the Company nevertheless expects additional cases of the virus will occur at these and other facilities.
The CARES Act, the PPPHCE Act, the CAA and the ARPA offer various forms of financial relief for healthcare providers, including, among other things, modifications to the limitation on business interest expense and net operating loss provisions relative to the payment of federal income taxes. In addition, these stimulus laws include over $178 billion of funding to be distributed through the PHSSEF to eligible providers, including public entities and Medicare and/or Medicaid enrolled providers. It is not clear how much of the funding remains available for distribution. PHSSEF payments are intended to assist healthcare providers with lost revenues and healthcare-related expenses incurred in response to the COVID-19 pandemic. As long as the recipient has sufficient COVID-19 attributable expenses and lost revenues between January 1, 2020 and June 30, 2021 and complies with certain terms and conditions, the PHSSEF payments are not required to be repaid. The terms and conditions include, among other things, complying with reporting requirements, limitations on balance billing and restrictions against using PHSSEF funds to reimburse expenses or losses that other sources are obligated to reimburse.
Additionally, the CARES Act and other enacted legislation authorized additional relief funding to skilled nursing facilities and nursing homes in the form of Nursing Home Infection Control distributions, with a fixed ten thousand dollars distributed for each facility and variable distributions based on number of beds. The legislation also provides for infection control quality incentive payments to skilled nursing facilities and nursing homes based on certain performance measures tied to COVID-19 infections and mortalities. These payments were calculated based on monthly performance periods running from September through December 2020, with the total available bonus payment for each performance period determined in part based on data reported via CASPER. The terms and conditions for this distribution limit use of payments to certain infection control expenses. HHS has not yet published reporting requirements for these distributions and has not yet stipulated a time period by which these funds must be used.
As of March 31, 2021, we received $51.6 million from the PHSSEF. We also applied for additional Phase 3 General Distribution PHSSEF payments; however, we have not received any payments as of March 31, 2021.
Recipients of more than ten thousand dollars in PHSSEF funds will be required to submit reports to HHS that include information about their expenses and lost revenues and use of the PHSSEF funds. Although registration for reporting is available, HHS has not yet opened the portal for reporting or finalized a deadline for submission of the initial report. HHS continues to update guidance regarding post-payment reporting requirements that provide some additional details and examples related to how recipients should calculate their COVID-19 attributable expenses and lost revenues for purposes of PHSSEF reporting. Ultimately, to the extent that reports submitted by a recipient do not demonstrate sufficient healthcare related lost revenues and expenses attributable to COVID-19 (as those terms are defined by HHS), the recipient may have to repay any excess funds received.
Due to the recent enactment of the CARES Act and other stimulus legislation and evolving guidance, there is still a high degree of uncertainty surrounding the PHSSEF funds. We are closely tracking our use of the funds received from PHSSEF in order to demonstrate compliance with the terms and conditions, including applicable reporting requirements. The Company is still evaluating the most recent guidance related to these funds; however, the Company currently anticipates, but cannot guarantee, that it will have sufficient COVID-19 attributable expenses and lost revenues to retain the PHSSEF payments it has received to date. The Company will not be able to determine the amount of used funds until the reporting rules are finalized by the federal government, and the Company knows the full extent of its COVID-19 attributable expenses and lost revenues. The Company can offer no assurance that it will be in compliance with all requirements related to retaining the PHSSEF payments. If we fail to appropriately comply with all of the terms and conditions or do not have sufficient expenses and lost revenues (as defined by these programs), the Company may be required to repay some or all of these amounts, which could have a material adverse impact.
The CARES Act and related legislation also make available or expanded other forms of financial assistance for healthcare providers. For example, the CARES Act provides for Medicare and Medicaid payment adjustments and an expansion of the Medicare Accelerated and Advance Payment Program, which made available accelerated payments of Medicare funds in order to increase cash flow to providers. CMS is no longer accepting applications for accelerated or advanced payments. The Company did not elect to participate in this program. In addition, the CARES Act and related legislation suspend the Medicare sequestration from May 1, 2020 through December 31, 2021, which would have otherwise reduced payments to Medicare providers by 2%, as required by the Budget Control Act of 2011, but also extended sequestration through 2030. The ARPA increases the federal budget deficit in a manner that triggers an additional statutorily mandated sequestration under the PAYGO Act. As a result, absent congressional action, Medicare spending will be reduced by up to 4 percentage points in FY 2022, in addition to the existing sequestration requirements of the Budget Control Act of 2011.
23


The Company is continuing to evaluate and consider the potential impact that the COVID-19 public health emergency may have on its liquidity, financial condition and results of operations due to numerous uncertainties. We also continue to assess the potential impact of the CARES Act, other enacted legislation, and other stimulus measures, if any, as well as the impact of other laws, regulations, and guidance related to COVID-19 on our business, results of operations, financial condition and cash flows. Given the uncertainty as to the duration and severity of the COVID-19 pandemic, it could have a material adverse effect on the Company's future results of operations, financial condition and liquidity.
Strategic Operating Initiatives
We identified several key strategic objectives to increase shareholder value through improved operations and business development. These strategic operating initiatives include: improving our facilities' quality metrics, improving skilled mix in our nursing centers, improving our average Medicare rate, implementing and maintaining Electronic Medical Records (“EMR”) to improve Medicaid capture, and completing strategic acquisitions and divestitures. We have experienced success in these initiatives and expect to continue to build on these improvements.
Improving skilled mix and average Medicare rate:
One of our key performance indicators is skilled mix. Our strategic operating initiatives of improving our skilled mix and our average Medicare rate required investing in nursing and clinical care to treat more acute patients along with nursing center-based marketing representatives to attract these patients. These initiatives developed referral and Managed Care relationships that have attracted and are expected to continue to attract payor sources for patients covered by Medicare and Managed Care. The Company's skilled mix for the three months ended March 31, 2021 and 2020 was 18.9% and 13.7%, respectively. The increase in skilled mix is due in part to the impact of COVID-19 on our patients and residents and the related skilled in place wiaver issued by CMS relative to the pandemic. For the past several years, census and skilled mix trends have been affected by healthcare reforms resulting in lower lengths of stay among our skilled patient population and lower admissions caused by initiatives among acute care providers, managed care payors and conveners to divert certain skilled nursing referrals to home health or other community-based care settings.
Utilizing Electronic Medical Records to improve Medicaid acuity capture:
As another part of our strategic operating initiatives, all of our nursing centers utilize EMR to improve Medicaid acuity capture, primarily in our states where the Medicaid payments are acuity based. By using EMR, we have increased our average Medicaid rate in certain acuity based states by accurate and timely capture of care delivery.
Completing strategic transactions and other business developments:
Our strategic operating initiatives include a focus on completing strategic acquisitions and divestitures. We continue to pursue and investigate opportunities to acquire or lease new centers, focusing primarily on opportunities within our existing geographic areas of operation. As part of our strategic efforts, we routinely perform thorough analyses on our existing centers in order to determine whether continuing operations within certain markets or regions is in line with the short-term and long-term strategy of the business. Additionally, we have expanded our participation in certain state sponsored quality incentive programs that reward providers for achievement of certain quality measures.
On December 1, 2020, the Company entered into an agreement with Omega Healthcare Investors ("Omega") to transfer operations of the facility located in Florida to another operator. The agreement effectively amended the Master Lease Agreement between the Company and Omega, dated October 1, 2018 (the "Omega Master Lease") to remove this center, reduced annual rent expense, and released the Company from further obligations arising under the Omega Master Lease with respect to the Florida facility.
Effective November 1, 2020, the Company entered into agreements with a third party therapy company to outsource the therapy services that have been provided by the Company through its wholly owned subsidiary Diversicare Therapy Services. The outsourced services include all physical, occupational, and speech therapy provided to patients of the Company’s facilities. The contracts are for a three year term, absent termination for cause by either party. The third party provider has extensive expertise in providing therapy, and the Company believes that the therapy company’s expertise in this area will benefit our patients and result in an overall operational cost savings for the Company.
During 2019, the Company expanded its participation in the Texas Quality Incentive Program ("QIPP") as administered by the Texas Health and Human Services Commission. QIPP provides supplemental Medicaid payments for skilled nursing centers that achieve certain quality measures. The Company previously had one of its Texas skilled nursing centers participating in the QIPP. During April 2019, the Company enrolled an additional eleven of its Texas skilled nursing centers in the program, such that twelve of the Company’s centers participate in the QIPP effective September 1, 2019. To allow four of these centers to meet the QIPP participation requirements, the Company entered into a transaction with a Texas medical district already participating in the QIPP, providing for the transfer of the related provider licenses from the Company to the medical district. The Company’s operating subsidiary retained the management of the centers on behalf of the medical district. In response to the
24


COVID-19 pandemic, the Texas Health and Human Services Commission waived some of the performance and reporting requirements for QIPP effective March 1, 2020 through the remainder of the state fiscal year 2021.
Basis of Financial Statements
Our patient revenues consist of the fees charged for the care of patients in the nursing centers we own and lease. Our other operating income consists of Medicare stimulus funds recognized. Our operating expenses include the costs, other than lease, professional liability, depreciation and amortization expenses, incurred in the operation of the nursing centers we own and lease. Our general and administrative expenses consist of the costs of the corporate office and regional support functions. Our interest, depreciation and amortization expenses include all such expenses across the range of our operations.
Critical Accounting Policies and Judgments
A “critical accounting policy” is one which is both important to the understanding of our financial condition and results of operations and requires management’s most difficult, subjective or complex judgments often involving estimates of the effect of matters that are inherently uncertain. Actual results could differ from those estimates and cause our reported net income or loss to vary significantly from period to period. Our critical accounting policies are more fully described in our 2020 Annual Report on Form 10-K.
Revenue Sources
We classify our revenues from patients and residents into four major categories: Medicaid, Medicare, Managed Care, and Private Pay and other. Medicaid revenues are composed of the traditional Medicaid and Managed Medicaid programs established to provide benefits to those in need of financial assistance in the securing of medical services. Medicare revenues include revenues received under both Part A and Part B of the Medicare program. Managed Care revenues include payments for patients who are insured by a third-party entity, typically called a Health Maintenance Organization, often referred to as an HMO plan, or are Medicare beneficiaries who assign their Medicare benefits to a Managed Care replacement plan often referred to as Medicare replacement products. The Private Pay and other revenues are composed primarily of individuals or parties who directly pay for their services. Included in the Private Pay and other payors are patients who are hospice beneficiaries as well as the recipients of Veterans Administration benefits. Veterans Administration payments are made pursuant to renewable contracts negotiated with these payors.
The Company recognized $3.8 million and $0.3 million of Medicaid and Hospice stimulus dollars, respectively, for the three month period ended March 31, 2021 that are reflected as patient revenues from Medicaid and Private Pay and Other, respectively, in the Company's results of operations. Refer to Note 4, "COVID-19 Pandemic" to the interim consolidated financial statements included in this report for more information. The following table summarizes revenue from contracts with customers by payor source from continuing operations for the periods presented (dollar amounts in thousands).
Three Months Ended March 31,
20212020
Medicaid$49,955 44.1 %$54,330 45.3 %
Medicare24,458 21.6 %20,672 17.2 %
Managed Care13,676 12.1 %12,596 10.5 %
Private Pay and other25,271 22.2 %32,389 27.0 %
Total$113,360 100.0 %$119,987 100.0 %

The following table sets forth average daily skilled nursing census by primary payor source for our continuing operations for the periods presented: 
 Three Months Ended March 31,
 20212020
Medicaid3,126 65.2 %3,818 68.2 %
Medicare612 12.8 %504 9.0 %
Managed Care
293 6.1 %265 4.7 %
Private Pay and other761 15.9 %1,015 18.1 %
Total4,792 100.0 %5,602 100.0 %
Consistent with the nursing home industry in general, changes in the mix of a facility’s patient population among Medicaid, Medicare, Managed Care, and Private Pay and other can significantly affect the profitability of the facility’s operations.
25


Health Care Industry
The health care industry is subject to numerous laws and regulations of federal, state, and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government health care program participation requirements, reimbursement for patient services, quality of patient care and Medicare and Medicaid fraud and abuse. Over the last several years, government activity has increased with respect to investigations and allegations concerning possible violations by health care providers of a number of statutes and regulations, including those regulating fraud and abuse, false claims, patient privacy and quality of care issues. Violations of these laws and regulations could result in exclusion from government health care programs, significant fines and penalties, as well as significant repayments for patient services previously billed. Compliance with such laws and regulations is subject to ongoing government review and interpretation. The Company is involved in regulatory actions of this type from time to time.
In recent years, the U.S. Congress and some state legislatures have considered and enacted significant reforms affecting the availability, payment and reimbursement of healthcare services in the United States. Reforms that we believe may have a material impact on the long-term care industry and on our business include, among others, possible modifications to the conditions of qualification for payment, bundling of payments to cover both acute and post-acute care and the imposition of enrollment limitations on new providers. The most prominent of the federal legislative reform efforts, the Affordable Care Act, affects how health care services are covered, delivered and reimbursed. The Affordable Care Act expands coverage through a combination of public program expansion and private sector reforms, provides for reduced growth in Medicare program spending, and promotes initiatives that tie reimbursement to quality and care coordination. Some of the provisions, such as the requirement that large employers provide health insurance benefits to full-time employees, have increased our operating expenses. The Affordable Care Act expands the role of home-based and community services, which may place downward pressure on our sustaining population of Medicaid patients. However, there is considerable uncertainty regarding the future of the Affordable Care Act. The law has been subject to legislative and regulatory changes and court challenges, and although the current presidential administration has indicated its intent to protect the Affordable Care Act, it is possible that there may be continued changes to the law, its implementation or its interpretation. For example, effective January 1, 2019, Congress eliminated the financial penalty associated with the individual mandate. As a result of this change, a federal judge in Texas ruled in December 2018 that the individual mandate was unconstitutional and determined that the rest of the Affordable Care Act was, therefore, invalid. In December 2019, the Fifth Circuit Court of Appeals upheld this decision with respect to the individual mandate, but remanded for further consideration of how this affects the rest of the law. In November 2020, the U.S. Supreme Court heard oral arguments regarding this case, and the law remains in place pending a decision.
Skilled nursing centers are required to bill Medicare on a consolidated basis for certain items and services that they furnish to patients, regardless of the cost to deliver these services. This consolidated billing requirement essentially makes the skilled nursing center responsible for billing Medicare for all care services delivered to the patient during the length of stay. CMS has instituted a number of test programs designed to extend the reimbursement and financial responsibilities under consolidating billing beyond the traditional discharge date to include a broader set of bundled services. Such examples may include, but are not exclusive to, home health, durable medical equipment, home and community based services, and the cost of re-hospitalizations during a specified bundled period. Currently, these test programs for bundled reimbursement are confined to a small set of clinical conditions, but CMS has indicated that it is developing additional bundled payment models. This bundled form of reimbursement could be extended to a broader range of diagnosis related conditions in the future. The potential impact on skilled nursing center utilization and reimbursement is currently unknown. The process for defining bundled services has not been fully determined by CMS and is therefore subject to change during the rulemaking process. CMS has indicated that it is working toward a unified payment system for post-acute care services, including those provided by skilled nursing centers.
On August 7, 2019, CMS issued a final rule outlining Medicare payment rates for skilled nursing facilities that became effective October 1, 2019. CMS projects that aggregate payments to skilled nursing facilities will increase by 2.4%, reflecting a skilled nursing facility market basket percentage update of 2.8% with a 0.4 percentage point reduction for the multifactor productivity adjustment. In addition, the Patient-Driven Payment Model ("PDPM") took effect October 1, 2019. The PDPM is a payment system for patients in a covered Medicare Part A skilled nursing facility stay that replaces the Resource Utilization Group ("RUG-IV") model, which primarily used volume of services as the basis for payment classification. The PDPM model instead classifies patients into payment groups based on specific patient characteristics and shifts the focus away from paying for the volume of services provided. CMS will use a budget neutrality factor to satisfy the requirement that PDPM be budget neutral relative to RUG-IV. CMS stated that it intends for the new model not to change the aggregate amount of Medicare payments to skilled nursing facilities, but to more accurately reflect resource utilization.
On July 31, 2020, CMS issued a final rule outlining Medicare payment rates for skilled nursing facilities for federal fiscal year 2021. Effective October 1, 2020, payments to skilled nursing facilities are estimated to increase by 2.2% based on a market basket percentage update of 2.2%, adjusted by a 0.0 percentage point multifactor productivity adjustment.
CMS publishes nursing home rankings based on performance scores on the Care Compare website, which is intended to assist the public in finding and comparing providers. The Care Compare website publishes for each nursing home a rating between 1
26


and 5 stars as part of CMS’s Five-Star Quality Rating System. An overall star rating is determined based on three components (information from the last three years of health inspections, staffing information, and quality measures), each of which also has its own five-star rating. The ratings are based, in part, on the quality data nursing centers are required to report. For example, nursing centers must report the rate of short-stay residents who are successfully discharged into the community and the percentage who had an outpatient emergency department visit. As a result of the COVID-19 pandemic, CMS issued temporary waivers and flexibilities that impact the information posted on the Care Compare website and used in the Five-Star Quality Rating System. For example, CMS temporarily waived the requirement to submit staffing data and issued guidance prioritizing or suspending certain nursing home surveys. Some of these measures have been lifted, while some are subject to phased re-opening criteria. However, due to these changes and their impact on data, CMS is adjusting some ratings (e.g., by holding specific quality measures constant). In addition to the standard Care Compare data, CMS is posting COVID-19 data submitted by nursing homes on the CDC National Healthcare Safety Network and linking to this information from the Care Compare website. The information posted includes the reported number of confirmed and suspected cases of COVID-19 in each facility, resident deaths related to COVID-19, availability of personal protective equipment and COVID-19 testing, and potential staffing shortages.
We remain diligent in continuing to provide outstanding patient care to achieve high rankings for our centers, as well as assuring that our rankings are correct and appropriately reflect our quality results. Our focus has been and continues to be on the delivery of quality care to our patients and residents.
Contractual Obligations and Commercial Commitments
We have certain contractual obligations of continuing operations as of March 31, 2021, summarized by the period in which payment is due, as follows (dollar amounts in thousands):
Contractual ObligationsTotalLess than
1  year
1 to 3
Years
3 to 5
Years
After
5 Years
Long-term debt obligations (1)
$69,125 $5,052 $64,064 $$— 
Settlement obligations (2)
3,518 3,518 — — — 
Settlement of civil investigative demand (3)
8,529 1,180 4,281 3,068 — 
Operating leases (4)
392,547 51,408 105,653 107,308 128,178 
Required capital expenditures under operating leases (5)
14,788 1,935 3,869 3,869 5,115 
Total$488,507 $63,093 $177,867 $114,254 $133,293 
 
(1)Long-term debt obligations include scheduled future payments of principal and interest of long-term debt and amounts outstanding on our finance lease obligations. Our long-term debt obligations decreased $1.2 million between December 31, 2020 and March 31, 2021. See Note 6, "Long-Term Debt" to the interim consolidated financial statements included in this report for additional information.
(2)Settlement obligations relate to professional liability cases that are expected to be paid. The professional liabilities are included in our self-insurance reserves.
(3)Settlement of civil investigative demand relates to our settlement agreement, including interest, with the U.S. Department of Justice and the State of Tennessee. See additional description of our contingencies in Note 8 "Commitments and Contingencies" to the interim consolidated financial statements and "Item 1. Legal Proceedings."
(4)Represents minimum annual undiscounted lease payments (exclusive of taxes, insurance, and maintenance costs) under our operating lease agreements, which does not include renewals. Our operating lease obligations decreased $12.7 million between December 31, 2020 and March 31, 2021. See Note 8, "Leases," to the interim consolidated financial statements included in this report for additional information.
(5)Includes annual expenditure requirements under operating leases. Our required capital expenditures decreased $0.8 million between December 31, 2020 and March 31, 2021.

Employment Agreements
We have employment agreements with certain members of management that provide for the payment to these members of amounts up to two times their annual salary in the event of a termination without cause, a constructive discharge (as defined therein), or upon a change of control of the Company (as defined therein). The maximum contingent liability under these agreements is approximately $1.6 million as of March 31, 2021. The terms of such agreements are for one year and automatically renew for one year if not terminated by us or the employee.

27


Results of Continuing Operations
The following tables present the unaudited interim consolidated statements of operations and related data for the three month period ended March 31, 2021 and 2020:
 
(in thousands)Three Months Ended March 31,
 20212020Change%
PATIENT REVENUES, NET$113,360 $119,987 $(6,627)(5.5)%
OTHER OPERATING INCOME11,321 — 11,321 100.0 %
EXPENSES:
Operating96,829 94,859 1,970 2.1 %
Lease and rent expense13,249 13,512 (263)(1.9)%
Professional liability2,083 1,839 244 13.3 %
General and administrative6,765 6,758 0.1 %
Depreciation and amortization2,295 2,288 0.3 %
Total expenses121,221 119,256 1,965 1.6 %
OPERATING INCOME 3,460 731 2,729 N/M
OTHER INCOME (EXPENSE):
Other income39 115 (76)(66.1)%
Interest expense, net(1,022)(1,460)438 30.0 %
Total other expenses(983)(1,345)362 26.9 %
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES2,477 (614)3,091 N/M
(PROVISION) BENEFIT FOR INCOME TAXES(343)104 (447)(429.8)%
INCOME (LOSS) FROM CONTINUING OPERATIONS$2,134 $(510)$2,644 N/M
N/M = Not Meaningful

Percentage of Total Patient Revenues Three Months Ended March 31,
 20212020
PATIENT REVENUES, NET100.0 %100.0 %
OTHER OPERATING INCOME10.0 — 
EXPENSES:
Operating85.4 79.1 
Lease and rent expense11.7 11.3 
Professional liability1.8 1.5 
General and administrative6.0 5.6 
Depreciation and amortization2.0 1.9 
Total expenses106.9 99.4 
OPERATING INCOME 3.1 0.6 
OTHER INCOME (EXPENSE):
Other income— 0.1 
Interest expense, net(0.9)(1.2)
Total other expenses(0.9)(1.1)
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES2.2 (0.5)
BENEFIT (PROVISION) FOR INCOME TAXES(0.3)0.1 
INCOME (LOSS) FROM CONTINUING OPERATIONS1.9 %(0.4)%
28


Three Months Ended March 31, 2021 Compared To Three Months Ended March 31, 2020
Patient Revenues
Patient revenues were $113.4 million and $120.0 million for the three months ended March 31, 2021 and 2020, respectively, a decrease of $6.6 million.
Our same store Medicaid, Medicare and Managed Care rates for the first quarter of 2021 increased 0.3%, 3.2% and 6.2%, respectively, resulting in a revenue increase of $0.4 million, $0.2 million and $0.7 million, respectively. Our Medicare and Managed care census for the first quarter of 2021 increased 23.0% and 11.3%, respectively, due in part to the impact of COVID-19 on our patients and residents and related skilled in place waiver issued by CMS relative to the pandemic, resulting in increased revenue of $5.1 million and $1.1 million, respectively. Conversely, our Medicaid, Private and Hospice average daily census for the first quarter of 2021 decreased 16.9%, 22.7% and 25.1%, respectively, resulting in reduced revenue of $10.7 million, $1.8 million and $2.3 million, respectively. The decline in census for the first quarter of 2021 was mainly due to the impact of the COVID-19 pandemic. We recognized Medicaid and Hospice state stimulus funds of $3.8 million and $0.3 million, respectively, during the first quarter of 2021. Additionally, the suspension of sequestration resulted in an increase in revenue of $0.8 million. for the first quarter of 2021. The QIPP and Intergovernmental Transfer ("IGT") programs resulted in $0.6 million of additional revenues for the first quarter of 2021. One less day of revenues for the first quarter of 2021 compared to the first quarter of 2020 resulted in $1.2 million less revenue.
The following table summarizes key revenue and census statistics for continuing operations for each period:
 
 Three Months Ended March 31,
 2021 2020
Skilled nursing occupancy66.1 %76.4 %
As a percent of total census:
Medicare census12.8 %9.0 %
Medicaid census65.2 %68.2 %
Managed Care census6.1 %4.7 %
As a percent of total revenues:
Medicare revenues21.6 %17.2 %
Medicaid revenues44.1 %45.3 %
Managed Care revenues12.1 %10.5 %
*Average rate per day:
Medicare$502.48   $487.01 
Medicaid$181.90   $181.31 
Managed Care$415.72   $391.34 
*Excludes COVID-19 federal and state stimulus payments

Other Operating Income
Since January 1, 2020, we have received $51.6 million of provider relief from the CARES Act, PPHCE Act, and the Families First Coronavirus Response Act. We recognized $10.5 million of the funds during the first quarter of 2021, which is classified as "Other Operating Income" in the Company's results of operations. We also recognized $0.8 million of grant funds from states, which is included in "Other Operating Income" in the Company's results of operation for the three months ended March 31, 2021. The Medicare stimulus funds that we recognized during the quarter were used to offset healthcare-related expenses and lost revenues attributable to COVID-19. Increased healthcare related expenses included but were not limited to increased wages and increased costs for personal protective equipment, testing and other supplies. Refer to Note 4, "COVID-19 Pandemic" to the interim consolidated financial statements.
Operating Expense
Operating expense increased in the first quarter of 2021 to $96.8 million from $94.9 million in the first quarter of 2020, an increase of $1.9 million. Operating expense increased as a percentage of patient revenues to 85.4% for the first quarter of 2021 as compared to 79.1% for the first quarter of 2020.
The primary driver for the increase in operating expense was incremental healthcare-related expenses attributable to COVID-19 of $12.0 million. Such expenses included increased labor expenses, testing and the increased costs of personal protective
29


equipment, food and infection control supplies. Excluding the increased healthcare-related expenses attributable to COVID-19, we benefited from our cost saving initiatives that favorably impacted certain clinical labor costs and nursing and ancillary costs in addition to decreased health insurance costs.
Lease Expense
Lease expense in the first quarter of 2021 decreased to $13.2 million as compared to $13.5 million in the first quarter of 2020, a decrease of $0.3 million. The decrease in lease expense was due to the amendment to the Omega Master Lease in conjunction with the transfer of operations of the facility located in Florida.
Professional Liability
Professional liability expense was $2.1 million and $1.8 million in the first quarters of 2021 and 2020, respectively. Our cash expenditures for professional liability costs, including those relative to claims for the centers that we formerly operated in the State of Kentucky, were $1.5 million and $1.8 million for the first quarters of 2021 and 2020, respectively. Professional liability expense fluctuates based on the results of our third-party professional liability actuarial studies, premiums and cash expenditures are incurred to defend and settle existing claims. See “Liquidity and Capital Resources” for further discussion of the accrual for professional liability.
General and Administrative Expense
General and administrative expense remained consistent at $6.8 million in the first quarter of 2021 and in 2020.
Depreciation and Amortization
Depreciation and amortization expense remained consistent at $2.3 million in the first quarter of 2021 and in 2020.
Interest Expense, Net
Interest expense was $1.0 million in the first quarter of 2021 and $1.5 million in the first quarter of 2020. The decrease of $0.5 million was due to a decrease in the outstanding borrowings on our loan facilities.
Income from Continuing Operations before Income Taxes; Loss from Continuing Operations per Common Share
As a result of the above, continuing operations reported income of $2.5 million before income taxes for the first quarter of 2021 as compared to a loss of $0.6 million for the first quarter of 2020. The basic and diluted income per common share from continuing operations were $0.33 and $0.32 for the first quarter of 2021, respectively, compared to both basic and diluted loss per common share from continuing operations of $0.08 in the first quarter of 2020.
COVID-19 Impact on Continuing Operations
Since the end of the quarter, there have been additional cases of COVID-19 at certain of our centers. The Company has continued to experience reduced occupancy and increased operating expenses at its centers in the form of increased labor costs, testing and the increased cost of personal protective equipment, food and infection control supplies. The Company expects such increased expenses to continue throughout 2021.
Liquidity and Capital Resources
COVID-19 Impact on Liquidity
The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business. While the Company incurred significant disruptions since the start of the COVID-19 pandemic, it is unable to fully predict the impact that the COVID-19 pandemic will have on its liquidity, financial condition and results of operations due to numerous uncertainties. As a result of the COVID-19 pandemic, we have recognized less revenue and increased operating expenses, but we have received additional stimulus funds through the PHSSEF since the start of the pandemic, which have been used and are expected to continue to be used to mitigate the impact of the reduced revenues and increased operating expenses, and any cash flow or liquidity impacts therefrom. The increased operating expenses include increased labor costs, testing and the increased costs of personal protective equipment, food and infection control supplies. Refer to Note 4, "COVID-19 Pandemic" to the interim consolidated financial statements.
Liquidity
Our primary sources of liquidity are the net cash flow provided by the operating activities of our centers and draws on our revolving credit facility. We believe that these internally generated cash flows will be adequate to service existing debt obligations and fund required capital expenditures for twelve months after the date of issuance of these interim financial statements. In determining priorities for our cash flow, we evaluate alternatives available to us and select the ones that we believe will most benefit us over the long-term. Options for our use of cash include, but are not limited to, capital improvements, purchase of additional shares of our common stock, acquisitions, payment of existing debt obligations as well as
30


initiatives to improve nursing center performance. We review these potential uses and align them to our cash flows with a goal of achieving long-term success.
Net cash provided by operating activities of continuing operations totaled $3.4 million for the three months ended March 31, 2021, compared to net cash provided by operating activities of continuing operations of $2.7 million in the same period of 2020. The primary drivers of the increase in net cash provided by operating activities were income from continuing operations. A decrease in accounts receivable due to a decline in census as well as increased collections also contributed to the increase in cash provided by operating activities for the three months ended March 31, 2021 compared to March 31, 2020.
Our cash expenditures related to professional liability claims of continuing operations were $1.5 million and $1.8 million for the three months ended March 31, 2021 and 2020, respectively. Although we work diligently to limit the cash required to settle and defend professional liability claims, a significant judgment entered against us in one or more legal actions could have a material adverse impact on our cash flows and could result in our inability to meet all of our cash needs as they become due.
Investing activities of continuing operations used cash of $1.5 million and $0.9 million for the three months ended March 31, 2021 and 2020, respectively. The cash used for investing activities represents capital expenditures for improvements to our centers and purchases of clinical equipment to assist with fighting and slowing the spread of COVID-19.
Net cash used in financing activities of continuing operation were nearly zero for the three months ended March 31, 2021 and 2020.
Professional Liability
The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC, which has issued a policy insuring claims made against all of the Company's nursing centers in Florida and Tennessee, and several of the Company's nursing centers in Alabama, Ohio, and Texas, as well as those previously operated by the Company in Kentucky. The insurance coverage provided for these centers under the SHC policy provides coverage limits of at least $1.0 million per medical incident with a sublimit per center of $3.0 million and total annual aggregate policy limits of $5.0 million. All other centers within the Company's portfolio are covered through various commercial insurance policies which provide similar coverage limits per medical incident, per location, and on an aggregate basis for covered centers. The deductibles for these policies are covered through the insurance subsidiary.
As of March 31, 2021, we have recorded total liabilities for reported and settled professional liability claims and estimates for incurred, but unreported claims of $24.8 million. Our calculation of this estimated liability is based on the Company's best estimate of the likelihood of adverse judgments with respect to any asserted claim; however, a significant judgment could be entered against us in one or more of these legal actions, and such a judgment could have a material adverse impact on our financial position and cash flows.
Capital Resources
The Company maintains a credit facility with a syndicate of banks. The Company originally entered into the credit facility in May 2013, and subsequently amended the facility. As of December 31, 2019, the credit facility consisted of a mortgage loan of $67.5 million, an acquisition loan with a borrowing capacity of $12.5 million, a revolver with a borrowing capacity of $40.3 million and an affiliated revolver with a borrowing capacity of $2.0 million.
On October 14, 2020, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") with a syndicate of banks, which consists of a $62.0 million mortgage loan subsequently amended ("Amended Mortgage Loan"), a $36.0 million revolver subsequently amended ("Amended Revolver") and a $2.0 million affiliated revolver amended ("Amended Affiliated Revolver"). The Amended Mortgage Loan, Amended Revolver and Amended Affiliated Revolver have a 3-year maturity through September 30, 2023. The Amended Mortgage Loan has a term of 3 years, with principal and interest payable monthly based on a 25-year amortization. Interest on the term loan facility is based on LIBOR plus 4.0% with a 1.0% floor. The Amended Mortgage Loan balance was $60.8 million as of March 31, 2021 with an interest rate of 5.0%. The Amended Mortgage Loan consolidated the mortgage and acquisition loans. The Amended Mortgage Loan is secured by 15 owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan, the Amended Revolver and the Amended Affiliated Revolver are cross-collateralized and cross-defaulted. The Company’s Amended Revolver and Amended Affiliated Revolver have an interest rate of LIBOR plus 4.0% and are secured by accounts receivable and are subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.
As of March 31, 2021, we had $61.2 million of outstanding long-term debt and finance lease obligations. The $61.2 million total includes $0.4 million in finance lease obligations.
31


As of March 31, 2021 and December 31, 2020, the Company had no outstanding borrowings under its revolvers. The interest rate related to the revolvers was 5.0% as of March 31, 2021. Annual fees for letters of credit issued under the Amended Revolver are 3.0% of the amount outstanding. The Company has four letters of credit with a total value of $12.4 million outstanding as of March 31, 2021. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the Amended Revolver and the Amended Affiliated Revolver, and the maximum loan amount of $24.4 million for these revolvers, the balance available for borrowing under the revolvers was $12.0 million at March 31, 2021.
Our lending agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. We are in compliance with all such covenants at March 31, 2021.
Our calculated compliance with financial covenants is presented below:
 Requirement  Level at
March 31, 2021
Credit Facility:
Minimum fixed charge coverage ratio1.05:1.001.26:1.00
Minimum adjusted EBITDA$13.0 million$25.8 million
Mortgaged Centers:
EBITDAR$10.0 million$20.4 million
Affiliated Revolver:
Minimum adjusted EBITDA$0.8 million$2.1 million
Off-Balance Sheet Arrangements
We have four letters of credit outstanding with an aggregate value of approximately $12.4 million as of March 31, 2021. The letters of credit serve as a security deposits for certain center leases. These letters of credit were issued under our revolving credit facility. Our accounts receivable serve as the collateral for this revolving credit facility. 
Forward-Looking Statements
The foregoing discussion and analysis provides information deemed by management to be relevant to an assessment and understanding of our consolidated results of operations and financial condition. This discussion and analysis should be read in conjunction with our interim consolidated financial statements included herein. Certain statements made by or on behalf of us, including those contained in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere, are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those contemplated by the forward-looking statements made herein. Forward-looking statements are predictive in nature and are frequently identified by the use of terms such as "may," "will," "should," "expect," "believe," "estimate," "intend," and similar words indicating possible future expectations, events or actions. In addition to any assumptions and other factors referred to specifically in connection with such statements, other factors, many of which are beyond our ability to control or predict, could cause our actual results to differ materially from the results expressed or implied in any forward-looking statements including, but not limited to:
the potential adverse effect of the COVID-19 pandemic on the economy, our patients and residents and supply chain, including, changes in the occupancy of our centers, increased operation costs in addressing COVID-19, supply chain disruptions and uncertain demand, and the impact of any initiatives or programs that the Company may undertake to address financial and operations challenges faced by its patients served,
the duration and severity of the COVID-19 pandemic and the extent and severity of the impact on the Company's patients and residents,
actions governments take in response to the COVID-19 pandemic, including the introduction of public health measures and other regulations affecting our centers, and the timing, availability, and adoption of effective medical treatments and vaccines,
the impact of the CARES Act, the PPPHCE Act, the CAA and the ARPA and any other COVID-19 relief aid adopted by governments or the implementation or modifications to such acts, including any obligation of the Company to repay any stimulus payments received under such relief aid,
perceptions regarding the safety of senior living communities during and after the pandemic, changes in demand for senior living communities and our ability to adapt our sales and marketing efforts to meet the demand, changes in the acuity levels of our new residents, the disproportionate impact of COVID-19 on seniors generally and those residing in our communities,
32


increased regulatory requirements, including unfunded mandatory testing, increased enforcement actions resulting from COVID-19, including those that may limit our collection efforts for delinquent accounts and the frequency and magnitude of legal actions and liability claims that may arise due to COVID-19 or our response efforts,
our ability to successfully integrate the operations of new nursing centers, as well as successfully operate all of our centers,
our ability to increase census at our centers and occupancy rates at our centers,
changes in governmental reimbursement, including the Patient-Driven Payment Model that was implemented in October of 2019,
government regulation,
the impact of the Affordable Care Act, efforts to repeal or further modify the Affordable Care Act, and other health care reform initiatives,
any increases in the cost of borrowing under our credit agreements,
our ability to comply with covenants contained in those credit agreements,
our ability to comply with the terms of our master lease agreements,
our ability to renew or extend our leases at or prior to the end of the existing lease terms,
the outcome of professional liability lawsuits and claims,
our ability to control ultimate professional liability costs,
the accuracy of our estimate of our anticipated professional liability expense,
the impact of future licensing surveys,
our ability to comply with the terms of our Corporate Integrity Agreement,
the outcome of proceedings alleging violations of state or Federal False Claims Acts,
laws and regulations governing quality of care or other laws and regulations applicable to our business including HIPAA and laws governing reimbursement from government payors,
the costs of investing in our business initiatives and development,
our ability to control costs,
our ability to attract and retain qualified healthcare professionals,
changes to our valuation of deferred tax assets,
changing economic and competitive conditions,
changes in anticipated revenue and cost growth,
changes in the anticipated results of operations,
the effect of changes in accounting policies as well as others. 
Investors also should refer to the risks identified in this “Management's Discussion and Analysis of Financial Condition and Results of Operations” as well as risks identified in “Part I. Item 1A. Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2020 and in "Part II. Item 1A. Risk Factors" below, for a discussion of various risk factors of the Company and that are inherent in the health care industry. Given these risks and uncertainties, we can give no assurances that these forward-looking statements will, in fact, transpire and, therefore, caution investors not to place undue reliance on them. These assumptions may not materialize to the extent assumed, and risks and uncertainties may cause actual results to be different from anticipated results. These risks and uncertainties also may result in changes to the Company’s business plans and prospects. Such cautionary statements identify important factors that could cause our actual results to materially differ from those projected in forward-looking statements. In addition, we disclaim any intent or obligation to update these forward-looking statements.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The chief market risk factor affecting our financial condition and operating results is interest rate risk. As of March 31, 2021, we had outstanding borrowings of approximately $60.8 million, which was subject to variable interest rates.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
As required by Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended (the Exchange Act), our management, including our chief executive officer and chief financial officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)) as of March 31, 2021. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed
33


in our reports filed or submitted under the Exchange Act, such as this Quarterly Report on Form 10-Q, is properly recorded, processed, summarized and reported within the time periods required by the Securities and Exchange Commission’s rules and forms. Management necessarily applied its judgment in assessing the costs and benefits of such controls and procedures that, by their nature, can provide only reasonable assurance regarding management’s control objectives. Management does not expect that its disclosure controls and procedures will prevent all errors and fraud. A control system, irrespective of how well it is designed and operated, can only provide reasonable assurance, and cannot guarantee that it will succeed in its stated objectives.
Based on an evaluation of the effectiveness of the design and operation of disclosure controls and procedures, our chief executive officer and chief financial officer concluded that, as of March 31, 2021, our disclosure controls and procedures were effective in reaching a reasonable level of assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time period specified in the Securities and Exchange Commission’s rules and forms.
Changes in Internal Control Over Financial Reporting
There have been no changes to our internal control over financial reporting during the quarter ended March 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

34


PART II — OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS.
The provision of health care services entails an inherent risk of liability. Participants in the health care industry are subject to lawsuits alleging malpractice, negligence, violations of false claims acts, product liability, or related legal theories, many of which involve large claims and significant defense costs. Like many other companies engaged in the long-term care profession in the United States, we have numerous pending liability claims, disputes and legal actions for professional liability and other related issues. It is expected that we will continue to be subject to such suits as a result of the nature of our business. Further, as with all health care providers, we are periodically subject to regulatory actions seeking fines and penalties for alleged violations of health care laws and are potentially subject to the increased scrutiny of regulators for issues related to compliance with health care fraud and abuse laws and with respect to the quality of care provided to residents of our facilities. Like other health care providers, in the ordinary course of our business, we are also subject to claims made by employees and other disputes and litigation arising from the conduct of our business.
As of March 31, 2021, we are engaged in 79 professional liability lawsuits. Twenty-one lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The ultimate results of any of our professional liability claims and disputes cannot be predicted. We have limited, and sometimes no, professional liability insurance with regard to most of these claims. A significant judgment entered against us in one or more of these legal actions could have a material adverse impact on our financial position and cash flows.
In February 2020, we entered into a settlement agreement with the U.S. Department of Justice and the State of Tennessee of actions alleging violations of the federal False Claims Act in connection with our provision of therapy and the completion of certain resident admission forms. This settlement resolved an investigation that had begun in 2012 and covers the time period from January 1, 2010 through December 31, 2015. This agreement requires material annual payments for a period of five years ending in February 2025 and also requires a contingent payment in the event the Company sells any of its owned facilities during the five year payment period. Failure to timely make any of these payments could result in rescission of the settlement and result in the government having a very large claim against us, including penalties, and/or make us ineligible to participate in certain government funded healthcare programs, any of which could in turn significantly harm our business and financial condition.
In conjunction with the settlement of the government investigation related to our therapy practices, we entered into a corporate integrity agreement (the "CIA") with the Office of the Inspector General of CMS. The CIA has a term of five years and imposes material burdens on the Company, its officers and directors to take actions designed to insure compliance with applicable healthcare laws, including requirements to maintain specific compliance positions within the Company, to report any non-compliance with the terms of the CIA, to return any overpayments received, to submit annual reports and for an annual audit of submitted claims by an independent review organization. The CIA sets forth penalties for non-compliance by the Company with the terms of the agreement, including possible exclusion from federally funded healthcare programs for material violations of the CIA.
In January 2009, a purported class action complaint was filed in the Circuit Court of Garland County, Arkansas against the Company and certain of its subsidiaries and Garland Nursing & Rehabilitation Center (the “Center”). The Company answered the original complaint in 2009, and there was no other activity in the case until May 2017. At that time, plaintiff filed an amended complaint asserting new causes of action. The amended complaint alleges that the defendants breached their statutory and contractual obligations to the patients of the Center over a multi-year period by failing to meet minimum staffing requirements, failing to otherwise adequately staff the Center and failing to provide a clean and safe living environment in the Center. The Company filed an answer to the amended complaint denying plaintiffs’ allegations and asked the Court to dismiss the new causes of action asserted in the amended complaint because the Company was prejudiced by plaintiff’s long delay in filing the amended complaint. The Court has not yet ruled on the motion to dismiss, so the lawsuit remains in its early stages and has not yet been certified by the court as a class action. The Company intends to defend the lawsuit vigorously.
We cannot currently predict with certainty the ultimate impact of any of the above cases on our financial condition, cash flows or results of operations. An unfavorable outcome in any of these lawsuits, any of our professional liability actions, any regulatory action, or any investigation or lawsuit alleging violations of fraud and abuse laws or of elderly abuse laws or any state or Federal False Claims Act law could subject us to fines, penalties and damages, including exclusion from the Medicare or Medicaid programs, and could have a material adverse impact on our financial condition, cash flows or results of operations.
ITEM 1A. RISK FACTORS.
In addition to the other information set forth in this report, you should carefully consider the risks and uncertainties discussed in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2020, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be not material also may materially and adversely affect our business, financial condition and/or operating results. We are
35


including the following revised risk factor, which updates and supersedes the corresponding risk factor disclosed in our Annual Report on Form 10-K for the year ended December 31, 2020, which should be read in conjunction with our description of risk factors in Part I, Item 1A, "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2020:
Changes in the method of determining LIBOR, or the replacement of LIBOR with an alternative reference rate, may adversely affect interest rates on our current or future indebtedness and may otherwise adversely affect our financial condition and results of operations.
On March 5, 2021, the Financial Conduct Authority (“FCA”) announced that USD LIBOR will no longer be published after June 30, 2023. This announcement has several implications, including setting the spread that may be used to automatically convert contracts from LIBOR to the Secured Overnight Financing Rate ("SOFR"). Additionally, banking regulators are encouraging banks to discontinue new LIBOR debt issuances by December 31, 2021.
The Company anticipates that LIBOR will continue to be available at least until June 30, 2023. Any changes adopted by the FCA or other governing bodies in the method used for determining LIBOR may result in a sudden or prolonged increase or decrease in reported LIBOR. If that were to occur, our interest payments could change. In addition, uncertainty about the extent and manner of future changes may result in interest rates and/or payments that are higher or lower than if LIBOR were to remain available in its current form.
The Company has contracts that are indexed to LIBOR and is monitoring and evaluating the related risks, which include interest on loans, amounts paid on securities, or amounts paid on derivative instruments. These risks arise in connection with transitioning contracts to an alternative rate, including any resulting value transfer that may occur, and are likely to vary by contract. The value of loans, securities, or derivative instruments tied to LIBOR, as well as interest rates on our current or future indebtedness, may also be impacted if LIBOR is limited or discontinued. For some instruments the method of transitioning to an alternative reference rate may be challenging, especially if we cannot agree with the respective counterparty about how to make the transition.
While we expect LIBOR to be available in substantially its current form until at least the end of June 30, 2023, it is possible that LIBOR will become unavailable prior to that point. This could result, for example, if sufficient banks decline to make submissions to the LIBOR administrator. In that case, the risks associated with the transition to an alternative reference rate will be accelerated and magnified.
Alternative rates and other market changes related to the replacement of LIBOR, including the introduction of financial products and changes in market practices, may lead to risk modeling and valuation challenges, such as adjusting interest rate accrual calculations and building a term structure for an alternative rate.
The introduction of an alternative rate also may create additional basis risk and increased volatility as alternative rates are phased in and utilized in parallel with LIBOR.
Adjustments to systems and mathematical models to properly process and account for alternative rates will be required, which may strain the model risk management and information technology functions and result in substantial incremental costs for the company.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES.
None.
ITEM 4. MINE SAFETY DISCLOSURE.
Not applicable.
ITEM 5. OTHER INFORMATION.
None.

ITEM 6. EXHIBITS
The following exhibits are filed as part of this report on Form 10-Q.
36


Exhibit
Number
  Description of Exhibits
3.1   Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement No. 33-76150 on Form S-1 filed in paper - hyperlink is not required pursuant to Rule 105 of Regulation S-T).
  Certificate of Designation of Registrant (incorporated by reference to Exhibit 3.5 to the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2006).
3.3   Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement No. 33-76150 on Form S-1 filed in paper - hyperlink is not required pursuant to Rule 105 of Regulation S-T).
  Bylaw Amendment adopted November 5, 2007 (incorporated by reference to Exhibit 3.4 to the Company’s annual report on Form 10-K for the year ended December 31, 2007).
3.5   Amendment to Certificate of Incorporation dated March 23, 1995 (incorporated by reference to Exhibit A of Exhibit 1 to the Company’s Form 8-A filed March 30, 1995 filed in paper - hyperlink is not required pursuant to Rule 105 of Regulation S-T).
  Certificate of Designation of Registrant (incorporated by reference to Exhibit 3.4 to the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2001).
Certificate of Ownership and Merger of Diversicare Healthcare Services, Inc. with and into Advocat Inc. (incorporated by reference to Exhibit 3.1 to the Company's current report on Form 8-K filed March 14, 2013).
Amendment to Certificate of Incorporation dated June 9, 2016 (incorporated by reference to Exhibit 3.8 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2016).
Bylaw Second Amendment adopted April 14, 2016.
4.1 Form of Common Stock Certificate (incorporated by reference to Exhibit 4 to the Company's Registration Statement No. 33-76150 on Form S-1 filed in paper - hyperlink is not required pursuant to Rule 105 of Regulation S-T).
  Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).
  Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b).
101.INSInline XBRL Instance Document
101.SCH  Inline XBRL Taxonomy Extension Schema Document
101.CAL  Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB  Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE  Inline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

37


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
Diversicare Healthcare Services, Inc.
May 11, 2021 
By: 
/s/ James R. McKnight, Jr.
 James R. McKnight, Jr.
 President and Chief Executive Officer, Principal Executive Officer
 (duly authorized officer)
By: 
/s/ Kerry D. Massey
 Kerry D. Massey
 Executive Vice President and Chief Financial Officer
 (principal financial officer)
38
EX-31.1 2 dvcrex31133121certificatio.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATIONS PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
(i) CERTIFICATION
I, James R. McKnight, Jr., certify that:
1. I have reviewed this quarterly report on Form 10-Q of Diversicare Healthcare Services, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 11, 2021
 
/s/ James R. McKnight, Jr.
James R. McKnight, Jr.
President and Chief Executive Officer, Principal Executive Officer and
An Officer Duly Authorized to Sign on Behalf of the Registrant


EX-31.2 3 dvcrex31233121certificatio.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATIONS PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
(ii) CERTIFICATION
I, Kerry D. Massey, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Diversicare Healthcare Services, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:  May 11, 2021
/s/ Kerry D. Massey
Kerry D. Massey
Executive Vice President and Chief Financial Officer and
An Officer Duly Authorized to Sign on Behalf of the Registrant


EX-32 4 dvcrex3233121certification.htm EX-32 Document

Exhibit 32
CERTIFICATION OF QUARTERLY REPORT ON FORM 10-Q
OF DIVERSICARE HEALTHCARE SERVICES, INC.
FOR THE QUARTER ENDED MARCH 31, 2021
The undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the undersigned’s best knowledge and belief, the Quarterly Report on Form 10-Q for Diversicare Healthcare Services, Inc. (the “Company”) for the period ending March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”):
(a)fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(b)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
This Certification is executed as of May 11, 2021.

 
/s/ James R. McKnight, Jr.
James R. McKnight, Jr.
President and Chief Executive Officer, Principal Executive Officer and
An Officer Duly Authorized to Sign on Behalf of the Registrant
/s/ Kerry D. Massey
Kerry D. Massey
Executive Vice President and Chief Financial Officer and
An Officer Duly Authorized to Sign on Behalf of the Registrant
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.


EX-101.SCH 5 dvcr-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - INTERIM CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - INTERIM CONSOLIDATED STATEMENTS OF SHAREHOLDERS' DEFICIT link:presentationLink link:calculationLink link:definitionLink 1007008 - Statement - INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - BUSINESS link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - BUSINESS (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Policies) link:presentationLink link:calculationLink link:definitionLink 2105103 - Disclosure - RECENT ACCOUNTING GUIDANCE link:presentationLink link:calculationLink link:definitionLink 2106104 - Disclosure - COVID-19 PANDEMIC link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - COVID-19 PANDEMIC (Details) link:presentationLink link:calculationLink link:definitionLink 2108105 - Disclosure - REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE - Summary of Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 2112106 - Disclosure - LONG-TERM DEBT link:presentationLink link:calculationLink link:definitionLink 2413405 - Disclosure - LONG-TERM DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 2114107 - Disclosure - DERIVATIVES AND HEDGING ACTIVITIES link:presentationLink link:calculationLink link:definitionLink 2315302 - Disclosure - DERIVATIVES AND HEDGING ACTIVITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2416406 - Disclosure - DERIVATIVES AND HEDGING ACTIVITIES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2417407 - Disclosure - DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 2418408 - Disclosure - DERIVATIVES AND HEDGING ACTIVITIES - Derivative Instruments in Statement of Financial Position, Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2419409 - Disclosure - DERIVATIVES AND HEDGING ACTIVITIES - Effect Of Cash Flow Hedge Accounting On Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2120108 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 2321303 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 2422410 - Disclosure - LEASES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2423411 - Disclosure - LEASES - Balance Sheet Classification (Details) link:presentationLink link:calculationLink link:definitionLink 2424412 - Disclosure - LEASES - Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2425413 - Disclosure - LEASES - Maturities of Operating and Financing Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2425413 - Disclosure - LEASES - Maturities of Operating and Financing Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2426414 - Disclosure - LEASES - Other Lease Information (Details) link:presentationLink link:calculationLink link:definitionLink 2127109 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2428415 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 2129110 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 2330304 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2431416 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2432417 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Activity of Equity Compensation Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2433418 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock and Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2434419 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Awards Outstanding and Exercisable (Details) link:presentationLink link:calculationLink link:definitionLink 2135111 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 2436420 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 2137112 - Disclosure - EARNINGS PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 2338305 - Disclosure - EARNINGS PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 2439421 - Disclosure - EARNINGS PER COMMON SHARE - Basic and Diluted Net Income (Loss) Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 2440422 - Disclosure - EARNINGS PER COMMON SHARE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2141113 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 2442423 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 dvcr-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 dvcr-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 dvcr-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Grant of restricted common stock (in shares) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Document Type Document Type Common stock granted to CEO (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Trade accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Treasury Stock Treasury Stock [Member] Estimated insurance recovery receivables Estimated Insurance Recoveries Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Malpractice insurance annual sublimit per center Malpractice Insurance, Annual Sublimit Per Center Malpractice Insurance, Annual Sublimit Per Center Statistical Measurement [Domain] Statistical Measurement [Domain] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Amortization of finance lease assets Finance Lease, Right-of-Use Asset, Amortization DERIVATIVES AND HEDGING ACTIVITIES Derivative Instruments and Hedging Activities Disclosure [Text Block] Net cash used in continuing operations Net Cash Provided by (Used in) Investing Activities, Continuing Operations Number of owned nursing centers to secure Amended Mortgage Loan Debt Instrument, Collateral, Number Of Owned Nursing Centers Debt Instrument, Collateral, Number Of Owned Nursing Centers OPERATING INCOME Operating Income (Loss) Amortization of right-of-use assets Amortization Of Right-of-Use Asset Amortization Of Right-of-Use Asset Total current liabilities Liabilities, Current Purchases of property and equipment with stimulus funds Payments For Capital Grant Property Improvements, CARES Act Payments For Capital Grant Property Improvements, CARES Act Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Variable Rate [Domain] Variable Rate [Domain] Managed Care Managed Care [Member] Managed Care [Member] Net cash provided by continuing operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Variable Rate [Axis] Variable Rate [Axis] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Total lease payments Finance Lease, Liability, Payment, Due Second anniversary Share-based Payment Arrangement, Tranche Two [Member] Assets: Assets [Abstract] Accounting Policies [Abstract] Accounting Policies [Abstract] Trial Or Arbitration Schedule Timeframe [Axis] Trial Or Arbitration Schedule Timeframe [Axis] Trial Or Arbitration Schedule Timeframe [Axis] Health Care Organizations [Abstract] Health Care Organizations [Abstract] Issuance of equity grants, net Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Entity Address, State or Province Entity Address, State or Province Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Operating cash flows for operating leases Operating Lease, Payments Government settlement accrual Estimated Litigation Liability, Noncurrent Unusual or Infrequent Item, or Both [Line Items] Unusual or Infrequent Item, or Both [Line Items] Accumulated deficit Retained Earnings (Accumulated Deficit) Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Number of licensed nursing beds Number Of Licensed Nursing Beds Number of licensed nursing beds. Operating lease liabilities Increase (Decrease) In Operating Lease Liabilities Increase (Decrease) In Operating Lease Liabilities 2022 Lessee, Operating Lease, Liability, to be Paid, Year One 2022 Finance Lease, Liability, to be Paid, Year One 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four Long-term debt and finance lease obligations, less current portion and deferred financing costs, net Long-term Debt and Lease Obligation Amended And Restated Credit Agreement Amended And Restated Credit Agreement [Member] Amended and Restated Credit Agreement [Member] Range of exercise prices, minimum (in dollars per share) Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit Continuing operations (in dollars per share) Income (loss) from continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Net lease cost Lease, Cost Liability for workers compensation claims Workers' Compensation Liability Discontinued operations (in dollars per share) Loss from discontinued operations (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share OTHER COMPREHENSIVE INCOME (LOSS): Other Comprehensive Income (Loss), Net of Tax [Abstract] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Financing costs Payments of Financing Costs Other noncurrent liabilities Other Liabilities, Noncurrent $5.86 Stock Options Exercise Price Range Two [Member] Stock Options Exercise Price Range Two [Member] Financing cash flows for finance leases Finance Lease, Principal Payments Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition COVID-19, supplies expense Supplies Expense, Coronavirus Aid, Relief And Economic Security Act (CARES Act) Supplies Expense, Coronavirus Aid, Relief And Economic Security Act (CARES Act) PATIENT REVENUES, NET Revenue from Contract with Customer, Excluding Assessed Tax Third anniversary Share-based Payment Arrangement, Tranche Three [Member] 2023 Operating And Finance Lease, Liability, Payments Due Year Two Operating And Finance Lease, Liability, Payments Due Year Two Statement [Line Items] Statement [Line Items] 2022 Operating And Finance Lease, Liability Payments Due Year One Operating And Finance Lease, Liability Payments Due Year One Per common share – basic and diluted Earnings Per Share, Basic and Diluted [Abstract] Debt instrument term Debt Instrument, Term Self-insurance receivables Self-Insurance Receivables, Current Self-Insurance Receivables, Current Noncurrent loss accrual Loss Contingency, Accrual, Noncurrent Total leased assets Lease Right-of-Use Asset Lease Right-of-Use Asset Schedule of Lease Assets and Liabilities Assets And Liabilities Leases [Table Text Block] Assets and Liabilities Leases [Table Text Block] Statement [Table] Statement [Table] Statistical Measurement [Axis] Statistical Measurement [Axis] Weighted-average remaining lease term (years) Lessee Operating And Finance Lease Weighted Average Remaining Lease Term [Abstract] Lessee Operating and Finance Lease Weighted Average Remaining Lease Term [Abstract] Credit Facility [Axis] Credit Facility [Axis] Provision for leases in excess of cash payments Provision For Leases In Excess Of Cash Payments Provision For Leases In Excess Of Cash Payments Unusual or Infrequent Items, or Both [Abstract] Business Combinations [Abstract] Business Combinations [Abstract] Entity Small Business Entity Small Business Operating Leases Lessee, Operating Lease, Liability, Payment, Due [Abstract] Exercisable (in shares) Share Based Compensation Arrangement By Share Based Payment Award, Exercisable Number Share Based Compensation Arrangement By Share Based Payment Award, Exercisable Number Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] COVID-19, Hospice funds received Hospice Funds Received, Coronavirus Aid, Relief and Economic Security Act (CARES Act) Hospice Funds Received, Coronavirus Aid, Relief and Economic Security Act (CARES Act) Total revenues, as a percent Revenue From Contract With Customer, Including Assessed Tax, Percentage Revenue From Contract With Customer, Including Assessed Tax, Percentage Discontinued operations Cash Provided by (Used in) Financing Activities, Discontinued Operations Exercisable, weighted average exercise price (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Awards Exercisable Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Exercisable Weighted Average Exercise Price Number of Instruments Derivative, Number of Instruments Held Amendment Flag Amendment Flag Annual lease fixed escalators, percent Operating Lease, Annual Lease Fixed Escalators, Percent Operating Lease, Annual Lease Fixed Escalators, Percent Schedule of Basic and Diluted Net Income (Loss) Per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Summarized Activity of Equity Compensation Plans Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Affiliated Revolving Credit Agreement Affiliated Revolving Credit Agreement [Member] Affiliated Revolving Credit Agreement [Member] Shares authorized under the plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized LEASES Lessee, Finance Leases [Text Block] Payments made during period Loss Contingency Accrual, Payments Numerator: Income (loss): Income Amounts Attributable to Parent, Disclosures [Abstract] Self-insurance reserves, less current portion Self Insurance Reserve, Noncurrent Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Type and Tier Identifier [Domain] Type and Tier Identifier [Domain] Entity Central Index Key Entity Central Index Key Balance available for borrowing under revolving credit center Line of Credit Facility, Current Borrowing Capacity Current loss accrual Loss Contingency, Accrual, Current Accrued expenses: Accrued Liabilities, Current [Abstract] Less: Interest Operating And Finance Lease Liability Undiscounted Excess Amount Operating And Finance Lease Liability Undiscounted Excess Amount Derivative Instrument Risk [Axis] Derivative Instrument [Axis] Number of nursing centers Number Of Nursing Center Facilities Number Of Nursing Center Facilities Other noncurrent liabilities Other Noncurrent Liabilities [Member] Options/SOSARs Stock Options And Stock Appreciation Rights (SARs) [Member] Stock Options and Stock Appreciation Rights (SARs) [Member] Income tax refundable Income Taxes Receivable, Current Accounting Policies [Line Items] Accounting Policies [Line Items] [Line Items] for Accounting Policies [Table] Provision for self-insured professional liability, net of cash payments Increase (Decrease) in Self Insurance Reserve Other leases renewal term Lease extension period Lessee, Operating Lease, Renewal Term 2024 Operating And Finance Lease Liability Payments Due Year Three Operating And Finance Lease Liability Payments Due Year Three Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Schedule of Summarized Activity of Restricted Share Units Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] After 2025 Operating And Finance Lease Liability Payments Due After Year Four Operating And Finance Lease Liability Payments Due After Year Four Income Statement Location [Axis] Income Statement Location [Axis] Scheduled For Trial Or Arbitration Over Next Twelve Months [Domain] Scheduled For Trial Or Arbitration Over Next Twelve Months [Domain] Scheduled For Trial Or Arbitration Over Next Twelve Months Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Income Statement Location [Domain] Income Statement Location [Domain] 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two COVID-19, Medicaid sequestration amount Medicaid Sequestration, Amount, Coronavirus Aid, Relief And Economic Security Act (CARES Act) Medicaid Sequestration, Amount, Coronavirus Aid, Relief And Economic Security Act (CARES Act) CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] After 2025 Lessee, Operating Lease, Liability, To Be Paid, After Year Four Lessee, Operating Lease, Liability, To Be Paid, After Year Four Notional Derivative, Notional Amount Outstanding, beginning (in dollars per share) Outstanding, ending (in dollars per share) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Outstanding, Weighted-Average Grant Date Fair Value Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Outstanding, Weighted-Average Grant Date Fair Value Schedule of Lease Cost of Continuing Operations Lease, Cost [Table Text Block] Line of Credit Facility [Table] Line of Credit Facility [Table] Expired or cancelled (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Awards Forfeitures And Expirations In Period Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Forfeitures And Expirations In Period Weighted Average Exercise Price 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three Other noncurrent assets Other Assets, Noncurrent Plan Name [Axis] Plan Name [Axis] INCOME (LOSS) FROM CONTINUING OPERATIONS INCOME (LOSS) FROM CONTINUING OPERATIONS Income (loss) from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Total assets Assets Exercise Price Range [Domain] Exercise Price Range [Domain] Total other assets Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment Outstanding, beginning (in shares) Outstanding, ending (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Title of 12(b) Security Title of 12(b) Security Finance Leases Finance Lease, Liability, Payment, Due [Abstract] CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS Business Description and Basis of Presentation [Text Block] Chief Executive Officer Chief Executive Officer [Member] Vesting [Domain] Vesting [Domain] Schedule of Maturity of Finance Lease Liabilities Finance Lease, Liability, Fiscal Year Maturity [Table Text Block] Interest expense, net Interest expense Interest Expense Number of lease extensions allowed Operating Lease, Number Of Lease Extensions Allowed Operating Lease, Number Of Lease Extensions Allowed Product and Service [Axis] Product and Service [Axis] OTHER OPERATING INCOME Revenue Not from Contract with Customer Other noncurrent assets Other Noncurrent Assets [Member] Aggregate policy limit Malpractice Insurance, Annual Coverage Limit Less: Interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Net income (loss) Net Income (Loss) Available to Common Stockholders, Basic Insurance Type and Tier Identifier [Axis] Insurance Type and Tier Identifier [Axis] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Total lease liabilities Lease Liability Lease Liability Number of states in which entity operates Number of States in which Entity Operates Liability for reported claims and estimates for incurred but unreported claims Liability for Future Policy Benefit, before Reinsurance Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Debt Instrument [Axis] Debt Instrument [Axis] Paid-in Capital Additional Paid-in Capital [Member] 2008 Stock Purchase Plan Two Thousand And Eight Stock Purchase Plan [Member] Two Thousand And Eight Stock Purchase Plan [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Number of nursing center facilities leased Number Of Nursing Center Facilities Leased Number Of Nursing Center Facilities Leased Adjustments to reconcile income (loss) from continuing operations to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Balance (in shares) Balance (in shares) Shares, Issued Continuing operations (in dollars per share) Income (loss) from continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Litigation Case [Axis] Litigation Case [Axis] Interest on finance lease liabilities Finance Lease, Interest Expense Exercised (in dollars per share) Share Based Compensation Arrangements By Share Based Payment Award Awards Exercises In Period Weighted Average Exercise Price Share Based Compensation Arrangements By Share Based Payment Award Awards Exercises In Period Weighted Average Exercise Price Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Operating cash flows for finance leases Variable Lease, Payment Amended Revolver Revolving Credit Facility [Member] Number of letters of credit Number Of Letters Of Credit Number Of Letters Of Credit Letters of credit security deposit for a lease Letters of Credit Outstanding, Amount Common stock, shares authorized (in shares) Common Stock, Shares Authorized Dilutive effect of stock options, SOSARs, Restricted Shares and Restricted Share Units (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Current portion of long-term debt and finance lease obligations Long-term Debt and Lease Obligation, Current Income Statement [Abstract] Income Statement [Abstract] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Acquired leasehold interest, net Acquired Leasehold Interest, Net Noncurrent Acquired leasehold interest, net. Operating lease liabilities, less current portion Operating Lease, Liability, Noncurrent Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Number of licensed nursing beds per center Number Of Licensed Nursing Beds Per Nursing Center Number Of Licensed Nursing Beds Per Nursing Center Discontinued operations Cash Provided by (Used in) Operating Activities, Discontinued Operations CURRENT ASSETS: Assets, Current [Abstract] After 2025 Finance Lease, Liability, To Be Paid, After Year Four Finance Lease, Liability, To Be Paid, After Year Four Weighted-average discount rate Lessee Operating And Finance Lease Weighted Average Discount Rate [Abstract] Lessee Operating and Finance Lease Weighted Average Discount Rate [Abstract] Tax refund Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Income Tax Refund Received Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Income Tax Refund Received COMPREHENSIVE INCOME (LOSS) Comprehensive Income (Loss), Net of Tax, Attributable to Parent 2024 Finance Lease, Liability, to be Paid, Year Three SHC Risk Carriers, Inc SHC Risk Carriers, Inc [Member] SHC Risk Carriers, Inc [Member] Professional malpractice liability insurance Professional Malpractice Liability Insurance [Member] COVID-19, PHSSEF funds received Public Health And Social Services Emergency Funds Received, Coronavirus Aid, Relief And Economic Security Act (CARES Act) Public Health And Social Services Emergency Funds Received, Coronavirus Aid, Relief And Economic Security Act (CARES Act) Mortgage Loan Mortgage Loan [Member] Mortgage Loan Interest Rate Cap Interest Rate Cap [Member] COVID-19, PHSSEF revenue Public Health And Social Services Emergency Revenue, Coronavirus Aid, Relief and Economic Security Act (CARES Act) Public Health And Social Services Emergency Revenue, Coronavirus Aid, Relief and Economic Security Act (CARES Act) Counterparty Name [Domain] Counterparty Name [Domain] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment City Area Code City Area Code Cash paid for amounts included in the measurement of lease liabilities Cash Flow, Operating Activities, Lessee [Abstract] Document Period End Date Document Period End Date Loss on contract termination Interest Rate Cash Flow Hedge, Gain (Loss) from Contract Termination Interest Rate Cash Flow Hedge, Gain (Loss) from Contract Termination LONG-TERM DEBT Long-term Debt [Text Block] Outstanding related to settlement agreement Loss Contingency Accrual Shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Original lease term Lessee, Operating Lease, Term of Contract Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] 2021 Operating And Finance Lease, Liability, Payments, Remainder Of Fiscal Year Operating And Finance Lease, Liability, Payments, Remainder Of Fiscal Year Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Stock-based compensation Share-based Payment Arrangement, Noncash Expense Cover [Abstract] Base Rate Base Rate [Member] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Loans Payable Loans Payable [Member] Borrowings outstanding Long-term Debt Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Deferred income Increase (Decrease) in Contract with Customer, Liability LEASES Lessee, Operating Leases [Text Block] Operating and Finance Lease Liabilities Payments Due [Abstract] Operating And Finance Lease Liabilities Payments Due [Abstract] Operating and Finance Lease Liabilities Payments Due [Abstract] CIA term Corporate Integrity Agreement Term Corporate Integrity Agreement Term Operating Cost of Goods and Services Sold Finance lease cost: Lease, Cost [Abstract] Loss from discontinued operations Loss from discontinued operations, net of income taxes Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Total expenses Costs and Expenses Equity Components [Axis] Equity Components [Axis] Change in fair value Interest rate cash flow hedge Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Restricted Stock Restricted Shares Restricted Stock [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Amount of Gain (Loss) Recognized in Other Comprehensive Income on Derivative Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Present value of lease liabilities Operating And Finance Lease Liability Operating And Finance Lease Liability Minimum Minimum [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Professional liability Malpractice Loss Contingency, Premium Costs Property and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Current portion of operating lease liabilities Operating Lease, Liability, Current Summary of Lease Term and Discount Rate and Other Lease Information Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Restriction period Stock Based Compensation Arrangement By Share Based Payment Award Restriction Period Stock Based Compensation Arrangement By Share Based Payment Award Restriction Period Liability for reported and estimated future claims Malpractice Loss Contingency, Accrual, Undiscounted Period of amortization Line of Credit Facility, Terms, Duration Of Amortization Period For Principal And Interest Payments Line of Credit Facility, Terms, Duration Of Amortization Period For Principal And Interest Payments Cancelled (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Number of licensed assisted and residential living beds Number Of Licensed Assisted Living Beds Number Of Licensed Assisted Living Beds Entity Interactive Data Current Entity Interactive Data Current Schedule of Fair Value of Derivative Instruments Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Interest Rate Swap Interest Rate Swap [Member] Paid-in capital Additional Paid in Capital, Common Stock Entity Registrant Name Entity Registrant Name Derivative [Table] Derivative [Table] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Operating leases Operating Lease, Weighted Average Discount Rate, Percent Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Exercise Price Range [Axis] Exercise Price Range [Axis] Less: Interest Finance Lease, Liability, Undiscounted Excess Amount Scheduled for trial or arbitration over next 12 months Trial Or Arbitration Schedule Timeframe [Member] Trial Or Arbitration Schedule Timeframe [Member] Schedule of Malpractice Insurance [Table] Schedule of Malpractice Insurance [Table] Expired or cancelled (in shares) Share Based Compensation Arrangement By Share Based Payment Award, Forfeitures And Expirations In Period Share Based Compensation Arrangement By Share Based Payment Award, Forfeitures And Expirations In Period Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Accounts receivable Total accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Total lease payments Lessee, Operating Lease, Liability, to be Paid Medicaid and Hospice revenue Medicaid and Hospice Revenue, Coronavirus Aid, Relief and Economic Security Act (CARES Act) Medicaid and Hospice Revenue, Coronavirus Aid, Relief and Economic Security Act (CARES Act) Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Net cash used in continuing operations Net Cash Provided by (Used in) Financing Activities, Continuing Operations Acquisition Loan Acquisition Loan [Member] Acquisition Loan Entity Address, Postal Zip Code Entity Address, Postal Zip Code Percentage of quoted market price offering rate Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Repayment of debt and finance lease obligations Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security Document Transition Report Document Transition Report Title of Individual [Axis] Title of Individual [Axis] Asset Derivatives Derivative Asset, Fair Value, Gross Asset OTHER INCOME (EXPENSE): Nonoperating Income (Expense) [Abstract] Cash expenditures for self-insured professional liability costs Malpractice Insurance Self Insured Costs Paid During Period Malpractice Insurance Self Insured Costs Paid During Period Document Quarterly Report Document Quarterly Report Interest rate cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss) Including Termination, after Reclassification and Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss) Including Termination, after Reclassification and Tax Vesting [Axis] Vesting [Axis] Receivables Increase (Decrease) in Receivables Discontinued operations (in dollars per share) Loss from discontinued operations (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Strike rate Derivative, Fixed Interest Rate Deferred income Contract with Customer, Liability, Current Health insurance, maximum self-insured annual amount per individual Employee Health Insurance Maximum Payable Per Individual Annually Employee Health Insurance Maximum Payable Per Individual Annually Trade accounts payable Accounts Payable, Trade, Current Malpractice Insurance [Line Items] Malpractice Insurance [Line Items] Workers compensation insurance, non current receivable for excess premiums paid Workers Compensation Receivable For Excess Premiums Paid Workers Compensation Receivable For Excess Premiums Paid Credit Facility [Domain] Credit Facility [Domain] RECENT ACCOUNTING GUIDANCE Accounting Standards Update and Change in Accounting Principle [Text Block] Derivative Contract Type [Domain] Derivative Contract [Domain] Diluted (in shares) Adjusted weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Litigation Case [Domain] Litigation Case [Domain] Letter of Credit Letter of Credit [Member] Net income (loss) per common share – basic (in dollars per share) Earnings Per Share, Basic Other leases termination period Lessee Lease Termination Period Lessee Lease Termination Period Entity File Number Entity File Number Cancelled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Debt Disclosure [Abstract] Debt Disclosure [Abstract] Operating leases Operating Lease, Weighted Average Remaining Lease Term Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Schedule of Stock Options and SOSAR Grants Outstanding Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Share-based compensation expense Share-based Payment Arrangement, Expense Outstanding, beginning (in dollars per share) Outstanding, ending (in dollars per share) Weighted average exercise prices (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Weighted Average Exercise Price Balance Sheet Location [Axis] Balance Sheet Location [Axis] Total revenues Revenue from Contract with Customer, Including Assessed Tax Counterparty Name [Axis] Counterparty Name [Axis] WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Common stock, authorized 20,000 shares, $.01 par value, 7,185 and 7,079 shares issued, and 6,953 and 6,847 shares outstanding, respectively Common Stock, Value, Issued Medicare Medicare [Member] Medicare [Member] Document Fiscal Year Focus Document Fiscal Year Focus Proceeds from issuance of debt Proceeds from Issuance of Long-term Debt and Capital Securities, Net Other Insurance Other Insurance Industry Disclosures [Abstract] OTHER ASSETS: Assets, Noncurrent [Abstract] Schedule of Accounts Receivable Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Entity Current Reporting Status Entity Current Reporting Status 2025 Finance Lease, Liability, to be Paid, Year Four Interest rate during period Debt Instrument, Interest Rate During Period Insurance policy coverage limits per claim Insurance policy coverage limits per claim Malpractice Insurance, Maximum Coverage Per Incident Issuance of equity grants, net (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vesting percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Proceeds from stimulus funds used to purchase property and equipment Proceeds From Government Assistance, CARES Act Proceeds From Government Assistance, CARES Act Outstanding, beginning (in shares) Outstanding, ending (in shares) Share Based Compensation Arrangement By Share Based Payment Award, Awards Outstanding Number Share Based Compensation Arrangement By Share Based Payment Award, Awards Outstanding Number Present value of lease liabilities Operating Lease, Liability Grants outstanding (in shares) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Number Of Outstanding Awards Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Number Of Outstanding Awards $8.14 to $10.21 Stock Options Exercise Price Range One [Member] Stock Options Exercise Price Range One [Member] Reclassified to earnings Interest Rate Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net COVID-19, Medicaid revenue from states Medicaid Funds Received, Coronavirus Aid, Relief And Economic Security Act (CARES Act) Medicaid Funds Received, Coronavirus Aid, Relief And Economic Security Act (CARES Act) Interest Expense Interest Expense [Member] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Total shareholders’ deficit Stockholders' Equity Attributable to Parent BUSINESS Nature of Operations [Text Block] Total liabilities and shareholder's equity Liabilities and Equity Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax INCOME TAXES Income Tax Disclosure [Text Block] Total noncurrent liabilities Liabilities, Noncurrent Entity Address, City or Town Entity Address, City or Town Annual fees for letters of credit issued under revolver (as a percentage) Line of Credit Facility, Fee Percentage On Amount Outstanding Line of Credit Facility, Fee Percentage On Amount Outstanding Payroll and employee benefits Employee-related Liabilities, Current RSU's Restricted Stock Units (RSUs) [Member] Lease and rent expense Operating lease cost Operating Lease, Cost Hedging Relationship [Axis] Hedging Relationship [Axis] General and administrative General and Administrative Expense Antidilutive shares excluded from computation of diluted earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Finance leases Finance Lease, Weighted Average Remaining Lease Term Other Other Noncash Income (Expense) Short term lease cost Short-term Lease, Cost Equity Component [Domain] Equity Component [Domain] Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Valuation allowance Deferred Tax Assets, Valuation Allowance Liabilities: Liabilities [Abstract] Total lease payments Operating And Finance Lease Liability Payments Due Operating And Finance Lease Liability Payments Due Medicaid Medicaid [Member] Medicaid [Member] Entity Tax Identification Number Entity Tax Identification Number Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] STOCK-BASED COMPENSATION Share-based Payment Arrangement [Text Block] NET INCOME (LOSS) NET INCOME (LOSS) Net income (loss) Net Income (Loss) Attributable to Parent Finance lease, noncurrent Finance Lease, Liability, Noncurrent Changes in assets and liabilities affecting operating activities: Increase (Decrease) in Operating Capital [Abstract] Other current liabilities Other Liabilities, Current 2021 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year 2025 Operating And Finance Lease Liability Payments Due Year Four Operating And Finance Lease Liability Payments Due Year Four LIBOR London Interbank Offered Rate (LIBOR) [Member] Total other comprehensive loss Other Comprehensive Income (Loss), Net of Tax Leases [Abstract] Leases [Abstract] Accounting Policies [Table] Accounting Policies [Table] Accounting Policies [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Total current assets Assets, Current Current Fiscal Year End Date Current Fiscal Year End Date Self-insurance reserves, current portion Self Insurance Reserve, Current NET INCOME (LOSS) PER COMMON SHARE: Earnings Per Share [Abstract] Number of professional liability lawsuits Number Of Professional Liability Lawsuits Number Of Professional Liability Lawsuits Present value of lease liabilities Finance Lease, Liability PROPERTY AND EQUIPMENT, at cost Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Accumulated amortization of finance leases Finance Lease, Right-of-Use Asset, Accumulated Amortization Other income Other Nonoperating Income COVID-19, remaining stimulus funds Proceeds From Government Assistance, Remaining Stimulus Funds, CARES Act Proceeds From Government Assistance, Remaining Stimulus Funds, CARES Act CID Civil Investigative Demand [Member] Civil Investigative Demand [Member] Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income Other Comprehensive Income (Loss), Cash Flow Hedge, Reclassification for Discontinuance, before Tax SHAREHOLDERS’ DEFICIT: Stockholders' Equity Attributable to Parent [Abstract] Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Document Fiscal Period Focus Document Fiscal Period Focus Less accumulated depreciation and amortization Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization Self-insurance receivables, current portion Self Insurance Receivable, Current [Member] Self Insurance Receivable, Current [Member] Other receivables Other Receivables, Net, Current SUPPLEMENTAL INFORMATION: Supplemental Cash Flow Information [Abstract] Mortgage Loan Mortgages [Member] Granted (in dollars per share) Share Based Compensation Arrangements By Share Based Payment Award Awards Grants In Period Weighted Average Exercise Price Share Based Compensation Arrangements By Share Based Payment Award Awards Grants In Period Weighted Average Exercise Price Entity Filer Category Entity Filer Category Prefunded deductible policy Prefunded Deductible Policy [Member] Prefunded deductible policy. Common Stock Common Stock [Member] Product and Service [Domain] Product and Service [Domain] Mortgage Term Loan Mortgage Term Loan [Member] Mortgage Term Loan [Member] Finance leases Finance Lease, Weighted Average Discount Rate, Percent Professional liability insurance, annual coverage limit per facility Malpractice Insurance Annual Coverage Limit Per Facility Malpractice Insurance Annual Coverage Limit Per Facility Other operating income Other Operating Income (Expense) [Member] Per common share – diluted Earnings Per Share, Diluted [Abstract] NET INCREASE IN CASH Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS Business Combination Disclosure [Text Block] 2010 Long Term Incentive Plan Two Thousand And Ten Long Term Incentive Plan [Member] Two Thousand And Ten Long Term Incentive Plan [Member] Total other expense Nonoperating Income (Expense) Finance lease assets Finance Lease, Right-of-Use Asset, after Accumulated Amortization Hedging Relationship [Domain] Hedging Relationship [Domain] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Schedule of Maturity of Operating Lease Liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Basis of Accounting Basis of Accounting, Policy [Policy Text Block] Basic (in shares) Denominator: Basic Weighted Average Common Shares Outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Interest rate percentage Debt Instrument, Basis Spread on Variable Rate EXPENSES: Costs and Expenses [Abstract] Number of nursing center facilities owned Number Of Nursing Center Facilities Owned Number Of Nursing Center Facilities Owned Treasury stock, shares (in shares) Treasury Stock, Shares Grants exercisable (in shares) Share-based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Number Of Exercisable Awards Share-based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Number Of Exercisable Awards Cash Flow Hedging Cash Flow Hedging [Member] COVID-19, salaries expense Salaries Expense, Coronavirus Aid, Relief And Economic Security Act (CARES Act) Salaries Expense, Coronavirus Aid, Relief And Economic Security Act (CARES Act) Plan Name [Domain] Plan Name [Domain] REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE Revenue from Contract with Customer [Text Block] Cash payments of interest Interest Paid, Excluding Capitalized Interest, Operating Activities Balance Balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 2021 Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Exercised (in shares) Share-Based Compensation Arrangement By Share Based Payment Award, Exercises In Period Share-Based Compensation Arrangement By Share Based Payment Award, Exercises In Period Schedule of Derivatives Schedule of Derivative Instruments [Table Text Block] (PROVISION) BENEFIT FOR INCOME TAXES Income Tax Expense (Benefit) Cash (refunds) payments of income taxes Income Taxes Paid, Net Cash CASH, beginning of period CASH, end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Title of Individual [Domain] Title of Individual [Domain] Payroll and employee benefits, less current portion Employee-Related Liabilities, Noncurrent Employee-Related Liabilities, Noncurrent Net income (loss) per common share – diluted (in dollars per share) Earnings Per Share, Diluted Finance lease, current Finance Lease, Liability, Current Local Phone Number Local Phone Number Derivative Instruments and Hedging Activities Disclosure [Abstract] Operating loss, net of tax benefit Disposal Group, Including Discontinued Operation, Operating Income (Loss) First anniversary Share-based Payment Arrangement, Tranche One [Member] Income tax benefit Discontinued Operation, Tax Effect of Discontinued Operation Derivative [Line Items] Derivative [Line Items] Range of exercise prices, maximum (in dollars per share) Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Settlement payment period Loss Contingency, Settlement, Payment Period Loss Contingency, Settlement, Payment Period Entity Address, Address Line One Entity Address, Address Line One Entity Emerging Growth Company Entity Emerging Growth Company Unusual or Infrequent Item, or Both [Table] Unusual or Infrequent Item, or Both [Table] Liability Derivatives Derivative Liability, Fair Value, Gross Liability Borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Award Type [Axis] Award Type [Axis] Weighted Average Granted Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Third-party contract term Outsourced Services Contract Term Outsourced Services Contract Term Maximum Maximum [Member] Discontinued operations Cash Provided by (Used in) Investing Activities, Discontinued Operations COVID-19 PANDEMIC Unusual or Infrequent Items, or Both, Disclosure [Text Block] Accumulated Deficit Retained Earnings [Member] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Domain] Award Type [Domain] NONCURRENT LIABILITIES: Liabilities, Noncurrent [Abstract] Liabilities, Noncurrent [Abstract] Trading Symbol Trading Symbol Issuance and redemption of employee equity awards, net Issuance (Redemption) Of Employee Equity Awards, Net Issuance (Redemption) Of Employee Equity Awards, Net LOSS FROM DISCONTINUED OPERATIONS: Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent [Abstract] Treasury stock at cost, 232 shares of common stock Treasury Stock, Value EARNINGS PER COMMON SHARE Earnings Per Share [Text Block] Private Pay and other Private Pay And Other [Member] Private Pay And Other [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Granted (in shares) Share-based Compensation Arrangement by Share-Based Payment Award, Grants in Period, Gross Share-based Compensation Arrangement by Share-Based Payment Award, Grants in Period, Gross CURRENT LIABILITIES: Liabilities, Current [Abstract] Liabilities, Current [Abstract] Entity Shell Company Entity Shell Company 2023 Finance Lease, Liability, to be Paid, Year Two Accounting Standards Recently Issued But Not Yet Adopted by the Company New Accounting Pronouncements, Policy [Policy Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Per common share – basic Per common share – basic Earnings Per Share, Basic [Abstract] EX-101.PRE 9 dvcr-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 dvcr-20210331_htm.xml IDEA: XBRL DOCUMENT 0000919956 2021-01-01 2021-03-31 0000919956 2021-05-05 0000919956 2021-03-31 0000919956 2020-12-31 0000919956 2020-01-01 2020-03-31 0000919956 us-gaap:CommonStockMember 2019-12-31 0000919956 us-gaap:TreasuryStockMember 2019-12-31 0000919956 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000919956 us-gaap:RetainedEarningsMember 2019-12-31 0000919956 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000919956 2019-12-31 0000919956 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000919956 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000919956 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000919956 us-gaap:InterestRateSwapMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000919956 us-gaap:InterestRateSwapMember 2020-01-01 2020-03-31 0000919956 us-gaap:CommonStockMember 2020-03-31 0000919956 us-gaap:TreasuryStockMember 2020-03-31 0000919956 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000919956 us-gaap:RetainedEarningsMember 2020-03-31 0000919956 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000919956 2020-03-31 0000919956 us-gaap:CommonStockMember 2020-12-31 0000919956 us-gaap:TreasuryStockMember 2020-12-31 0000919956 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000919956 us-gaap:RetainedEarningsMember 2020-12-31 0000919956 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000919956 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000919956 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000919956 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000919956 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000919956 us-gaap:CommonStockMember 2021-03-31 0000919956 us-gaap:TreasuryStockMember 2021-03-31 0000919956 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000919956 us-gaap:RetainedEarningsMember 2021-03-31 0000919956 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000919956 srt:MinimumMember 2021-03-31 0000919956 srt:MaximumMember 2021-03-31 0000919956 us-gaap:OtherOperatingIncomeExpenseMember 2021-01-01 2021-03-31 0000919956 dvcr:MedicaidMember 2021-01-01 2021-03-31 0000919956 dvcr:MedicaidMember 2020-01-01 2020-03-31 0000919956 dvcr:MedicareMember 2021-01-01 2021-03-31 0000919956 dvcr:MedicareMember 2020-01-01 2020-03-31 0000919956 dvcr:ManagedCareMember 2021-01-01 2021-03-31 0000919956 dvcr:ManagedCareMember 2020-01-01 2020-03-31 0000919956 dvcr:PrivatePayAndOtherMember 2021-01-01 2021-03-31 0000919956 dvcr:PrivatePayAndOtherMember 2020-01-01 2020-03-31 0000919956 dvcr:MedicaidMember 2021-03-31 0000919956 dvcr:MedicaidMember 2020-12-31 0000919956 dvcr:MedicareMember 2021-03-31 0000919956 dvcr:MedicareMember 2020-12-31 0000919956 dvcr:ManagedCareMember 2021-03-31 0000919956 dvcr:ManagedCareMember 2020-12-31 0000919956 dvcr:PrivatePayAndOtherMember 2021-03-31 0000919956 dvcr:PrivatePayAndOtherMember 2020-12-31 0000919956 us-gaap:MortgagesMember 2019-12-31 0000919956 dvcr:AcquisitionLoanMember 2019-12-31 0000919956 us-gaap:RevolvingCreditFacilityMember 2019-12-31 0000919956 dvcr:AffiliatedRevolvingCreditAgreementMember 2019-12-31 0000919956 us-gaap:MortgagesMember dvcr:AmendedAndRestatedCreditAgreementMember 2020-10-14 0000919956 us-gaap:RevolvingCreditFacilityMember dvcr:MortgageLoanMember 2020-10-14 0000919956 us-gaap:RevolvingCreditFacilityMember dvcr:AmendedAndRestatedCreditAgreementMember 2020-10-14 0000919956 us-gaap:RevolvingCreditFacilityMember dvcr:AmendedAndRestatedCreditAgreementMember 2020-10-14 2020-10-14 0000919956 us-gaap:MortgagesMember dvcr:AmendedAndRestatedCreditAgreementMember 2020-10-14 2020-10-14 0000919956 dvcr:AmendedAndRestatedCreditAgreementMember dvcr:MortgageTermLoanMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-10-14 2020-10-14 0000919956 dvcr:AmendedAndRestatedCreditAgreementMember dvcr:MortgageTermLoanMember us-gaap:BaseRateMember 2020-10-14 2020-10-14 0000919956 dvcr:MortgageLoanMember us-gaap:LoansPayableMember 2021-03-31 0000919956 us-gaap:MortgagesMember dvcr:AmendedAndRestatedCreditAgreementMember dvcr:MortgageTermLoanMember 2021-01-01 2021-03-31 0000919956 dvcr:AmendedAndRestatedCreditAgreementMember 2020-10-14 0000919956 us-gaap:RevolvingCreditFacilityMember dvcr:AffiliatedRevolvingCreditAgreementMember 2021-03-31 0000919956 us-gaap:RevolvingCreditFacilityMember dvcr:AffiliatedRevolvingCreditAgreementMember 2020-12-31 0000919956 us-gaap:RevolvingCreditFacilityMember dvcr:AmendedAndRestatedCreditAgreementMember 2021-01-01 2021-03-31 0000919956 us-gaap:LetterOfCreditMember dvcr:AmendedAndRestatedCreditAgreementMember 2021-01-01 2021-03-31 0000919956 dvcr:AmendedAndRestatedCreditAgreementMember 2021-03-31 0000919956 us-gaap:RevolvingCreditFacilityMember dvcr:AmendedAndRestatedCreditAgreementMember 2021-03-31 0000919956 us-gaap:InterestRateCapMember us-gaap:CashFlowHedgingMember 2021-03-31 0000919956 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateCapMember 2021-03-31 0000919956 us-gaap:InterestRateSwapMember 2020-10-01 2020-10-31 0000919956 us-gaap:InterestRateSwapMember 2021-01-01 2021-03-31 0000919956 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateSwapMember 2021-03-31 0000919956 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateSwapMember 2020-12-31 0000919956 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateSwapMember 2021-03-31 0000919956 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateSwapMember 2020-12-31 0000919956 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateCapMember 2020-12-31 0000919956 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateCapMember 2021-03-31 0000919956 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateCapMember 2020-12-31 0000919956 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2021-01-01 2021-03-31 0000919956 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2020-01-01 2020-03-31 0000919956 us-gaap:InterestRateCapMember 2021-01-01 2021-03-31 0000919956 us-gaap:InterestRateCapMember 2020-01-01 2020-03-31 0000919956 us-gaap:InterestRateCapMember us-gaap:InterestExpenseMember 2021-01-01 2021-03-31 0000919956 us-gaap:InterestRateCapMember us-gaap:InterestExpenseMember 2020-01-01 2020-03-31 0000919956 dvcr:SHCRiskCarriersIncMember us-gaap:ProfessionalMalpracticeLiabilityMember 2021-01-01 2021-03-31 0000919956 us-gaap:ProfessionalMalpracticeLiabilityMember 2021-03-31 0000919956 us-gaap:ProfessionalMalpracticeLiabilityMember 2020-12-31 0000919956 dvcr:TrialOrArbitrationScheduleTimeframeMember 2021-03-31 0000919956 dvcr:SelfInsuranceReceivableCurrentMember 2021-03-31 0000919956 dvcr:SelfInsuranceReceivableCurrentMember 2020-12-31 0000919956 dvcr:CivilInvestigativeDemandMember 2021-01-01 2021-03-31 0000919956 dvcr:CivilInvestigativeDemandMember 2020-01-01 2020-03-31 0000919956 dvcr:CivilInvestigativeDemandMember 2021-03-31 0000919956 dvcr:CivilInvestigativeDemandMember 2020-12-31 0000919956 dvcr:PrefundedDeductiblePolicyMember 2021-01-01 2021-03-31 0000919956 dvcr:PrefundedDeductiblePolicyMember 2021-03-31 0000919956 dvcr:PrefundedDeductiblePolicyMember 2020-12-31 0000919956 dvcr:TwoThousandAndEightStockPurchasePlanMember 2008-06-01 2008-06-30 0000919956 dvcr:TwoThousandAndEightStockPurchasePlanMember 2016-05-31 0000919956 dvcr:TwoThousandAndEightStockPurchasePlanMember 2016-06-30 0000919956 dvcr:TwoThousandAndTenLongTermIncentivePlanMember 2017-05-31 0000919956 dvcr:TwoThousandAndTenLongTermIncentivePlanMember 2017-06-30 0000919956 us-gaap:RestrictedStockMember 2021-01-01 2021-03-31 0000919956 us-gaap:RestrictedStockMember 2020-01-01 2020-03-31 0000919956 srt:ChiefExecutiveOfficerMember 2020-03-13 2020-03-13 0000919956 dvcr:StockOptionsAndStockAppreciationRightsSARsMember 2020-12-31 0000919956 dvcr:StockOptionsAndStockAppreciationRightsSARsMember 2021-01-01 2021-03-31 0000919956 dvcr:StockOptionsAndStockAppreciationRightsSARsMember 2021-03-31 0000919956 us-gaap:RestrictedStockMember 2020-12-31 0000919956 us-gaap:RestrictedStockMember 2021-03-31 0000919956 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0000919956 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0000919956 us-gaap:RestrictedStockUnitsRSUMember 2021-03-31 0000919956 dvcr:StockOptionsAndStockAppreciationRightsSARsMember dvcr:StockOptionsExercisePriceRangeOneMember 2021-01-01 2021-03-31 0000919956 dvcr:StockOptionsAndStockAppreciationRightsSARsMember dvcr:StockOptionsExercisePriceRangeOneMember 2021-03-31 0000919956 dvcr:StockOptionsAndStockAppreciationRightsSARsMember dvcr:StockOptionsExercisePriceRangeTwoMember 2021-01-01 2021-03-31 0000919956 dvcr:StockOptionsAndStockAppreciationRightsSARsMember dvcr:StockOptionsExercisePriceRangeTwoMember 2021-03-31 0000919956 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-01-01 2020-03-31 0000919956 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2020-01-01 2020-03-31 0000919956 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2020-01-01 2020-03-31 0000919956 2020-03-27 2020-03-27 0000919956 2020-11-01 2020-11-01 0000919956 2020-12-01 shares iso4217:USD iso4217:USD shares dvcr:state dvcr:nursing_center dvcr:nursing_bed pure dvcr:letter_of_credit dvcr:lawsuit 0000919956 false 2021 Q1 --12-31 P1Y 0.3333 0.3333 0.3333 10-Q true 2021-03-31 false 1-12996 Diversicare Healthcare Services, Inc. DE 62-1559667 1621 Galleria Boulevard Brentwood TN 37027 615 771-7575 Common Stock, $0.01 par value per share DVCR Yes Yes Non-accelerated Filer true false false 6952773 32437000 30821000 49008000 53691000 1159000 1025000 4064000 4622000 4348000 5356000 234000 1746000 91250000 97261000 135608000 135234000 93242000 91914000 42366000 43320000 282931000 290296000 5069000 5202000 3846000 3773000 291846000 299271000 425462000 439852000 1677000 1660000 29429000 28583000 16955000 13901000 14420000 15393000 14126000 12665000 19505000 25900000 10485000 14743000 106597000 112845000 58225000 58526000 266435000 274155000 14081000 15476000 7000000 8000000 2353000 2155000 348094000 358312000 20000000 20000000 0.01 0.01 7185000 7079000 6953000 6847000 72000 71000 232000 232000 2500000 2500000 24754000 24596000 -51584000 -53510000 29000 38000 -29229000 -31305000 425462000 439852000 113360000 119987000 11321000 0 96829000 94859000 13249000 13512000 2083000 1839000 6765000 6758000 2295000 2288000 121221000 119256000 3460000 731000 39000 115000 1022000 1460000 -983000 -1345000 2477000 -614000 343000 -104000 2134000 -510000 -72000 -65000 -246000 -243000 1888000 -753000 0.33 -0.08 -0.04 -0.04 0.29 -0.12 0.32 -0.08 -0.04 -0.04 0.28 -0.12 6573000 6506000 6741000 6506000 1888000 -753000 -9000 -279000 -9000 -279000 1879000 -1032000 6908000 69000 232000 -2500000 24026000 -59079000 568000 -36916000 -753000 -753000 190000 1000 3000 4000 -279000 -279000 338000 338000 7098000 70000 232000 -2500000 24367000 -59832000 289000 -37606000 7079000 71000 232000 -2500000 24596000 -53510000 38000 -31305000 1888000 1888000 106000 1000 63000 64000 38000 -9000 29000 95000 95000 7185000 72000 232000 -2500000 24754000 -51584000 29000 -29229000 1888000 -753000 -246000 -243000 2134000 -510000 2295000 2288000 474000 173000 6880000 5663000 95000 338000 485000 821000 -93000 -517000 -4549000 -246000 -1136000 -792000 -1461000 -2021000 -6395000 0 -6874000 -5656000 3411000 2651000 -246000 -243000 3165000 2408000 1208000 927000 305000 0 -1513000 -927000 0 0 -1513000 -927000 377000 2113000 0 2500000 305000 0 0 419000 36000 4000 -36000 -28000 0 0 -36000 -28000 1616000 1453000 30821000 2710000 32437000 4163000 1101000 1599000 -1217000 10000 BUSINESS<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare” or the “Company”) provides long-term care services to nursing center patients in eight states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Indiana, Kansas, Mississippi, Missouri, Ohio, Tennessee, and Texas. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company’s continuing operations consist of 61 nursing centers with 7,250 licensed nursing beds. The Company owns 15 and leases 46 of its nursing centers. Our nursing centers range in size from 50 to 320 licensed nursing beds. The licensed nursing bed count does not include 397 licensed assisted and residential living beds.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the Secretary of U.S. Department of Health and Human Services (“HHS”) declared a national public health emergency due to a novel coronavirus. In March 2020, the World Health Organization categorized COVID-19, a disease caused by this coronavirus (“COVID-19”), as a pandemic. According to the Centers for Disease Control and Prevention (“CDC”), older adults and people with certain underlying medical conditions are at higher risk for serious illness from COVID-19. CDC has identified nursing home populations as being at high risk of being affected by pathogens like COVID-19 as a result of the congregate nature of nursing homes and the resident population served.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Centers for Medicare &amp; Medicaid Services (“CMS”) and the CDC have issued guidance to state and local governments and long-term care facilities to help mitigate the spread of COVID-19. For example, on March 13, 2020, CMS issued a memorandum directing long-term care facilities to significantly restrict visitors and nonessential workers and to restrict communal activities, among other measures. On May 18, 2020, CMS provided “reopening” recommendations for state and local officials to determine the level of mitigation needed to prevent the transmission of COVID-19 in nursing homes, including criteria for relaxing various restrictions. On March 10, 2021, CMS updated its guidance for visitation in nursing homes to account for the availability of COVID-19 vaccines, further relaxing visitation restrictions while emphasizing the importance of maintaining infection prevention practices. To help nursing homes and other providers respond to and contain the spread of COVID-19, CMS has also issued temporary emergency blanket waivers to various government healthcare program requirements. For example, through the end of the public health emergency declaration, CMS is waiving the requirement for a three-day hospital stay prior to Medicare Part A coverage of skilled nursing facility benefits, which allows Medicare beneficiaries that require a new or changed skilled level of care to receive that care under Medicare Part A from a skilled nursing facility without satisfying the hospital stay requirement (sometimes referred to as “skilled in place”). CMS continues to review the need for the waivers and has announced early termination of some waivers as the pandemic and nursing home practices have evolved. In addition, CMS has announced COVID-19 reporting requirements and focused infection control surveys intended to assess long-term care facility compliance with infection control requirements in connection with the COVID-19 pandemic. CDC guidance includes infection prevention and control practices intended to protect both nursing home residents and healthcare personnel.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) which includes, among other things, modifications to the limitation on business interest expense and net operating loss provisions relative to the payment of Federal income taxes and allows an optional payment deferral of the employer's portion of Social Security taxes that were otherwise due through December 31, 2020. These provisions of the CARES Act were effective after the date of enactment and also include the appropriation of stimulus funds to Medicare and Medicaid providers. The Paycheck Protection Program and Health Care Enhancement Act ("PPPHCE Act"), enacted on April 24, 2020, the Consolidated Appropriations Act, 2021 ("CAA"), enacted December 27, 2020, and American Rescue Plan Act of 2021 ("ARPA"), enacted on March 11, 2021, provide for additional emergency appropriations for COVID-19 response.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Together, the CARES Act and other enacted legislation, authorize funding to healthcare entities to be distributed through the Public Health and Social Services Emergency Fund ("PHSSEF"), also known as the Provider Relief Fund. Payments from PHSSEF, as made to providers through general and targeted distributions, are intended to compensate providers for lost revenues and healthcare-related expenses attributable to the COVID-19 pandemic only. As long as the recipient has sufficient COVID-19 attributable expenses and lost revenues, as defined by the PHSSEF, between January 1, 2020 and June 30, 2021 and complies with certain terms and conditions, these payments are not required to be repaid. The terms and conditions include, among others, requirements to comply with certain reporting requirements, limitations on balance billing and restrictions </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">against using PHSSEF funds to reimburse expenses or losses that have been reimbursed from other sources or that other sources are obligated to reimburse. The CAA provides that targeted distribution payments made to an eligible entity may be allocated by the entity's parent organization among its subsidiary eligible health care providers and the entity receiving the targeted distribution payments remains responsible for reporting obligations. The Company is utilizing the funds it received from the PHSSEF to compensate for COVID-19 attributable lost revenues and pay for permissible expenses, including but are not limited to increased wages and increased costs for personal protective equipment, infection control supplies, and COVID-19 testing. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the CARES Act and other enacted legislation authorized additional relief funding to skilled nursing facilities and nursing homes in the form of Nursing Home Infection Control distributions, with a fixed $10,000 distributed for each facility and variable distributions based on number of beds. The legislation also provides for infection control quality incentive payments to skilled nursing facilities and nursing homes based on certain performance measures tied to COVID-19 infections and mortalities. These payments were calculated based on monthly performance periods running from September through December 2020, with the total available bonus payment for each performance period determined in part based on data reported via Certification and Survey Provider Enhanced Reports ("CASPER"). The terms and conditions for this distribution limit use of payments to certain infection control expenses. HHS has not yet published reporting requirements for these distributions and has not yet stipulated a time period by which these funds must be used.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is still evaluating the most recent guidance for amounts distributed under the CARES Act and other enacted legislation; however, the Company currently anticipates, but cannot guarantee, that it will have sufficient COVID-19 attributable expenses and lost revenues to retain the PPSSEF payments it has received to date. The Company will not be able to determine the amount of used funds until the form, process and reporting rules are finalized by the federal government, and the Company knows the full extent of its COVID-19 attributable expenses and lost revenues. There also can be no assurance that the PHSSEF funds will ultimately be enough to reimburse the Company for the full extent of its COVID-19 attributable expenses and losses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the COVID-19 pandemic, we have experienced and may continue to experience price increases in equipment, pharmaceuticals, and medical supplies due to increased demand and limited availability for certain items. Staffing, equipment, pharmaceutical and medical supplies and vaccine shortages may impact our ability to admit and treat patients. We have incurred, and may continue to incur, increased expenses arising from the COVID-19 pandemic, particularly in the form of increased labor costs, testing and the increased costs of personal protective equipment, food and infection control supplies. The Company expects such increased expenses to continue and likely increase further into 2021. Refer to Note 4 "COVID-19 Pandemic" for further information.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the end of calendar year 2020, there have been additional cases of COVID-19 at certain of our centers. We have experienced and may continue to experience reduced occupancy in our centers, in part due to perceived risks by patients and family members of residential care and their perception of restrictions such as limited visitation policies (which have been relaxed pursuant to CMS guidance), a reduction in patients released to nursing homes from hospitals and other healthcare facilities, and a general reluctance to seek medical care or interface with the healthcare system during the pandemic or for an undetermined period of time. Occupancy may also be affected by the data each nursing home is required to report, including the number of confirmed and suspected cases of COVID-19 and resident deaths related to COVID-19, which is made publicly available through the CDC National Healthcare Safety Network.</span></div> 8 61 7250 15 46 50 320 397 CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim consolidated financial statements for the three month periods ended March 31, 2021 and 2020, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at March 31, 2021, the results of operations, changes in shareholders' deficit and cash flows for the three month period ended March 31, 2021 and 2020. The Company’s balance sheet information at December 31, 2020, was derived from its audited consolidated financial statements as of December 31, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the periods ended March 31, 2021 and 2020 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PHSSEF Funds</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, the Company implemented certain changes to its accounting policies related to the recognition of stimulus funds through the PHSSEF, which it has applied consistently throughout the period ended March 31, 2021. There is no U.S. GAAP that explicitly covers accounting for government "grants" to for-profit entities with the exception of certain agricultural subsidies. In the absence of authoritative U.S. GAAP guidance, the Company considered the application of other authoritative accounting guidance by analogy and concluded that the guidance outlined in International Accounting Standards 20 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Government Grants and Disclosures of Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("IAS 20") was the most appropriate analogy for the purpose of recording and classifying the federal and certain state stimulus funds received by the Company. Under IAS 20, once it is reasonably assured that the entity will comply with the conditions of the grant, the grant money should be recognized on a systematic basis over the periods in which the entity recognizes the related expenses or losses for which the grant money is intended to compensate. The Company recognizes grants once both of the following conditions are met: (1) the Company is eligible to receive the grant, and (2) the Company is able to comply with the relevant conditions of the grant. Federal and certain state stimulus funds that are recognized to offset healthcare related expenses and lost revenue attributable to COVID-19 are reflected as "other operating income" on the accompanying interim consolidated statement of operations. Federal stimulus funds received and used toward capital improvements that assist with the response to and prevention and spread of COVID-19 is accounted for as a capital grant. For such an asset acquired with the use of a stimulus funds, the Company will recognize the asset as a net zero asset. Refer to Note 4, "COVID-19 Pandemic" to the interim consolidated financial statements included in this report for additional information.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company has received Medicaid stimulus funds, which are recognized in accordance with ASC 606. Refer to Note 5, "Revenue Recognition and Accounts Receivable" to the interim consolidated financial statements included in this report for additional information.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim consolidated financial statements for the three month periods ended March 31, 2021 and 2020, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at March 31, 2021, the results of operations, changes in shareholders' deficit and cash flows for the three month period ended March 31, 2021 and 2020. The Company’s balance sheet information at December 31, 2020, was derived from its audited consolidated financial statements as of December 31, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the periods ended March 31, 2021 and 2020 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PHSSEF Funds</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, the Company implemented certain changes to its accounting policies related to the recognition of stimulus funds through the PHSSEF, which it has applied consistently throughout the period ended March 31, 2021. There is no U.S. GAAP that explicitly covers accounting for government "grants" to for-profit entities with the exception of certain agricultural subsidies. In the absence of authoritative U.S. GAAP guidance, the Company considered the application of other authoritative accounting guidance by analogy and concluded that the guidance outlined in International Accounting Standards 20 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Government Grants and Disclosures of Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("IAS 20") was the most appropriate analogy for the purpose of recording and classifying the federal and certain state stimulus funds received by the Company. Under IAS 20, once it is reasonably assured that the entity will comply with the conditions of the grant, the grant money should be recognized on a systematic basis over the periods in which the entity recognizes the related expenses or losses for which the grant money is intended to compensate. The Company recognizes grants once both of the following conditions are met: (1) the Company is eligible to receive the grant, and (2) the Company is able to comply with the relevant conditions of the grant. Federal and certain state stimulus funds that are recognized to offset healthcare related expenses and lost revenue attributable to COVID-19 are reflected as "other operating income" on the accompanying interim consolidated statement of operations. Federal stimulus funds received and used toward capital improvements that assist with the response to and prevention and spread of COVID-19 is accounted for as a capital grant. For such an asset acquired with the use of a stimulus funds, the Company will recognize the asset as a net zero asset. Refer to Note 4, "COVID-19 Pandemic" to the interim consolidated financial statements included in this report for additional information.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company has received Medicaid stimulus funds, which are recognized in accordance with ASC 606. Refer to Note 5, "Revenue Recognition and Accounts Receivable" to the interim consolidated financial statements included in this report for additional information.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Standards Recently Issued But Not Yet Adopted by the Company</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new guidance intends to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for smaller reporting companies for the fiscal year beginning after December 15, 2022 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848). The new guidance contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU No. 2020-04 is optional and may be elected over time as reference rate reform activities occur. During the first quarter of 2020, the Company elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The amendments in the ASU are effective for all entities as of March 12, 2020 through December 31, 2022. The Company continues to evaluate changes in the market and may apply other elections, as applicable, in the future as allowed under ASU No. 2020-04.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Standards Recently Issued But Not Yet Adopted by the Company</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new guidance intends to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for smaller reporting companies for the fiscal year beginning after December 15, 2022 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848). The new guidance contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU No. 2020-04 is optional and may be elected over time as reference rate reform activities occur. During the first quarter of 2020, the Company elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The amendments in the ASU are effective for all entities as of March 12, 2020 through December 31, 2022. The Company continues to evaluate changes in the market and may apply other elections, as applicable, in the future as allowed under ASU No. 2020-04.</span></div> COVID-19 PANDEMICAs of March 31, 2021, the Company has received $51,607 from the PHSSEF. The Company recognized $10,534 as income, which is reflected in "other operating income" in the Company's results of operations for the three month period ended March 31, 2021. For the three months ended March 31, 2021, the Company utilized $305 of these stimulus dollars to fund capital improvements to prevent the spread of COVID-19. The remaining stimulus funds of $19,505 as of March 31, 2021 are classified as "deferred income" on the interim consolidated balance sheet, which also includes Nursing Home Infection Control Distributions. The Nursing Home Infection Control Distributions, which also include infection control quality incentive payments, are subject to terms and conditions that require recipients to use the funds for infection control expenses. HHS has not yet published reporting requirements for these distributions and has not yet stipulated a time period by which these funds must be used. The Company recognized $787 of grant funds from states, which is included in "other operating income" in the Company's results of operations for the three month period ended March 31, 2021. Additionally, the Families First Coronavirus Response Act provided states with a temporary increase in the regular federal matching rate, or federal medical assistance percentage, used to determine the federal government's share of the cost of covered services in state Medicaid programs, provided the states agreed to certain conditions such as not imposing cost-sharing requirements for COVID-19-related testing <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and treatment. The Company recognized $4,056 for the three month period ended March 31, 2021 of Medicaid and Hospice dollars related to this temporary increase in the federal matching rate, which related to patient services rendered and is reflected in "patient revenues, net" in the Company's results of operations for the three month period ended March 31, 2021. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company initially elected to participate in the payment deferral of the employer's portion of Social Security taxes. During the third quarter of 2020, the Company ceased the deferral election and paid $3,185. As of March 31, 2021, the Company has no remaining liability related to the payment deferral and does not expect to participate in the payment deferral going forward.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act and other stimulus legislation also include other provisions offering financial relief, for example lifting the Medicare sequestration from May 1, 2020 through December 31, 2021, which would have otherwise reduced payments to Medicare providers by 2% as required by the Budget Control Act of 2011 (but also extending sequestration through 2030). For the three month period ended March 31, 2021, the suspension of the Medicare sequestration positively impacted net patient revenues by $751. However, in addition to providing funding for healthcare providers, the ARPA increases the federal budget deficit in a manner that triggers an additional statutorily mandated sequestration under the Pay-As-You-Go Act of 2010 ("PAYGO Act"). As a result, absent congressional action, Medicare spending will be reduced by up to 4 percentage points in FY 2022, in addition to the existing sequestration requirements of the Budget Control Act of 2011.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred an additional $8,088 of labor expense and $3,905 for testing and the increased costs of personal protective equipment, food and infection control supplies related to the COVID-19 pandemic for the three month period ended March 31, 2021. These expenses are reflected in "operating expense" in the Company's results of operations for the three month period ended March 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is closely monitoring and evaluating the impact of the COVID-19 pandemic on all aspects of its business. We have identified team members and patients who have tested positive for COVID-19 at all of our centers, and we have incurred an increase in the costs of caring for the team members, patients, and residents in those centers. The Company has also experienced reduced occupancy at its centers and has incurred additional expenditures preparing its centers for potential outbreaks and maintaining the healthcare delivery capacity of its centers. While we have experienced reduced occupancy and increased expenses, we received additional PHSSEF and other stimulus funds during 2020 and the first quarter of 2021, which have been used, and are expected to continue to be used to mitigate the impact of COVID-19 derived lost revenues associated with the reduced occupancy as well as increased expenses, and any cash flow or liquidity impacts therefrom. The Company has an interdisciplinary team monitoring and staying up to date on the latest information about COVID-19. The Company has implemented precautionary measures and response protocols to minimize the spread of COVID-19, following guidance from CMS and the CDC. Nevertheless, the Company expects additional COVID-19 cases will occur at its centers. The Company is continuing to evaluate and consider the potential impact that COVID-19 may have on its liquidity, financial condition and results of operations due to numerous uncertainties. However, given the uncertainty as to the duration of the COVID-19 pandemic and the timing and availability of effective medical treatment and vaccines, it could have a material adverse effect on the Company's future results of operations, financial condition and liquidity.</span></div> 51607000 10534000 305000 19505000 787000 4056000 3185000 751000 8088000 3905000 REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenue is derived from providing quality healthcare services to its patients. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. The promise to provide quality care is accounted for as a single performance obligation satisfied at a point in time, when those services are rendered on a daily basis.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue and Accounts Receivable</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, the Company recognized $3,757 and $299 of Medicaid and Hospice stimulus dollars, respectively, for the three month period ended March 31, 2021 that are reflected as patient revenues in the Company's results of operations and in the table below. Refer to Note 4, "COVID-19 Pandemic" for more information. The following table summarizes revenue from contracts with customers by payor source from continuing operations for the periods presented (dollar amounts in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.801%"><tr><td style="width:1.0%"/><td style="width:23.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.269%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,955 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,330 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,458 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,672 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,676 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,596 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private Pay and other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,271 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,389 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,360 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,987 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable from continuing operations as of March 31, 2021 and December 31, 2020 are summarized in the following table:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:368.25pt"><tr><td style="width:1.0pt"/><td style="width:208.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:4.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.75pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,254 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,354 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,861 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private Pay and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,543 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,043 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts receivable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,008 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,691 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenue is derived from providing quality healthcare services to its patients. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. The promise to provide quality care is accounted for as a single performance obligation satisfied at a point in time, when those services are rendered on a daily basis.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans).</span></div> 3757000 299000 The following table summarizes revenue from contracts with customers by payor source from continuing operations for the periods presented (dollar amounts in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.801%"><tr><td style="width:1.0%"/><td style="width:23.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.269%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,955 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,330 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,458 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,672 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,676 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,596 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private Pay and other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,271 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,389 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,360 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,987 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> 49955000 0.441 54330000 0.453 24458000 0.216 20672000 0.172 13676000 0.121 12596000 0.105 25271000 0.222 32389000 0.270 113360000 1.000 119987000 1.000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable from continuing operations as of March 31, 2021 and December 31, 2020 are summarized in the following table:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:368.25pt"><tr><td style="width:1.0pt"/><td style="width:208.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:4.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.75pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,254 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,354 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,861 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private Pay and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,543 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,043 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts receivable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,008 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,691 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 17254000 17354000 9350000 14273000 7861000 8021000 14543000 14043000 49008000 53691000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">LONG-TERM</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> DEBT </span><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a credit facility with a syndicate of banks. The Company originally entered into the credit facility in May 2013, and subsequently amended the facility. As of December 31, 2019, the credit facility consisted of a mortgage loan of $67,500, an acquisition loan with a borrowing capacity of $12,500, a revolver with a borrowing capacity of $40,250 and an affiliated revolver with a borrowing capacity of $2,000. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 14, 2020, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") with a syndicate of banks, which consists of a $62,000 mortgage loan subsequently amended ("Amended Mortgage Loan"), a $36,000 revolver subsequently amended ("Amended Revolver") and a $2,000 affiliated revolver amended ("Amended Affiliated Revolver"). The Amended Mortgage Loan, Amended Revolver and Amended Affiliated Revolver have a 3-year maturity through September 30, 2023. The Amended Mortgage Loan has a term of 3 years, with principal and interest payable monthly based on a 25-year amortization. Interest on the term loan facility is based on LIBOR plus 4.0% with a 1.0% floor. The Amended Mortgage Loan balance was $60,767 as of March 31, 2021 with an interest rate of 5.0%. The Amended Mortgage Loan consolidated the mortgage and acquisition loans. The Amended Mortgage Loan is secured by 15 owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan, the Amended Revolver and the Amended Affiliated Revolver are cross-collateralized and cross-defaulted. The Company’s Amended Revolver and Amended Affiliated Revolver have an interest rate of LIBOR plus 4.0% and are secured by accounts receivable and are subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the Company had no outstanding borrowings under its revolvers. The interest rate related to the revolvers was 5.0% as of March 31, 2021. Annual fees for letters of credit issued under the Amended Revolver are 3.0% of the amount outstanding. The Company has four letters of credit with a total value of $12,387 outstanding as of March 31, 2021. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the Amended Revolver and the Amended Affiliated Revolver, and the maximum loan amount of $24,377 for these revolvers, the balance available for borrowing under the revolvers was $11,990 at March 31, 2021.</span></div>The Company’s debt agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. The Company is in compliance with all such covenants at March 31, 2021. 67500000 12500000 40250000 2000 62000000 36000000 2000000 P3Y P3Y P25Y 0.040 0.010 60767000 0.050 15 0.040 0 0 0.050 0.030 4 12387000 24377000 11990000 DERIVATIVES AND HEDGING ACTIVITIES <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company entered into an interest rate cap agreement with a member of the bank syndicate as the counterparty. The Company entered into the interest rate cap agreement to mitigate the variable interest rate risk associated with its outstanding mortgage borrowings.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company designated the interest rate cap as a cash flow hedge, and the effective portion of the hedge is reflected as a component of other comprehensive income. The interest rate cap has the same maturity date as the Amended Mortgage Loan and has an amortizing notional amount that was $60,767 as of March 31, 2021. The interest rate cap agreement requires the counterparty to pay the Company an amount equal to the applicable notional amount multiplied by the rate by which the LIBOR index exceeds a 1% strike rate during the period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the effectiveness of the interest rate cap on a quarterly basis and at March 31, 2021, the Company has determined that the interest rate cap was effective. Accordingly, the gain or loss related to the change in fair value of the interest rate cap is recorded in Accumulated Other Comprehensive Income and subsequently reclassified into interest expense in the same period during which the hedged forecasted transaction affects earnings. The fair value of the interest rate cap of $78 at March 31, 2021 was included in other noncurrent assets on the Company's Consolidated Balance Sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the refinancing of its outstanding borrowings during October 2020, the Company terminated its interest rate swap and incurred a loss of $177. Following the termination, $90 was recorded in other comprehensive income and was reclassified as an adjustment to earnings over the remaining term of the original hedge. Of this amount, $38 was recorded as a decrease to retained earnings for the three months ended March 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk: </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:60.818%"><tr><td style="width:1.0%"/><td style="width:31.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.594%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Rate Derivative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Cap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,767 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the balance sheets as of March 31, 2021 and December 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.210%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liability Derivatives</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Cap</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the effect of cash flow hedge accounting on Accumulated Other Comprehensive Income for the three months ended March 31, 2021 and March 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.456%"><tr><td style="width:1.0%"/><td style="width:22.304%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.041%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effect of Derivative Instruments on the Consolidated Statement of Income</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Other Comprehensive Income on Derivative</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Cap</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Total interest expense presented in the consolidated income statements for the three months ended March 31, 2021 and 2020 was $1,022 and $1,460, respectively.</span></div></td></tr></table></div> 60767000 0.01 78000 177000 90000 38000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk: </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:60.818%"><tr><td style="width:1.0%"/><td style="width:31.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.594%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Rate Derivative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Cap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,767 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1 60767000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the balance sheets as of March 31, 2021 and December 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.210%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liability Derivatives</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Cap</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 0 0 0 78000 0 0 0 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the effect of cash flow hedge accounting on Accumulated Other Comprehensive Income for the three months ended March 31, 2021 and March 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.456%"><tr><td style="width:1.0%"/><td style="width:22.304%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.041%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effect of Derivative Instruments on the Consolidated Statement of Income</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Other Comprehensive Income on Derivative</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Cap</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Total interest expense presented in the consolidated income statements for the three months ended March 31, 2021 and 2020 was $1,022 and $1,460, respectively.</span></div></td></tr></table></div> 0 -329000 -38000 50000 29000 0 0 0 29000 -329000 -38000 50000 1022000 1460000 LEASES<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating and finance leases for facilities, corporate offices, and certain equipment. The Company recognizes lease expense for these operating leases on a straight-line basis over the lease term. Leases with an initial term of one year or less are not recorded on the balance sheet. The Company's other leases have original lease terms of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjljM2YwYWExNWNiNzRkYmJhMWU3ZmI1YTVmYmVlMGVmL3NlYzo5YzNmMGFhMTVjYjc0ZGJiYTFlN2ZiNWE1ZmJlZTBlZl82MS9mcmFnOjU1YjhlMWMzOGE5MTRkMWVhOTI3YzI2ZGY5ODI3YTAxL3RleHRyZWdpb246NTViOGUxYzM4YTkxNGQxZWE5MjdjMjZkZjk4MjdhMDFfMzc0_7b5422c2-ff69-45ba-bb94-820c1e667018">one</span> to twelve years, some of which include options to extend the lease for up to twenty years, and some of which include options to terminate the leases within one year. The exercise of lease renewal options is at our sole discretion. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants. Upon adoption of Topic 842, the Company elected the practical expedient to not separate lease and non-lease components for all of its leases as the non-lease components are not significant to the overall lease costs. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.301%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Operating lease assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,931 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,296 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,378 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,804 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,429 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt and finance lease obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, less current portion</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,435 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,155 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt and finance lease obligations, less current portion and deferred financing costs, net<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,343 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,269 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease assets are recorded net of accumulated amortization of $532 and $471 as of March 31, 2021 and December 31, 2020, respectively.</span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Lease Cost of Continuing Operations</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.520%"><tr><td style="width:1.0%"/><td style="width:33.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.077%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.376%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.077%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.992%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.918%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.996%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease and rent expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,249 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,512 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Amortization of finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Interest on finance lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,470 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,761 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Includes variable lease costs, which are immaterial.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Maturity of Lease Liabilities</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.309%"><tr><td style="width:1.0%"/><td style="width:31.404%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.168%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.168%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.196%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,408 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,398 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,565 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,311 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,115 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,124 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,193 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,193 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,178 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,178 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392,547 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393,062 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,683)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,719)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,864 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,343 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Operating and finance lease payments exclude option to extend lease terms that are not reasonably certain of being exercised.</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measurement of right-of-use assets and lease liabilities requires the Company to estimate appropriate discount rates. To the extent the rate implicit in the lease is readily determinable, such rate is utilized. However, based on information available at lease commencement for the majority of our leases, the rate implicit in the lease is not known. In these instances, the Company utilizes an incremental borrowing rate, which represents the rate of interest that it would pay to borrow on a collateralized basis over a similar term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Lease Term and Discount Rate</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.994%"><tr><td style="width:1.0%"/><td style="width:50.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.702%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.907%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.465%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.91</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Finance leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.04</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.26</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Finance leases</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2%</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Information</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.128%"><tr><td style="width:1.0%"/><td style="width:64.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.072%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Operating cash flows for operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,740 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,673 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Operating cash flows for finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Financing cash flows for finance leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> LEASES<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating and finance leases for facilities, corporate offices, and certain equipment. The Company recognizes lease expense for these operating leases on a straight-line basis over the lease term. Leases with an initial term of one year or less are not recorded on the balance sheet. The Company's other leases have original lease terms of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjljM2YwYWExNWNiNzRkYmJhMWU3ZmI1YTVmYmVlMGVmL3NlYzo5YzNmMGFhMTVjYjc0ZGJiYTFlN2ZiNWE1ZmJlZTBlZl82MS9mcmFnOjU1YjhlMWMzOGE5MTRkMWVhOTI3YzI2ZGY5ODI3YTAxL3RleHRyZWdpb246NTViOGUxYzM4YTkxNGQxZWE5MjdjMjZkZjk4MjdhMDFfMzc0_7b5422c2-ff69-45ba-bb94-820c1e667018">one</span> to twelve years, some of which include options to extend the lease for up to twenty years, and some of which include options to terminate the leases within one year. The exercise of lease renewal options is at our sole discretion. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants. Upon adoption of Topic 842, the Company elected the practical expedient to not separate lease and non-lease components for all of its leases as the non-lease components are not significant to the overall lease costs. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.301%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Operating lease assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,931 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,296 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,378 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,804 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,429 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt and finance lease obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, less current portion</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,435 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,155 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt and finance lease obligations, less current portion and deferred financing costs, net<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,343 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,269 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease assets are recorded net of accumulated amortization of $532 and $471 as of March 31, 2021 and December 31, 2020, respectively.</span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Lease Cost of Continuing Operations</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.520%"><tr><td style="width:1.0%"/><td style="width:33.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.077%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.376%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.077%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.992%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.918%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.996%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease and rent expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,249 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,512 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Amortization of finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Interest on finance lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,470 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,761 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Includes variable lease costs, which are immaterial.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Maturity of Lease Liabilities</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.309%"><tr><td style="width:1.0%"/><td style="width:31.404%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.168%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.168%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.196%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,408 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,398 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,565 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,311 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,115 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,124 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,193 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,193 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,178 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,178 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392,547 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393,062 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,683)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,719)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,864 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,343 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Operating and finance lease payments exclude option to extend lease terms that are not reasonably certain of being exercised.</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measurement of right-of-use assets and lease liabilities requires the Company to estimate appropriate discount rates. To the extent the rate implicit in the lease is readily determinable, such rate is utilized. However, based on information available at lease commencement for the majority of our leases, the rate implicit in the lease is not known. In these instances, the Company utilizes an incremental borrowing rate, which represents the rate of interest that it would pay to borrow on a collateralized basis over a similar term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Lease Term and Discount Rate</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.994%"><tr><td style="width:1.0%"/><td style="width:50.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.702%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.907%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.465%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.91</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Finance leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.04</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.26</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Finance leases</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2%</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Information</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.128%"><tr><td style="width:1.0%"/><td style="width:64.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.072%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Operating cash flows for operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,740 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,673 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Operating cash flows for finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Financing cash flows for finance leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> P12Y P20Y P1Y <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.301%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Operating lease assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,931 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,296 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,378 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,804 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,429 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt and finance lease obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, less current portion</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,435 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,155 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt and finance lease obligations, less current portion and deferred financing costs, net<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,343 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,269 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease assets are recorded net of accumulated amortization of $532 and $471 as of March 31, 2021 and December 31, 2020, respectively.</span></div></td></tr></table> 282931000 290296000 447000 508000 283378000 290804000 29429000 28583000 255000 251000 266435000 274155000 224000 280000 296343000 303269000 532000 471000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Lease Cost of Continuing Operations</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.520%"><tr><td style="width:1.0%"/><td style="width:33.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.077%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.376%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.077%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.992%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.918%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.996%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease and rent expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,249 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,512 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Amortization of finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Interest on finance lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,470 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,761 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Includes variable lease costs, which are immaterial.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 13249000 13512000 61000 61000 9000 9000 151000 179000 13470000 13761000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Maturity of Lease Liabilities</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.309%"><tr><td style="width:1.0%"/><td style="width:31.404%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.168%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.168%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.196%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,408 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,398 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,565 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,311 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,115 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,124 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,193 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,193 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,178 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,178 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392,547 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393,062 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,683)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,719)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,864 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,343 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Operating and finance lease payments exclude option to extend lease terms that are not reasonably certain of being exercised.</span></div></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Maturity of Lease Liabilities</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.309%"><tr><td style="width:1.0%"/><td style="width:31.404%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.168%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.168%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.196%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,408 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,398 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,565 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,311 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,115 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,124 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,193 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,193 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,178 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,178 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392,547 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393,062 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,683)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,719)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,864 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,343 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Operating and finance lease payments exclude option to extend lease terms that are not reasonably certain of being exercised.</span></div></td></tr></table></div> 51408000 283000 51691000 52398000 167000 52565000 53255000 56000 53311000 53115000 9000 53124000 54193000 0 54193000 128178000 0 128178000 392547000 515000 393062000 96683000 36000 96719000 295864000 479000 296343000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Lease Term and Discount Rate</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.994%"><tr><td style="width:1.0%"/><td style="width:50.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.702%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.907%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.465%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.91</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Finance leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.04</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.26</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Finance leases</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2%</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Information</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.128%"><tr><td style="width:1.0%"/><td style="width:64.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.072%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Operating cash flows for operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,740 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,673 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Operating cash flows for finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Financing cash flows for finance leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> P7Y8M4D P7Y10M28D P2Y14D P2Y3M3D 0.079 0.079 0.061 0.062 12740000 12673000 9000 9000 57000 52000 COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Professional Liability and Other Liability Insurance</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. All of the Company's nursing centers in Tennessee are now covered under the captive insurance policies along with many of the nursing centers in Alabama, Ohio and Texas, as well as those previously operated by the Company in Kentucky and Florida. The insurance coverage provided for these centers under the SHC policy provides coverage limits of at least $1,000 per medical incident with a sublimit per center of $3,000 and total annual aggregate policy limits of $5,000. All other centers within the Company's portfolio are covered through </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">various commercial insurance policies which provide similar coverage limits per medical incident, per location, and on an aggregate basis for covered centers. The deductibles for these policies are covered through the insurance subsidiary. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserve for Estimated Self-Insured Professional Liability Claims</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the Company’s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company’s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of $24,824 and $24,744 as of March 31, 2021 and December 31, 2020, respectively. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this reserve. Since May 2012, the actuary has assisted management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished as of May 31 and November 30 of each year. The actuary primarily utilizes historical data regarding the frequency and cost of the Company’s past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company’s ultimate professional liability cost for current periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company’s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator’s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company’s evaluation of the actual claims information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company is engaged in 79 professional liability lawsuits. Twenty-one lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company’s cash expenditures for self-insured professional liability costs were $1,549 and $1,840 for the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the accounting guidance in ASC Topic 954 that clarifies that a health care entity should not net insurance recoveries against a related professional liability claim and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the estimated insurance recovery receivables are included within "Self-insurance receivables" on the Consolidated Balance Sheet. As of March 31, 2021 and December 31, 2020 there are estimated insurance recovery receivables of $1,159 and $1,025 in "Self-insurance receivable", respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Any potential claims or settlements related to COVID-19 are uncertain at this time. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company’s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company’s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company’s reported earnings and financial position for the period in which the change in accrual is made.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Civil Investigative Demand ("CID") </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we entered into a settlement agreement with the U.S. Department of Justice and the State of Tennessee of actions alleging violations of the federal False Claims Act in connection with our provision of therapy and the completion of certain resident admission forms. This settlement resolved an investigation that had begun in 2012 and covers the time period from January 1, 2010 through December 31, 2015. This agreement requires annual payments for a period of five years ending in February 2025 and also requires a contingent payment in the event the Company sells any of its owned facilities during the five-year payment period. Relative to the settlement agreement, the Company paid $1,000 and $500 during the first quarters of 2021 and 2020, respectively. As of March 31, 2021 and December 31, 2020, the Company has $8,000 and $9,000 outstanding related to the settlement agreement, respectively. Of the outstanding balance related to the settlement agreement, $1,000 is reflected as "Other current liabilities" and the remaining $7,000 and $8,000 is reflected as "Government settlement </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accrual" on the Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020, respectively. Failure to timely make any of these payments could result in rescission of the settlement and result in the government having a very large claim against us, including penalties, and/or make us ineligible to participate in certain government funded healthcare programs, any of which could in turn significantly harm our business and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the settlement of the government investigation related to our therapy practices, we entered into a corporate integrity agreement ("CIA") with the Office of the Inspector General of CMS. The CIA has a term of five years and imposes material burdens on the Company, its officers and directors to take actions designed to ensure compliance with applicable healthcare laws, including requirements to maintain specific compliance positions within the Company, to report any non-compliance with the terms of the CIA, to return any overpayments received, to submit annual reports and for an annual audit of submitted claims by an independent review organization. The CIA sets forth penalties for non-compliance by the Company with the terms of the agreement, including possible exclusion from federally funded healthcare programs for material violations of the agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Insurance</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to workers’ compensation insurance, substantially all of the Company’s employees are covered under either a prefunded deductible policy or state-sponsored programs. The Company has been and remains a non-subscriber to the Texas workers’ compensation system and, therefore, is completely self-insured for employee injuries with respect to its Texas operations. From the period from July 1, 2008 through March 31, 2021, the Company is covered by a prefunded deductible policy. Under this prefunded policy, the Company is self-insured for the first $500 per claim, subject to an aggregate maximum of $3,000. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers’ compensation claims was $1,115 and $1,039 at March 31, 2021 and December 31, 2020, respectively. The Company has a non-current receivable for workers’ compensation policies covering previous years of $2,123 and $2,050 which is included in "other noncurrent assets" on the Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020, respectively. The non-current receivable is a function of payments paid to the Company’s insurance carrier in excess of the estimated level of claims expected to be incurred. Any potential claims or settlements related to COVID-19 are uncertain at this time. </span></div>As of March 31, 2021, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to $200 per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims was $2,268 and $2,358 at March 31, 2021 and December 31, 2020, respectively. The differences between actual settlements and reserves are included in expense in the period finalized. Any potential claims or settlements related to COVID-19 are uncertain at this time. 1000000 3000000 5000000 24824000 24744000 79 21 1549000 1840000 1159000 1025000 P5Y P5Y 1000000 500000 8000000 9000000 1000000 7000000 8000000 P5Y 500000 3000000 1115000 1039000 2123000 2050000 200000 2268000 2358000 STOCK-BASED COMPENSATION<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Plans</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (“Stock Purchase Plan”). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers. The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (“RSU's”) at 85% of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally two years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. In June 2016, our shareholders approved an amendment to the Stock Purchase Plan to increase the number of shares of our common stock authorized under the Plan from 150 shares to 350 shares. No grants can be made under the Stock Purchase Plan after April 25, 2028.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (“2010 Plan”), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. In June 2017, our shareholders approved an amendment to the 2010 Plan to increase the number of shares of our common stock authorized under the 2010 Plan from 380 shares to 680 shares. No grants can be made under the 2010 Plan after May 31, 2027.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Grants and Valuations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021 and 2020, the Compensation Committee of the Board of Directors approved grants totaling approximately 106 and 198 shares of restricted common stock, respectively, to certain employees and members of the Board of Directors. The fair value of restricted shares is determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest one-third on the first, second and third anniversaries of the </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">grant date. Unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. On March 13, 2020, the Compensation Committee of the Board of Directors approved the grant of 100 shares of common stock to the Company's Chief Executive Officer, as a one-time bonus in lieu of a 2020 salary increase and as recognition for completing the settlement with the Office of the Inspector General and the disposition of all of the Company's facilities in the State of Kentucky. The stock was fully vested on the date of the grant, and the grant date fair value of which was expensed during the quarter ended March 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In computing the fair value estimates for options and stock-only stock appreciation rights ("SOSARs") using the Black-Scholes-Merton valuation method, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon vesting of equity awards, all restrictions are removed. Our policy is to account for forfeitures of share-based compensation awards as they occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized activity of the equity compensation plans is presented below: </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:65.350%"><tr><td style="width:1.0%"/><td style="width:46.327%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.813%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.181%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options/</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SOSARs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.92 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired or cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.92 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.92 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:65.497%"><tr><td style="width:1.0%"/><td style="width:46.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.123%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.125%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.32 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.51 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized activity of the RSU's for the Stock Purchase Plan is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:66.666%"><tr><td style="width:1.0%"/><td style="width:47.364%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.680%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.773%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.683%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSU's</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.27 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SOSARs and Options were valued and recorded in the same manner, and, other than amounts that may be settled pursuant to employment agreements with certain members of management, will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation related to SOSARs and stock options using the Black-Scholes-Merton equity grant valuation model.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding stock options and SOSAR grants outstanding as of March 31, 2021:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:65.935%"><tr><td style="width:1.0%"/><td style="width:23.068%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.068%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.068%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.072%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range of</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Prices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8.14 to $10.21</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.83 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.86 </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of $95 and $338 in the three month periods ended March 31, 2021 and 2020, respectively. 0.85 P2Y 150000 350000 380000 680000 106000 198000 100000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized activity of the equity compensation plans is presented below: </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:65.350%"><tr><td style="width:1.0%"/><td style="width:46.327%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.813%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.181%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options/</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SOSARs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.92 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired or cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.92 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.92 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 65000 7.92 0 0 0 0 0 0 65000 7.92 65000 7.92 <div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:65.497%"><tr><td style="width:1.0%"/><td style="width:46.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.123%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.125%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.32 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.51 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized activity of the RSU's for the Stock Purchase Plan is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:66.666%"><tr><td style="width:1.0%"/><td style="width:47.364%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.680%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.773%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.683%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSU's</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.27 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 193000 3.32 106000 4.25 88000 3.99 0 0 211000 3.51 55000 2.92 37000 4.25 26000 3.93 66000 3.27 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding stock options and SOSAR grants outstanding as of March 31, 2021:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:65.935%"><tr><td style="width:1.0%"/><td style="width:23.068%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.068%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.068%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.072%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range of</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Prices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8.14 to $10.21</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.83 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.86 </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 8.14 10.21 8.83 45000 45000 5.86 5.86 5.86 20000 20000 65000 65000 95000 338000 INCOME TAXES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded an income tax expense from continuing operations of $343 during the three months ended March 31, 2021 and a benefit of $104 during the three months ended March 31, 2020.</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When assessing the recoverability of the Company’s recorded deferred tax assets, the accounting guidance, ASC 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requires that all available positive and negative evidence be considered in evaluating the likelihood that the Company will be able to realize the benefit of its deferred tax assets in the future, which is highly judgmental. Such evidence includes, but may not be limited to, scheduled reversals of deferred tax assets and liabilities, projected future taxable income, tax-planning strategies, and the results of recent operations. </span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company has a valuation allowance in the amount of $18,609. The Company will continue to periodically assess the realizability of its future deferred tax assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the CARES Act was enacted and signed into law. Certain provisions of the CARES Act impact the 2019 income tax provision computations of the Company and were reflected in the first quarter of 2020, or the period of enactment. The CARES Act contains modifications on the depreciation of qualified improvement property, as well as the limitation of business interest for tax years beginning in 2019 and 2020. The new life classification of the qualified improvement property, allowing for bonus depreciation to be taken, along with the modification to Section 163(j) to increase the allowable business interest deduction from 30% of adjusted taxable income to 50% of adjusted taxable income significantly increased the allowable deductions of the Company and result in additional taxable losses for the year-ended 2019, resulting in greater net operating losses (“NOL”) to be carried back. The NOL carryback resulted in a tax refund of $321 and an increase to the Work Opportunity Tax Credit (“WOTC”) deferred tax asset, which is offset by a full valuation allowance. These changes pursuant to the CARES Act did not have an impact during the three-month period ended March 31, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently under examination by any major income tax jurisdiction. During 2021, the statutes of limitations will lapse on the Company's 2017 Federal tax year and certain 2016 and 2017 state tax years. The Company does not believe the Federal or state statute lapses or any other event will significantly impact the balance of unrecognized tax benefits in the next twelve months. The net balance of unrecognized tax benefits was not material to the interim consolidated financial statements for the three months ended March 31, 2021 and 2020.</span></div> 343000 -104000 18609000 321000 EARNINGS PER COMMON SHARE<div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to basic and diluted net loss per common share is presented below in thousands, except per share:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.473%"><tr><td style="width:1.0%"/><td style="width:77.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.943%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.869%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator: Income (loss):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(510)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(243)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(753)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator: Basic Weighted Average Common Shares Outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,573</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,506</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options, SOSARs, Restricted Shares and Restricted Share Units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,741</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,506</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.614%"><tr><td style="width:1.0%"/><td style="width:70.949%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.249%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.152%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Per common share – basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:60.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share – basic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Per common share – diluted</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:60.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share – diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.28 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>The effects of 65 and 75 SOSARs and options outstanding were excluded from the computation of diluted earnings per common share in the three months ended March 31, 2021 and 2020, respectively, because these securities would have been anti-dilutive. <div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to basic and diluted net loss per common share is presented below in thousands, except per share:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.473%"><tr><td style="width:1.0%"/><td style="width:77.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.943%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.869%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator: Income (loss):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(510)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(243)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(753)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator: Basic Weighted Average Common Shares Outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,573</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,506</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options, SOSARs, Restricted Shares and Restricted Share Units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,741</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,506</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.614%"><tr><td style="width:1.0%"/><td style="width:70.949%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.249%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.152%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Per common share – basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:60.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share – basic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Per common share – diluted</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:60.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share – diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.28 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 2134000 -510000 -246000 -243000 1888000 -753000 6573000 6506000 168000 0 6741000 6506000 0.33 -0.08 -0.04 -0.04 0.29 -0.12 0.32 -0.08 -0.04 -0.04 0.28 -0.12 65000 75000 BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Therapy Services</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective November 1, 2020, the Company entered into agreements with a third party therapy company to outsource the therapy services that were previously provided by the Company through its wholly owned subsidiary Diversicare Therapy Services. The outsourced services include all physical, occupational, and speech therapy provided to patients of the Company’s facilities. The costs associated with these outsourced therapy services are included in Operating Expenses in the Company's Consolidated Statement of Operations. The contracts are for a three-year term, absent termination for cause by either party.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Lease Amendment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 1, 2020, the Company entered into an agreement with Omega to transfer operations of a facility located in Florida to another operator. The agreement effectively amended the Omega Master Lease to remove this center, reduce the annual rent expense, and release the Company from any further obligations arising under the Omega Master Lease with respect to the Florida facility. The remaining Lease terms remain unchanged with an initial term of twelve years and two optional 10-year extensions. The annual lease fixed escalator remains at 2.15%.</span></div> P3Y P12Y 2 P10Y 0.0215 XML 11 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Cover Page - shares
3 Months Ended
Mar. 31, 2021
May 05, 2021
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2021  
Document Transition Report false  
Entity File Number 1-12996  
Entity Registrant Name Diversicare Healthcare Services, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 62-1559667  
Entity Address, Address Line One 1621 Galleria Boulevard  
Entity Address, City or Town Brentwood  
Entity Address, State or Province TN  
Entity Address, Postal Zip Code 37027  
City Area Code 615  
Local Phone Number 771-7575  
Title of 12(b) Security Common Stock, $0.01 par value per share  
Trading Symbol DVCR  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   6,952,773
Entity Central Index Key 0000919956  
Amendment Flag false  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q1  
Current Fiscal Year End Date --12-31  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.21.1
INTERIM CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
CURRENT ASSETS:    
Cash $ 32,437 $ 30,821
Accounts receivable 49,008 53,691
Self-insurance receivables 1,159 1,025
Other receivables 4,064 4,622
Prepaid expenses and other current assets 4,348 5,356
Income tax refundable 234 1,746
Total current assets 91,250 97,261
PROPERTY AND EQUIPMENT, at cost 135,608 135,234
Less accumulated depreciation and amortization (93,242) (91,914)
Property and equipment, net 42,366 43,320
OTHER ASSETS:    
Operating lease right-of-use assets 282,931 290,296
Acquired leasehold interest, net 5,069 5,202
Other noncurrent assets 3,846 3,773
Total other assets 291,846 299,271
Total assets 425,462 439,852
CURRENT LIABILITIES:    
Current portion of long-term debt and finance lease obligations 1,677 1,660
Current portion of operating lease liabilities 29,429 28,583
Trade accounts payable 16,955 13,901
Accrued expenses:    
Payroll and employee benefits 14,420 15,393
Self-insurance reserves, current portion 14,126 12,665
Deferred income 19,505 25,900
Other current liabilities 10,485 14,743
Total current liabilities 106,597 112,845
NONCURRENT LIABILITIES:    
Long-term debt and finance lease obligations, less current portion and deferred financing costs, net 58,225 58,526
Operating lease liabilities, less current portion 266,435 274,155
Self-insurance reserves, less current portion 14,081 15,476
Government settlement accrual 7,000 8,000
Other noncurrent liabilities 2,353 2,155
Total noncurrent liabilities 348,094 358,312
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ DEFICIT:    
Common stock, authorized 20,000 shares, $.01 par value, 7,185 and 7,079 shares issued, and 6,953 and 6,847 shares outstanding, respectively 72 71
Treasury stock at cost, 232 shares of common stock (2,500) (2,500)
Paid-in capital 24,754 24,596
Accumulated deficit (51,584) (53,510)
Accumulated other comprehensive income 29 38
Total shareholders’ deficit (29,229) (31,305)
Total liabilities and shareholder's equity $ 425,462 $ 439,852
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.21.1
INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Mar. 31, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Common stock, shares authorized (in shares) 20,000,000 20,000,000
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares issued (in shares) 7,185,000 7,079,000
Common stock, shares outstanding (in shares) 6,953,000 6,847,000
Treasury stock, shares (in shares) 232,000 232,000
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.21.1
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Income Statement [Abstract]    
PATIENT REVENUES, NET $ 113,360 $ 119,987
OTHER OPERATING INCOME 11,321 0
EXPENSES:    
Operating 96,829 94,859
Lease and rent expense 13,249 13,512
Professional liability 2,083 1,839
General and administrative 6,765 6,758
Depreciation and amortization 2,295 2,288
Total expenses 121,221 119,256
OPERATING INCOME 3,460 731
OTHER INCOME (EXPENSE):    
Other income 39 115
Interest expense, net (1,022) (1,460)
Total other expense (983) (1,345)
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES 2,477 (614)
(PROVISION) BENEFIT FOR INCOME TAXES (343) 104
INCOME (LOSS) FROM CONTINUING OPERATIONS 2,134 (510)
LOSS FROM DISCONTINUED OPERATIONS:    
Operating loss, net of tax benefit (246) (243)
NET INCOME (LOSS) $ 1,888 $ (753)
Per common share – basic    
Continuing operations (in dollars per share) $ 0.33 $ (0.08)
Discontinued operations (in dollars per share) (0.04) (0.04)
Net income (loss) per common share – basic (in dollars per share) 0.29 (0.12)
Per common share – diluted    
Continuing operations (in dollars per share) 0.32 (0.08)
Discontinued operations (in dollars per share) (0.04) (0.04)
Net income (loss) per common share – diluted (in dollars per share) $ 0.28 $ (0.12)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:    
Basic (in shares) 6,573 6,506
Diluted (in shares) 6,741 6,506
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.21.1
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Income Statement [Abstract]    
Income tax benefit $ 72 $ 65
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.21.1
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Statement of Comprehensive Income [Abstract]    
NET INCOME (LOSS) $ 1,888 $ (753)
OTHER COMPREHENSIVE INCOME (LOSS):    
Change in fair value (9) (279)
Total other comprehensive loss (9) (279)
COMPREHENSIVE INCOME (LOSS) $ 1,879 $ (1,032)
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.21.1
INTERIM CONSOLIDATED STATEMENTS OF SHAREHOLDERS' DEFICIT - USD ($)
shares in Thousands, $ in Thousands
Total
Interest Rate Swap
Common Stock
Treasury Stock
Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss)
Interest Rate Swap
Balance (in shares) at Dec. 31, 2019     6,908 232        
Balance at Dec. 31, 2019 $ (36,916)   $ 69 $ (2,500) $ 24,026 $ (59,079) $ 568  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) (753)         (753)    
Issuance of equity grants, net (in shares)     190          
Issuance of equity grants, net 4   $ 1   3      
Interest rate cash flow hedge (279) $ (279)           $ (279)
Stock-based compensation 338       338      
Balance (in shares) at Mar. 31, 2020     7,098 232        
Balance at Mar. 31, 2020 (37,606)   $ 70 $ (2,500) 24,367 (59,832) 289  
Balance (in shares) at Dec. 31, 2020     7,079 232        
Balance at Dec. 31, 2020 (31,305)   $ 71 $ (2,500) 24,596 (53,510) 38  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) 1,888         1,888    
Issuance of equity grants, net (in shares)     106          
Issuance of equity grants, net 64   $ 1   63      
Interest rate cash flow hedge (9)              
Interest rate cash flow hedges 29         38 (9)  
Stock-based compensation 95       95      
Balance (in shares) at Mar. 31, 2021     7,185 232        
Balance at Mar. 31, 2021 $ (29,229)   $ 72 $ (2,500) $ 24,754 $ (51,584) $ 29  
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.21.1
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:    
NET INCOME (LOSS) $ 1,888 $ (753)
Loss from discontinued operations (246) (243)
INCOME (LOSS) FROM CONTINUING OPERATIONS 2,134 (510)
Adjustments to reconcile income (loss) from continuing operations to net cash provided by operating activities:    
Depreciation and amortization 2,295 2,288
Provision for self-insured professional liability, net of cash payments 474 173
Amortization of right-of-use assets 6,880 5,663
Stock-based compensation 95 338
Provision for leases in excess of cash payments 485 821
Other 93 517
Changes in assets and liabilities affecting operating activities:    
Receivables 4,549 246
Prepaid expenses and other assets 1,136 792
Trade accounts payable and accrued expenses (1,461) (2,021)
Deferred income (6,395) 0
Operating lease liabilities (6,874) (5,656)
Net cash provided by continuing operations 3,411 2,651
Discontinued operations (246) (243)
Net cash provided by operating activities 3,165 2,408
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property and equipment (1,208) (927)
Purchases of property and equipment with stimulus funds (305) 0
Net cash used in continuing operations (1,513) (927)
Discontinued operations 0 0
Net cash used in investing activities (1,513) (927)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Repayment of debt and finance lease obligations (377) (2,113)
Proceeds from issuance of debt 0 2,500
Proceeds from stimulus funds used to purchase property and equipment 305 0
Financing costs 0 (419)
Issuance and redemption of employee equity awards, net 36 4
Net cash used in continuing operations (36) (28)
Discontinued operations 0 0
Net cash used in financing activities (36) (28)
NET INCREASE IN CASH 1,616 1,453
CASH, beginning of period 30,821 2,710
CASH, end of period 32,437 4,163
SUPPLEMENTAL INFORMATION:    
Cash payments of interest 1,101 1,599
Cash (refunds) payments of income taxes $ (1,217) $ 10
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.21.1
BUSINESS
3 Months Ended
Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BUSINESS BUSINESS
Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare” or the “Company”) provides long-term care services to nursing center patients in eight states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Indiana, Kansas, Mississippi, Missouri, Ohio, Tennessee, and Texas.
As of March 31, 2021, the Company’s continuing operations consist of 61 nursing centers with 7,250 licensed nursing beds. The Company owns 15 and leases 46 of its nursing centers. Our nursing centers range in size from 50 to 320 licensed nursing beds. The licensed nursing bed count does not include 397 licensed assisted and residential living beds.
COVID-19 Pandemic
In January 2020, the Secretary of U.S. Department of Health and Human Services (“HHS”) declared a national public health emergency due to a novel coronavirus. In March 2020, the World Health Organization categorized COVID-19, a disease caused by this coronavirus (“COVID-19”), as a pandemic. According to the Centers for Disease Control and Prevention (“CDC”), older adults and people with certain underlying medical conditions are at higher risk for serious illness from COVID-19. CDC has identified nursing home populations as being at high risk of being affected by pathogens like COVID-19 as a result of the congregate nature of nursing homes and the resident population served.
The Centers for Medicare & Medicaid Services (“CMS”) and the CDC have issued guidance to state and local governments and long-term care facilities to help mitigate the spread of COVID-19. For example, on March 13, 2020, CMS issued a memorandum directing long-term care facilities to significantly restrict visitors and nonessential workers and to restrict communal activities, among other measures. On May 18, 2020, CMS provided “reopening” recommendations for state and local officials to determine the level of mitigation needed to prevent the transmission of COVID-19 in nursing homes, including criteria for relaxing various restrictions. On March 10, 2021, CMS updated its guidance for visitation in nursing homes to account for the availability of COVID-19 vaccines, further relaxing visitation restrictions while emphasizing the importance of maintaining infection prevention practices. To help nursing homes and other providers respond to and contain the spread of COVID-19, CMS has also issued temporary emergency blanket waivers to various government healthcare program requirements. For example, through the end of the public health emergency declaration, CMS is waiving the requirement for a three-day hospital stay prior to Medicare Part A coverage of skilled nursing facility benefits, which allows Medicare beneficiaries that require a new or changed skilled level of care to receive that care under Medicare Part A from a skilled nursing facility without satisfying the hospital stay requirement (sometimes referred to as “skilled in place”). CMS continues to review the need for the waivers and has announced early termination of some waivers as the pandemic and nursing home practices have evolved. In addition, CMS has announced COVID-19 reporting requirements and focused infection control surveys intended to assess long-term care facility compliance with infection control requirements in connection with the COVID-19 pandemic. CDC guidance includes infection prevention and control practices intended to protect both nursing home residents and healthcare personnel.
On March 27, 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) which includes, among other things, modifications to the limitation on business interest expense and net operating loss provisions relative to the payment of Federal income taxes and allows an optional payment deferral of the employer's portion of Social Security taxes that were otherwise due through December 31, 2020. These provisions of the CARES Act were effective after the date of enactment and also include the appropriation of stimulus funds to Medicare and Medicaid providers. The Paycheck Protection Program and Health Care Enhancement Act ("PPPHCE Act"), enacted on April 24, 2020, the Consolidated Appropriations Act, 2021 ("CAA"), enacted December 27, 2020, and American Rescue Plan Act of 2021 ("ARPA"), enacted on March 11, 2021, provide for additional emergency appropriations for COVID-19 response.
Together, the CARES Act and other enacted legislation, authorize funding to healthcare entities to be distributed through the Public Health and Social Services Emergency Fund ("PHSSEF"), also known as the Provider Relief Fund. Payments from PHSSEF, as made to providers through general and targeted distributions, are intended to compensate providers for lost revenues and healthcare-related expenses attributable to the COVID-19 pandemic only. As long as the recipient has sufficient COVID-19 attributable expenses and lost revenues, as defined by the PHSSEF, between January 1, 2020 and June 30, 2021 and complies with certain terms and conditions, these payments are not required to be repaid. The terms and conditions include, among others, requirements to comply with certain reporting requirements, limitations on balance billing and restrictions
against using PHSSEF funds to reimburse expenses or losses that have been reimbursed from other sources or that other sources are obligated to reimburse. The CAA provides that targeted distribution payments made to an eligible entity may be allocated by the entity's parent organization among its subsidiary eligible health care providers and the entity receiving the targeted distribution payments remains responsible for reporting obligations. The Company is utilizing the funds it received from the PHSSEF to compensate for COVID-19 attributable lost revenues and pay for permissible expenses, including but are not limited to increased wages and increased costs for personal protective equipment, infection control supplies, and COVID-19 testing.
Additionally, the CARES Act and other enacted legislation authorized additional relief funding to skilled nursing facilities and nursing homes in the form of Nursing Home Infection Control distributions, with a fixed $10,000 distributed for each facility and variable distributions based on number of beds. The legislation also provides for infection control quality incentive payments to skilled nursing facilities and nursing homes based on certain performance measures tied to COVID-19 infections and mortalities. These payments were calculated based on monthly performance periods running from September through December 2020, with the total available bonus payment for each performance period determined in part based on data reported via Certification and Survey Provider Enhanced Reports ("CASPER"). The terms and conditions for this distribution limit use of payments to certain infection control expenses. HHS has not yet published reporting requirements for these distributions and has not yet stipulated a time period by which these funds must be used.
The Company is still evaluating the most recent guidance for amounts distributed under the CARES Act and other enacted legislation; however, the Company currently anticipates, but cannot guarantee, that it will have sufficient COVID-19 attributable expenses and lost revenues to retain the PPSSEF payments it has received to date. The Company will not be able to determine the amount of used funds until the form, process and reporting rules are finalized by the federal government, and the Company knows the full extent of its COVID-19 attributable expenses and lost revenues. There also can be no assurance that the PHSSEF funds will ultimately be enough to reimburse the Company for the full extent of its COVID-19 attributable expenses and losses.
As a result of the COVID-19 pandemic, we have experienced and may continue to experience price increases in equipment, pharmaceuticals, and medical supplies due to increased demand and limited availability for certain items. Staffing, equipment, pharmaceutical and medical supplies and vaccine shortages may impact our ability to admit and treat patients. We have incurred, and may continue to incur, increased expenses arising from the COVID-19 pandemic, particularly in the form of increased labor costs, testing and the increased costs of personal protective equipment, food and infection control supplies. The Company expects such increased expenses to continue and likely increase further into 2021. Refer to Note 4 "COVID-19 Pandemic" for further information.
Since the end of calendar year 2020, there have been additional cases of COVID-19 at certain of our centers. We have experienced and may continue to experience reduced occupancy in our centers, in part due to perceived risks by patients and family members of residential care and their perception of restrictions such as limited visitation policies (which have been relaxed pursuant to CMS guidance), a reduction in patients released to nursing homes from hospitals and other healthcare facilities, and a general reluctance to seek medical care or interface with the healthcare system during the pandemic or for an undetermined period of time. Occupancy may also be affected by the data each nursing home is required to report, including the number of confirmed and suspected cases of COVID-19 and resident deaths related to COVID-19, which is made publicly available through the CDC National Healthcare Safety Network.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
3 Months Ended
Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
The interim consolidated financial statements for the three month periods ended March 31, 2021 and 2020, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at March 31, 2021, the results of operations, changes in shareholders' deficit and cash flows for the three month period ended March 31, 2021 and 2020. The Company’s balance sheet information at December 31, 2020, was derived from its audited consolidated financial statements as of December 31, 2020.
The results of operations for the periods ended March 31, 2021 and 2020 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020.
PHSSEF Funds
During the year ended December 31, 2020, the Company implemented certain changes to its accounting policies related to the recognition of stimulus funds through the PHSSEF, which it has applied consistently throughout the period ended March 31, 2021. There is no U.S. GAAP that explicitly covers accounting for government "grants" to for-profit entities with the exception of certain agricultural subsidies. In the absence of authoritative U.S. GAAP guidance, the Company considered the application of other authoritative accounting guidance by analogy and concluded that the guidance outlined in International Accounting Standards 20 - Accounting for Government Grants and Disclosures of Government Assistance ("IAS 20") was the most appropriate analogy for the purpose of recording and classifying the federal and certain state stimulus funds received by the Company. Under IAS 20, once it is reasonably assured that the entity will comply with the conditions of the grant, the grant money should be recognized on a systematic basis over the periods in which the entity recognizes the related expenses or losses for which the grant money is intended to compensate. The Company recognizes grants once both of the following conditions are met: (1) the Company is eligible to receive the grant, and (2) the Company is able to comply with the relevant conditions of the grant. Federal and certain state stimulus funds that are recognized to offset healthcare related expenses and lost revenue attributable to COVID-19 are reflected as "other operating income" on the accompanying interim consolidated statement of operations. Federal stimulus funds received and used toward capital improvements that assist with the response to and prevention and spread of COVID-19 is accounted for as a capital grant. For such an asset acquired with the use of a stimulus funds, the Company will recognize the asset as a net zero asset. Refer to Note 4, "COVID-19 Pandemic" to the interim consolidated financial statements included in this report for additional information.
Additionally, the Company has received Medicaid stimulus funds, which are recognized in accordance with ASC 606. Refer to Note 5, "Revenue Recognition and Accounts Receivable" to the interim consolidated financial statements included in this report for additional information.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.21.1
RECENT ACCOUNTING GUIDANCE
3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
RECENT ACCOUNTING GUIDANCE
Accounting Standards Recently Issued But Not Yet Adopted by the Company
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new guidance intends to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for smaller reporting companies for the fiscal year beginning after December 15, 2022 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related disclosures.
In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848). The new guidance contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU No. 2020-04 is optional and may be elected over time as reference rate reform activities occur. During the first quarter of 2020, the Company elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The amendments in the ASU are effective for all entities as of March 12, 2020 through December 31, 2022. The Company continues to evaluate changes in the market and may apply other elections, as applicable, in the future as allowed under ASU No. 2020-04.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.21.1
COVID-19 PANDEMIC
3 Months Ended
Mar. 31, 2021
Unusual or Infrequent Items, or Both [Abstract]  
COVID-19 PANDEMIC COVID-19 PANDEMICAs of March 31, 2021, the Company has received $51,607 from the PHSSEF. The Company recognized $10,534 as income, which is reflected in "other operating income" in the Company's results of operations for the three month period ended March 31, 2021. For the three months ended March 31, 2021, the Company utilized $305 of these stimulus dollars to fund capital improvements to prevent the spread of COVID-19. The remaining stimulus funds of $19,505 as of March 31, 2021 are classified as "deferred income" on the interim consolidated balance sheet, which also includes Nursing Home Infection Control Distributions. The Nursing Home Infection Control Distributions, which also include infection control quality incentive payments, are subject to terms and conditions that require recipients to use the funds for infection control expenses. HHS has not yet published reporting requirements for these distributions and has not yet stipulated a time period by which these funds must be used. The Company recognized $787 of grant funds from states, which is included in "other operating income" in the Company's results of operations for the three month period ended March 31, 2021. Additionally, the Families First Coronavirus Response Act provided states with a temporary increase in the regular federal matching rate, or federal medical assistance percentage, used to determine the federal government's share of the cost of covered services in state Medicaid programs, provided the states agreed to certain conditions such as not imposing cost-sharing requirements for COVID-19-related testing
and treatment. The Company recognized $4,056 for the three month period ended March 31, 2021 of Medicaid and Hospice dollars related to this temporary increase in the federal matching rate, which related to patient services rendered and is reflected in "patient revenues, net" in the Company's results of operations for the three month period ended March 31, 2021.
The Company initially elected to participate in the payment deferral of the employer's portion of Social Security taxes. During the third quarter of 2020, the Company ceased the deferral election and paid $3,185. As of March 31, 2021, the Company has no remaining liability related to the payment deferral and does not expect to participate in the payment deferral going forward.
The CARES Act and other stimulus legislation also include other provisions offering financial relief, for example lifting the Medicare sequestration from May 1, 2020 through December 31, 2021, which would have otherwise reduced payments to Medicare providers by 2% as required by the Budget Control Act of 2011 (but also extending sequestration through 2030). For the three month period ended March 31, 2021, the suspension of the Medicare sequestration positively impacted net patient revenues by $751. However, in addition to providing funding for healthcare providers, the ARPA increases the federal budget deficit in a manner that triggers an additional statutorily mandated sequestration under the Pay-As-You-Go Act of 2010 ("PAYGO Act"). As a result, absent congressional action, Medicare spending will be reduced by up to 4 percentage points in FY 2022, in addition to the existing sequestration requirements of the Budget Control Act of 2011.
The Company incurred an additional $8,088 of labor expense and $3,905 for testing and the increased costs of personal protective equipment, food and infection control supplies related to the COVID-19 pandemic for the three month period ended March 31, 2021. These expenses are reflected in "operating expense" in the Company's results of operations for the three month period ended March 31, 2021.
The Company is closely monitoring and evaluating the impact of the COVID-19 pandemic on all aspects of its business. We have identified team members and patients who have tested positive for COVID-19 at all of our centers, and we have incurred an increase in the costs of caring for the team members, patients, and residents in those centers. The Company has also experienced reduced occupancy at its centers and has incurred additional expenditures preparing its centers for potential outbreaks and maintaining the healthcare delivery capacity of its centers. While we have experienced reduced occupancy and increased expenses, we received additional PHSSEF and other stimulus funds during 2020 and the first quarter of 2021, which have been used, and are expected to continue to be used to mitigate the impact of COVID-19 derived lost revenues associated with the reduced occupancy as well as increased expenses, and any cash flow or liquidity impacts therefrom. The Company has an interdisciplinary team monitoring and staying up to date on the latest information about COVID-19. The Company has implemented precautionary measures and response protocols to minimize the spread of COVID-19, following guidance from CMS and the CDC. Nevertheless, the Company expects additional COVID-19 cases will occur at its centers. The Company is continuing to evaluate and consider the potential impact that COVID-19 may have on its liquidity, financial condition and results of operations due to numerous uncertainties. However, given the uncertainty as to the duration of the COVID-19 pandemic and the timing and availability of effective medical treatment and vaccines, it could have a material adverse effect on the Company's future results of operations, financial condition and liquidity.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.21.1
REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE
3 Months Ended
Mar. 31, 2021
Revenue from Contract with Customer [Abstract]  
REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE
The Company's revenue is derived from providing quality healthcare services to its patients. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. The promise to provide quality care is accounted for as a single performance obligation satisfied at a point in time, when those services are rendered on a daily basis.
The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans).
Disaggregation of Revenue and Accounts Receivable
In accordance with ASC 606, the Company recognized $3,757 and $299 of Medicaid and Hospice stimulus dollars, respectively, for the three month period ended March 31, 2021 that are reflected as patient revenues in the Company's results of operations and in the table below. Refer to Note 4, "COVID-19 Pandemic" for more information. The following table summarizes revenue from contracts with customers by payor source from continuing operations for the periods presented (dollar amounts in thousands):
Three Months Ended March 31,
20212020
Medicaid$49,955 44.1 %$54,330 45.3 %
Medicare24,458 21.6 %20,672 17.2 %
Managed Care13,676 12.1 %12,596 10.5 %
Private Pay and other25,271 22.2 %32,389 27.0 %
Total$113,360 100.0 %$119,987 100.0 %

Accounts receivable from continuing operations as of March 31, 2021 and December 31, 2020 are summarized in the following table:
March 31,December 31,
20212020
Medicaid$17,254 $17,354 
Medicare9,350 14,273 
Managed Care7,861 8,021 
Private Pay and other14,543 14,043 
Total accounts receivable$49,008 $53,691 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.21.1
LONG-TERM DEBT
3 Months Ended
Mar. 31, 2021
Debt Disclosure [Abstract]  
LONG-TERM DEBT LONG-TERM DEBT
The Company maintains a credit facility with a syndicate of banks. The Company originally entered into the credit facility in May 2013, and subsequently amended the facility. As of December 31, 2019, the credit facility consisted of a mortgage loan of $67,500, an acquisition loan with a borrowing capacity of $12,500, a revolver with a borrowing capacity of $40,250 and an affiliated revolver with a borrowing capacity of $2,000.
On October 14, 2020, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") with a syndicate of banks, which consists of a $62,000 mortgage loan subsequently amended ("Amended Mortgage Loan"), a $36,000 revolver subsequently amended ("Amended Revolver") and a $2,000 affiliated revolver amended ("Amended Affiliated Revolver"). The Amended Mortgage Loan, Amended Revolver and Amended Affiliated Revolver have a 3-year maturity through September 30, 2023. The Amended Mortgage Loan has a term of 3 years, with principal and interest payable monthly based on a 25-year amortization. Interest on the term loan facility is based on LIBOR plus 4.0% with a 1.0% floor. The Amended Mortgage Loan balance was $60,767 as of March 31, 2021 with an interest rate of 5.0%. The Amended Mortgage Loan consolidated the mortgage and acquisition loans. The Amended Mortgage Loan is secured by 15 owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan, the Amended Revolver and the Amended Affiliated Revolver are cross-collateralized and cross-defaulted. The Company’s Amended Revolver and Amended Affiliated Revolver have an interest rate of LIBOR plus 4.0% and are secured by accounts receivable and are subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.
As of March 31, 2021 and December 31, 2020, the Company had no outstanding borrowings under its revolvers. The interest rate related to the revolvers was 5.0% as of March 31, 2021. Annual fees for letters of credit issued under the Amended Revolver are 3.0% of the amount outstanding. The Company has four letters of credit with a total value of $12,387 outstanding as of March 31, 2021. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the Amended Revolver and the Amended Affiliated Revolver, and the maximum loan amount of $24,377 for these revolvers, the balance available for borrowing under the revolvers was $11,990 at March 31, 2021.
The Company’s debt agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. The Company is in compliance with all such covenants at March 31, 2021.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.21.1
DERIVATIVES AND HEDGING ACTIVITIES
3 Months Ended
Mar. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
DERIVATIVES AND HEDGING ACTIVITIES DERIVATIVES AND HEDGING ACTIVITIES
In February 2021, the Company entered into an interest rate cap agreement with a member of the bank syndicate as the counterparty. The Company entered into the interest rate cap agreement to mitigate the variable interest rate risk associated with its outstanding mortgage borrowings.
The Company designated the interest rate cap as a cash flow hedge, and the effective portion of the hedge is reflected as a component of other comprehensive income. The interest rate cap has the same maturity date as the Amended Mortgage Loan and has an amortizing notional amount that was $60,767 as of March 31, 2021. The interest rate cap agreement requires the counterparty to pay the Company an amount equal to the applicable notional amount multiplied by the rate by which the LIBOR index exceeds a 1% strike rate during the period.
The Company assesses the effectiveness of the interest rate cap on a quarterly basis and at March 31, 2021, the Company has determined that the interest rate cap was effective. Accordingly, the gain or loss related to the change in fair value of the interest rate cap is recorded in Accumulated Other Comprehensive Income and subsequently reclassified into interest expense in the same period during which the hedged forecasted transaction affects earnings. The fair value of the interest rate cap of $78 at March 31, 2021 was included in other noncurrent assets on the Company's Consolidated Balance Sheets.
In conjunction with the refinancing of its outstanding borrowings during October 2020, the Company terminated its interest rate swap and incurred a loss of $177. Following the termination, $90 was recorded in other comprehensive income and was reclassified as an adjustment to earnings over the remaining term of the original hedge. Of this amount, $38 was recorded as a decrease to retained earnings for the three months ended March 31, 2021.
As of March 31, 2021, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:
Interest Rate DerivativeNumber of InstrumentsNotional
Interest Rate Cap1$60,767 

The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the balance sheets as of March 31, 2021 and December 31, 2020.
Asset DerivativesLiability Derivatives
Fair Value at:Fair Value at:
Balance Sheet ClassificationMarch 31, 2021December 31, 2020Balance Sheet ClassificationMarch 31, 2021December 31, 2020
Interest Rate SwapOther noncurrent assets$— $— Other noncurrent liabilities$— $— 
Interest Rate CapOther noncurrent assets$78 $— Other noncurrent liabilities$— $— 

The table below presents the effect of cash flow hedge accounting on Accumulated Other Comprehensive Income for the three months ended March 31, 2021 and March 31, 2020.
Effect of Derivative Instruments on the Consolidated Statement of Income
Amount of Gain (Loss) Recognized in Other Comprehensive Income on DerivativeLocation of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into IncomeAmount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income
Three months ended March 31, Three months ended March 31,
2021202020212020
Interest Rate Swap$— $(329)
Interest Expense (a)
$(38)$50 
Interest Rate Cap$29 $— 
Interest Expense (a)
$— $— 
Total$29 $(329)$(38)$50 
(a) Total interest expense presented in the consolidated income statements for the three months ended March 31, 2021 and 2020 was $1,022 and $1,460, respectively.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.21.1
LEASES
3 Months Ended
Mar. 31, 2021
Leases [Abstract]  
LEASES LEASES
The Company has operating and finance leases for facilities, corporate offices, and certain equipment. The Company recognizes lease expense for these operating leases on a straight-line basis over the lease term. Leases with an initial term of one year or less are not recorded on the balance sheet. The Company's other leases have original lease terms of one to twelve years, some of which include options to extend the lease for up to twenty years, and some of which include options to terminate the leases within one year. The exercise of lease renewal options is at our sole discretion. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants. Upon adoption of Topic 842, the Company elected the practical expedient to not separate lease and non-lease components for all of its leases as the non-lease components are not significant to the overall lease costs.
ClassificationMarch 31, 2021December 31, 2020
Assets
   Operating lease assetsOperating lease right-of-use assets$282,931 $290,296 
   Finance lease assets
Property and equipment, net (a)
447 508 
Total leased assets$283,378 $290,804 
Liabilities
Current
   OperatingCurrent portion of operating lease liabilities$29,429 $28,583 
   FinanceCurrent portion of long-term debt and finance lease obligations255 251 
Noncurrent
   OperatingOperating lease liabilities, less current portion266,435 274,155 
   FinanceLong-term debt and finance lease obligations, less current portion and deferred financing costs, net
224 280 
Total lease liabilities $296,343 $303,269 
(a) Finance lease assets are recorded net of accumulated amortization of $532 and $471 as of March 31, 2021 and December 31, 2020, respectively.

Lease Cost of Continuing Operations
Three Months Ended March 31,
Classification20212020
Operating lease cost (a)
Lease and rent expense$13,249 $13,512 
Finance lease cost:
   Amortization of finance lease assetsDepreciation and amortization61 61 
   Interest on finance lease liabilitiesInterest expense, net
Short term lease costOperating expense151 179 
Net lease cost$13,470 $13,761 
(a) Includes variable lease costs, which are immaterial.
Maturity of Lease Liabilities
As of March 31, 2021
Operating Leases (a)
Finance Leases (a)
Total
2021$51,408 $283 $51,691 
202252,398 167 52,565 
202353,255 56 53,311 
202453,115 53,124 
202554,193 — 54,193 
After 2025128,178 — 128,178 
Total lease payments$392,547 $515 $393,062 
Less: Interest(96,683)(36)(96,719)
Present value of lease liabilities$295,864 $479 $296,343 
(a) Operating and finance lease payments exclude option to extend lease terms that are not reasonably certain of being exercised.
The measurement of right-of-use assets and lease liabilities requires the Company to estimate appropriate discount rates. To the extent the rate implicit in the lease is readily determinable, such rate is utilized. However, based on information available at lease commencement for the majority of our leases, the rate implicit in the lease is not known. In these instances, the Company utilizes an incremental borrowing rate, which represents the rate of interest that it would pay to borrow on a collateralized basis over a similar term.

Lease Term and Discount Rate
March 31, 2021December 31, 2020
Weighted-average remaining lease term (years)
   Operating leases7.687.91
   Finance leases2.042.26
Weighted-average discount rate
   Operating leases7.9%7.9%
   Finance leases6.1%6.2%

Other Information
Three Months Ended March 31,
20212020
Cash paid for amounts included in the measurement of lease liabilities
   Operating cash flows for operating leases$12,740 $12,673 
   Operating cash flows for finance leases
   Financing cash flows for finance leases57 52 
LEASES LEASES
The Company has operating and finance leases for facilities, corporate offices, and certain equipment. The Company recognizes lease expense for these operating leases on a straight-line basis over the lease term. Leases with an initial term of one year or less are not recorded on the balance sheet. The Company's other leases have original lease terms of one to twelve years, some of which include options to extend the lease for up to twenty years, and some of which include options to terminate the leases within one year. The exercise of lease renewal options is at our sole discretion. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants. Upon adoption of Topic 842, the Company elected the practical expedient to not separate lease and non-lease components for all of its leases as the non-lease components are not significant to the overall lease costs.
ClassificationMarch 31, 2021December 31, 2020
Assets
   Operating lease assetsOperating lease right-of-use assets$282,931 $290,296 
   Finance lease assets
Property and equipment, net (a)
447 508 
Total leased assets$283,378 $290,804 
Liabilities
Current
   OperatingCurrent portion of operating lease liabilities$29,429 $28,583 
   FinanceCurrent portion of long-term debt and finance lease obligations255 251 
Noncurrent
   OperatingOperating lease liabilities, less current portion266,435 274,155 
   FinanceLong-term debt and finance lease obligations, less current portion and deferred financing costs, net
224 280 
Total lease liabilities $296,343 $303,269 
(a) Finance lease assets are recorded net of accumulated amortization of $532 and $471 as of March 31, 2021 and December 31, 2020, respectively.

Lease Cost of Continuing Operations
Three Months Ended March 31,
Classification20212020
Operating lease cost (a)
Lease and rent expense$13,249 $13,512 
Finance lease cost:
   Amortization of finance lease assetsDepreciation and amortization61 61 
   Interest on finance lease liabilitiesInterest expense, net
Short term lease costOperating expense151 179 
Net lease cost$13,470 $13,761 
(a) Includes variable lease costs, which are immaterial.
Maturity of Lease Liabilities
As of March 31, 2021
Operating Leases (a)
Finance Leases (a)
Total
2021$51,408 $283 $51,691 
202252,398 167 52,565 
202353,255 56 53,311 
202453,115 53,124 
202554,193 — 54,193 
After 2025128,178 — 128,178 
Total lease payments$392,547 $515 $393,062 
Less: Interest(96,683)(36)(96,719)
Present value of lease liabilities$295,864 $479 $296,343 
(a) Operating and finance lease payments exclude option to extend lease terms that are not reasonably certain of being exercised.
The measurement of right-of-use assets and lease liabilities requires the Company to estimate appropriate discount rates. To the extent the rate implicit in the lease is readily determinable, such rate is utilized. However, based on information available at lease commencement for the majority of our leases, the rate implicit in the lease is not known. In these instances, the Company utilizes an incremental borrowing rate, which represents the rate of interest that it would pay to borrow on a collateralized basis over a similar term.

Lease Term and Discount Rate
March 31, 2021December 31, 2020
Weighted-average remaining lease term (years)
   Operating leases7.687.91
   Finance leases2.042.26
Weighted-average discount rate
   Operating leases7.9%7.9%
   Finance leases6.1%6.2%

Other Information
Three Months Ended March 31,
20212020
Cash paid for amounts included in the measurement of lease liabilities
   Operating cash flows for operating leases$12,740 $12,673 
   Operating cash flows for finance leases
   Financing cash flows for finance leases57 52 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.21.1
COMMITMENTS AND CONTINGENCIES
3 Months Ended
Mar. 31, 2021
Health Care Organizations [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Professional Liability and Other Liability Insurance
The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. All of the Company's nursing centers in Tennessee are now covered under the captive insurance policies along with many of the nursing centers in Alabama, Ohio and Texas, as well as those previously operated by the Company in Kentucky and Florida. The insurance coverage provided for these centers under the SHC policy provides coverage limits of at least $1,000 per medical incident with a sublimit per center of $3,000 and total annual aggregate policy limits of $5,000. All other centers within the Company's portfolio are covered through
various commercial insurance policies which provide similar coverage limits per medical incident, per location, and on an aggregate basis for covered centers. The deductibles for these policies are covered through the insurance subsidiary.
Reserve for Estimated Self-Insured Professional Liability Claims
Because the Company’s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company’s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of $24,824 and $24,744 as of March 31, 2021 and December 31, 2020, respectively. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.
The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this reserve. Since May 2012, the actuary has assisted management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished as of May 31 and November 30 of each year. The actuary primarily utilizes historical data regarding the frequency and cost of the Company’s past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company’s ultimate professional liability cost for current periods.
On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company’s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator’s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company’s evaluation of the actual claims information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period.
As of March 31, 2021, the Company is engaged in 79 professional liability lawsuits. Twenty-one lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company’s cash expenditures for self-insured professional liability costs were $1,549 and $1,840 for the three months ended March 31, 2021 and 2020, respectively.
The Company follows the accounting guidance in ASC Topic 954 that clarifies that a health care entity should not net insurance recoveries against a related professional liability claim and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the estimated insurance recovery receivables are included within "Self-insurance receivables" on the Consolidated Balance Sheet. As of March 31, 2021 and December 31, 2020 there are estimated insurance recovery receivables of $1,159 and $1,025 in "Self-insurance receivable", respectively.
Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Any potential claims or settlements related to COVID-19 are uncertain at this time. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company’s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company’s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company’s reported earnings and financial position for the period in which the change in accrual is made.
Civil Investigative Demand ("CID")
In February 2020, we entered into a settlement agreement with the U.S. Department of Justice and the State of Tennessee of actions alleging violations of the federal False Claims Act in connection with our provision of therapy and the completion of certain resident admission forms. This settlement resolved an investigation that had begun in 2012 and covers the time period from January 1, 2010 through December 31, 2015. This agreement requires annual payments for a period of five years ending in February 2025 and also requires a contingent payment in the event the Company sells any of its owned facilities during the five-year payment period. Relative to the settlement agreement, the Company paid $1,000 and $500 during the first quarters of 2021 and 2020, respectively. As of March 31, 2021 and December 31, 2020, the Company has $8,000 and $9,000 outstanding related to the settlement agreement, respectively. Of the outstanding balance related to the settlement agreement, $1,000 is reflected as "Other current liabilities" and the remaining $7,000 and $8,000 is reflected as "Government settlement
accrual" on the Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020, respectively. Failure to timely make any of these payments could result in rescission of the settlement and result in the government having a very large claim against us, including penalties, and/or make us ineligible to participate in certain government funded healthcare programs, any of which could in turn significantly harm our business and financial condition.
In conjunction with the settlement of the government investigation related to our therapy practices, we entered into a corporate integrity agreement ("CIA") with the Office of the Inspector General of CMS. The CIA has a term of five years and imposes material burdens on the Company, its officers and directors to take actions designed to ensure compliance with applicable healthcare laws, including requirements to maintain specific compliance positions within the Company, to report any non-compliance with the terms of the CIA, to return any overpayments received, to submit annual reports and for an annual audit of submitted claims by an independent review organization. The CIA sets forth penalties for non-compliance by the Company with the terms of the agreement, including possible exclusion from federally funded healthcare programs for material violations of the agreement.
Other Insurance
With respect to workers’ compensation insurance, substantially all of the Company’s employees are covered under either a prefunded deductible policy or state-sponsored programs. The Company has been and remains a non-subscriber to the Texas workers’ compensation system and, therefore, is completely self-insured for employee injuries with respect to its Texas operations. From the period from July 1, 2008 through March 31, 2021, the Company is covered by a prefunded deductible policy. Under this prefunded policy, the Company is self-insured for the first $500 per claim, subject to an aggregate maximum of $3,000. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers’ compensation claims was $1,115 and $1,039 at March 31, 2021 and December 31, 2020, respectively. The Company has a non-current receivable for workers’ compensation policies covering previous years of $2,123 and $2,050 which is included in "other noncurrent assets" on the Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020, respectively. The non-current receivable is a function of payments paid to the Company’s insurance carrier in excess of the estimated level of claims expected to be incurred. Any potential claims or settlements related to COVID-19 are uncertain at this time.
As of March 31, 2021, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to $200 per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims was $2,268 and $2,358 at March 31, 2021 and December 31, 2020, respectively. The differences between actual settlements and reserves are included in expense in the period finalized. Any potential claims or settlements related to COVID-19 are uncertain at this time.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.21.1
STOCK-BASED COMPENSATION
3 Months Ended
Mar. 31, 2021
Share-based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION
Overview of Plans
In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (“Stock Purchase Plan”). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers. The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (“RSU's”) at 85% of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally two years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. In June 2016, our shareholders approved an amendment to the Stock Purchase Plan to increase the number of shares of our common stock authorized under the Plan from 150 shares to 350 shares. No grants can be made under the Stock Purchase Plan after April 25, 2028.
In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (“2010 Plan”), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. In June 2017, our shareholders approved an amendment to the 2010 Plan to increase the number of shares of our common stock authorized under the 2010 Plan from 380 shares to 680 shares. No grants can be made under the 2010 Plan after May 31, 2027.
Equity Grants and Valuations
During the three months ended March 31, 2021 and 2020, the Compensation Committee of the Board of Directors approved grants totaling approximately 106 and 198 shares of restricted common stock, respectively, to certain employees and members of the Board of Directors. The fair value of restricted shares is determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest one-third on the first, second and third anniversaries of the
grant date. Unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. On March 13, 2020, the Compensation Committee of the Board of Directors approved the grant of 100 shares of common stock to the Company's Chief Executive Officer, as a one-time bonus in lieu of a 2020 salary increase and as recognition for completing the settlement with the Office of the Inspector General and the disposition of all of the Company's facilities in the State of Kentucky. The stock was fully vested on the date of the grant, and the grant date fair value of which was expensed during the quarter ended March 31, 2020.
In computing the fair value estimates for options and stock-only stock appreciation rights ("SOSARs") using the Black-Scholes-Merton valuation method, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.
Upon vesting of equity awards, all restrictions are removed. Our policy is to account for forfeitures of share-based compensation awards as they occur.
Summarized activity of the equity compensation plans is presented below:
Weighted
Options/Average
SOSARsExercise Price
Outstanding, December 31, 202065 $7.92 
Granted— — 
Exercised— — 
Expired or cancelled— — 
Outstanding, March 31, 202165 $7.92 
Exercisable, March 31, 202165 $7.92 
Weighted
Average
RestrictedGrant Date
SharesFair Value
Outstanding, December 31, 2020193 $3.32 
Granted106 4.25 
Vested(88)3.99 
Cancelled— — 
Outstanding, March 31, 2021211 $3.51 

Summarized activity of the RSU's for the Stock Purchase Plan is as follows:
Weighted
Average
Grant Date
RSU'sFair Value
Outstanding, December 31, 202055 $2.92 
Granted37 4.25 
Vested(26)3.93 
Outstanding, March 31, 202166 $3.27 
The SOSARs and Options were valued and recorded in the same manner, and, other than amounts that may be settled pursuant to employment agreements with certain members of management, will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation related to SOSARs and stock options using the Black-Scholes-Merton equity grant valuation model.
The following table summarizes information regarding stock options and SOSAR grants outstanding as of March 31, 2021:
Weighted
Average
Range ofExerciseGrantsGrants
Exercise PricesPricesOutstandingExercisable
$8.14 to $10.21
$8.83 45 45 
$5.86
$5.86 20 20 
65 65 
Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of $95 and $338 in the three month periods ended March 31, 2021 and 2020, respectively.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.21.1
INCOME TAXES
3 Months Ended
Mar. 31, 2021
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
The Company recorded an income tax expense from continuing operations of $343 during the three months ended March 31, 2021 and a benefit of $104 during the three months ended March 31, 2020.
When assessing the recoverability of the Company’s recorded deferred tax assets, the accounting guidance, ASC 740, Income Taxes, requires that all available positive and negative evidence be considered in evaluating the likelihood that the Company will be able to realize the benefit of its deferred tax assets in the future, which is highly judgmental. Such evidence includes, but may not be limited to, scheduled reversals of deferred tax assets and liabilities, projected future taxable income, tax-planning strategies, and the results of recent operations.
As of March 31, 2021, the Company has a valuation allowance in the amount of $18,609. The Company will continue to periodically assess the realizability of its future deferred tax assets.
On March 27, 2020, the CARES Act was enacted and signed into law. Certain provisions of the CARES Act impact the 2019 income tax provision computations of the Company and were reflected in the first quarter of 2020, or the period of enactment. The CARES Act contains modifications on the depreciation of qualified improvement property, as well as the limitation of business interest for tax years beginning in 2019 and 2020. The new life classification of the qualified improvement property, allowing for bonus depreciation to be taken, along with the modification to Section 163(j) to increase the allowable business interest deduction from 30% of adjusted taxable income to 50% of adjusted taxable income significantly increased the allowable deductions of the Company and result in additional taxable losses for the year-ended 2019, resulting in greater net operating losses (“NOL”) to be carried back. The NOL carryback resulted in a tax refund of $321 and an increase to the Work Opportunity Tax Credit (“WOTC”) deferred tax asset, which is offset by a full valuation allowance. These changes pursuant to the CARES Act did not have an impact during the three-month period ended March 31, 2021.
The Company is not currently under examination by any major income tax jurisdiction. During 2021, the statutes of limitations will lapse on the Company's 2017 Federal tax year and certain 2016 and 2017 state tax years. The Company does not believe the Federal or state statute lapses or any other event will significantly impact the balance of unrecognized tax benefits in the next twelve months. The net balance of unrecognized tax benefits was not material to the interim consolidated financial statements for the three months ended March 31, 2021 and 2020.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.21.1
EARNINGS PER COMMON SHARE
3 Months Ended
Mar. 31, 2021
Earnings Per Share [Abstract]  
EARNINGS PER COMMON SHARE EARNINGS PER COMMON SHARE
Information with respect to basic and diluted net loss per common share is presented below in thousands, except per share:
 
 Three Months Ended March 31,
 20212020
Numerator: Income (loss):
Income (loss) from continuing operations
$2,134 $(510)
Loss from discontinued operations, net of income taxes(246)(243)
Net income (loss)$1,888 $(753)
Denominator: Basic Weighted Average Common Shares Outstanding:6,5736,506
Dilutive effect of stock options, SOSARs, Restricted Shares and Restricted Share Units168 — 
Adjusted weighted average common shares outstanding6,7416,506
 
 Three Months Ended March 31,
 20212020
Net income (loss) per common share:
Per common share – basic
Income (loss) from continuing operations$0.33 $(0.08)
Loss from discontinued operations
(0.04)(0.04)
Net income (loss) per common share – basic$0.29 $(0.12)
Per common share – diluted
Income (loss) from continuing operations$0.32 $(0.08)
Loss from discontinued operations
(0.04)(0.04)
Net income (loss) per common share – diluted$0.28 $(0.12)
The effects of 65 and 75 SOSARs and options outstanding were excluded from the computation of diluted earnings per common share in the three months ended March 31, 2021 and 2020, respectively, because these securities would have been anti-dilutive.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.21.1
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS
3 Months Ended
Mar. 31, 2021
Business Combinations [Abstract]  
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS
Therapy Services
Effective November 1, 2020, the Company entered into agreements with a third party therapy company to outsource the therapy services that were previously provided by the Company through its wholly owned subsidiary Diversicare Therapy Services. The outsourced services include all physical, occupational, and speech therapy provided to patients of the Company’s facilities. The costs associated with these outsourced therapy services are included in Operating Expenses in the Company's Consolidated Statement of Operations. The contracts are for a three-year term, absent termination for cause by either party.
2020 Lease Amendment
On December 1, 2020, the Company entered into an agreement with Omega to transfer operations of a facility located in Florida to another operator. The agreement effectively amended the Omega Master Lease to remove this center, reduce the annual rent expense, and release the Company from any further obligations arising under the Omega Master Lease with respect to the Florida facility. The remaining Lease terms remain unchanged with an initial term of twelve years and two optional 10-year extensions. The annual lease fixed escalator remains at 2.15%.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Policies)
3 Months Ended
Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Accounting
The interim consolidated financial statements for the three month periods ended March 31, 2021 and 2020, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at March 31, 2021, the results of operations, changes in shareholders' deficit and cash flows for the three month period ended March 31, 2021 and 2020. The Company’s balance sheet information at December 31, 2020, was derived from its audited consolidated financial statements as of December 31, 2020.
The results of operations for the periods ended March 31, 2021 and 2020 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020.
PHSSEF Funds
During the year ended December 31, 2020, the Company implemented certain changes to its accounting policies related to the recognition of stimulus funds through the PHSSEF, which it has applied consistently throughout the period ended March 31, 2021. There is no U.S. GAAP that explicitly covers accounting for government "grants" to for-profit entities with the exception of certain agricultural subsidies. In the absence of authoritative U.S. GAAP guidance, the Company considered the application of other authoritative accounting guidance by analogy and concluded that the guidance outlined in International Accounting Standards 20 - Accounting for Government Grants and Disclosures of Government Assistance ("IAS 20") was the most appropriate analogy for the purpose of recording and classifying the federal and certain state stimulus funds received by the Company. Under IAS 20, once it is reasonably assured that the entity will comply with the conditions of the grant, the grant money should be recognized on a systematic basis over the periods in which the entity recognizes the related expenses or losses for which the grant money is intended to compensate. The Company recognizes grants once both of the following conditions are met: (1) the Company is eligible to receive the grant, and (2) the Company is able to comply with the relevant conditions of the grant. Federal and certain state stimulus funds that are recognized to offset healthcare related expenses and lost revenue attributable to COVID-19 are reflected as "other operating income" on the accompanying interim consolidated statement of operations. Federal stimulus funds received and used toward capital improvements that assist with the response to and prevention and spread of COVID-19 is accounted for as a capital grant. For such an asset acquired with the use of a stimulus funds, the Company will recognize the asset as a net zero asset. Refer to Note 4, "COVID-19 Pandemic" to the interim consolidated financial statements included in this report for additional information.
Additionally, the Company has received Medicaid stimulus funds, which are recognized in accordance with ASC 606. Refer to Note 5, "Revenue Recognition and Accounts Receivable" to the interim consolidated financial statements included in this report for additional information.
Accounting Standards Recently Issued But Not Yet Adopted by the Company
Accounting Standards Recently Issued But Not Yet Adopted by the Company
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new guidance intends to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for smaller reporting companies for the fiscal year beginning after December 15, 2022 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related disclosures.
In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848). The new guidance contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU No. 2020-04 is optional and may be elected over time as reference rate reform activities occur. During the first quarter of 2020, the Company elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The amendments in the ASU are effective for all entities as of March 12, 2020 through December 31, 2022. The Company continues to evaluate changes in the market and may apply other elections, as applicable, in the future as allowed under ASU No. 2020-04.
Revenue Recognition
The Company's revenue is derived from providing quality healthcare services to its patients. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. The promise to provide quality care is accounted for as a single performance obligation satisfied at a point in time, when those services are rendered on a daily basis.
The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans).
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.21.1
REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE (Tables)
3 Months Ended
Mar. 31, 2021
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue The following table summarizes revenue from contracts with customers by payor source from continuing operations for the periods presented (dollar amounts in thousands):
Three Months Ended March 31,
20212020
Medicaid$49,955 44.1 %$54,330 45.3 %
Medicare24,458 21.6 %20,672 17.2 %
Managed Care13,676 12.1 %12,596 10.5 %
Private Pay and other25,271 22.2 %32,389 27.0 %
Total$113,360 100.0 %$119,987 100.0 %
Schedule of Accounts Receivable
Accounts receivable from continuing operations as of March 31, 2021 and December 31, 2020 are summarized in the following table:
March 31,December 31,
20212020
Medicaid$17,254 $17,354 
Medicare9,350 14,273 
Managed Care7,861 8,021 
Private Pay and other14,543 14,043 
Total accounts receivable$49,008 $53,691 
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.21.1
DERIVATIVES AND HEDGING ACTIVITIES (Tables)
3 Months Ended
Mar. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Derivatives
As of March 31, 2021, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:
Interest Rate DerivativeNumber of InstrumentsNotional
Interest Rate Cap1$60,767 
Schedule of Fair Value of Derivative Instruments
The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the balance sheets as of March 31, 2021 and December 31, 2020.
Asset DerivativesLiability Derivatives
Fair Value at:Fair Value at:
Balance Sheet ClassificationMarch 31, 2021December 31, 2020Balance Sheet ClassificationMarch 31, 2021December 31, 2020
Interest Rate SwapOther noncurrent assets$— $— Other noncurrent liabilities$— $— 
Interest Rate CapOther noncurrent assets$78 $— Other noncurrent liabilities$— $— 
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)
The table below presents the effect of cash flow hedge accounting on Accumulated Other Comprehensive Income for the three months ended March 31, 2021 and March 31, 2020.
Effect of Derivative Instruments on the Consolidated Statement of Income
Amount of Gain (Loss) Recognized in Other Comprehensive Income on DerivativeLocation of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into IncomeAmount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income
Three months ended March 31, Three months ended March 31,
2021202020212020
Interest Rate Swap$— $(329)
Interest Expense (a)
$(38)$50 
Interest Rate Cap$29 $— 
Interest Expense (a)
$— $— 
Total$29 $(329)$(38)$50 
(a) Total interest expense presented in the consolidated income statements for the three months ended March 31, 2021 and 2020 was $1,022 and $1,460, respectively.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.21.1
LEASES (Tables)
3 Months Ended
Mar. 31, 2021
Leases [Abstract]  
Schedule of Lease Assets and Liabilities
ClassificationMarch 31, 2021December 31, 2020
Assets
   Operating lease assetsOperating lease right-of-use assets$282,931 $290,296 
   Finance lease assets
Property and equipment, net (a)
447 508 
Total leased assets$283,378 $290,804 
Liabilities
Current
   OperatingCurrent portion of operating lease liabilities$29,429 $28,583 
   FinanceCurrent portion of long-term debt and finance lease obligations255 251 
Noncurrent
   OperatingOperating lease liabilities, less current portion266,435 274,155 
   FinanceLong-term debt and finance lease obligations, less current portion and deferred financing costs, net
224 280 
Total lease liabilities $296,343 $303,269 
(a) Finance lease assets are recorded net of accumulated amortization of $532 and $471 as of March 31, 2021 and December 31, 2020, respectively.
Schedule of Lease Cost of Continuing Operations
Lease Cost of Continuing Operations
Three Months Ended March 31,
Classification20212020
Operating lease cost (a)
Lease and rent expense$13,249 $13,512 
Finance lease cost:
   Amortization of finance lease assetsDepreciation and amortization61 61 
   Interest on finance lease liabilitiesInterest expense, net
Short term lease costOperating expense151 179 
Net lease cost$13,470 $13,761 
(a) Includes variable lease costs, which are immaterial.
Schedule of Maturity of Operating Lease Liabilities
Maturity of Lease Liabilities
As of March 31, 2021
Operating Leases (a)
Finance Leases (a)
Total
2021$51,408 $283 $51,691 
202252,398 167 52,565 
202353,255 56 53,311 
202453,115 53,124 
202554,193 — 54,193 
After 2025128,178 — 128,178 
Total lease payments$392,547 $515 $393,062 
Less: Interest(96,683)(36)(96,719)
Present value of lease liabilities$295,864 $479 $296,343 
(a) Operating and finance lease payments exclude option to extend lease terms that are not reasonably certain of being exercised.
Schedule of Maturity of Finance Lease Liabilities
Maturity of Lease Liabilities
As of March 31, 2021
Operating Leases (a)
Finance Leases (a)
Total
2021$51,408 $283 $51,691 
202252,398 167 52,565 
202353,255 56 53,311 
202453,115 53,124 
202554,193 — 54,193 
After 2025128,178 — 128,178 
Total lease payments$392,547 $515 $393,062 
Less: Interest(96,683)(36)(96,719)
Present value of lease liabilities$295,864 $479 $296,343 
(a) Operating and finance lease payments exclude option to extend lease terms that are not reasonably certain of being exercised.
Summary of Lease Term and Discount Rate and Other Lease Information
Lease Term and Discount Rate
March 31, 2021December 31, 2020
Weighted-average remaining lease term (years)
   Operating leases7.687.91
   Finance leases2.042.26
Weighted-average discount rate
   Operating leases7.9%7.9%
   Finance leases6.1%6.2%

Other Information
Three Months Ended March 31,
20212020
Cash paid for amounts included in the measurement of lease liabilities
   Operating cash flows for operating leases$12,740 $12,673 
   Operating cash flows for finance leases
   Financing cash flows for finance leases57 52 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.21.1
STOCK-BASED COMPENSATION (Tables)
3 Months Ended
Mar. 31, 2021
Share-based Payment Arrangement [Abstract]  
Summarized Activity of Equity Compensation Plans
Summarized activity of the equity compensation plans is presented below:
Weighted
Options/Average
SOSARsExercise Price
Outstanding, December 31, 202065 $7.92 
Granted— — 
Exercised— — 
Expired or cancelled— — 
Outstanding, March 31, 202165 $7.92 
Exercisable, March 31, 202165 $7.92 
Schedule of Summarized Activity of Restricted Share Units
Weighted
Average
RestrictedGrant Date
SharesFair Value
Outstanding, December 31, 2020193 $3.32 
Granted106 4.25 
Vested(88)3.99 
Cancelled— — 
Outstanding, March 31, 2021211 $3.51 

Summarized activity of the RSU's for the Stock Purchase Plan is as follows:
Weighted
Average
Grant Date
RSU'sFair Value
Outstanding, December 31, 202055 $2.92 
Granted37 4.25 
Vested(26)3.93 
Outstanding, March 31, 202166 $3.27 
Schedule of Stock Options and SOSAR Grants Outstanding
The following table summarizes information regarding stock options and SOSAR grants outstanding as of March 31, 2021:
Weighted
Average
Range ofExerciseGrantsGrants
Exercise PricesPricesOutstandingExercisable
$8.14 to $10.21
$8.83 45 45 
$5.86
$5.86 20 20 
65 65 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.21.1
EARNINGS PER COMMON SHARE (Tables)
3 Months Ended
Mar. 31, 2021
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Net Income (Loss) Per Common Share
Information with respect to basic and diluted net loss per common share is presented below in thousands, except per share:
 
 Three Months Ended March 31,
 20212020
Numerator: Income (loss):
Income (loss) from continuing operations
$2,134 $(510)
Loss from discontinued operations, net of income taxes(246)(243)
Net income (loss)$1,888 $(753)
Denominator: Basic Weighted Average Common Shares Outstanding:6,5736,506
Dilutive effect of stock options, SOSARs, Restricted Shares and Restricted Share Units168 — 
Adjusted weighted average common shares outstanding6,7416,506
 
 Three Months Ended March 31,
 20212020
Net income (loss) per common share:
Per common share – basic
Income (loss) from continuing operations$0.33 $(0.08)
Loss from discontinued operations
(0.04)(0.04)
Net income (loss) per common share – basic$0.29 $(0.12)
Per common share – diluted
Income (loss) from continuing operations$0.32 $(0.08)
Loss from discontinued operations
(0.04)(0.04)
Net income (loss) per common share – diluted$0.28 $(0.12)
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.21.1
BUSINESS (Details)
Mar. 31, 2021
nursing_bed
nursing_center
state
Accounting Policies [Line Items]  
Number of states in which entity operates | state 8
Number of nursing centers | nursing_center 61
Number of licensed nursing beds 7,250
Number of nursing center facilities owned | nursing_center 15
Number of nursing center facilities leased | nursing_center 46
Number of licensed assisted and residential living beds 397
Minimum  
Accounting Policies [Line Items]  
Number of licensed nursing beds per center 50
Maximum  
Accounting Policies [Line Items]  
Number of licensed nursing beds per center 320
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.21.1
COVID-19 PANDEMIC (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Unusual or Infrequent Item, or Both [Line Items]    
COVID-19, PHSSEF funds received $ 51,607  
COVID-19, PHSSEF revenue 10,534  
Proceeds from stimulus funds used to purchase property and equipment 305 $ 0
COVID-19, remaining stimulus funds 19,505  
COVID-19, Medicaid revenue from states 3,757  
Medicaid and Hospice revenue 4,056  
Payroll and employee benefits, less current portion 3,185  
COVID-19, Medicaid sequestration amount 751  
COVID-19, salaries expense 8,088  
COVID-19, supplies expense 3,905  
Other operating income    
Unusual or Infrequent Item, or Both [Line Items]    
COVID-19, Medicaid revenue from states $ 787  
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.21.1
REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Revenue from Contract with Customer [Abstract]    
COVID-19, Medicaid revenue from states $ 3,757  
COVID-19, Hospice funds received 299  
Disaggregation of Revenue [Line Items]    
Total revenues $ 113,360 $ 119,987
Total revenues, as a percent 100.00% 100.00%
Medicaid    
Disaggregation of Revenue [Line Items]    
Total revenues $ 49,955 $ 54,330
Total revenues, as a percent 44.10% 45.30%
Medicare    
Disaggregation of Revenue [Line Items]    
Total revenues $ 24,458 $ 20,672
Total revenues, as a percent 21.60% 17.20%
Managed Care    
Disaggregation of Revenue [Line Items]    
Total revenues $ 13,676 $ 12,596
Total revenues, as a percent 12.10% 10.50%
Private Pay and other    
Disaggregation of Revenue [Line Items]    
Total revenues $ 25,271 $ 32,389
Total revenues, as a percent 22.20% 27.00%
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.21.1
REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE - Summary of Accounts Receivable (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Total accounts receivable $ 49,008 $ 53,691
Medicaid    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Total accounts receivable 17,254 17,354
Medicare    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Total accounts receivable 9,350 14,273
Managed Care    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Total accounts receivable 7,861 8,021
Private Pay and other    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Total accounts receivable $ 14,543 $ 14,043
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.21.1
LONG-TERM DEBT (Details)
3 Months Ended
Oct. 14, 2020
USD ($)
nursing_center
Mar. 31, 2021
USD ($)
letter_of_credit
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Acquisition Loan        
Line of Credit Facility [Line Items]        
Borrowing capacity       $ 12,500,000
Affiliated Revolving Credit Agreement        
Line of Credit Facility [Line Items]        
Borrowing capacity       2,000
Amended And Restated Credit Agreement        
Line of Credit Facility [Line Items]        
Number of owned nursing centers to secure Amended Mortgage Loan | nursing_center 15      
Number of letters of credit | letter_of_credit   4    
Amended And Restated Credit Agreement | Mortgage Term Loan | LIBOR        
Line of Credit Facility [Line Items]        
Interest rate percentage 4.00%      
Amended And Restated Credit Agreement | Mortgage Term Loan | Base Rate        
Line of Credit Facility [Line Items]        
Interest rate percentage 1.00%      
Mortgage Loan | Loans Payable        
Line of Credit Facility [Line Items]        
Borrowings outstanding   $ 60,767,000    
Mortgage Loan        
Line of Credit Facility [Line Items]        
Borrowing capacity       67,500,000
Mortgage Loan | Amended And Restated Credit Agreement        
Line of Credit Facility [Line Items]        
Borrowing capacity $ 62,000,000      
Period of amortization 25 years      
Mortgage Loan | Amended And Restated Credit Agreement | Mortgage Term Loan        
Line of Credit Facility [Line Items]        
Interest rate during period   5.00%    
Amended Revolver        
Line of Credit Facility [Line Items]        
Borrowing capacity       $ 40,250,000
Amended Revolver | Affiliated Revolving Credit Agreement        
Line of Credit Facility [Line Items]        
Borrowings outstanding   $ 0 $ 0  
Amended Revolver | Amended And Restated Credit Agreement        
Line of Credit Facility [Line Items]        
Borrowing capacity $ 2,000,000 $ 24,377,000    
Debt instrument term 3 years      
Interest rate during period   5.00%    
Letters of credit security deposit for a lease   $ 12,387,000    
Balance available for borrowing under revolving credit center   $ 11,990,000    
Amended Revolver | Mortgage Loan        
Line of Credit Facility [Line Items]        
Borrowing capacity $ 36,000,000      
Letter of Credit | Amended And Restated Credit Agreement        
Line of Credit Facility [Line Items]        
Annual fees for letters of credit issued under revolver (as a percentage)   3.00%    
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.21.1
DERIVATIVES AND HEDGING ACTIVITIES - Additional Information (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Oct. 31, 2020
Mar. 31, 2021
Interest Rate Cap | Cash Flow Hedging    
Derivative Instruments, Gain (Loss) [Line Items]    
Notional   $ 60,767
Strike rate   1.00%
Interest Rate Swap    
Derivative Instruments, Gain (Loss) [Line Items]    
Loss on contract termination $ 177  
Reclassified to earnings $ 90 $ 38
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.21.1
DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Derivatives (Details) - Interest Rate Cap - Cash Flow Hedging
$ in Thousands
Mar. 31, 2021
USD ($)
state
Derivative [Line Items]  
Number of Instruments | state 1
Notional | $ $ 60,767
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.21.1
DERIVATIVES AND HEDGING ACTIVITIES - Derivative Instruments in Statement of Financial Position, Fair Value (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Interest Rate Swap | Other noncurrent assets    
Derivatives, Fair Value [Line Items]    
Asset Derivatives $ 0 $ 0
Interest Rate Swap | Other noncurrent liabilities    
Derivatives, Fair Value [Line Items]    
Liability Derivatives 0 0
Interest Rate Cap | Other noncurrent assets    
Derivatives, Fair Value [Line Items]    
Asset Derivatives 78 0
Interest Rate Cap | Other noncurrent liabilities    
Derivatives, Fair Value [Line Items]    
Liability Derivatives $ 0 $ 0
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.21.1
DERIVATIVES AND HEDGING ACTIVITIES - Effect Of Cash Flow Hedge Accounting On Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of Gain (Loss) Recognized in Other Comprehensive Income on Derivative $ 29 $ (329)
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income (38) 50
Interest expense 1,022 1,460
Interest Rate Swap    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of Gain (Loss) Recognized in Other Comprehensive Income on Derivative 0 (329)
Interest expense 1,022 1,460
Interest Rate Swap | Interest Expense    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income (38) 50
Interest Rate Cap    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of Gain (Loss) Recognized in Other Comprehensive Income on Derivative 29 0
Interest Rate Cap | Interest Expense    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income $ 0 $ 0
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.21.1
LEASES - Narrative (Details)
3 Months Ended
Mar. 31, 2021
Dec. 01, 2020
Lessee, Lease, Description [Line Items]    
Original lease term   12 years
Other leases renewal term 20 years 10 years
Other leases termination period 1 year  
Minimum    
Lessee, Lease, Description [Line Items]    
Original lease term 1 year  
Maximum    
Lessee, Lease, Description [Line Items]    
Original lease term 12 years  
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.21.1
LEASES - Balance Sheet Classification (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Assets:    
Operating lease right-of-use assets $ 282,931 $ 290,296
Finance lease assets 447 508
Total leased assets 283,378 290,804
Liabilities, Current [Abstract]    
Current portion of operating lease liabilities 29,429 28,583
Finance lease, current 255 251
Liabilities, Noncurrent [Abstract]    
Operating lease liabilities, less current portion 266,435 274,155
Finance lease, noncurrent 224 280
Total lease liabilities 296,343 303,269
Accumulated amortization of finance leases $ 532 $ 471
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.21.1
LEASES - Lease Cost (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Leases [Abstract]    
Operating lease cost $ 13,249 $ 13,512
Finance lease cost:    
Amortization of finance lease assets 61 61
Interest on finance lease liabilities 9 9
Short term lease cost 151 179
Net lease cost $ 13,470 $ 13,761
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.21.1
LEASES - Maturities of Operating and Financing Lease Liabilities (Details)
$ in Thousands
Mar. 31, 2021
USD ($)
Operating Leases  
2021 $ 51,408
2022 52,398
2023 53,255
2024 53,115
2025 54,193
After 2025 128,178
Total lease payments 392,547
Less: Interest (96,683)
Present value of lease liabilities 295,864
Finance Leases  
2021 283
2022 167
2023 56
2024 9
2025 0
After 2025 0
Total lease payments 515
Less: Interest (36)
Present value of lease liabilities 479
Operating and Finance Lease Liabilities Payments Due [Abstract]  
2021 51,691
2022 52,565
2023 53,311
2024 53,124
2025 54,193
After 2025 128,178
Total lease payments 393,062
Less: Interest (96,719)
Present value of lease liabilities $ 296,343
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.21.1
LEASES - Other Lease Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Weighted-average remaining lease term (years)      
Operating leases 7 years 8 months 4 days   7 years 10 months 28 days
Finance leases 2 years 14 days   2 years 3 months 3 days
Weighted-average discount rate      
Operating leases 7.90%   7.90%
Finance leases 6.10%   6.20%
Cash paid for amounts included in the measurement of lease liabilities      
Operating cash flows for operating leases $ 12,740 $ 12,673  
Operating cash flows for finance leases 9 9  
Financing cash flows for finance leases $ 57 $ 52  
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.21.1
COMMITMENTS AND CONTINGENCIES (Details)
3 Months Ended
Mar. 31, 2021
USD ($)
lawsuit
Mar. 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
Malpractice Insurance [Line Items]      
Number of professional liability lawsuits | lawsuit 79    
Cash expenditures for self-insured professional liability costs $ 1,549,000 $ 1,840,000  
Other Insurance      
Liability for workers compensation claims 1,115,000   $ 1,039,000
Workers compensation insurance, non current receivable for excess premiums paid $ 2,123,000   2,050,000
CID      
Malpractice Insurance [Line Items]      
Settlement payment period 5 years    
Payments made during period $ 1,000,000 $ 500,000  
Outstanding related to settlement agreement 8,000,000   9,000,000
Current loss accrual 1,000,000    
Noncurrent loss accrual $ 7,000,000   8,000,000
CIA term 5 years    
Self-insurance receivables, current portion      
Malpractice Insurance [Line Items]      
Estimated insurance recovery receivables $ 1,159,000   1,025,000
Scheduled for trial or arbitration over next 12 months      
Malpractice Insurance [Line Items]      
Number of professional liability lawsuits | lawsuit 21    
Professional malpractice liability insurance      
Malpractice Insurance [Line Items]      
Liability for reported and estimated future claims $ 24,824,000   24,744,000
Professional malpractice liability insurance | SHC Risk Carriers, Inc      
Malpractice Insurance [Line Items]      
Insurance policy coverage limits per claim 1,000,000    
Malpractice insurance annual sublimit per center 3,000,000    
Aggregate policy limit 5,000,000    
Other Insurance      
Insurance policy coverage limits per claim 1,000,000    
Prefunded deductible policy      
Malpractice Insurance [Line Items]      
Insurance policy coverage limits per claim 500,000    
Other Insurance      
Insurance policy coverage limits per claim 500,000    
Professional liability insurance, annual coverage limit per facility 3,000,000    
Health insurance, maximum self-insured annual amount per individual 200,000    
Liability for reported claims and estimates for incurred but unreported claims $ 2,268,000   $ 2,358,000
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.21.1
STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Mar. 13, 2020
Jun. 30, 2008
Mar. 31, 2021
Mar. 31, 2020
Jun. 30, 2017
May 31, 2017
Jun. 30, 2016
May 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Share-based compensation expense     $ 95 $ 338        
Restricted Stock                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Grant of restricted common stock (in shares)     106,000 198,000        
Restricted Stock | First anniversary                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Vesting percentage       33.33%        
Restricted Stock | Second anniversary                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Vesting percentage       33.33%        
Restricted Stock | Third anniversary                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Vesting percentage       33.33%        
Chief Executive Officer                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Common stock granted to CEO (in shares) 100,000              
2008 Stock Purchase Plan                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Percentage of quoted market price offering rate   85.00%            
Restriction period   2 years            
Shares authorized under the plan (in shares)             350,000 150,000
2010 Long Term Incentive Plan                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Shares reserved for future issuance (in shares)         680,000 380,000    
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.21.1
STOCK-BASED COMPENSATION - Schedule of Activity of Equity Compensation Plans (Details) - Options/SOSARs
shares in Thousands
3 Months Ended
Mar. 31, 2021
$ / shares
shares
Number of Shares  
Outstanding, beginning (in shares) | shares 65
Granted (in shares) | shares 0
Exercised (in shares) | shares 0
Expired or cancelled (in shares) | shares 0
Outstanding, ending (in shares) | shares 65
Exercisable (in shares) | shares 65
Weighted Average Exercise Price  
Outstanding, beginning (in dollars per share) | $ / shares $ 7.92
Granted (in dollars per share) | $ / shares 0
Exercised (in dollars per share) | $ / shares 0
Expired or cancelled (in dollars per share) | $ / shares 0
Outstanding, ending (in dollars per share) | $ / shares 7.92
Exercisable, weighted average exercise price (in dollars per share) | $ / shares $ 7.92
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.21.1
STOCK-BASED COMPENSATION - Schedule of Restricted Stock and Restricted Stock Units Activity (Details) - $ / shares
shares in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Restricted Shares    
Number of Shares    
Outstanding, beginning (in shares) 193  
Granted (in shares) 106 198
Vested (in shares) (88)  
Cancelled (in shares) 0  
Outstanding, ending (in shares) 211  
Weighted Average Granted Date Fair Value    
Outstanding, beginning (in dollars per share) $ 3.32  
Granted (in dollars per share) 4.25  
Vested (in dollars per share) 3.99  
Cancelled (in dollars per share) 0  
Outstanding, ending (in dollars per share) $ 3.51  
RSU's    
Number of Shares    
Outstanding, beginning (in shares) 55  
Granted (in shares) 37  
Vested (in shares) (26)  
Outstanding, ending (in shares) 66  
Weighted Average Granted Date Fair Value    
Outstanding, beginning (in dollars per share) $ 2.92  
Granted (in dollars per share) 4.25  
Vested (in dollars per share) 3.93  
Outstanding, ending (in dollars per share) $ 3.27  
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.21.1
STOCK-BASED COMPENSATION - Schedule of Awards Outstanding and Exercisable (Details) - Options/SOSARs - $ / shares
shares in Thousands
3 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Weighted average exercise prices (in dollars per share) $ 7.92 $ 7.92
Grants outstanding (in shares) 65  
Grants exercisable (in shares) 65  
$8.14 to $10.21    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Range of exercise prices, minimum (in dollars per share) $ 8.14  
Range of exercise prices, maximum (in dollars per share) 10.21  
Weighted average exercise prices (in dollars per share) $ 8.83  
Grants outstanding (in shares) 45  
Grants exercisable (in shares) 45  
$5.86    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Range of exercise prices, minimum (in dollars per share) $ 5.86  
Range of exercise prices, maximum (in dollars per share) 5.86  
Weighted average exercise prices (in dollars per share) $ 5.86  
Grants outstanding (in shares) 20  
Grants exercisable (in shares) 20  
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.21.1
INCOME TAXES (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 27, 2020
Mar. 31, 2021
Mar. 31, 2020
Income Tax Disclosure [Abstract]      
(PROVISION) BENEFIT FOR INCOME TAXES   $ (343) $ 104
Valuation allowance   $ 18,609  
Tax refund $ 321    
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.21.1
EARNINGS PER COMMON SHARE - Basic and Diluted Net Income (Loss) Per Common Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Numerator: Income (loss):    
Income (loss) from continuing operations $ 2,134 $ (510)
Loss from discontinued operations, net of income taxes (246) (243)
Net income (loss) $ 1,888 $ (753)
Denominator: Basic Weighted Average Common Shares Outstanding (in shares) 6,573 6,506
Dilutive effect of stock options, SOSARs, Restricted Shares and Restricted Share Units (in shares) 168 0
Adjusted weighted average common shares outstanding (in shares) 6,741 6,506
Per common share – basic    
Income (loss) from continuing operations (in dollars per share) $ 0.33 $ (0.08)
Loss from discontinued operations (in dollars per share) (0.04) (0.04)
Net income (loss) per common share – basic (in dollars per share) 0.29 (0.12)
Per common share – diluted    
Income (loss) from continuing operations (in dollars per share) 0.32 (0.08)
Loss from discontinued operations (in dollars per share) (0.04) (0.04)
Net income (loss) per common share – diluted (in dollars per share) $ 0.28 $ (0.12)
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.21.1
EARNINGS PER COMMON SHARE - Narrative (Details) - shares
shares in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Earnings Per Share [Abstract]    
Antidilutive shares excluded from computation of diluted earnings per share (in shares) 65 75
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.21.1
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS (Details) - nursing_center
Nov. 01, 2020
Mar. 31, 2021
Dec. 01, 2020
Business Combinations [Abstract]      
Third-party contract term 3 years    
Original lease term     12 years
Number of lease extensions allowed     2
Lease extension period   20 years 10 years
Annual lease fixed escalators, percent     2.15%
EXCEL 61 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( !B!JU('04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " 8@:M2SJ&ULS9+! M2L0P$(9?17)OIVFQ2.CFLN))07!!\1:2V=U@DX9DI-VWMXV[740?P&-F_GSS M#4RG@]!#Q.8T8 ].O24@)<7_*ZA?6) ME-621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M !B!JU(SL.CA)04 -X4 8 >&PO=V]R:W-H965T&UL ME5A=<^(V%'W>_@H-TX=V)L26'"#L$&8"278SWSBZDL[1U6@CU4L>"J'):Q*G^54GU#K[Z#BY'XJ$Y^&3?S=1X) L=1ZF8*9(72<+5 M=B)BN;GJT,[AQ5.T"K5YX8Q'&5^)N=!_9C,%3TZ)$D2)2/-(ID2)Y57GFGZ< M>C; MO@>B4U^=$],5Q92OIB'^^"JXQI&(A:^-A <+FLQ%7%LD(#'SSUHI_Q- M$WA\?T"_LYV'SBQX+J8R_BL*='C5N>R00"QY$>LGN?DL]AWJ&3Q?QKG]3S:[ MMA<7'>(7N9;)/A@8)%&ZN_+7?2*. ]P3 6P?P-X%4.]$@+A.E9ACG6L'7".+T>"K70I$9C!CIDCSD2N0C1P.P M^>SX>Y#)#H2= /'(5YGJ,">W:2""M_$.$"I9L0.K"4,!OW)U3CQZ1IC+: V? M:5/XEKB]NN@W;+PR1YZ%\] <_7.]R+6":?&:3 HN0U:CIGB(&-6A4ZG"\=:\CC'\G59DMN8MB01Z*9"%4'1<<@W8I&P[[")MAR6;8ALV36$5FJ4"J'GA2.W8X MS@THN\HC']2(?!8\UJ&]G0NUCGR1GY'[U#]'^%*W4C^W#6/ DPI&DIM!/2-S M#5..2$6FLDBUVL(UJ.U& _K-+4;R2*)I&Y+/_)7 -EG M7=KK#?O] <:050Q9&X;700#^ >.SOR%?H!WYEM;G#H>D?4;))Q['( 2<3&01 MBS57F+G02L^I][_H3LT3#/>SW*2U5'&XB8)!V4B)DJN<@>+:_IY<.1EG2JZC MU*]/)H[Y_(!1J^R"XB+_GMI,YIK'Y.\H.[U"<$1OX#)T"E;&07&]MV-X#3O9 MTU1P@#[M840JEZ"XM'^1/N1D%LH4D^0&D,& =@>] Y))0 M]MOB=Y!1OU"0K5I:.-)4)@G(SEQ+_^6,_.J>NY1D7)$UCPM!,M@EV2TDQKKR M$HJ; +AL$*4K,M\F"QG7DFUPD>_3)VPO6ID$:V42TT*9A;[W?$L-EF91NU]N M0/SQ?I?]EEGE#*R5,]RGL'G;%41FM\0/5&N9X8@-S"I'8*T R9%#E\SNO'$L=IV/FR2OA9 M*^&_381:F=GU"1!T"'*69#RMSQT.V+3)9)7PLU;"/P^AW$8)X3"-A"JU9[A8 M'Y;D&SV:V_*5?"LTV%)JQ*.V=-PA]RRR.>58C_O#'AL,O)&SKB-5*3_#1?M M"E:> @NXAV+XE?PAZC.%0[GP-Z3#80_;EK/* 1BNV]=0MP2V=KF+>5U6)@T MC2-7R3IK4.5#%747Y<8H?PCPCSMX6;_V<+"F K^2>*]AI_Z.U;[\/,FK >X1 M957)NX>+\<%QCE.%5<0-<%TH]+I>+37GZ 3)Z(\]6,N);^J?W6%2^;8\O+NV M1U9.U7QW\@>%-\A73F*QA%#W? K3>T.TW8/6F;V/&HAM9:)O0T%#X0R#>#[ M4DI]># _4!YICO\#4$L#!!0 ( !B!JU))"Y70Q < -D? 8 >&PO M=V]R:W-H965T&ULK9EK<^(X%H;_BHKMFMVM(HUU\:TW214- MS(2J!+) S]1\5(P(KK8M1A:D,[]^99M@8EU(5^V7Q#9'\GMDG?,<2=]8H7[9<)%3J6[%\Z#<"4;7=:,\&R#/ M"P8Y38O>[77][%'<7O.]S-*"/0I0[O.O+.,O-SW8>WNP2)^WLGHPN+W> MT6>V9/+;[E&HN\&IEW6:LZ),>0$$V]STAO#+B)"J06WQ>\I>RK-K4+GRQ/GW MZF:ZONEYE2*6L41675#U[\!&+,NJGI2.OXZ=]D[OK!J>7[_U_FOMO'+FB99L MQ+,_TK72?2EY?FRL%.1I MT?RG/XX#<=8 $DL#=&R /MH 'QO@VM%&6>W6F$IZ>RWX"Q"5M>JMNJC'IFZM MO$F+ZC,NI5"_IJJ=O)W.5I/%] &,YK/E_'XZ'JXF8_!U>#^3>9K);@ M"GQ;CL&_/OT;? )I 59;OB]IL2ZO!U(IJ/H9),>W?6W>ABQO>Z#B,\"P#Y"' MH*'YR-U\S))3<^]]\X'R^^0\.CF/ZOZPI;_1M\5B,EN!X7*I_/SBZ!&?>L1U MC\36(RVWIF%I6@5UJRJR#K<8$1Q>#P[GWANLO*@:J(-!$CE)(DY)PR3A^T*6 M*N@2EA[H4\9,"IM._+-WD]CSHHY"WR# M@IF''.E1AG 0=.4:S#!&GD5M2R:(G;";K^XFBP^@#K9@@6ZRS)7WZNL4SR!C MJI("HBJ9KOCF:J]N[*$"=8B@",48=@?"8!=[*+9$-&QQ ]V\&2;J6PDUY6K9 M6YZM55DCF6"EX^/I1/&]H(L=DY6J52R"6_# CY"GX,7E/ 1UMN"(:'/,8!6& MV**S11!T,ZA)E@UT'!)UD* 8&D2:[&(4VM)ERQSHADXCTR%0!PE!OD)T5Z#! M#L>1;_O>+7-@_*&Z]'XZ_#J]GZZF$V?$HA84R V*T7'^[*K,JM(LWX",%\]7 M:O+G*@$_R3J5;=*B+L2:J.9/6?I<)V'C8"$#((*P6]D:K0)+3D,M1) ;(@9_ M>"EP0#%!W< VF45^9(D8=+8 <2-D)>B:51AL2O0=?;45 M0$C' @QBW^\*-9CAV+/$#&KI@=ST4*L(L6=M>>FX,=:DC380101 MV[=O>8+>P4"4("-:<,-B%!/J6B8%; M_& W?JSY[,,>&'!#O*A;RIO,?!+:OL+9;IM[N^TW?F"BJ%9=0!5S,F/U):U8 M13.C7JP)"3VOBP^#5>39$AQN:8Z9?R%O($-"R#LXZY8@Y5]:K2HPV[4 M-1GN)\3JW,(D\N+N)HW)3A52T%(TXQ9PV VXT?SA8;JJ-CZ6]3[(:#Y;36>_ M368CE>N,BIW]5>N]SBTP<.A/[\FZXF-S- M[\>3Q?*7?T0(AO\!X\FOT]%TY>PFW,CGN2)]_[@.[EEHOT;Y6F MD==7$0'*+155OOCTV8.J>A7@0+,]ZX.P#R._3NQAWPOCHQU(RU(5D?WZAZ ? M^_AX%9'PS83O92G54Y5:^U5"VK'ZH"=[-7Y"G9AA=Y5FLK&4P[@E*KZP+2A4 MUM^+UV9DWC;:^@!A=')DHYZUHV>4K^\'7B%?3T>7S-Z?"[3H)A>V#6FZ5MD? M)'272G.^)#H^$0G];E ;S7S;3@UI*4OA$CD[RW(CM%%]AJ(Z@9QY\<^RWHF5 MQG1Q[/S\@,VXL6.R,VWL#,[.7:M#[PZ>3O-O_P=02P,$% @ &(&K4JQ[ ME-VO @ @0< !@ !X;"]W;W)KFZ,LD@Q[+%"V!Z9\E%CI6>BI4K"P$X MM:"8_%R!91O>H[OO"X\DE6FS(+; M[Q9X!3-0/XJIT#.W84E)#DP2SI" 9<\9^)?#V,3;@)\$-G)KC$PE"\Z?S&22 M]AS/" (*B3(,6#_6, 1*#9&6\;?F=)J4!K@]?F6_MK7K6A98PI#37R156<\Y M=U *2UQ2]<@W-U#7$QF^A%-I_]&FBNU$#DI*J7A>@[6"G+#JB9]K'[8 ?OL M(*@!P6[B=C ;S\0A=#6X']\,QFMV,Q_,9.IEB 4QEH$B"Z2GZCKXA M%\E,K\JNJ[0*P^4F=<:K*F-P(.,=%BT4^FT@PJ7*N"#_($4GA-6KI_N,K<@C2VX^SW5??ZSVUW77 MVQ9^(O"-_G:CO_T%_046:(UI"59WRBG%0J("1%7#WA(J_GA+F=?R_'?RCP2] MD1XUTJ.O6T^D+(_;'NVX&?OGT:[K>^*\^.*@Z9U&>>?KRG5#E@JSE+#5,?F= M'5F=BRC4B2_'RKH CHN/=$QP&NYJ/AE62W:T& M:2XGW8-6A$E$8:F!7BO6#*)J^-5$\<+VS 57N@/;8:;O2! F0.\O.5>O$].& MFUNW_Q]02P,$% @ &(&K4N'78< &!@ Q@ !@ !X;"]W;W)KI[_) PG$CKL/;X"$\>0WGO'\8U^_\>A;O&5,H/? #^.; MQE:(W56K%:^V+'#C2[YC(?RSX5'@"KB,7EKQ+F+N.AT4^"UB&)U6X'IAHW^= MWIM'_6N^%[X7LGF$XGT0N-'W6^;SMYL&;AQN++R7K4ANM/K7._>%.4P\[N81 M7+4*+VLO8&'L\1!%;'/3&."K(363 :G%D\?>XJ/?* GEF?-OR<5X?=,P$B+F MLY5(7+CP]@GEV8S;D_A=O+;8W#:N! MUFSC[GVQX&\/+ ^HG?A;<3]./]%;;FLTT&H?"Q[D@X$@\,+LVWW/)^)H /A1 M#R#Y %(=8-8,H/D F@::D:5AC5SA]J\C_H:BQ!J\)3_2N4E'0S1>F*31$1'\ MZ\$XT1]/E_9B/$'#V=29?1Z/!DM[A)PE?$WLZ=)!LSLTF]N+P7(,!JB)'IT1 M.OMTCN*M&[$8>2%:;OD^=L-U?($^G5Q?MP0 )H]IK7*8VPR&U,!0-.&AV,;( M#M=L?3J^!8$5T9%#=+=$ZW#B1I>(X@M$#((5/,,?'VYH<&@QV33U1^LF.USQ M@"%'N(+!4A#H[\%S+"(HY7\TWLW"NYEZ-VN\SR%)D#.TL)_LZ:/M7*"IO50E M(7/32=TDR_RUCS&E'8CP]7AN5&:]GM4MS$XHVP5E6TLY6S[8BT--3>_1>#J< M36P59N:G?8J9I/&$4K8RU("= K"C39+]=6Y/'=NYTJ2D6_CJZH/=L<@57OBB MBJ\KD?(;UB5][5S7UW#9Q?$';5QL601RGPB:,FZY+]-JUU#88-RNB;ILW[BC)1N'@L&K M2='5+E#(A!*Q(SV^B0U"JI0JL^,4GG*6TH#UVI 5.$_G4=. L2P S9[4W%16 MF)IUDUGJ!-8+Q:%X/L\P [SGP3NV[\1(!]K,**UH MS@DK4I"*K]]6T>JFA/*5LUNNXZP% ZB%XXYM"1H[ &\)Z3[ M//3G'Q;!^*]DP^RM='DK]8/H]6,(&STOW">)XUD*>1BC,]@_KKGONU&,X&[V M=/7\9.Z[Q^_]E[2Z)A563>/2J'DY(:7&$+W&C+QXE07 UK_(GSW JI!)B_,C ML], 2O$A>O&9PC+)Q!N=)0OG/,6MS_G/1-:5D(U+:5NCL(+ ZK8,I!0L8OU: MZ:X]?R_TAPJED!"]D/QV\?844T2K+QX**TWQTE)2J%Y2?K]X\P=\5+P?FIT& M4$H+U6]D?J)X\ZS_3&Q8T5A(M?$JK#3E2TLYHT1;OE_L\?U#<@0W> *=O+=! M[">3V10Y#X.%[:#9X])9#J8CT'Z=?-*C RF]%MT6BSL[T%-/B;P[Z;2[U5ZK MM#)J-EFTU"*J/]4:'650QV@J]LQF=2NHLI(96T?'J0&+7M)3YA@*;!^*[.RQ MN%N<9 _2\]O*_5M\-/%AS/MN 2^.R"TA1=N*<70B^2P]M MG[D0/$A_;IF[9E%B /]O.!>'B^0!Q;E__W]02P,$% @ &(&K4HZ=)*1. M @ ( 4 !@ !X;"]W;W)KYCV8)(+L9K8S+Y ]^]G.R%C78OV$OO:]QR? M<^/K^"#5LRX0"5ZJ4NB>5Q!M[WU?9P563%_++0JSLY:J8F1"M?'U5B'+':@J M_3 (;OV*<>$EL5N;JR26.RJYP+D"O:LJIGX-L)2'GM?QC@L+OBG(+OA)O&4; M3)&>MG-E(K]ER7F%0G,I0.&ZY_4[]\.NS7<)7SD>],D#H_LC\X[\;+BFD9\\R''- M=B4MY.$S-GYN+%\F2^V^<&AR P^RG299-6"CH.*B'ME+4X<3@.%Y&Q V@/ U MH/L.(&H D3-:*W.V1HQ8$BMY &6S#9N=N-HXM''#A?V+*2FSRPV.DLGCTQG7R:C_G(\@G1IANGX<9G"[ %F\_&BOYR8!+B<,X6""B2>L?(*/L)3 M.H++BRNX "Y@6G44F*X24&*%I H+O M_94F96[QCS/LW9:]Z]B[Y]F)O< *!:XYO?4':HY;QV&[>Y_ 1%>HUTJ%O3P@HM\6HIO15.NOW H?"T#5CLN:%: MI8(L(?D??19U. %(GFJ 70#L2T#S"L I (Y.-%>FTQHA@7H=1@_ E+=D4P-= M&XV6V21$[6(@F%Q-)$[TQM/07XPG,)Q-@]GK>-0/_1$$H?Q-_&D8P.Q9+DWF M"__%GP;C=Q_&4VG[W8 2W-W=P PF!,*8[CDC$.Z:0XE0(1"["M"')A0(F(./HEP=(XW95)E9O8QLX%=2SA![ &P+;M1H6?X_W"K M1HY3%MK1?,X5OD @@>7Q%T#7,*29O'.QN@Q[#&.RHAF&'_TE%TR>ZY\UX9IE MN*8.U[P2;NJ'YUM5M2,Y15M3J.N^[S4\S^N8^],R?76Z=UM.Z72FKE6J:]46 M8Q:^^(NZ@_544X)V&:1=6X)AC,@&JV.Y1@F#/4IWN*H*.4OK-,''BQI4N-CN M8W4-W%*>6RLOI *E0$6,&:S.SD-*>>4%Z>RZID+U8#V/Y6F*F'.3ZFE)Q-%2 M\OWM_0%02P,$% @ &(&K4D2.<3.WZ5K)-BG!?@&*(P6IJJG$.$QZ@W[QVU,Z MZ-,MB\*$/*4@V\8Q3M^&)**[ZQ[LO?\P#]! M^=C/T&?!=<_N 9^L\#9B M<[J;D3(@(_?GT2@K/L&NM%5[P-MFC,8EF#.(PV3_C7^6B3@"0*T%@$H $@%. M"T K =JY*^@E0!'Q>.=.[Y93L9@L>1?]Y.'Y0(\3L%B=C.?S![OQI/YXC,83Z;NR%V" M2_!],09?/EV +, IR4"8@&5 MQE._.PK^%2[[RN,<\U75+R2UW#/"[7P6E*& M(PELU US$T8X&0;FF!&PV.&-Q,>XV\>(QC'?A@M&O1<)>G*".!\YV39]:\5/ MN_%/./0O>>Y&>!/*4W#;[>#&\[;Q-N+Q^V!,5J$7,HF3V?E.'EE 4L"SPJ=I MD(^Y5P+'4_[NCT8QJ<:.S< _\P!*6[1RU[):AT6B82\O0A 2>,*JQ,RMV M9B<[-\NV15_1%2#[#*Q3G# ^P1-._&AWR#:#V6 $'55.R*H(6;]!2)8[JT%" M%QK=:K04%#JXZ:,EKW85AMT=QOO,2O.9Y>$L "M^K@0!\==$%H7=+"X2]\;( MEFQ'T<@]850+QZG"<3K#*;;*97ZH] %O97[2SG!^5I5%XC1SJ0D#P=%7K$4G=-4G>HJ898]Z9T6E",YCQ%ERR)=,,1)5W& MS- ,J(IU;]JU;O>#J,/_0=7A0=;A!^@Z;&HVM&U;3.,)JSK#@[3#_U+;H43< MCT9-G=-!W>%'RSML:K,I"CP\K? R-RT:#P\B#S]8Y:%$YMOFWT&;8;\W3R#)[#TE5=)QPD=LE88F3.@80MV,YD[L3>5H_=F^:M=GI9UF&0@(BL.4J\L7H%T_[9T M?\/HIGB5]DP9HW%Q&1#,I28WX/^O*&7O-_G;N>J=]> ?4$L#!!0 ( !B! MJU*:+]ZW<0< X? 8 >&PO=V]R:W-H965T&ULG9E; M<]HX%,>_BH;9AW:F%$LRMTZ2&4K(EID$&*#ML[%%T-:VJ"5RV4^_DFQL8\EJ MLB\)F"/YKZ-SSD^7JV>6_>('0@1X2>*47W<.0AR_]'H\/) DX)_9D:3RESW+ MDD#(K]ECCQ\S$D2Z41+WD.<->DE T\[-E7ZVRFZNV$G$-"6K#/!3D@39ZU<2 ML^?K#NR<'ZSIXT&H![V;JV/P2#9$?#^N,OFM5_82T82DG+(49&1_W9G +U,? MJP;:X@ M"UNO \(3%RPI&DL%"4WS_\%+X8A: ]F/O0$J&J!F [^E 2X::,_U! M"&ZN,O8,,F4M>U,?M&]T:SD:FJIIW(A,_DIE.W$S7VQGZ_D#F"X7F^7]_':R MG=V"S5;^>Y@MMANPO /3R>8;N+M?_MR +OB^N04?_OH(_@(T!=L#._$@C?A5 M3T@MJL=>6+SW:_Y>U/)>#!Y8*@XW(,Y4#0>2!?D;/#AR#[###\ M!)"'H$7/].W-/8<<7/H5Z_YP2W\UI]VMEP]@N9JM)]OYXF\PF6[G/^;;^6SS MQ?$>OWR/K]_CM[QG,=N"^6*Z?)B!#_?+S>:C;2KR+@:Z"Y773S=P-!I=]9[J M_C&-NL,^+HTNU/5+=7VGNGO&.=AG+ $1Y:&<<)J>2 1D$% M('_04&LU:E$[*-4.G&HO_)A/FTP+.6G?U;P5,RCSQ"9Z8.A!$/L-T:91MP\] MN^AA*7KH#+1)](^L$K*P"@X$DY55NCFD,9'Y&;*$@ ^QG(./^204,T#3Q]H4 MJ%:IY$48\ ,X9NR)RH0$N]>SB336M98*2K@K9$>EXI'3S;=$ B>D05[&TP@$ M"> M&NP%%W5)1BQ8K'!N"56(*I4HG=$2TRD7*XH25Y"&2EOBHKB M#1=A,3+4FT8CA3RK^HI7$#O5+\6!9%9-V'0H;DHR;?IPV"*I0AOTW0P]!.EC M[L,\,'6U.">;K$8@V._5+U7",6@17K()# MI^!M%D2RRH0A.RE>R510?LTA$(:96AN$+JHPA-P86MA6'-;UB4T\,CF#?=B, XL5&O1;P@!5-$)N&MV^?2F+ M3-!8UK)VJQ9JHHI'R,TCJXMM==*JW(0,AH-F'%NLD.^UD!15+$+OVSS-%S]F MFW=LGE"%&.3>/JU.67C0H)9XEGZ2WA&ONAZ1WR=Z5*"V>L>W%"+D-;=4-K,Q M:N$BJHB$W$1Z@VCP3,4!<$&34WR26[!3RR8=6?91V#.FV;1J*5>H8A=RLZN, MSA/7%?4=R6_91L$^;*Y);&;MSJ\0AMP(>T_VFQQJ+IB=)I<**TPA-Z8,S]+T MB?"WY+P%7C;'6LS:'5OQ"XW?E?1W\\5D,7U[TN.*/=C-GC4IUN J?R*R$SIW M]C0-TI 4]&2[F#ZV3RTVT=+%PV'#4S8K!&%+9<<5@;";0'*G$1(2%4>Z-TI^-$95/(N'V)CC;9S.0'?1%AE6@""0Z@H=%BY;<=<.,*6]B][5*B/H$=>:1I MJF-4+LE(1EED56KNIK!7/[PII)IF:-AV4.Q7W//=W,NE$G5&X!+I6S974%Z!W_P'4$L#!!0 ( !B!JU)&#^^O>1 %XK 8 >&PO M=V]R:W-H965T&ULI5IKC]PVLOTKQ-R+O0G0F:<=9] M8[P7MAON9//AXGY@2^QN8B11(:4>=W[]GJHB*?;TC#?9!8)X6A*+Q7J<.E72 MJWOG[\+6F$%];9LNO#[9#D/_M[.S4&U-J\.IZTV'.VOG6SW@I]^7GY3X$?M3]75Q4Q=GE]>?$/>53[:%D+>9[_1G?U=D_=GZMIU MP36VUA(,7:T6W@33#7+!K=5[V^FNLKI12UPTB+PAJ/^;K\+@$3O__PV-GF6- MGK%&S_X-8_^QE>H=8M@'6VEOU*W1S;#E/Y?&[VQEPDQ]Z*I3]=W@-F;8&H]H M&K;*XB!A7 5;6^TM/?67__KI\O+\92&-KUR\5,XK+$P/7+NVU]T^WOQ>]=[M M;&V":ERW^6$POE6\?XC[J\&I;H3(;J,J&! :]# PF])VBG-$!3(OE.B]!1#8 M9D^W:-,E4&-K=!AFZJ.M[PW]09[BZ_3S5/V,QPJE+EZ\#'&CD)136GG=;0SY M=,LF.M81V]A"-=H$T8#%]&O8Z@$J5/0C)]W@E7FC M5[K5%%:(G0Y__*_N@@[DH!#HO[ZW\L.-'G]]WEHW4S^;KC,AF&BGG\U73=8) M=#*D>;7->?ZXE1[7#U>QY4!"?KPXLB1'^HO9Y?-SU>#,73!U?F9EZD,;*'P>/8C2:9<>2#Z5'T>_=%^$F.P4;"_&[7VKE78&K%U=?E-#1Z[ MA:.-W:!J!S4Z-P7?U5]?3,]K,OA ?Q312O'7V-VTQ?7G?WQX]\/%7]4"CYG6 M5G"=^KON1I1*O;L=5=1ACU M782&V]MEAH7:5 VR JJI3L<8[,<55$\9"#CU&]-5>U6/AJR$)]W.()NS<1[6K_.I$6^JMH$E3L6E1VY!?KE3=Y= M3_)=4U.JUR - CN]<7UC)'HKXP?P*#5B>]_L:=O6U(!G,E,GT()5P#( U!98 M"E'>ACO6!KEN'Y:;7$ZB9JU+0)PZUJC>M>/34PT/+8R M="=N(YL@*N)5P%4UB&D!H5O4&BQJ[)V9HH_MB"#%.6DAF0Y'V'BS@=J[-A>,!R5PK2M":"L%9FN:'GQML'Q>VDI( M,YUY<@J(I0(VMH@ A$8*_HNK64P J)PTTPB%U@%TZK%%B'MBM;#;-Y4(=M/! MU97N!A19&!45HAK4S@8[."^GZ!PCM2 ),6@3;V!]7H%JU(Z4U$RB63Y2I76$ MSTPS6B0"/$I02:?8JXN?RC/$REPG6N$-=170/[$.' =;F*Z.$<@!_<#^J)*6 MZBT?K39T:+ DMFUC"$I@VFAQBI?.&-H1S_:2D_PDN%P76BI<0OIRP"+M#F)Q M%D&8(1^%%=FE62UO&OV5KE*UIH1+5B+%X_G9B^>IPI$%QAY'@SI47G*0D3AV MAFC\4 6&R4I*PSKR,KW3MA$NL#_0?X4ZXD<1XX1P_XXIR5(8A1X-EGO M),;H-I5['3G@<9J( 0F[F"S%? !!AYY4P*;2LFIT=X=&]EXSKR7QR4E3\L:* MQ.D"C39>M]#GMQ$IQ;G]("N'K7V+O1P5$.1OR=V3#YW$\ M4)_5'-;"4;3PVW 'N"^@/.8_3&$Z MLT:PS+4>9.<92R!\:$R1$]Y M.5_DRG6D,9INOC]EGT1Z*1F&4*;A 6U(D)$S+041!2@'7]B!45WHR#D>Z&QQ$F(03M-MFM/ 32>, ZM0+.'-IY:NK8C47FJ:^F,::M70[-U#6D=?!L=$3P8IS MZ)99R/S+S9*N9"XB"9IL<%A7P5R[#:ZUKN9"+L =N6ACVX3K^&\U!LO$CRQ# M. \,ZZESD.@#+,96BEE#B.UR8(%4*@;.9!<#=Y\:@?>HHAXY"/W(H(/^&C$] M(@I: ]T@'(4[8#?,8&WE\#\<(!2I. 3$)SR1/>NM#[:FNJ.[0)'+$D;1%K M$+=:4DZN2(1(N90K5&7S\KPG>9=>&9> MZA](@G 3"+V>STMIV;Q3,I!B MO"?C<&3==>Z^2S5B$2,D0@@O.:5 $43ETBGKN3EM=6TBY$4NE73#CIRHS-TU M%"#%\R'(GC-N'4O@)'@'1% 23 +)Z@ ((@2 X-$\Q,X?&"VH#@J^X/X@F^A5 MDR'D"/,1$,V>AT!4;-+Q02%L;YF6:1I2,L>GGU,G60J?MN2VH%"2K0/@ 0;& MGM]DNZW,<&_,- :)R,%"_CZBA[B*7#W6&JIY)ASVY%0<0ZI%L17G P9+J4U MI_E-+(IU#"54:X"!0,!C35A@.KW# V_//Y-'OF]8^&^.2)E"> *>35QG+P4(+O<8OH M,=>O2@]3M,AMJE'0AHI?.6P2QQP,TO>3Y'+,/"52&C+$?84M)W+[+_2''\D? M"?5X%^D^D[NCN:3K+$>;Z#@@K)DZ.O&B'1)?CWZ9,N0!%!S [D'Z'<,"%.;G M>V+#0?1,(5*VT)"0LX-#4]R,!SS-T&I0YTT4.5VKL%U(XF7X'JD>57$*]YZL M-7N4Z_:712_\?JR%1&ZK*&>4'OHK(\T>W8>,K#)CDVO_22 ME4KJIWCSEBC7AWRX-&A\@.J,!UJM[5=L]]\7Y[/S\_.#\D46-!JE./-ZTH!: M8_;J@3A^Q\G5NQN9"/#8+P^O2T-0+\8TLO.@&\ MY8X]C5N15G[L>#C"*;4T_2#TZ8BN"I?*+='@J+&-TQSX8.6Z,60"G1UVO.,T M^9+NECKLK"C8GHX0@0L[J]4UC)4[!V$KW 5.O"/RS!H$A-8%YH3+Q2KM+$+%'N\(CEK U]5/=;NS4 MP\,(3AU[$H24[Z-+M:*I03(E@%^:+Y$B.-F.P#C4!VJBCX 5HAKHO-/-*)T4 M^;(55*0(/YSMH6B,I&B9BS(A^1. \Q+Q?P_(]0>ORA2:)JI2#>4R.F+;RSM5 MPMF*!@:DBO:X9WB(16\TT0>1]ERI_P.F)>4Y#^P6"RXAV=M6J%RN-32LA6Z' MIF1%2$DJQ)$U'HYTQ7841SS-$-_@"AJ=A)3<4%34\@J;R4$R-I%2@ TBV7^? M:OPZ=K-37S^;W@5$W8B>AU@XR=E?A]@*4_7_L\;B8U-72&!)#=2*:B"-748O M+QJ8S$RE6 [*]AD;!"M,US!?,9VT("49*]5.YLC)@\8,W%N M]94RR3!\,+KJ?1ZND:;3?1IGRJ3'R]M6^AI@*N#]5@/E*H,,!@#'JIW>?:5: MGEX=3@0!ZG"_3@>(I.)@0$XVR= #9,8!EX-&Y-,+_2>W?WQS*9D\9%=A2V6$ M" N=V,(!U J/R/BX,3'/FK"0@PO:#OEC@U/U:[0>SD%)7,\>M1W?G16'G?SE M;<@EYPD/45VP5,C\]'E%8A>32!B*+$0T:Y:X4EK'#=PIJAA]2X&?GZ"A>J9. MCEZ(GW!83$OERS8HB^"PDI)YU(\(H)=2'G5$^VFZXDW1[Q0LL.+0+E_+T& \ M!B N4XCDCPI^_?-)A& 9Z3%752,,6+%K"Z&S3 EBJF!EA&%ZA1OB&]OIHY>U M;NG[FY8Y"FM>?EB0YUGQ2D2&\.RK=/Q:1GXIF2 M>CH/3R 7N^4WP,;<36_@N4?U,EZ%!#.1N4)TV ?@#,SO$SN8YA]>2(&\W\\D M+G(1 EM0DU/U.?N6 H'K!A7)XIU['%QJH8@'\VX;#F8/4A/+/HQ?TW=0G\Q ;Z1/'_OT[JSXYI'G;?1E9Y /:>3SQWPU?SPZEV\FI\?E MR]./:,6IUV[,&DO/3U\\/T&Z\-><\F-P/7]!N7+#X%K^$RX'DZ 'GA.> &OB M#]H@?U+[YI]02P,$% @ &(&K4DP5(*^C!P ZA, !D !X;"]W;W)K M&ULO5A=<]NX%?TK&':FSX:6[:RF M&]MC)=N'3A\@$B31!0$N -I6?GW/!4B*4AS7?>B^V"0^+NX]]]QS(9X^&ON; MJX3P[*E6VITEE??-A]G,996HN9N:1FC,%,;6W./5EC/76,'SL*E6L\5\_GY6 MRK#P-S,Y/&UZ*M?!? MFCN+M]E@)9>UT$X:S:PHSI+TZ,/%":T/"WZ5XM&-GAE%LC'F-WI9Y6?)G!P2 M2F2>+'#\>Q!+H109@AN_=S:3X4C:.'[NK5^'V!'+ACNQ-.H?,O?56?)3PG)1 M\%;Y>_/XL^CB>4?V,J-<^,L>N[7SA&6M\Z;N-L.#6NKXGS]U.+QFPZ+;L A^ MQX."EY?<\_-3:QZ9I=6P1@\AU+ ;SDE-25E[BUF)??Y\>7NSOOUE=9E^7MW> ML/3FDEVDZ]6:W5ZSN_NK]=7-YSB#]^O537JS7*6_L#4&KSYA;GTZ\W""3,VR M[L"+>.#B.P<>LT]&^\JQ*YV+?'__#,X/$2SZ""X6+QK\Q.V4'1]-V&*^.'K! MWO& R'&P=_P=>[>VY%I^Y42:"5L:[8R2.8\. *=BUU%QGDBNV MQJ 8;UC_TPWSEM0[E\O>'0R>'02/#KYXW+T?SV0?:X$D]H+*VN6#0"*G!4# M5FZ'%92%>>SPE16"U<0.UF"OR1T31!*&%&?5D..0!3S,)S@D4RVMJ(054K.* M/PBV$4(S*%3#+68VVV!\:>J&Z^T$Y>4KB!/C;2[]A#6M=2W7GGD3UME6"1=. ML*)L5=BNNGK**ZS(8KZ4CG9JRI; >6@C7HF+VM"F,\=IX MP7+I,F5<"QHQ34N4VNX"PTR$Q]$)NAU=R_/4,@I"3RC-@T$$Z MP1AR94ZHSC]3W9_H*\=9\"TXS M\=2 *Q0"CN:L:$&:K: F B_=_R)<#D*B@:&CF7A.7JF6K>P<2\:8U%1FM%-A1W-W_Y] +: W/ 880?N,_FY^WF] MOH*8MQHIN&Q#V=#FEW9-QAXQ64-A* R*M)/ GOL4"(4WTB0 D9&,6J$"'KWZ MBLR46O:MU7E9MZH%2X)CJ G3EA'5Z#$86TDP!754@7R\:93LH);.PYM0UF$7 M:?Z.:,_R+# #),DS.S+=#UEI(>1/: -^4P6,_. $A['0V"7-*J#M"6EA3JZ MA,+"U-O&F@(N8BHVCX$;XHGTNHNVAXV7$&/0MK5$CW;C9(Y-@YKR#40K"V3G M+7H9&E)D_\[ALI6A/>RG**""ZB:XR0Z!E0W7&$.<.[ XBK W2?T4&JY,N8W2 M97J*!I3(\+"T^PT0V+NBJM+A-$25[@RC"^F<6Z07]?UV/$.@?MR!^C%@&@Z] M'+50N#Y:E#I*?#C]3;)*US"*=D:R1I[5QGF*VQHT1?!NB&10H=9"YP.V1$6; MA_Y!82H.R\6V+XQ"Y-1RXUR7MU#)AYR%&1'D=/\>,D43A@4679R@=.$Q*")I M!W< :4/MW%&,(V@#@[;@#S2+.J7:[KA$G5KN75<""R>[1VHG8KLG6Z'_*,,&/%C;P9K+BNAF-)D\[BXN#HXH!DT1/!O-L^ M]DFZH+NA*%$T%!LVP\Y>7QL?%4LL K?N@"Z/02"E/(T"H;]3"?V!OCG[8 MERUT'"5+N5&"SNVR-4:/,OQF\A&[!<^^MW+2^]WIY^^OJ\NW17SOSX?9$ MMT;'DJ@#NQ:*%F1JD1!!7G=#&QK:?J??!?Z]"B&O6Q>"?(0@X%;40(@4M18+ M(L8>&4$)53X&W34X(H1&5IH0]W#UCI\KR)TA;CG(=W\1P,!P8I\I8^/UEFLZ M$J#S[/=64D4.1[=1+?A!5/O*&^IUR&+$,=JC4S4>O@IKXM@4W;R@JC/LAGXN MG$Q8,KA]AW!$+;.D;YBOOZSL7R6"SH1+0P@^CU0EL'=WQ"E+AW&UW8^(NNV0 MN$^";F R_P:#6.L'%'[F!TRZ7K+W\_>'H;]#Z/<=@^]'-P/*:=-.$KSG0/&_J\ @I0&71 LS3[\S^A0X8/N^=_P=02P,$% M @ &(&K4J^[H'2R!0 OPP !D !X;"]W;W)K&ULK5?;;MPV$/T58I\:8+U7)S4"V\#NVDE=)([A2XNBZ -7&JV(4*1"4EZ[ M7]\SI"3+@>VGOGA%<68X<^;,$7V\M^Z[+XF">*BT\2>C,H3ZXW3JLY(JZ2>V M)H.=PKI*!BS=;NIK1S*/3I6>+F:S#]-**C,Z/8[OKMSIL6V"5H:NG/!-54GW MN"9M]R>C^:A[<:UV9> 7T]/C6N[HAL)=?>6PFO91' M;!\-_E"T]X-GP95LK?W.BXO\9#3CA$A3%CB"Q,\];4AK#H0T?K0Q1_V1[#A\ M[J)_BK6CEJWTM+'Z3Y6'\F1T-!(Y%;+1X=KN?Z.VGO<<+[/:Q[]BGVR7.#%K M?+!5ZXQUI4SZE0\M#@.'H]DK#HO681'S3@?%+,]DD*?'SNZ%8VM$XX=8:O1& M[R]N+RL_A\=W&VNMR<'T\#XK/5-&MC MK5.LQ2NQEN*K-:'TXMSDE#_WGR*O/KE%E]QZ\6; K])-Q'(^%HO98OY&O&5? M[#+&6[X2;Y5EMC%!F9VXLEIEBKSX>[7UP8$<_[QQP&%_P&$\X/!_0?/M6(-D M;X(TN72Y%]>4D0GZ45QXWU NUDT0ES:(OS"^J]S6 >^VCR*4)#:VJJ6!I1&_ M-X: X?S#..Y\6MVLA4H!5C=W"#")NP?SY5A\4D::3$D-1P#38 "#/]@XRE40 M7ZSWP.R76UNK3"P7']Y]%%])^L81VPE;B.>6F+L7 T[$+1(Q&-I=HW+LDU F MD$&)P0I5U<[>DRAZ5T>U=1$+5.?H1Z,<+P+T02MR>)79G5%QT)%$EI+0?1+: M2N,%4!06"+A!9/64%,"104B'Q "I3/@#(TB?P$8AE1/W4C<$0V>;78D" @)D MMJ(Q_^HFYZS2827IY*K,/?G )XSCRX-@#R GC5/A$0*R#<)3QBO0$0UR,J=! MIJB,U+W<:MY,YW7A\"@TT*=A9;[)2H&,*A5ZI)4739W+0"UTU);ZA((/V(TQ M)2 #%%7J:LZ%2XAGQ?#_BW5F?1!;$O@$>(KPP"+$9@8V V2"'FJ(+K;02YA" MHW1B;Z>$':DH*.I] M#.XK'!:Q[%B4Q>'@^>=]#EPHGP&(1Y*0>=HI8]A.%@%^9^A!M<7#_'W4H@5$ M.I0"IIA$R6/'O*O) 71DF\C=S1^R09_X",4$36#OF):%(*:3C!E% WAD85!L M%QJF@4OD@>G+M"EJ9HV'F'%[\Y#'&4"9+06L$$:(+'@"VJ:O:4- MB]G![' ,]2G($;?LFLF$)3Z,G1H<'1Z]>V&LD5[ W<"#,/P%9HR9'KF*J3'Z MKH_J$D5CU"[A^-F.L]&R(F'$"C^=!6;09*\W-IW*0$ M-=+C )5\9.92XJV &+DH-AB/5_(=Y&DSC/-$G#6N:VRA',CZHY&.Z81N/@'> MT:0["B,CZUHG#2\IWU&G1!QL %T'$!R@EENY59H%A;./W.%!\HD S+1N( S> M1MB+!A)$XLO%^MOU@<(7^X&'2OI2%!C,J,.( 65,N"<"PPI2 N;M2P7>M#%B MFCE+E_$RWK8\)D1KAI"O3(QGP'72#Z+T['6@(B)&Y1ST<2)6@ %\>1H ",X0 M@*A [KZ-VNI1;SZD!(^(\H'E+0YN+=&-H4,BB 1:>4*LG5BF"7\/GLL)Q$3 M*C5;1GC3&,T741YFO8A;/I8$)JDQ#$>Q6"P!)*0WK0YL#[LK?65I; M5B9R)()W=UM, -*0"2]\*<:=;]L?WF2U12,:@.]^IO_DI:O/='"IK,CMXM69 ML005T_VR?]O?SE?I4OIDGJ[V0&?'$J"I@.ML\NO[D7#INIP6P=;QBKJU 1?> M^%CB/PQR;(#]PMK0+?B _G^6T_\ 4$L#!!0 ( !B!JU+=T<==V0D , 9 M 9 >&PO=V]R:W-H965TVTW(_?I[JNQN.I#,[NSI[KY M7NQRU5-//57NG*ZL^^(+I8)X*DWEWP^*$.J?1B.?%:J4?M_6JL(W"^M*&?#6 M+4>^=DKFO*DTH^EX_'942ET-SD[YLSMW=FJ;8'2E[ISP35E*MSY7QJ[>#R:# M]H-[O2P"?3 Z.ZWE4CVH\&M]Y_!NU%G)=:DJKVTEG%J\'\PF/YT?TGI>\)M6 M*]][+2B2N;5?Z,U-_GXP)H>445D@"Q+_'M6%,H8,P8VOR>:@.Y(V]E^WUJ\X M=L0REUY=6/-)YZ%X/S@9B%PM9&/"O5U=JQ3/$=G+K/'\5ZSBVD,LSAH?;)DV MPX-25_&_?$HX]#:7LH@STZ=70E'JV&-7G"HO!O.Z8J2 M\A ?KB]N3@=!9BE+T=9,G$>34QWF#@0M[8* MA1P0Y[OU:- M;Z01UHF;:N'4UT950=P$5?HA?7AN0R'^/IO[X$"2?WSCQ,/NQ$,^\? _0?4[ M32[>'$V&;\?'8N%LR:ONKA\> M/ESMB[_U=F"U75;Z7[1^,AX>'1P*V-!59DLU%*M"XRQ-1A=415BE*S$ 6LH) MR(*305?+M'Q W_6\^2MM\Z@-=CNMMI47$!)>%PJGE"B).@+?:IL+101Z$>*^ MN'J]P6]=NHE&$[2)D1V,C\@'?.F5\$&7C6F\R*TQTGD1K%@T52XR6>L ENBR M=O9107@"?PFM>R2^D.TH?&2L34_$TRG2/P*C,T\V.?0WDW?#(W@@M^1/2*=$ M9J3W>J'A*M8,("G*.<8ZXFHCKKH*0*D4&4"T1N>2\C&71E89'",!:#,FC;>T MVS2Y\N)CXSQY=@UCQ/\DAQ? T4%N+C5HK^<-)R=&\ST[MIV)_^V>+.WYBOK3 M84TK@"4(*FJY9HB'C(%OYO_$%L(;499>2,J(K7(=21,*&015KG:$=J9KW>:G M\8KQB8 3NUX?KY[0Q+Q"?-?7#UPGE0UBC9Y7-W.C@5X.J[5U3.AT3F1 HBL. MR?MQLX-]0TA\W1A.BA0@@6I)/5\GB**5Z&8)91=S1<[GNTOR^.28.+-T$OQ+ M\5$Y^X!S?*] $_#_G_J^3,5HJV>K3G5"0A#N'L$T\#0 RT=C?5#H?CH[??FWL6 MM#9>.NC:^AIP=-K:.8.R+L#3W9G=D='(\)Z9&BPE->Z =^08I8+.?]6KVN6L MX0W53*7"?Z\4^NBB'P1--2%4; :CXD%EC2-!#?*)9.VR85I$9[7+27!=(!E8D&OCS=:8$?*1CMVI MSW,R<*PIH6\.AI.3(]3W'QH\*MOK@D;+N6;!WV# EF#IM-RJR'62Z=@$_@A. M2TM'(4&!I(;M1"+N.;-12>R-CD/UV%==QE7K.NUW@"#:N*T@' M 8XXM%H,F1+J22(W"E$N0HMZ+ /J9#1>TB3)Y[!QSXA&KJ]L8ZBS/":_5MJ3[N5-IO*N:1)$W8E)7E!N:#73OPB> ED>N/F0 M=^=-OE2AZ^ $$!-C,A$_H*%%.-13 *MYB-F(H75Y.CX8_[AU'/M6442F^,;7 MZ2:7Z+T#,!([F@]0-E ^R75349]^4<@4V9OC(]3PC:2^"=9I!(/E<6+;#+9]OL_6Q[&1J+'P9WL\\__T*? M#7[D][H@< M:.(8PKSZ3#FE)QPZS&=%&9TJYWDV_EY()58M:WL?QS*VJ8^\ MFB!]4]<\TKP0M.Z:A@!R5>KL3S4-K[H1EN;I1+B_Y'#?5-0[%"/N!GP1 M"DJ6F.%((7WJ2"%._*O"QM64;I+$)!@;4Y"0@8\D-!HGB-AS N\:N$#7U3HZW=]. =2@?$4C"3 )<\3[)9JEIAU2 MXZ8@>Q*9H^M!6]=T.989]?.4O"ZR3X5&)VPQ_9V0N++:HFP)/Z3=W6.+7ECQ M@<6V3AZO0GF<>;BMMC6_X O'YO#3M59V<:Y4Q>-_S!I%&<>.-(VC1C0:#+U. M]S-Z6<*I)0TCFWSO^ 859_<-W0^Z'H7+!XUK9)JO-O$*\PH6D%IQ?6Q%A[VD MH4WZ0BR,7=$UQVBH5LXW:G:&^Q54 ^/&%K95\>$!+K 8J0QF&F0T4GFSKM&P MUO0Z]@3J5^W#!](\3YTO/@;F$6H.&KUX#M(_5=.,1+I*18K\2KXXT]$E0F2N MIK*)%T*29$N/,R/>E2YQ,]GQU(6DV@ *U#1X:+RXM]\9&& M [PSD)K-J36FW?&5PUI<+PYC%GI&LF%,OW9J8E M6!LS_+R"&9G:&VI,AM[4]EK<6[!1FRV-Y*/4IKT 8*-:+%*O;6_EW864US_* M+*-6@#IEN_J4ABYYYT4B3PUWJDFRJ9>5S^ULTI'[;P=B-70?O_K9GOJ/> M4W7 N.3?#BC5317B _;NT^[GB5E\*O^\//ZV@3:[U!5=01;8.MX_/AH(%W\O MB&^"K?D9_=R&8$M^"1D&:V@!OL=D$MHW=$#WH\W9OP%02P,$% @ &(&K M4H;2S3?\!0 ?0T !D !X;"]W;W)K&ULM5?; M;N,V$/V5@;%%MX#6EF4YMH,D@..DW0";"Y)L^E#T@99HFUA)U))4O.[7]PQU MB9,F*?K0%XND.(=GSEQ$'VVU^68W4CKZD6>%/>YMG"L/!P.;;&0N;%^7LL"; ME3:Y<)B:]<"61HK4&^79( K#@T$N5-$[.?)K-^;D2%G,>_W M&QZ4W-J],;$G2ZV_\>0B/>Z%3$AF,G&,(/!XE N990P$&M\;S%YW)!ONCUOT M7[WO\&4IK%SH['>5NLUQ;]JC5*Y$E;E;O?TL&W_&C)?HS/I?VM9[XTF/DLHZ MG3?&8)"KHGZ*'XT.>P;3\ V#J#&(/._Z(,_R3#AQ&N14 MP4&YSWYP_G5UW.Z/5]<_W9U<7]Q?47SJS.:+Q;77Z_N[_C%^<7# M_/3+^=' X4 V&R0-^&D-'KT!/J)+7;B-I?,BE>ES^P&(=FRCENUI]"[@I3!] M&@T#BL)H^ [>J/-^Y/%&;WDO'V5125H9G=,"7 VR!!%P&UIX[:6A/^9+Z]?_ M?.? N#LP]@?&_X_<[X)S_1[:4B3RN(<"M=(\RMY_.9'N-Q(JY*4H=C];E%PM MCK)(I%$[) GW# M@XM<5X4CO>K C4STNE!_ 1SER+4*4^Q,-.H>QPI?NP#;;E2R\:\:AB1_E/5V M34M).$2Y##"8 E2"+ZD"FY*-*-8(L39L;9\HUI3@3:ZP"K/:,=FYY1V"]R)) MF#;[#Q"!!;)P/X.Q-+XO%HDDO"%R'86UA73\=J(LLQ44K. RKQ4 M:N-6.E.:7QHMH*)WH>2*U@A#L4=AJZLLI4([#AEZ*A!$!C]3M5K!=Z: <)%: M(7EHBQ62CR*KA&ME:0E]6NX^M>,]E:!IIXHJ$FUPM#=^GD\^ 56^K(R5.:J7T"41*@V:D4'X+G' &H@+/[M!86 _W8A=0',+'GS:%_4( MI( ^:ULBO@%(I?0@X:XHK)>FBWR3=*E/5@X.2*-X2UWX$K,.Z'VZ@!J"ZQ 0 M^ IPFK/83:4T(>(D8FE?U;7)?SPS?(@9VD?:'OZKDY[\GI]^KH%EZ.-;'C]S M^)<^G2DKUFLCUYW^;>OEC?.ZP"P6N7#%$J5U4?BZ,ZDO+I]]\[L%'80'P;,N ML-= /HR"R7CB$3]$LQF?TOKF%UMNR-F\RBK("2V$0?JRX-+?#S*$L97*;8Q$ MEO(GC*M.Z92X1%.H8Q"H]CM4AZ*N8-_!N#2[SM<6A/4-X$6#M;@[6.:)2U:= MFM8S;;8ZK\22;TY]:(-(
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

#J 7D0"[I1MSY5>YTC8Z^5Z?BO4P1G8("+* M41P?<09W$Z/D-8L%21 M5E!3]G/.:;9#120)FT=HWEO11W-L<@5__Z%4PK7$5/S3 :A? >H;0/T3@+X: M/B@K]!ZYXC=@D7J$/8\#E<\/*J$A2Q+*!>R1%VG^V);9PM#(&-)=YGXVZHW= MB7W?#/?_7'KBPZ#R8=#IPZ\J=%( :Q2Q1ET49"O40M^@@6(X:,',[Y$^2 9GQ.D]K_8G&OU*H_]SE.NX C3N=/%66]6- MZUF9?M(]-$[S] WU.GY1BCI^3N./M.>#.'43=KX7+GUX(]S2E-_ 6Z:Y%6/C MAX+\J Y06GH:4M\[@="M$;KOS.]289-<_1/D(G7K)MX[4[Q4^"H8=<,FW1W[ M;-#SAQU4(G7;)(.?@]VD[J*DNXV^)[]+4\UJ+$+7&O^ZR9+N+ONNG!Z]X'0' MQ+IK$_^'4=I_2Q#K-DZZ^_AW4'K\@DOZBZP-AEOW9[>[/[^=TJ7"3AAVX[,] M1;XSTXR @.69++[@J]-J8IJ;.<&NKQ?CEOI\W<69@ 2W2M3IC91A7DPPQ4:R MO1D"-DRJD<(L(S7U(=<7U/LM8_*XT0:J.7+V'U!+ P04 " 8@:M2M)ZN M[5<" #,!0 &0 'AL+W=O90Z@T%M!F>P[N5+EO>O*-(<"RPXO@>F3-1<%5MH4&U>6 G!F M005U?<^[<0M,F!-'=F\JXHA7BA(&4X%D5118O#\"Y;N^TW4^-F9DDRNSX<91 MB3VMD*EEQ_FJ,4=9W M/),04$B5B8#U;PL#H-0$TFG\;6(Z+:4![J\_HC_9VG4M*RQAP.E/DJF\[]PY M*(,UKJB:\=T/:.JQ"::<2OM%N]HWU,YI)14O&K#.H""L_N.W1H<]0#<\ O ; M@'\N(&@ P;F L &$5IFZ%*M#@A6.(\%W2!AO'3??D.^YWL'X(,SX$'7PKL'X,GY\/_87:U4*Y??RN7;>,$Q MN5C*"T +_(82(E/*924 _7Y8227T$_YS@B)H*0)+$1ZAN)S.)LO1?#097Z'' MX7CX-%J@I\D,[=_4(1WKJ##+? M):85KGN8ZB&"60J'T@N_,M_=>-\/<_=:[MY);G,/>DY4+#OT,'M?* /SACX1 MNGNM8^:#Q/U!+ P04 " 8@:M2NTYA(34$ B#P &0 'AL+W=O797N][^CHM7N:%4H?V=9TM_0B,@6W](8WJRXB(B"I5A;MB+"X,>R;O;D8 M]GFB0A;3N4 RB2(B_A[3D.\&#=S8;RS8>J/TAC7L;\F:+JEZWLX%K*S<2L B M&DO&8R3H:M 8X;L)[FD%(_$'HSM9>$::R@OGKWKQ$ P:MD9$0^HK;8+ WQN= MT##4E@#'7YG11GZF5BP^[ZU_->2!S N1=,+#[RQ0FT'#:Z" KD@2J@7??:,9 MH8ZVY_-0FE^TRV3M!O(3J7B4*0."B,7I/WG/'%%0 #O5"DZFX)05VF<4W$S! M-4139(;6E"@R[ N^0T)+@S7]8'QCM($-BW48ETK 6P9Z:G@_6LP>9K\NT?Q^ M@29/CX]/,[3\-EK350^SSB*+KW[B47]"<"C3A M400166Z(@/TI582%\*J)GI=3='WU!5TA"TG]5B(6H^>8*7E3V/A]PQ,)Q\#F MU=&Z;RF@J(%:?D9GG-)QSM!QT2./U4:B^SB@P;&^!:[)_>/L_3-V:@T^$M%" M+KY!CNW@"CR3SZO;-7#>>L3=+(BJ(XN(NCT.HXW!78[N=VVX;V^TS MMH\,HI7@$?+!F2Q.6+Q&4#C@8+AYE5%)+7>-95TYWH8.=MM]ZZWHJE.A9@?; MN= 1Z$X.NE,+6F=ABC5@,H,+B7I >X-B2%J^@L0R]!1YIY44TG,Z171.NUNB M4"GD5E/HYA2ZM13TI6)%WU>AZY[X#GN>5T)W*M3L=K7HIC3F4'?2 MG$LKPG=3&\'+HS?P\IH>%0")GA(E%5Q?G377<)W3BU[)JG?BSFZGYY9850G9 MW6I67L[*JV>E"QKT#T17*V@H.C^@U/JOD#A9UBR?EJ,%_"^H5(+YFF[&3Q?$ M\FY:U#ZBZYTPP=UR#$]ESMR0VYSJ;2W54? GM!$ NMN'C61A\].P9868?SYL MMZ<1Z;5QB4B%T-FP8?O0KNS: JC[31$W^ODGS\'X%]W+F5]3!7&A(^(?4@>- MEP(>AD1(!+LIH$J'92?VBE%MN>5$KY!JVBW;.^,SYT#(^6\U\A(FZ5%>"6.Y MU'\H=DSET/ZP>UFM-'#/)\0ES-P3R';+N2T3.Y4"8M@Y0^S0>W'[W^5UD'YZ MU67VH5?B^F;Y?V1VI\)KKE/VVJE4768?.B>N;YT_-+.[G\OLC\2.J1S:+*[O MLQ=D=I82EW#K5=0?I]QZ*J2JH3/YC6#Z(5T!2;M5@_R1Z0#6;I0?&MFFA>N8$(RCQL88JG0 M O!^Q;G:+_0!^5@\_ =02P,$% @ &(&K4A:AI"UD @ 704 !D !X M;"]W;W)K&ULC51-;]LP#/TKA$\ML-6.DZY#X1A( MTFSM(6F0[.,P[*#8="Q4ECQ);KI_/TIVW*QKBETLB>)[>B1-)GNE'TR):.&I M$M*,@]+:^CH,359BQU EPCB*/H05XS)($V]; MZ311C15J7I%/8L.:]0 M&JXD:"S&P61P/1LY?^_PC>/>'.W!1;)5ZL$=[O)Q$#E!*#"SCH'1\H@S%,(1 MD8Q?'6?0/^F Q_L#^R<;!9 UQJJJ Y."BLMV94]='HX Q/,Z(.X \4O Z 1@V &&/M!6F0_K MAEF6)EKM03MO8G,;GQN/IFBX=%7<6$VWG' VG4_6R[OEYPVLYFN8W2\6]TO8 MW$[6,.M>G[:O MQR=>'\)"25L:F,L<\[_Q(472AQ,?PIG&;Q(NF+Z X> =Q%$\>$7/[/_AT1MR MAGUVAYYO>"J[3$LN=P96J&'C,@8_)EMC-?V]/]_@'_7\(\\_.L$_D9;G7#2^ M2%U%\"D3#643"JTJR%15-Y;YEE$%>&>ZPX.PFH1Y()Q1*5N*\]<*V0JY]$+< M:'A,/UPFX>-Q;O]UN7IV:>,+C_[4"O7.-[ AE8VT;95[:S\C)KXU7MBG-#O: M5G^F:0&PO=V]R:W-H M965T$804$B48<#Z=X I4&J(M(R_%:=3 MAS3 \_8[^[W-7>>RP1*FG/XDJ=J/G.\.2F&+"ZI6_/@ 53Y]PY=P*NT7':NU MGH.20BJ>56"M(".L_.-3Y<,9P.]= 05(/@LH%L!NI\%]"I SSI3IF)]"+'" MXZ'@1R3,:LUF&M9,B];I$V:V/59"SQ*-4^.[YW@>S>(8A;.7V>-B^32+UC&: M1"%:K!]F*Q3/?T3S^_ET$JW1>C6)XLET/5]$,?H:@L*$RF_H&K%"2,)V?Q)@ M"L3055J8H7>32L1=*2*X("+BAP[R_"L4>('7 )^VPY^PZ*!N"?<;X&$[/(3D M4G17NUE;&M26!I:O>\G20IL!4J(ISS:$87.^)?HUV4@E]#'_W1*B6X?HVA"] M"R'6>R+2ZQP+]882SBPOTM9G3=ZW4W71&V A6T3U:E&]5J:%(#N=+D44]$6\ M)"=L)_&#_^KIUWKZK511D6U (+ZM!,%)E>5*(DQUN8.T25[)V;>QL'0 M/33(N*EEW+3*>/P8'.4@"&\*/6WG";PF9TK1[4B_$?DAF4&=S*"5:L)84>_P MEIP@12 33+'B0EZ9W$P-:)+8SAMT_/Z7)GWN66DS[Y"^Z_J02:U@JXF\SD#O ME"AK>]E1/+?5;L.5KIVVN=?/(0BS0,]O.5?O'5- ZP=V_ ]02P,$% @ M&(&K4CP;5<$$ P +1 T !X;"]S='EL97,N>&ULW5AM;YLP$/XKB$Y3 M*TTEA)6%-43:D"I-6J=*[8=]JYQ@B"5C,V.ZI+]^/DS(2WU5UP];-J(&^Q[? M/<^=CQAUVN@UI[=+2K6WJKAH4G^I=?TQ")K%DE:D.9#!Y]O8E3_TP?N][-EPFO&"H. M/D[%A%0=MV6PW_-^^0&PF8% QOE>K<$PF]9$:ZK$E9ETBSOC$\CKQW?KVB@L M%5F'XPM_Z]#=#,E[%7Q'12UWS]B;-25-3F_F+"V91L_+RE5.S1 ML$&G+(R!*M][H$JSQ:[EIR+U'5WI33>M"ESS^!_4_&?K7%)!%>&[HDWK'W.5 M7ZTX^O"W)'<_*H>"G1K[\^3815XO.6<_'-^IP6I.7Z;@!3?SN^ICEKJV18 M=0.%Z%=MQU\AO3 >W@L,%Q,Y7=$\ZZ>JG'=#SPP,:W^!PR%RU5UN!/.QF!L! M#./!%& ^U@OC^9_RF:#Y6 S3-G$B$]1G@OI8+Q>2=1^,Q^V3F,N=:9)$41QC M%8/J]6N.[C7?(\WV [>ES'8)EBG:T#< M=0./)''O-L8#'M@N8+T#_&X>Z"FW3Q3!KF+:L"<81Y($0Z 7W3T:QTAU8OBX M]P=[2J(H2=P(8&X%480A\#3B"*8 -&!(%'7GX,%Y%&S.J6#[#X+9+U!+ P04 M " 8@:M2EXJ[', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_ MQ=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+ MJ1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D M5XA-/E_G;@ M2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/ M['X 4$L#!!0 ( !B!JU)QU94&2P0 &(A / >&PO=V]R:V)O;VLN M>&ULQ9I=;^(X%$#_BI6G[D,7\@$SK8:1TN"!:"%!)$7S-G*#*=:$&-FFG9U? MOTY2J*.A5_MBY0GB('-RC>_QM?GRRL7/)\Y_HE^'LI(39Z_4\7XPD,6>'HC\ MFQ]II>_LN#@0I2_%\T >!25;N:=4'_$:=Z7U$$'5K$#^TVW$V?H(+GGKW,NV&]> M*5)FA>!E.7'<]L:&"L6*/YJS&C(G3[)I4>1I333(Q!D/=8<[)J1J/M'T3S3C M"]4?;J].BG]CI:)B2A2="7XZLNJY[D8_Q MG ZT4FT(DSPS( ( ,>H3L1'($0([ZA/0-R#$ .>X3,C @/P&0G_J$'!F0GP'( MSW8A'QZS.,&9.4/N )H[NS3OH8K3!(5)G6BR.$/I-[1:8Q/2'4)I>V@7#JK?WUAI-OB#B9D$->R0A8XS+J3%5*%:]D54;IWZARRP8MT]?X;3/,Y M7IN8D"L\ZZX I-M9EGI@&=*G.;J8D#D\R^8 );U N<;LQ#V(^>"N:!$4A1QJ:[' M$C*/;]D\%\@E42?!%*,2\1U*C[0>_-)B64 @9J<* M"R !!7V5.PVFN>H(( $%UH];WG=_KJ;+ %)/8%D]'Q=CM8VDB0FI)["L'@A3 MSW 3$Y)/8%D^X*95]Y 2DL^HD<_@?*:_I3M6T6VBOT+J]H*4Q4J@^J4]D0A& M]5;B[E26D6Y+JP4GV_-?!,Y_;_CZ'U!+ P04 " 8@:M2.(-O)L0! - M'@ &@ 'AL+U]R96QS+W=O^9H[=3'_\SL5NO=ZOXTJT^]_&0_Q@7!E&ULS=G);L(P M% 707T'95L1X@ X"-FVW+8O^@)L\("*)+=M0^/LZ89!:T:B(2KV;1(GM=U]L MZ6PR?MM9\KUM5=9^DBQ#L ^,^6Q)E?:IL53'D;EQE0[QT2V8U=E*+XB)P6#$ M,E,'JD,_-#62Z?B)YGI=AM[S-K[VA:DGB:/2)[W'_<0F:Y)H:\LBTR&.LTV= M?TOI'Q+2N+*=XY>%]3=Q0L+.)C0C/P<M.='.(.T_[*K\YORW0%QIDS M9ZR/)^;H\KCCD32K^S86(A>*[D\\)<;25W\?-:>=4_[+[+B]'\:MVO/PK+U= MO\=?S_A4_\(^!$@?$J0/!=+'$*2/$4@?MR!]W('T<0_2!Q^@-((B*D&UL4$L! A0#% @ &(&K4LZG-H?N *P( !$ M ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ &(&K4IE< MG",0!@ G"< !, ( !S $ 'AL+W1H96UE+W1H96UE,2YX M;6Q02P$"% ,4 " 8@:M2,[#HX24% #>% & @($- M" >&PO=V]R:W-H965T&UL4$L! A0#% @ &(&K4DD+ ME=#$!P V1\ !@ ("!: T 'AL+W=OY3=KP( ($' 8 M " @6(5 !X;"]W;W)K&PO=V]R:W-H965T M&UL4$L! A0#% @ &(&K4HZ=)*1. @ ( 4 !@ M ("!@QX 'AL+W=O&PO=V]R:W-H965T&UL4$L! M A0#% @ &(&K4IHOWK=Q!P #A\ !@ ("!<"D 'AL M+W=O1 M %XK 8 " @1&PO=V]R:W-H965T&UL4$L! A0#% @ &(&K4MW1QUW9"0 P!D !D M ("!B4\ 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ &(&K4@R'I?ZY!@ Y!( !D ("!:V4 'AL M+W=O&PO=V]R:W-H965TW0\ +TL 9 " M@9]S !X;"]W;W)K&UL4$L! A0#% @ &(&K M4M(Y8>CE"0 21H !D ("!LX, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ &(&K4NO390\R! @@D M !D ("!_Y< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ &(&K4O^ 4]"0! ! T !D M ("! ZT 'AL+W=O,% 7$@ &0 @('*L0 >&PO=V]R:W-H965T M2W !X;"]W;W)K&UL4$L! A0# M% @ &(&K4D#\NV.+ P J @ !D ("!^KL 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ &(&K4CPY MY.P,! 6A !D ("!JL8 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ &(&K4HWCJN_R @ &0@ !D M ("!T], 'AL+W=O'.D4" "7! &0 @('\U@ >&PO M=V]R:W-H965T&UL4$L! A0#% @ &(&K4HM5S%FB P GPX !D ("! MA]P 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ &(&K4L0FF,'& @ Z@< !D ("!M>8 'AL+W=O80$ "X$P &0 M@(%A]P >&PO=V]R:W-H965T&UL4$L! A0#% @ &(&K4MSM(4_I P )Q !D M ("!EO\ 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ &(&K4KM.82$U! (@\ !D ("!*0H! M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M&(&K4CP;5<$$ P +1 T ( !'10! 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ &(&K M4CB#;R;$ 0 #1X !H ( !K1P! 'AL+U]R96QS+W=O XML 62 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 63 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 131 375 1 false 46 0 false 9 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.dvcr.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - INTERIM CONSOLIDATED BALANCE SHEETS Sheet http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS INTERIM CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1002003 - Statement - INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETSParenthetical INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1004005 - Statement - INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Sheet http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONSParenthetical INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Statements 5 false false R6.htm 1005006 - Statement - INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Sheet http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statements 6 false false R7.htm 1006007 - Statement - INTERIM CONSOLIDATED STATEMENTS OF SHAREHOLDERS' DEFICIT Sheet http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT INTERIM CONSOLIDATED STATEMENTS OF SHAREHOLDERS' DEFICIT Statements 7 false false R8.htm 1007008 - Statement - INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 2101101 - Disclosure - BUSINESS Sheet http://www.dvcr.com/role/BUSINESS BUSINESS Notes 9 false false R10.htm 2103102 - Disclosure - CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS Sheet http://www.dvcr.com/role/CONSOLIDATIONANDBASISOFPRESENTATIONOFFINANCIALSTATEMENTS CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS Notes 10 false false R11.htm 2105103 - Disclosure - RECENT ACCOUNTING GUIDANCE Sheet http://www.dvcr.com/role/RECENTACCOUNTINGGUIDANCE RECENT ACCOUNTING GUIDANCE Notes 11 false false R12.htm 2106104 - Disclosure - COVID-19 PANDEMIC Sheet http://www.dvcr.com/role/COVID19PANDEMIC COVID-19 PANDEMIC Notes 12 false false R13.htm 2108105 - Disclosure - REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE Sheet http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLE REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE Notes 13 false false R14.htm 2112106 - Disclosure - LONG-TERM DEBT Sheet http://www.dvcr.com/role/LONGTERMDEBT LONG-TERM DEBT Notes 14 false false R15.htm 2114107 - Disclosure - DERIVATIVES AND HEDGING ACTIVITIES Sheet http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIES DERIVATIVES AND HEDGING ACTIVITIES Notes 15 false false R16.htm 2120108 - Disclosure - LEASES Sheet http://www.dvcr.com/role/LEASES LEASES Notes 16 false false R17.htm 2127109 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 17 false false R18.htm 2129110 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.dvcr.com/role/STOCKBASEDCOMPENSATION STOCK-BASED COMPENSATION Notes 18 false false R19.htm 2135111 - Disclosure - INCOME TAXES Sheet http://www.dvcr.com/role/INCOMETAXES INCOME TAXES Notes 19 false false R20.htm 2137112 - Disclosure - EARNINGS PER COMMON SHARE Sheet http://www.dvcr.com/role/EARNINGSPERCOMMONSHARE EARNINGS PER COMMON SHARE Notes 20 false false R21.htm 2141113 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS Sheet http://www.dvcr.com/role/BUSINESSDEVELOPMENTSANDOTHERSIGNIFICANTTRANSACTIONS BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS Notes 21 false false R22.htm 2204201 - Disclosure - CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Policies) Sheet http://www.dvcr.com/role/CONSOLIDATIONANDBASISOFPRESENTATIONOFFINANCIALSTATEMENTSPolicies CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Policies) Policies 22 false false R23.htm 2309301 - Disclosure - REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE (Tables) Sheet http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLETables REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE (Tables) Tables http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLE 23 false false R24.htm 2315302 - Disclosure - DERIVATIVES AND HEDGING ACTIVITIES (Tables) Sheet http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESTables DERIVATIVES AND HEDGING ACTIVITIES (Tables) Tables http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIES 24 false false R25.htm 2321303 - Disclosure - LEASES (Tables) Sheet http://www.dvcr.com/role/LEASESTables LEASES (Tables) Tables http://www.dvcr.com/role/LEASES 25 false false R26.htm 2330304 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONTables STOCK-BASED COMPENSATION (Tables) Tables http://www.dvcr.com/role/STOCKBASEDCOMPENSATION 26 false false R27.htm 2338305 - Disclosure - EARNINGS PER COMMON SHARE (Tables) Sheet http://www.dvcr.com/role/EARNINGSPERCOMMONSHARETables EARNINGS PER COMMON SHARE (Tables) Tables http://www.dvcr.com/role/EARNINGSPERCOMMONSHARE 27 false false R28.htm 2402401 - Disclosure - BUSINESS (Details) Sheet http://www.dvcr.com/role/BUSINESSDetails BUSINESS (Details) Details http://www.dvcr.com/role/BUSINESS 28 false false R29.htm 2407402 - Disclosure - COVID-19 PANDEMIC (Details) Sheet http://www.dvcr.com/role/COVID19PANDEMICDetails COVID-19 PANDEMIC (Details) Details http://www.dvcr.com/role/COVID19PANDEMIC 29 false false R30.htm 2410403 - Disclosure - REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details) Sheet http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details) Details 30 false false R31.htm 2411404 - Disclosure - REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE - Summary of Accounts Receivable (Details) Sheet http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLESummaryofAccountsReceivableDetails REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE - Summary of Accounts Receivable (Details) Details 31 false false R32.htm 2413405 - Disclosure - LONG-TERM DEBT (Details) Sheet http://www.dvcr.com/role/LONGTERMDEBTDetails LONG-TERM DEBT (Details) Details http://www.dvcr.com/role/LONGTERMDEBT 32 false false R33.htm 2416406 - Disclosure - DERIVATIVES AND HEDGING ACTIVITIES - Additional Information (Details) Sheet http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESAdditionalInformationDetails DERIVATIVES AND HEDGING ACTIVITIES - Additional Information (Details) Details 33 false false R34.htm 2417407 - Disclosure - DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Derivatives (Details) Sheet http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesDetails DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Derivatives (Details) Details 34 false false R35.htm 2418408 - Disclosure - DERIVATIVES AND HEDGING ACTIVITIES - Derivative Instruments in Statement of Financial Position, Fair Value (Details) Sheet http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails DERIVATIVES AND HEDGING ACTIVITIES - Derivative Instruments in Statement of Financial Position, Fair Value (Details) Details 35 false false R36.htm 2419409 - Disclosure - DERIVATIVES AND HEDGING ACTIVITIES - Effect Of Cash Flow Hedge Accounting On Accumulated Other Comprehensive Income (Details) Sheet http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESEffectOfCashFlowHedgeAccountingOnAccumulatedOtherComprehensiveIncomeDetails DERIVATIVES AND HEDGING ACTIVITIES - Effect Of Cash Flow Hedge Accounting On Accumulated Other Comprehensive Income (Details) Details 36 false false R37.htm 2422410 - Disclosure - LEASES - Narrative (Details) Sheet http://www.dvcr.com/role/LEASESNarrativeDetails LEASES - Narrative (Details) Details 37 false false R38.htm 2423411 - Disclosure - LEASES - Balance Sheet Classification (Details) Sheet http://www.dvcr.com/role/LEASESBalanceSheetClassificationDetails LEASES - Balance Sheet Classification (Details) Details 38 false false R39.htm 2424412 - Disclosure - LEASES - Lease Cost (Details) Sheet http://www.dvcr.com/role/LEASESLeaseCostDetails LEASES - Lease Cost (Details) Details 39 false false R40.htm 2425413 - Disclosure - LEASES - Maturities of Operating and Financing Lease Liabilities (Details) Sheet http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails LEASES - Maturities of Operating and Financing Lease Liabilities (Details) Details 40 false false R41.htm 2426414 - Disclosure - LEASES - Other Lease Information (Details) Sheet http://www.dvcr.com/role/LEASESOtherLeaseInformationDetails LEASES - Other Lease Information (Details) Details 41 false false R42.htm 2428415 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIES 42 false false R43.htm 2431416 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) Sheet http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails STOCK-BASED COMPENSATION - Narrative (Details) Details 43 false false R44.htm 2432417 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Activity of Equity Compensation Plans (Details) Sheet http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofEquityCompensationPlansDetails STOCK-BASED COMPENSATION - Schedule of Activity of Equity Compensation Plans (Details) Details 44 false false R45.htm 2433418 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock and Restricted Stock Units Activity (Details) Sheet http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockandRestrictedStockUnitsActivityDetails STOCK-BASED COMPENSATION - Schedule of Restricted Stock and Restricted Stock Units Activity (Details) Details 45 false false R46.htm 2434419 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Awards Outstanding and Exercisable (Details) Sheet http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofAwardsOutstandingandExercisableDetails STOCK-BASED COMPENSATION - Schedule of Awards Outstanding and Exercisable (Details) Details 46 false false R47.htm 2436420 - Disclosure - INCOME TAXES (Details) Sheet http://www.dvcr.com/role/INCOMETAXESDetails INCOME TAXES (Details) Details http://www.dvcr.com/role/INCOMETAXES 47 false false R48.htm 2439421 - Disclosure - EARNINGS PER COMMON SHARE - Basic and Diluted Net Income (Loss) Per Common Share (Details) Sheet http://www.dvcr.com/role/EARNINGSPERCOMMONSHAREBasicandDilutedNetIncomeLossPerCommonShareDetails EARNINGS PER COMMON SHARE - Basic and Diluted Net Income (Loss) Per Common Share (Details) Details 48 false false R49.htm 2440422 - Disclosure - EARNINGS PER COMMON SHARE - Narrative (Details) Sheet http://www.dvcr.com/role/EARNINGSPERCOMMONSHARENarrativeDetails EARNINGS PER COMMON SHARE - Narrative (Details) Details 49 false false R50.htm 2442423 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS (Details) Sheet http://www.dvcr.com/role/BUSINESSDEVELOPMENTSANDOTHERSIGNIFICANTTRANSACTIONSDetails BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS (Details) Details http://www.dvcr.com/role/BUSINESSDEVELOPMENTSANDOTHERSIGNIFICANTTRANSACTIONS 50 false false All Reports Book All Reports dvcr-20210331.htm dvcr-20210331.xsd dvcr-20210331_cal.xml dvcr-20210331_def.xml dvcr-20210331_lab.xml dvcr-20210331_pre.xml dvcrex31133121certificatio.htm dvcrex31233121certificatio.htm dvcrex3233121certification.htm http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true JSON 67 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "dvcr-20210331.htm": { "axisCustom": 1, "axisStandard": 19, "contextCount": 131, "dts": { "calculationLink": { "local": [ "dvcr-20210331_cal.xml" ] }, "definitionLink": { "local": [ "dvcr-20210331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "dvcr-20210331.htm" ] }, "labelLink": { "local": [ "dvcr-20210331_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "dvcr-20210331_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "dvcr-20210331.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 471, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 4, "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 9 }, "keyCustom": 72, "keyStandard": 303, "memberCustom": 19, "memberStandard": 27, "nsprefix": "dvcr", "nsuri": "http://www.dvcr.com/20210331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.dvcr.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS", "role": "http://www.dvcr.com/role/CONSOLIDATIONANDBASISOFPRESENTATIONOFFINANCIALSTATEMENTS", "shortName": "CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105103 - Disclosure - RECENT ACCOUNTING GUIDANCE", "role": "http://www.dvcr.com/role/RECENTACCOUNTINGGUIDANCE", "shortName": "RECENT ACCOUNTING GUIDANCE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106104 - Disclosure - COVID-19 PANDEMIC", "role": "http://www.dvcr.com/role/COVID19PANDEMIC", "shortName": "COVID-19 PANDEMIC", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108105 - Disclosure - REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE", "role": "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLE", "shortName": "REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112106 - Disclosure - LONG-TERM DEBT", "role": "http://www.dvcr.com/role/LONGTERMDEBT", "shortName": "LONG-TERM DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114107 - Disclosure - DERIVATIVES AND HEDGING ACTIVITIES", "role": "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIES", "shortName": "DERIVATIVES AND HEDGING ACTIVITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120108 - Disclosure - LEASES", "role": "http://www.dvcr.com/role/LEASES", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127109 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129110 - Disclosure - STOCK-BASED COMPENSATION", "role": "http://www.dvcr.com/role/STOCKBASEDCOMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2135111 - Disclosure - INCOME TAXES", "role": "http://www.dvcr.com/role/INCOMETAXES", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "ie1a02ebbdc8c40beaa0d478b24025567_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - INTERIM CONSOLIDATED BALANCE SHEETS", "role": "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS", "shortName": "INTERIM CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "ie1a02ebbdc8c40beaa0d478b24025567_I20210331", "decimals": "-3", "lang": "en-US", "name": "dvcr:SelfInsuranceReceivablesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137112 - Disclosure - EARNINGS PER COMMON SHARE", "role": "http://www.dvcr.com/role/EARNINGSPERCOMMONSHARE", "shortName": "EARNINGS PER COMMON SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2141113 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS", "role": "http://www.dvcr.com/role/BUSINESSDEVELOPMENTSANDOTHERSIGNIFICANTTRANSACTIONS", "shortName": "BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Policies)", "role": "http://www.dvcr.com/role/CONSOLIDATIONANDBASISOFPRESENTATIONOFFINANCIALSTATEMENTSPolicies", "shortName": "CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE (Tables)", "role": "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLETables", "shortName": "REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315302 - Disclosure - DERIVATIVES AND HEDGING ACTIVITIES (Tables)", "role": "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESTables", "shortName": "DERIVATIVES AND HEDGING ACTIVITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dvcr:AssetsAndLiabilitiesLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321303 - Disclosure - LEASES (Tables)", "role": "http://www.dvcr.com/role/LEASESTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dvcr:AssetsAndLiabilitiesLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2330304 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "role": "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONTables", "shortName": "STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2338305 - Disclosure - EARNINGS PER COMMON SHARE (Tables)", "role": "http://www.dvcr.com/role/EARNINGSPERCOMMONSHARETables", "shortName": "EARNINGS PER COMMON SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "ie1a02ebbdc8c40beaa0d478b24025567_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfStatesInWhichEntityOperates", "reportCount": 1, "unique": true, "unitRef": "state", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - BUSINESS (Details)", "role": "http://www.dvcr.com/role/BUSINESSDetails", "shortName": "BUSINESS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "ie1a02ebbdc8c40beaa0d478b24025567_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfStatesInWhichEntityOperates", "reportCount": 1, "unique": true, "unitRef": "state", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "ie1a02ebbdc8c40beaa0d478b24025567_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "dvcr:PublicHealthAndSocialServicesEmergencyFundsReceivedCoronavirusAidReliefAndEconomicSecurityActCARESAct", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - COVID-19 PANDEMIC (Details)", "role": "http://www.dvcr.com/role/COVID19PANDEMICDetails", "shortName": "COVID-19 PANDEMIC (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "ie1a02ebbdc8c40beaa0d478b24025567_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "dvcr:PublicHealthAndSocialServicesEmergencyFundsReceivedCoronavirusAidReliefAndEconomicSecurityActCARESAct", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "ie1a02ebbdc8c40beaa0d478b24025567_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "ie1a02ebbdc8c40beaa0d478b24025567_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "dvcr:MedicaidFundsReceivedCoronavirusAidReliefAndEconomicSecurityActCARESAct", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410403 - Disclosure - REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details)", "role": "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "shortName": "REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "dvcr:HospiceFundsReceivedCoronavirusAidReliefAndEconomicSecurityActCARESAct", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "ie1a02ebbdc8c40beaa0d478b24025567_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE - Summary of Accounts Receivable (Details)", "role": "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLESummaryofAccountsReceivableDetails", "shortName": "REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE - Summary of Accounts Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "i3aa3fba97b5c442b835896697e28651f_I20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "ifb9ca207fbe142a98de324c97fe4e793_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413405 - Disclosure - LONG-TERM DEBT (Details)", "role": "http://www.dvcr.com/role/LONGTERMDEBTDetails", "shortName": "LONG-TERM DEBT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "ifb9ca207fbe142a98de324c97fe4e793_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "i64259d81e1b54e3997c7eb629b599c01_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416406 - Disclosure - DERIVATIVES AND HEDGING ACTIVITIES - Additional Information (Details)", "role": "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESAdditionalInformationDetails", "shortName": "DERIVATIVES AND HEDGING ACTIVITIES - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "i64259d81e1b54e3997c7eb629b599c01_I20210331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DerivativeFixedInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "i64259d81e1b54e3997c7eb629b599c01_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNumberOfInstrumentsHeld", "reportCount": 1, "unique": true, "unitRef": "state", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417407 - Disclosure - DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Derivatives (Details)", "role": "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesDetails", "shortName": "DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Derivatives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "i64259d81e1b54e3997c7eb629b599c01_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNumberOfInstrumentsHeld", "reportCount": 1, "unique": true, "unitRef": "state", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "i5ae38539986c46a0b9a4a2a2262d4afd_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418408 - Disclosure - DERIVATIVES AND HEDGING ACTIVITIES - Derivative Instruments in Statement of Financial Position, Fair Value (Details)", "role": "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails", "shortName": "DERIVATIVES AND HEDGING ACTIVITIES - Derivative Instruments in Statement of Financial Position, Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "i5ae38539986c46a0b9a4a2a2262d4afd_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419409 - Disclosure - DERIVATIVES AND HEDGING ACTIVITIES - Effect Of Cash Flow Hedge Accounting On Accumulated Other Comprehensive Income (Details)", "role": "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESEffectOfCashFlowHedgeAccountingOnAccumulatedOtherComprehensiveIncomeDetails", "shortName": "DERIVATIVES AND HEDGING ACTIVITIES - Effect Of Cash Flow Hedge Accounting On Accumulated Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "iccfb65197be746dba48e510f63cc27f0_I20201201", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422410 - Disclosure - LEASES - Narrative (Details)", "role": "http://www.dvcr.com/role/LEASESNarrativeDetails", "shortName": "LEASES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "lang": "en-US", "name": "dvcr:LesseeLeaseTerminationPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "ie1a02ebbdc8c40beaa0d478b24025567_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423411 - Disclosure - LEASES - Balance Sheet Classification (Details)", "role": "http://www.dvcr.com/role/LEASESBalanceSheetClassificationDetails", "shortName": "LEASES - Balance Sheet Classification (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "dvcr:AssetsAndLiabilitiesLeasesTableTextBlock", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "ie1a02ebbdc8c40beaa0d478b24025567_I20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424412 - Disclosure - LEASES - Lease Cost (Details)", "role": "http://www.dvcr.com/role/LEASESLeaseCostDetails", "shortName": "LEASES - Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS", "shortName": "INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "ie1a02ebbdc8c40beaa0d478b24025567_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425413 - Disclosure - LEASES - Maturities of Operating and Financing Lease Liabilities (Details)", "role": "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails", "shortName": "LEASES - Maturities of Operating and Financing Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "ie1a02ebbdc8c40beaa0d478b24025567_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "ie1a02ebbdc8c40beaa0d478b24025567_I20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426414 - Disclosure - LEASES - Other Lease Information (Details)", "role": "http://www.dvcr.com/role/LEASESOtherLeaseInformationDetails", "shortName": "LEASES - Other Lease Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "ie1a02ebbdc8c40beaa0d478b24025567_I20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "ie1a02ebbdc8c40beaa0d478b24025567_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "dvcr:NumberOfProfessionalLiabilityLawsuits", "reportCount": 1, "unique": true, "unitRef": "lawsuit", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428415 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "role": "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "ie1a02ebbdc8c40beaa0d478b24025567_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "dvcr:NumberOfProfessionalLiabilityLawsuits", "reportCount": 1, "unique": true, "unitRef": "lawsuit", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431416 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)", "role": "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "ibf42a039d3e24ee6a74e56c21de54eaf_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "dvcr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432417 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Activity of Equity Compensation Plans (Details)", "role": "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofEquityCompensationPlansDetails", "shortName": "STOCK-BASED COMPENSATION - Schedule of Activity of Equity Compensation Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "ibf42a039d3e24ee6a74e56c21de54eaf_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "dvcr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "i9c73f1d8d4f7443fa30fc6a4bbb1a08f_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433418 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock and Restricted Stock Units Activity (Details)", "role": "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockandRestrictedStockUnitsActivityDetails", "shortName": "STOCK-BASED COMPENSATION - Schedule of Restricted Stock and Restricted Stock Units Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "i9c73f1d8d4f7443fa30fc6a4bbb1a08f_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "i373e4194523948b2805cfe628ed972d8_I20210331", "decimals": "2", "first": true, "lang": "en-US", "name": "dvcr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingWeightedAverageExercisePrice", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434419 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Awards Outstanding and Exercisable (Details)", "role": "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofAwardsOutstandingandExercisableDetails", "shortName": "STOCK-BASED COMPENSATION - Schedule of Awards Outstanding and Exercisable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "i373e4194523948b2805cfe628ed972d8_I20210331", "decimals": "-3", "lang": "en-US", "name": "dvcr:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingAwards", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436420 - Disclosure - INCOME TAXES (Details)", "role": "http://www.dvcr.com/role/INCOMETAXESDetails", "shortName": "INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "ie1a02ebbdc8c40beaa0d478b24025567_I20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperations", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439421 - Disclosure - EARNINGS PER COMMON SHARE - Basic and Diluted Net Income (Loss) Per Common Share (Details)", "role": "http://www.dvcr.com/role/EARNINGSPERCOMMONSHAREBasicandDilutedNetIncomeLossPerCommonShareDetails", "shortName": "EARNINGS PER COMMON SHARE - Basic and Diluted Net Income (Loss) Per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440422 - Disclosure - EARNINGS PER COMMON SHARE - Narrative (Details)", "role": "http://www.dvcr.com/role/EARNINGSPERCOMMONSHARENarrativeDetails", "shortName": "EARNINGS PER COMMON SHARE - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)", "role": "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONSParenthetical", "shortName": "INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "ie28f8ef2933749a1afab6687662664d1_D20201101-20201101", "decimals": null, "first": true, "lang": "en-US", "name": "dvcr:OutsourcedServicesContractTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442423 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS (Details)", "role": "http://www.dvcr.com/role/BUSINESSDEVELOPMENTSANDOTHERSIGNIFICANTTRANSACTIONSDetails", "shortName": "BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "ie28f8ef2933749a1afab6687662664d1_D20201101-20201101", "decimals": null, "first": true, "lang": "en-US", "name": "dvcr:OutsourcedServicesContractTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "role": "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "shortName": "INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "ib4ebdd343bbc44b391b767f9af305b80_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - INTERIM CONSOLIDATED STATEMENTS OF SHAREHOLDERS' DEFICIT", "role": "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT", "shortName": "INTERIM CONSOLIDATED STATEMENTS OF SHAREHOLDERS' DEFICIT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "ib4ebdd343bbc44b391b767f9af305b80_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007008 - Statement - INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IncreaseDecreaseInSelfInsuranceReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - BUSINESS", "role": "http://www.dvcr.com/role/BUSINESS", "shortName": "BUSINESS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dvcr-20210331.htm", "contextRef": "id8697232d2be46a58ec3e6b42fa7bb9f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 46, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dvcr_AccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Accounting Policies [Table]", "label": "Accounting Policies [Line Items]", "terseLabel": "Accounting Policies [Line Items]" } } }, "localname": "AccountingPoliciesLineItems", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/BUSINESSDetails" ], "xbrltype": "stringItemType" }, "dvcr_AccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounting Policies [Table]", "label": "Accounting Policies [Table]", "terseLabel": "Accounting Policies [Table]" } } }, "localname": "AccountingPoliciesTable", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/BUSINESSDetails" ], "xbrltype": "stringItemType" }, "dvcr_AcquiredLeaseholdInterestNetNoncurrent": { "auth_ref": [], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Acquired leasehold interest, net.", "label": "Acquired Leasehold Interest, Net Noncurrent", "terseLabel": "Acquired leasehold interest, net" } } }, "localname": "AcquiredLeaseholdInterestNetNoncurrent", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "dvcr_AcquisitionLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquisition Loan", "label": "Acquisition Loan [Member]", "terseLabel": "Acquisition Loan" } } }, "localname": "AcquisitionLoanMember", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "domainItemType" }, "dvcr_AffiliatedRevolvingCreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Affiliated Revolving Credit Agreement [Member]", "label": "Affiliated Revolving Credit Agreement [Member]", "terseLabel": "Affiliated Revolving Credit Agreement" } } }, "localname": "AffiliatedRevolvingCreditAgreementMember", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "domainItemType" }, "dvcr_AmendedAndRestatedCreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended and Restated Credit Agreement [Member]", "label": "Amended And Restated Credit Agreement [Member]", "terseLabel": "Amended And Restated Credit Agreement" } } }, "localname": "AmendedAndRestatedCreditAgreementMember", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "domainItemType" }, "dvcr_AmortizationOfRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization Of Right-of-Use Asset", "label": "Amortization Of Right-of-Use Asset", "terseLabel": "Amortization of right-of-use assets" } } }, "localname": "AmortizationOfRightOfUseAsset", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "dvcr_AssetsAndLiabilitiesLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets and Liabilities Leases [Table Text Block]", "label": "Assets And Liabilities Leases [Table Text Block]", "terseLabel": "Schedule of Lease Assets and Liabilities" } } }, "localname": "AssetsAndLiabilitiesLeasesTableTextBlock", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "dvcr_CivilInvestigativeDemandMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Civil Investigative Demand [Member]", "label": "Civil Investigative Demand [Member]", "terseLabel": "CID" } } }, "localname": "CivilInvestigativeDemandMember", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "dvcr_CoronavirusAidReliefAndEconomicSecuritiesCARESActIncomeTaxRefundReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Income Tax Refund Received", "label": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Income Tax Refund Received", "terseLabel": "Tax refund" } } }, "localname": "CoronavirusAidReliefAndEconomicSecuritiesCARESActIncomeTaxRefundReceived", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_CorporateIntegrityAgreementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corporate Integrity Agreement Term", "label": "Corporate Integrity Agreement Term", "terseLabel": "CIA term" } } }, "localname": "CorporateIntegrityAgreementTerm", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "durationItemType" }, "dvcr_DebtInstrumentCollateralNumberOfOwnedNursingCenters": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Collateral, Number Of Owned Nursing Centers", "label": "Debt Instrument, Collateral, Number Of Owned Nursing Centers", "terseLabel": "Number of owned nursing centers to secure Amended Mortgage Loan" } } }, "localname": "DebtInstrumentCollateralNumberOfOwnedNursingCenters", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "integerItemType" }, "dvcr_EmployeeHealthInsuranceMaximumPayablePerIndividualAnnually": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Employee Health Insurance Maximum Payable Per Individual Annually", "label": "Employee Health Insurance Maximum Payable Per Individual Annually", "verboseLabel": "Health insurance, maximum self-insured annual amount per individual" } } }, "localname": "EmployeeHealthInsuranceMaximumPayablePerIndividualAnnually", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_EmployeeRelatedLiabilitiesNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Employee-Related Liabilities, Noncurrent", "label": "Employee-Related Liabilities, Noncurrent", "terseLabel": "Payroll and employee benefits, less current portion" } } }, "localname": "EmployeeRelatedLiabilitiesNoncurrent", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/COVID19PANDEMICDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_FinanceLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "dvcr_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFour", "weight": 1.0 }, "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Lease, Liability, To Be Paid, After Year Four", "label": "Finance Lease, Liability, To Be Paid, After Year Four", "terseLabel": "After 2025" } } }, "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_HospiceFundsReceivedCoronavirusAidReliefAndEconomicSecurityActCARESAct": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Hospice Funds Received, Coronavirus Aid, Relief and Economic Security Act (CARES Act)", "label": "Hospice Funds Received, Coronavirus Aid, Relief and Economic Security Act (CARES Act)", "terseLabel": "COVID-19, Hospice funds received" } } }, "localname": "HospiceFundsReceivedCoronavirusAidReliefAndEconomicSecurityActCARESAct", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Operating Lease Liabilities", "label": "Increase (Decrease) In Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "dvcr_InterestRateCashFlowHedgeGainLossFromContractTermination": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest Rate Cash Flow Hedge, Gain (Loss) from Contract Termination", "label": "Interest Rate Cash Flow Hedge, Gain (Loss) from Contract Termination", "terseLabel": "Loss on contract termination" } } }, "localname": "InterestRateCashFlowHedgeGainLossFromContractTermination", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_IssuanceRedemptionOfEmployeeEquityAwardsNet": { "auth_ref": [], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Issuance (Redemption) Of Employee Equity Awards, Net", "label": "Issuance (Redemption) Of Employee Equity Awards, Net", "terseLabel": "Issuance and redemption of employee equity awards, net" } } }, "localname": "IssuanceRedemptionOfEmployeeEquityAwardsNet", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "dvcr_LeaseLiability": { "auth_ref": [], "calculation": { "http://www.dvcr.com/role/LEASESBalanceSheetClassificationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease Liability", "label": "Lease Liability", "totalLabel": "Total lease liabilities" } } }, "localname": "LeaseLiability", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LEASESBalanceSheetClassificationDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_LeaseRightofUseAsset": { "auth_ref": [], "calculation": { "http://www.dvcr.com/role/LEASESBalanceSheetClassificationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lease Right-of-Use Asset", "label": "Lease Right-of-Use Asset", "totalLabel": "Total leased assets" } } }, "localname": "LeaseRightofUseAsset", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LEASESBalanceSheetClassificationDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_LesseeLeaseTerminationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee Lease Termination Period", "label": "Lessee Lease Termination Period", "terseLabel": "Other leases termination period" } } }, "localname": "LesseeLeaseTerminationPeriod", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LEASESNarrativeDetails" ], "xbrltype": "durationItemType" }, "dvcr_LesseeOperatingAndFinanceLeaseWeightedAverageDiscountRateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee Operating and Finance Lease Weighted Average Discount Rate [Abstract]", "label": "Lessee Operating And Finance Lease Weighted Average Discount Rate [Abstract]", "terseLabel": "Weighted-average discount rate" } } }, "localname": "LesseeOperatingAndFinanceLeaseWeightedAverageDiscountRateAbstract", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LEASESOtherLeaseInformationDetails" ], "xbrltype": "stringItemType" }, "dvcr_LesseeOperatingAndFinanceLeaseWeightedAverageRemainingLeaseTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee Operating and Finance Lease Weighted Average Remaining Lease Term [Abstract]", "label": "Lessee Operating And Finance Lease Weighted Average Remaining Lease Term [Abstract]", "terseLabel": "Weighted-average remaining lease term (years)" } } }, "localname": "LesseeOperatingAndFinanceLeaseWeightedAverageRemainingLeaseTermAbstract", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LEASESOtherLeaseInformationDetails" ], "xbrltype": "stringItemType" }, "dvcr_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four", "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four", "terseLabel": "After 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_LineOfCreditFacilityFeePercentageOnAmountOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line of Credit Facility, Fee Percentage On Amount Outstanding", "label": "Line of Credit Facility, Fee Percentage On Amount Outstanding", "verboseLabel": "Annual fees for letters of credit issued under revolver (as a percentage)" } } }, "localname": "LineOfCreditFacilityFeePercentageOnAmountOutstanding", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "percentItemType" }, "dvcr_LineOfCreditFacilityTermsDurationOfAmortizationPeriodForPrincipalAndInterestPayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line of Credit Facility, Terms, Duration Of Amortization Period For Principal And Interest Payments", "label": "Line of Credit Facility, Terms, Duration Of Amortization Period For Principal And Interest Payments", "verboseLabel": "Period of amortization" } } }, "localname": "LineOfCreditFacilityTermsDurationOfAmortizationPeriodForPrincipalAndInterestPayments", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "durationItemType" }, "dvcr_LossContingencySettlementPaymentPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Settlement, Payment Period", "label": "Loss Contingency, Settlement, Payment Period", "terseLabel": "Settlement payment period" } } }, "localname": "LossContingencySettlementPaymentPeriod", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "durationItemType" }, "dvcr_MalpracticeInsuranceAnnualCoverageLimitPerFacility": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Malpractice Insurance Annual Coverage Limit Per Facility", "label": "Malpractice Insurance Annual Coverage Limit Per Facility", "terseLabel": "Professional liability insurance, annual coverage limit per facility" } } }, "localname": "MalpracticeInsuranceAnnualCoverageLimitPerFacility", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_MalpracticeInsuranceAnnualSublimitPerCenter": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Malpractice Insurance, Annual Sublimit Per Center", "label": "Malpractice Insurance, Annual Sublimit Per Center", "terseLabel": "Malpractice insurance annual sublimit per center" } } }, "localname": "MalpracticeInsuranceAnnualSublimitPerCenter", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_MalpracticeInsuranceSelfInsuredCostsPaidDuringPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Malpractice Insurance Self Insured Costs Paid During Period", "label": "Malpractice Insurance Self Insured Costs Paid During Period", "verboseLabel": "Cash expenditures for self-insured professional liability costs" } } }, "localname": "MalpracticeInsuranceSelfInsuredCostsPaidDuringPeriod", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_ManagedCareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Managed Care [Member]", "label": "Managed Care [Member]", "terseLabel": "Managed Care" } } }, "localname": "ManagedCareMember", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLESummaryofAccountsReceivableDetails" ], "xbrltype": "domainItemType" }, "dvcr_MedicaidAndHospiceRevenueCoronavirusAidReliefAndEconomicSecurityActCARESAct": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Medicaid and Hospice Revenue, Coronavirus Aid, Relief and Economic Security Act (CARES Act)", "label": "Medicaid and Hospice Revenue, Coronavirus Aid, Relief and Economic Security Act (CARES Act)", "terseLabel": "Medicaid and Hospice revenue" } } }, "localname": "MedicaidAndHospiceRevenueCoronavirusAidReliefAndEconomicSecurityActCARESAct", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/COVID19PANDEMICDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_MedicaidFundsReceivedCoronavirusAidReliefAndEconomicSecurityActCARESAct": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Medicaid Funds Received, Coronavirus Aid, Relief And Economic Security Act (CARES Act)", "label": "Medicaid Funds Received, Coronavirus Aid, Relief And Economic Security Act (CARES Act)", "terseLabel": "COVID-19, Medicaid revenue from states" } } }, "localname": "MedicaidFundsReceivedCoronavirusAidReliefAndEconomicSecurityActCARESAct", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/COVID19PANDEMICDetails", "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_MedicaidMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medicaid [Member]", "label": "Medicaid [Member]", "terseLabel": "Medicaid" } } }, "localname": "MedicaidMember", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLESummaryofAccountsReceivableDetails" ], "xbrltype": "domainItemType" }, "dvcr_MedicaidSequestrationAmountCoronavirusAidReliefAndEconomicSecurityActCARESAct": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Medicaid Sequestration, Amount, Coronavirus Aid, Relief And Economic Security Act (CARES Act)", "label": "Medicaid Sequestration, Amount, Coronavirus Aid, Relief And Economic Security Act (CARES Act)", "terseLabel": "COVID-19, Medicaid sequestration amount" } } }, "localname": "MedicaidSequestrationAmountCoronavirusAidReliefAndEconomicSecurityActCARESAct", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/COVID19PANDEMICDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_MedicareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medicare [Member]", "label": "Medicare [Member]", "terseLabel": "Medicare" } } }, "localname": "MedicareMember", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLESummaryofAccountsReceivableDetails" ], "xbrltype": "domainItemType" }, "dvcr_MortgageLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mortgage Loan", "label": "Mortgage Loan [Member]", "terseLabel": "Mortgage Loan" } } }, "localname": "MortgageLoanMember", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "domainItemType" }, "dvcr_MortgageTermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mortgage Term Loan [Member]", "label": "Mortgage Term Loan [Member]", "terseLabel": "Mortgage Term Loan" } } }, "localname": "MortgageTermLoanMember", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "domainItemType" }, "dvcr_NumberOfLettersOfCredit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Letters Of Credit", "label": "Number Of Letters Of Credit", "terseLabel": "Number of letters of credit" } } }, "localname": "NumberOfLettersOfCredit", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "integerItemType" }, "dvcr_NumberOfLicensedAssistedLivingBeds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Licensed Assisted Living Beds", "label": "Number Of Licensed Assisted Living Beds", "terseLabel": "Number of licensed assisted and residential living beds" } } }, "localname": "NumberOfLicensedAssistedLivingBeds", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/BUSINESSDetails" ], "xbrltype": "integerItemType" }, "dvcr_NumberOfLicensedNursingBeds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of licensed nursing beds.", "label": "Number Of Licensed Nursing Beds", "terseLabel": "Number of licensed nursing beds" } } }, "localname": "NumberOfLicensedNursingBeds", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/BUSINESSDetails" ], "xbrltype": "integerItemType" }, "dvcr_NumberOfLicensedNursingBedsPerNursingCenter": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Licensed Nursing Beds Per Nursing Center", "label": "Number Of Licensed Nursing Beds Per Nursing Center", "terseLabel": "Number of licensed nursing beds per center" } } }, "localname": "NumberOfLicensedNursingBedsPerNursingCenter", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/BUSINESSDetails" ], "xbrltype": "integerItemType" }, "dvcr_NumberOfNursingCenterFacilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Nursing Center Facilities", "label": "Number Of Nursing Center Facilities", "terseLabel": "Number of nursing centers" } } }, "localname": "NumberOfNursingCenterFacilities", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/BUSINESSDetails" ], "xbrltype": "integerItemType" }, "dvcr_NumberOfNursingCenterFacilitiesLeased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Nursing Center Facilities Leased", "label": "Number Of Nursing Center Facilities Leased", "terseLabel": "Number of nursing center facilities leased" } } }, "localname": "NumberOfNursingCenterFacilitiesLeased", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/BUSINESSDetails" ], "xbrltype": "integerItemType" }, "dvcr_NumberOfNursingCenterFacilitiesOwned": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Nursing Center Facilities Owned", "label": "Number Of Nursing Center Facilities Owned", "terseLabel": "Number of nursing center facilities owned" } } }, "localname": "NumberOfNursingCenterFacilitiesOwned", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/BUSINESSDetails" ], "xbrltype": "integerItemType" }, "dvcr_NumberOfProfessionalLiabilityLawsuits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Professional Liability Lawsuits", "label": "Number Of Professional Liability Lawsuits", "terseLabel": "Number of professional liability lawsuits" } } }, "localname": "NumberOfProfessionalLiabilityLawsuits", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "integerItemType" }, "dvcr_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating and Finance Lease Liabilities Payments Due [Abstract]", "label": "Operating And Finance Lease Liabilities Payments Due [Abstract]", "terseLabel": "Operating and Finance Lease Liabilities Payments Due [Abstract]" } } }, "localname": "OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "dvcr_OperatingAndFinanceLeaseLiability": { "auth_ref": [], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "dvcr_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating And Finance Lease Liability", "label": "Operating And Finance Lease Liability", "totalLabel": "Present value of lease liabilities" } } }, "localname": "OperatingAndFinanceLeaseLiability", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_OperatingAndFinanceLeaseLiabilityPaymentsDue": { "auth_ref": [], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating And Finance Lease Liability Payments Due", "label": "Operating And Finance Lease Liability Payments Due", "totalLabel": "Total lease payments" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDue", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": 6.0, "parentTag": "dvcr_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating And Finance Lease Liability Payments Due After Year Four", "label": "Operating And Finance Lease Liability Payments Due After Year Four", "totalLabel": "After 2025" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": 5.0, "parentTag": "dvcr_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating And Finance Lease Liability Payments Due Year Four", "label": "Operating And Finance Lease Liability Payments Due Year Four", "totalLabel": "2025" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_OperatingAndFinanceLeaseLiabilityPaymentsDueYearOne": { "auth_ref": [], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "dvcr_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating And Finance Lease, Liability Payments Due Year One", "label": "Operating And Finance Lease, Liability Payments Due Year One", "totalLabel": "2022" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearOne", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": 4.0, "parentTag": "dvcr_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating And Finance Lease Liability Payments Due Year Three", "label": "Operating And Finance Lease Liability Payments Due Year Three", "totalLabel": "2024" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": 3.0, "parentTag": "dvcr_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating And Finance Lease, Liability, Payments Due Year Two", "label": "Operating And Finance Lease, Liability, Payments Due Year Two", "totalLabel": "2023" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_OperatingAndFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "dvcr_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating And Finance Lease, Liability, Payments, Remainder Of Fiscal Year", "label": "Operating And Finance Lease, Liability, Payments, Remainder Of Fiscal Year", "totalLabel": "2021" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "dvcr_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating And Finance Lease Liability Undiscounted Excess Amount", "label": "Operating And Finance Lease Liability Undiscounted Excess Amount", "negatedTotalLabel": "Less: Interest" } } }, "localname": "OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_OperatingLeaseAnnualLeaseFixedEscalatorsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease, Annual Lease Fixed Escalators, Percent", "label": "Operating Lease, Annual Lease Fixed Escalators, Percent", "terseLabel": "Annual lease fixed escalators, percent" } } }, "localname": "OperatingLeaseAnnualLeaseFixedEscalatorsPercent", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/BUSINESSDEVELOPMENTSANDOTHERSIGNIFICANTTRANSACTIONSDetails" ], "xbrltype": "percentItemType" }, "dvcr_OperatingLeaseNumberOfLeaseExtensionsAllowed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease, Number Of Lease Extensions Allowed", "label": "Operating Lease, Number Of Lease Extensions Allowed", "terseLabel": "Number of lease extensions allowed" } } }, "localname": "OperatingLeaseNumberOfLeaseExtensionsAllowed", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/BUSINESSDEVELOPMENTSANDOTHERSIGNIFICANTTRANSACTIONSDetails" ], "xbrltype": "integerItemType" }, "dvcr_OtherComprehensiveIncomeLossCashFlowHedgeGainLossIncludingTerminationAfterReclassificationAndTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss) Including Termination, after Reclassification and Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss) Including Termination, after Reclassification and Tax", "terseLabel": "Interest rate cash flow hedges" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossIncludingTerminationAfterReclassificationAndTax", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT" ], "xbrltype": "monetaryItemType" }, "dvcr_OutsourcedServicesContractTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outsourced Services Contract Term", "label": "Outsourced Services Contract Term", "terseLabel": "Third-party contract term" } } }, "localname": "OutsourcedServicesContractTerm", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/BUSINESSDEVELOPMENTSANDOTHERSIGNIFICANTTRANSACTIONSDetails" ], "xbrltype": "durationItemType" }, "dvcr_PaymentsForCapitalGrantPropertyImprovementsCARESAct": { "auth_ref": [], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Capital Grant Property Improvements, CARES Act", "label": "Payments For Capital Grant Property Improvements, CARES Act", "negatedLabel": "Purchases of property and equipment with stimulus funds" } } }, "localname": "PaymentsForCapitalGrantPropertyImprovementsCARESAct", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "dvcr_PrefundedDeductiblePolicyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prefunded deductible policy.", "label": "Prefunded Deductible Policy [Member]", "verboseLabel": "Prefunded deductible policy" } } }, "localname": "PrefundedDeductiblePolicyMember", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "dvcr_PrivatePayAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private Pay And Other [Member]", "label": "Private Pay And Other [Member]", "terseLabel": "Private Pay and other" } } }, "localname": "PrivatePayAndOtherMember", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLESummaryofAccountsReceivableDetails" ], "xbrltype": "domainItemType" }, "dvcr_ProceedsFromGovernmentAssistanceCARESAct": { "auth_ref": [], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Government Assistance, CARES Act", "label": "Proceeds From Government Assistance, CARES Act", "terseLabel": "Proceeds from stimulus funds used to purchase property and equipment" } } }, "localname": "ProceedsFromGovernmentAssistanceCARESAct", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/COVID19PANDEMICDetails", "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "dvcr_ProceedsFromGovernmentAssistanceRemainingStimulusFundsCARESAct": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Government Assistance, Remaining Stimulus Funds, CARES Act", "label": "Proceeds From Government Assistance, Remaining Stimulus Funds, CARES Act", "terseLabel": "COVID-19, remaining stimulus funds" } } }, "localname": "ProceedsFromGovernmentAssistanceRemainingStimulusFundsCARESAct", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/COVID19PANDEMICDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_ProvisionForLeasesInExcessOfCashPayments": { "auth_ref": [], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Provision For Leases In Excess Of Cash Payments", "label": "Provision For Leases In Excess Of Cash Payments", "verboseLabel": "Provision for leases in excess of cash payments" } } }, "localname": "ProvisionForLeasesInExcessOfCashPayments", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "dvcr_PublicHealthAndSocialServicesEmergencyFundsReceivedCoronavirusAidReliefAndEconomicSecurityActCARESAct": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Public Health And Social Services Emergency Funds Received, Coronavirus Aid, Relief And Economic Security Act (CARES Act)", "label": "Public Health And Social Services Emergency Funds Received, Coronavirus Aid, Relief And Economic Security Act (CARES Act)", "terseLabel": "COVID-19, PHSSEF funds received" } } }, "localname": "PublicHealthAndSocialServicesEmergencyFundsReceivedCoronavirusAidReliefAndEconomicSecurityActCARESAct", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/COVID19PANDEMICDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_PublicHealthAndSocialServicesEmergencyRevenueCoronavirusAidReliefAndEconomicSecurityActCARESAct": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Public Health And Social Services Emergency Revenue, Coronavirus Aid, Relief and Economic Security Act (CARES Act)", "label": "Public Health And Social Services Emergency Revenue, Coronavirus Aid, Relief and Economic Security Act (CARES Act)", "terseLabel": "COVID-19, PHSSEF revenue" } } }, "localname": "PublicHealthAndSocialServicesEmergencyRevenueCoronavirusAidReliefAndEconomicSecurityActCARESAct", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/COVID19PANDEMICDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_RevenueFromContractWithCustomerIncludingAssessedTaxPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue From Contract With Customer, Including Assessed Tax, Percentage", "label": "Revenue From Contract With Customer, Including Assessed Tax, Percentage", "terseLabel": "Total revenues, as a percent" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTaxPercentage", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" ], "xbrltype": "percentItemType" }, "dvcr_SHCRiskCarriersIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SHC Risk Carriers, Inc [Member]", "label": "SHC Risk Carriers, Inc [Member]", "terseLabel": "SHC Risk Carriers, Inc" } } }, "localname": "SHCRiskCarriersIncMember", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "dvcr_SalariesExpenseCoronavirusAidReliefAndEconomicSecurityActCARESAct": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Salaries Expense, Coronavirus Aid, Relief And Economic Security Act (CARES Act)", "label": "Salaries Expense, Coronavirus Aid, Relief And Economic Security Act (CARES Act)", "terseLabel": "COVID-19, salaries expense" } } }, "localname": "SalariesExpenseCoronavirusAidReliefAndEconomicSecurityActCARESAct", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/COVID19PANDEMICDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_ScheduledForTrialOrArbitrationOverNextTwelveMonthsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Scheduled For Trial Or Arbitration Over Next Twelve Months", "label": "Scheduled For Trial Or Arbitration Over Next Twelve Months [Domain]", "terseLabel": "Scheduled For Trial Or Arbitration Over Next Twelve Months [Domain]" } } }, "localname": "ScheduledForTrialOrArbitrationOverNextTwelveMonthsDomain", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "dvcr_SelfInsuranceReceivableCurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Self Insurance Receivable, Current [Member]", "label": "Self Insurance Receivable, Current [Member]", "terseLabel": "Self-insurance receivables, current portion" } } }, "localname": "SelfInsuranceReceivableCurrentMember", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "dvcr_SelfInsuranceReceivablesCurrent": { "auth_ref": [], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Self-Insurance Receivables, Current", "label": "Self-Insurance Receivables, Current", "terseLabel": "Self-insurance receivables" } } }, "localname": "SelfInsuranceReceivablesCurrent", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "dvcr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsExercisableWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Awards Exercisable Weighted Average Exercise Price", "label": "Share Based Compensation Arrangement By Share Based Payment Award Awards Exercisable Weighted Average Exercise Price", "terseLabel": "Exercisable, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsExercisableWeightedAverageExercisePrice", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofEquityCompensationPlansDetails" ], "xbrltype": "perShareItemType" }, "dvcr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Awards Forfeitures And Expirations In Period Weighted Average Exercise Price", "label": "Share Based Compensation Arrangement By Share Based Payment Award Awards Forfeitures And Expirations In Period Weighted Average Exercise Price", "terseLabel": "Expired or cancelled (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofEquityCompensationPlansDetails" ], "xbrltype": "perShareItemType" }, "dvcr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Awards Outstanding Number", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Awards Outstanding Number", "periodEndLabel": "Outstanding, ending (in shares)", "periodStartLabel": "Outstanding, beginning (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofEquityCompensationPlansDetails" ], "xbrltype": "sharesItemType" }, "dvcr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Weighted Average Exercise Price", "label": "Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Weighted Average Exercise Price", "periodEndLabel": "Outstanding, ending (in dollars per share)", "periodStartLabel": "Outstanding, beginning (in dollars per share)", "terseLabel": "Weighted average exercise prices (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingWeightedAverageExercisePrice", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofEquityCompensationPlansDetails", "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofAwardsOutstandingandExercisableDetails" ], "xbrltype": "perShareItemType" }, "dvcr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Outstanding, Weighted-Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Outstanding, Weighted-Average Grant Date Fair Value", "periodEndLabel": "Outstanding, ending (in dollars per share)", "periodStartLabel": "Outstanding, beginning (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "dvcr_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Exercisable Number", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Exercisable Number", "terseLabel": "Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableNumber", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofEquityCompensationPlansDetails" ], "xbrltype": "sharesItemType" }, "dvcr_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share Based Payment Award, Exercises In Period", "label": "Share-Based Compensation Arrangement By Share Based Payment Award, Exercises In Period", "negatedTerseLabel": "Exercised (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriod", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofEquityCompensationPlansDetails" ], "xbrltype": "sharesItemType" }, "dvcr_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresAndExpirationsInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Forfeitures And Expirations In Period", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Forfeitures And Expirations In Period", "negatedTerseLabel": "Expired or cancelled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresAndExpirationsInPeriod", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofEquityCompensationPlansDetails" ], "xbrltype": "sharesItemType" }, "dvcr_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-Based Payment Award, Grants in Period, Gross", "label": "Share-based Compensation Arrangement by Share-Based Payment Award, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofEquityCompensationPlansDetails" ], "xbrltype": "sharesItemType" }, "dvcr_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangements By Share Based Payment Award Awards Exercises In Period Weighted Average Exercise Price", "label": "Share Based Compensation Arrangements By Share Based Payment Award Awards Exercises In Period Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofEquityCompensationPlansDetails" ], "xbrltype": "perShareItemType" }, "dvcr_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangements By Share Based Payment Award Awards Grants In Period Weighted Average Exercise Price", "label": "Share Based Compensation Arrangements By Share Based Payment Award Awards Grants In Period Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofEquityCompensationPlansDetails" ], "xbrltype": "perShareItemType" }, "dvcr_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableAwards": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Number Of Exercisable Awards", "label": "Share-based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Number Of Exercisable Awards", "terseLabel": "Grants exercisable (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableAwards", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofAwardsOutstandingandExercisableDetails" ], "xbrltype": "sharesItemType" }, "dvcr_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingAwards": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Number Of Outstanding Awards", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Number Of Outstanding Awards", "terseLabel": "Grants outstanding (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingAwards", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofAwardsOutstandingandExercisableDetails" ], "xbrltype": "sharesItemType" }, "dvcr_StockBasedCompensationArrangementByShareBasedPaymentAwardRestrictionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Based Compensation Arrangement By Share Based Payment Award Restriction Period", "label": "Stock Based Compensation Arrangement By Share Based Payment Award Restriction Period", "terseLabel": "Restriction period" } } }, "localname": "StockBasedCompensationArrangementByShareBasedPaymentAwardRestrictionPeriod", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "durationItemType" }, "dvcr_StockOptionsAndStockAppreciationRightsSARsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Options and Stock Appreciation Rights (SARs) [Member]", "label": "Stock Options And Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Options/SOSARs" } } }, "localname": "StockOptionsAndStockAppreciationRightsSARsMember", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofEquityCompensationPlansDetails", "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofAwardsOutstandingandExercisableDetails" ], "xbrltype": "domainItemType" }, "dvcr_StockOptionsExercisePriceRangeOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Options Exercise Price Range One [Member]", "label": "Stock Options Exercise Price Range One [Member]", "terseLabel": "$8.14 to $10.21" } } }, "localname": "StockOptionsExercisePriceRangeOneMember", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofAwardsOutstandingandExercisableDetails" ], "xbrltype": "domainItemType" }, "dvcr_StockOptionsExercisePriceRangeTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Options Exercise Price Range Two [Member]", "label": "Stock Options Exercise Price Range Two [Member]", "terseLabel": "$5.86" } } }, "localname": "StockOptionsExercisePriceRangeTwoMember", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofAwardsOutstandingandExercisableDetails" ], "xbrltype": "domainItemType" }, "dvcr_SuppliesExpenseCoronavirusAidReliefAndEconomicSecurityActCARESAct": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Supplies Expense, Coronavirus Aid, Relief And Economic Security Act (CARES Act)", "label": "Supplies Expense, Coronavirus Aid, Relief And Economic Security Act (CARES Act)", "terseLabel": "COVID-19, supplies expense" } } }, "localname": "SuppliesExpenseCoronavirusAidReliefAndEconomicSecurityActCARESAct", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/COVID19PANDEMICDetails" ], "xbrltype": "monetaryItemType" }, "dvcr_TrialOrArbitrationScheduleTimeframeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trial Or Arbitration Schedule Timeframe [Axis]", "label": "Trial Or Arbitration Schedule Timeframe [Axis]", "terseLabel": "Trial Or Arbitration Schedule Timeframe [Axis]" } } }, "localname": "TrialOrArbitrationScheduleTimeframeAxis", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "dvcr_TrialOrArbitrationScheduleTimeframeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trial Or Arbitration Schedule Timeframe [Member]", "label": "Trial Or Arbitration Schedule Timeframe [Member]", "terseLabel": "Scheduled for trial or arbitration over next 12 months" } } }, "localname": "TrialOrArbitrationScheduleTimeframeMember", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "dvcr_TwoThousandAndEightStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand And Eight Stock Purchase Plan [Member]", "label": "Two Thousand And Eight Stock Purchase Plan [Member]", "terseLabel": "2008 Stock Purchase Plan" } } }, "localname": "TwoThousandAndEightStockPurchasePlanMember", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "dvcr_TwoThousandAndTenLongTermIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand And Ten Long Term Incentive Plan [Member]", "label": "Two Thousand And Ten Long Term Incentive Plan [Member]", "terseLabel": "2010 Long Term Incentive Plan" } } }, "localname": "TwoThousandAndTenLongTermIncentivePlanMember", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "dvcr_WorkersCompensationReceivableForExcessPremiumsPaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Workers Compensation Receivable For Excess Premiums Paid", "label": "Workers Compensation Receivable For Excess Premiums Paid", "terseLabel": "Workers compensation insurance, non current receivable for excess premiums paid" } } }, "localname": "WorkersCompensationReceivableForExcessPremiumsPaid", "nsuri": "http://www.dvcr.com/20210331", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r54", "r103" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r226", "r227", "r344", "r345", "r346", "r347", "r348", "r349", "r351", "r390", "r393" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dvcr.com/role/BUSINESSDetails", "http://www.dvcr.com/role/LEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r226", "r227", "r344", "r345", "r346", "r347", "r348", "r349", "r351", "r390", "r393" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dvcr.com/role/BUSINESSDetails", "http://www.dvcr.com/role/LEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r163", "r210", "r213", "r352", "r387", "r391" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLESummaryofAccountsReceivableDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r163", "r210", "r213", "r352", "r387", "r391" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLESummaryofAccountsReceivableDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r225", "r226", "r227", "r344", "r345", "r346", "r347", "r348", "r349", "r351", "r390", "r393" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dvcr.com/role/BUSINESSDetails", "http://www.dvcr.com/role/LEASESNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r225", "r226", "r227", "r344", "r345", "r346", "r347", "r348", "r349", "r351", "r390", "r393" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dvcr.com/role/BUSINESSDetails", "http://www.dvcr.com/role/LEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r166", "r343" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]" } } }, "localname": "AccountsNotesAndLoansReceivableLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLESummaryofAccountsReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableTradeCurrent": { "auth_ref": [ "r16", "r38" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Trade, Current", "verboseLabel": "Trade accounts payable" } } }, "localname": "AccountsPayableTradeCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r11", "r28", "r167", "r168" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Total accounts receivable", "verboseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS", "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLESummaryofAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]", "verboseLabel": "Accrued expenses:" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r31", "r59", "r60", "r61", "r375", "r399", "r402" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r58", "r61", "r62", "r107", "r108", "r109", "r280", "r394", "r395" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r29" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "verboseLabel": "Paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r107", "r108", "r109", "r246", "r247", "r248" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r228", "r230", "r252", "r253" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile income (loss) from continuing operations to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r230", "r244", "r251" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Antidilutive shares excluded from computation of diluted earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/EARNINGSPERCOMMONSHARENarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r101", "r153", "r156", "r161", "r170", "r278", "r281", "r313", "r356", "r372" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESBalanceSheetClassificationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r12", "r13", "r51", "r101", "r170", "r278", "r281", "r313" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "CURRENT ASSETS:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "verboseLabel": "OTHER ASSETS:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets, excluding property, plant, and equipment and other property and investments, that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Charges and Other Assets.", "label": "Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment", "totalLabel": "Total other assets" } } }, "localname": "AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r232", "r245" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofEquityCompensationPlansDetails", "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofAwardsOutstandingandExercisableDetails", "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r292", "r296" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Accounting" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CONSOLIDATIONANDBASISOFPRESENTATIONOFFINANCIALSTATEMENTSPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "verboseLabel": "BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/BUSINESSDEVELOPMENTSANDOTHERSIGNIFICANTTRANSACTIONS" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r10", "r106", "r148" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "verboseLabel": "CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CONSOLIDATIONANDBASISOFPRESENTATIONOFFINANCIALSTATEMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r91", "r97", "r99" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "CASH, end of period", "periodStartLabel": "CASH, beginning of period", "verboseLabel": "Cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS", "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r91", "r314" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET INCREASE IN CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities" } } }, "localname": "CashFlowOperatingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESOtherLeaseInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": { "auth_ref": [ "r91" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations", "terseLabel": "Discontinued operations" } } }, "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "auth_ref": [ "r7", "r91" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations", "terseLabel": "Discontinued operations" } } }, "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "auth_ref": [ "r7", "r91" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations", "terseLabel": "Discontinued operations" } } }, "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r45", "r182", "r362", "r378" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "verboseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r179", "r180", "r181", "r183" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares reserved for future issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r107", "r108" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r27", "r187" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "verboseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r27" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, authorized 20,000 shares, $.01 par value, 7,185 and 7,079 shares issued, and 6,953 and 6,847 shares outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r65", "r67", "r68", "r76", "r367", "r384" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "COMPREHENSIVE INCOME (LOSS)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r191", "r192", "r211" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred income" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r81", "r352" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "verboseLabel": "Operating" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r79" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "verboseLabel": "EXPENSES:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r21", "r22", "r23", "r357", "r359", "r371" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Interest rate percentage" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r42", "r323" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt Instrument, Interest Rate During Period", "terseLabel": "Interest rate during period" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r258" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "terseLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r95", "r174" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 }, "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract Type [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails", "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESEffectOfCashFlowHedgeAccountingOnAccumulatedOtherComprehensiveIncomeDetails", "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesDetails", "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r53", "r55", "r294", "r350" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Asset Derivatives" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r53", "r55", "r294", "r350" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "terseLabel": "Liability Derivatives" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative, Fixed Interest Rate", "terseLabel": "Strike rate" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r293", "r295", "r301", "r305" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument Risk [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails", "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESEffectOfCashFlowHedgeAccountingOnAccumulatedOtherComprehensiveIncomeDetails", "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesDetails", "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "DERIVATIVES AND HEDGING ACTIVITIES" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r290", "r293", "r301" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r290", "r293", "r301", "r305", "r306", "r309", "r311" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESEffectOfCashFlowHedgeAccountingOnAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESEffectOfCashFlowHedgeAccountingOnAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r286", "r288" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeNumberOfInstrumentsHeld": { "auth_ref": [ "r286", "r288" ], "lang": { "en-us": { "role": { "documentation": "The number of derivative instruments of a particular group held by the entity.", "label": "Derivative, Number of Instruments Held", "terseLabel": "Number of Instruments" } } }, "localname": "DerivativeNumberOfInstrumentsHeld", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r285", "r287", "r288", "r290", "r291", "r297", "r301", "r307", "r308", "r311" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r210", "r213", "r214", "r215", "r216", "r217", "r218", "r219" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "verboseLabel": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r232", "r245" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]", "terseLabel": "Summarized Activity of Equity Compensation Plans" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "auth_ref": [ "r1", "r2", "r3", "r4", "r5", "r8", "r255", "r266", "r269" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.", "label": "Discontinued Operation, Tax Effect of Discontinued Operation", "negatedLabel": "Income tax benefit" } } }, "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "auth_ref": [ "r6" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)", "terseLabel": "Operating loss, net of tax benefit" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "NET INCOME (LOSS) PER COMMON SHARE:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r77", "r116", "r117", "r118", "r119", "r120", "r127", "r130", "r137", "r138", "r139", "r143", "r144", "r368", "r385" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "totalLabel": "Net income (loss) per common share \u2013 basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/EARNINGSPERCOMMONSHAREBasicandDilutedNetIncomeLossPerCommonShareDetails", "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Per common share \u2013 basic", "verboseLabel": "Per common share \u2013 basic" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/EARNINGSPERCOMMONSHAREBasicandDilutedNetIncomeLossPerCommonShareDetails", "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "verboseLabel": "Per common share \u2013 basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/EARNINGSPERCOMMONSHAREBasicandDilutedNetIncomeLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]", "verboseLabel": "WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r77", "r116", "r117", "r118", "r119", "r120", "r130", "r137", "r138", "r139", "r143", "r144", "r368", "r385" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "totalLabel": "Net income (loss) per common share \u2013 diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/EARNINGSPERCOMMONSHAREBasicandDilutedNetIncomeLossPerCommonShareDetails", "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Per common share \u2013 diluted" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/EARNINGSPERCOMMONSHAREBasicandDilutedNetIncomeLossPerCommonShareDetails", "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r140", "r141", "r142", "r145" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "EARNINGS PER COMMON SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/EARNINGSPERCOMMONSHARE" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "verboseLabel": "Payroll and employee benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r107", "r108", "r109", "r113", "r121", "r123", "r146", "r171", "r187", "r188", "r246", "r247", "r248", "r260", "r261", "r315", "r316", "r317", "r318", "r319", "r321", "r394", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT" ], "xbrltype": "domainItemType" }, "us-gaap_EstimatedInsuranceRecoveries": { "auth_ref": [ "r37" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts expected to be recovered under the terms of insurance contracts.", "label": "Estimated Insurance Recoveries", "terseLabel": "Estimated insurance recovery receivables" } } }, "localname": "EstimatedInsuranceRecoveries", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExtraordinaryAndUnusualItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unusual or Infrequent Items, or Both [Abstract]" } } }, "localname": "ExtraordinaryAndUnusualItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r292", "r297", "r309" ], "lang": { "en-us": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r327", "r333", "r341" ], "calculation": { "http://www.dvcr.com/role/LEASESLeaseCostDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest on finance lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Finance Leases" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r326", "r340" ], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Present value of lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r326" ], "calculation": { "http://www.dvcr.com/role/LEASESBalanceSheetClassificationDetails": { "order": 2.0, "parentTag": "dvcr_LeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance lease, current" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESBalanceSheetClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Schedule of Maturity of Finance Lease Liabilities" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r326" ], "calculation": { "http://www.dvcr.com/role/LEASESBalanceSheetClassificationDetails": { "order": 4.0, "parentTag": "dvcr_LeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance lease, noncurrent" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESBalanceSheetClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r340" ], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Total lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r340" ], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "dvcr_OperatingAndFinanceLeaseLiabilityPaymentsDueYearOne", "weight": 1.0 }, "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r340" ], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "dvcr_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour", "weight": 1.0 }, "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r340" ], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "dvcr_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree", "weight": 1.0 }, "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r340" ], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "dvcr_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo", "weight": 1.0 }, "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r340" ], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "dvcr_OperatingAndFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "weight": 1.0 }, "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r340" ], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: Interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r328", "r336" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "terseLabel": "Financing cash flows for finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESOtherLeaseInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r325" ], "calculation": { "http://www.dvcr.com/role/LEASESBalanceSheetClassificationDetails": { "order": 2.0, "parentTag": "dvcr_LeaseRightofUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Finance lease assets" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESBalanceSheetClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": { "auth_ref": [ "r327", "r333" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization", "terseLabel": "Accumulated amortization of finance leases" } } }, "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESBalanceSheetClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r327", "r333", "r341" ], "calculation": { "http://www.dvcr.com/role/LEASESLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization of finance lease assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r338", "r341" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESOtherLeaseInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r337", "r341" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESOtherLeaseInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r82" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "verboseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_HealthCareOrganizationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Health Care Organizations [Abstract]", "terseLabel": "Health Care Organizations [Abstract]" } } }, "localname": "HealthCareOrganizationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Amounts Attributable to Parent, Disclosures [Abstract]", "verboseLabel": "Numerator: Income (loss):" } } }, "localname": "IncomeAmountsAttributableToReportingEntityDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/EARNINGSPERCOMMONSHAREBasicandDilutedNetIncomeLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r80", "r96", "r116", "r117", "r118", "r119", "r135", "r139", "r276" ], "calculation": { "http://www.dvcr.com/role/EARNINGSPERCOMMONSHAREBasicandDilutedNetIncomeLossPerCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 }, "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 }, "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "terseLabel": "INCOME (LOSS) FROM CONTINUING OPERATIONS", "totalLabel": "INCOME (LOSS) FROM CONTINUING OPERATIONS", "verboseLabel": "Income (loss) from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/EARNINGSPERCOMMONSHAREBasicandDilutedNetIncomeLossPerCommonShareDetails", "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r105", "r153", "r155", "r157", "r160", "r162" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r70", "r77", "r112", "r116", "r117", "r118", "r119", "r130", "r137", "r138", "r363", "r364", "r368", "r380" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Continuing operations (in dollars per share)", "verboseLabel": "Income (loss) from continuing operations (in dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/EARNINGSPERCOMMONSHAREBasicandDilutedNetIncomeLossPerCommonShareDetails", "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "auth_ref": [ "r70", "r77", "r112", "r116", "r117", "r118", "r119", "r130", "r137", "r138", "r139", "r368", "r380", "r383", "r385" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Continuing operations (in dollars per share)", "verboseLabel": "Income (loss) from continuing operations (in dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/EARNINGSPERCOMMONSHAREBasicandDilutedNetIncomeLossPerCommonShareDetails", "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r5", "r8", "r277" ], "calculation": { "http://www.dvcr.com/role/EARNINGSPERCOMMONSHAREBasicandDilutedNetIncomeLossPerCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 }, "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "netLabel": "Loss from discontinued operations, net of income taxes", "terseLabel": "Loss from discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/EARNINGSPERCOMMONSHAREBasicandDilutedNetIncomeLossPerCommonShareDetails", "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "LOSS FROM DISCONTINUED OPERATIONS:" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "auth_ref": [ "r73", "r77", "r134", "r137", "r138", "r368", "r381", "r383", "r385" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share", "terseLabel": "Loss from discontinued operations (in dollars per share)", "verboseLabel": "Discontinued operations (in dollars per share)" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/EARNINGSPERCOMMONSHAREBasicandDilutedNetIncomeLossPerCommonShareDetails", "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "auth_ref": [ "r134", "r137", "r138", "r284" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share", "terseLabel": "Loss from discontinued operations (in dollars per share)", "verboseLabel": "Discontinued operations (in dollars per share)" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/EARNINGSPERCOMMONSHAREBasicandDilutedNetIncomeLossPerCommonShareDetails", "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COVID19PANDEMICDetails", "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESEffectOfCashFlowHedgeAccountingOnAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COVID19PANDEMICDetails", "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESEffectOfCashFlowHedgeAccountingOnAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r256", "r257", "r259", "r265", "r267", "r270", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INCOMETAXES" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r102", "r122", "r123", "r152", "r255", "r266", "r268", "r386" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "(PROVISION) BENEFIT FOR INCOME TAXES" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INCOMETAXESDetails", "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r98" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash (refunds) payments of income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesReceivable": { "auth_ref": [ "r49", "r361", "r379" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income Taxes Receivable, Current", "verboseLabel": "Income tax refundable" } } }, "localname": "IncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r94" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Trade accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r94" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred income" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in assets and liabilities affecting operating activities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r94" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r94" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedLabel": "Receivables" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInSelfInsuranceReserve": { "auth_ref": [ "r94" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the carrying amount of accrued known and estimated losses incurred for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's' compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property.", "label": "Increase (Decrease) in Self Insurance Reserve", "verboseLabel": "Provision for self-insured professional liability, net of cash payments" } } }, "localname": "IncreaseDecreaseInSelfInsuranceReserve", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r131", "r132", "r133", "r139" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Dilutive effect of stock options, SOSARs, Restricted Shares and Restricted Share Units (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/EARNINGSPERCOMMONSHAREBasicandDilutedNetIncomeLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r71", "r151", "r322", "r324", "r369" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense, net", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESEffectOfCashFlowHedgeAccountingOnAccumulatedOtherComprehensiveIncomeDetails", "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest Expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESEffectOfCashFlowHedgeAccountingOnAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r90", "r92", "r98" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash payments of interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCapMember": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Contract in which the cap writer, in return for a premium, agrees to limit, or cap, the cap holder's risk associated with an increase in interest rates. If rates go above a specified interest-rate-level (the strike price or the cap rate), the cap holder is entitled to receive cash payments equal to the excess of the market rate over the strike price multiplied by the notional principal amount.", "label": "Interest Rate Cap [Member]", "terseLabel": "Interest Rate Cap" } } }, "localname": "InterestRateCapMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails", "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESEffectOfCashFlowHedgeAccountingOnAccumulatedOtherComprehensiveIncomeDetails", "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossReclassifiedToEarningsNet": { "auth_ref": [ "r299" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of net gains or losses on interest rate cash flow hedges reclassified during the period to earnings from accumulated other comprehensive income upon the hedged transaction affecting earnings.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net", "terseLabel": "Reclassified to earnings" } } }, "localname": "InterestRateCashFlowHedgeGainLossReclassifiedToEarningsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESAdditionalInformationDetails", "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails", "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESEffectOfCashFlowHedgeAccountingOnAccumulatedOtherComprehensiveIncomeDetails", "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r339", "r341" ], "calculation": { "http://www.dvcr.com/role/LEASESLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Net lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Finance lease cost:" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESLeaseCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease Cost of Continuing Operations" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASES" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Maturity of Operating Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r340" ], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r340" ], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r340" ], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r340" ], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r340" ], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r340" ], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "dvcr_OperatingAndFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r340" ], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "dvcr_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount", "weight": 1.0 }, "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: Interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lease extension period", "verboseLabel": "Other leases renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/BUSINESSDEVELOPMENTSANDOTHERSIGNIFICANTTRANSACTIONSDetails", "http://www.dvcr.com/role/LEASESNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Original lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/BUSINESSDEVELOPMENTSANDOTHERSIGNIFICANTTRANSACTIONSDetails", "http://www.dvcr.com/role/LEASESNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASES" ], "xbrltype": "textBlockItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of credit security deposit for a lease" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESBalanceSheetClassificationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r34", "r101", "r170", "r313", "r360", "r377" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholder's equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r41", "r101", "r170", "r279", "r281", "r282", "r313" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Liabilities, Current [Abstract]", "verboseLabel": "CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS", "http://www.dvcr.com/role/LEASESBalanceSheetClassificationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r17", "r18", "r19", "r23", "r24", "r101", "r170", "r279", "r281", "r282", "r313" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total noncurrent liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Liabilities, Noncurrent [Abstract]", "verboseLabel": "NONCURRENT LIABILITIES:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS", "http://www.dvcr.com/role/LEASESBalanceSheetClassificationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForFuturePolicyBenefits": { "auth_ref": [ "r370", "r388", "r389", "r392", "r397" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before effect of reinsurance, of present value of future benefit to be paid to or on behalf of policyholder and related expense less present value of future net premium receivable under insurance contract.", "label": "Liability for Future Policy Benefit, before Reinsurance", "verboseLabel": "Liability for reported claims and estimates for incurred but unreported claims" } } }, "localname": "LiabilityForFuturePolicyBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "auth_ref": [ "r39" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Current Borrowing Capacity", "terseLabel": "Balance available for borrowing under revolving credit center" } } }, "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r39" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r39", "r104" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationReserveNoncurrent": { "auth_ref": [ "r45", "r182" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.", "label": "Estimated Litigation Liability, Noncurrent", "terseLabel": "Government settlement accrual" } } }, "localname": "LitigationReserveNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowing supported by a written promise to pay an obligation.", "label": "Loans Payable [Member]", "terseLabel": "Loans Payable" } } }, "localname": "LoansPayableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r23", "r185", "r359", "r374" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Borrowings outstanding" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r23" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.", "label": "Long-term Debt and Lease Obligation", "terseLabel": "Long-term debt and finance lease obligations, less current portion and deferred financing costs, net" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as current.", "label": "Long-term Debt and Lease Obligation, Current", "terseLabel": "Current portion of long-term debt and finance lease obligations" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "LONG-TERM DEBT" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBT" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r43", "r184" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r182" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Outstanding related to settlement agreement" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyAccrualCarryingValueCurrent": { "auth_ref": [ "r182" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer.", "label": "Loss Contingency, Accrual, Current", "terseLabel": "Current loss accrual" } } }, "localname": "LossContingencyAccrualCarryingValueCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyAccrualCarryingValueNoncurrent": { "auth_ref": [ "r182" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability expected to be resolved after one year or beyond the normal operating cycle, if longer.", "label": "Loss Contingency, Accrual, Noncurrent", "terseLabel": "Noncurrent loss accrual" } } }, "localname": "LossContingencyAccrualCarryingValueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyAccrualPayments": { "auth_ref": [ "r182" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow reducing loss contingency liability.", "label": "Loss Contingency Accrual, Payments", "terseLabel": "Payments made during period" } } }, "localname": "LossContingencyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MalpracticeInsuranceAnnualCoverageLimit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Annual coverage limit provided by the insurance arrangement for malpractice claims.", "label": "Malpractice Insurance, Annual Coverage Limit", "verboseLabel": "Aggregate policy limit" } } }, "localname": "MalpracticeInsuranceAnnualCoverageLimit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MalpracticeInsuranceLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Malpractice Insurance [Line Items]", "terseLabel": "Malpractice Insurance [Line Items]" } } }, "localname": "MalpracticeInsuranceLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MalpracticeInsuranceMaximumCoveragePerIncident": { "auth_ref": [ "r403" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum coverage per malpractice claim provided by the insurance arrangement.", "label": "Malpractice Insurance, Maximum Coverage Per Incident", "terseLabel": "Insurance policy coverage limits per claim", "verboseLabel": "Insurance policy coverage limits per claim" } } }, "localname": "MalpracticeInsuranceMaximumCoveragePerIncident", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MalpracticeLossContingencyAccrualUndiscounted": { "auth_ref": [ "r182" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability) at the end of the accounting period.", "label": "Malpractice Loss Contingency, Accrual, Undiscounted", "terseLabel": "Liability for reported and estimated future claims" } } }, "localname": "MalpracticeLossContingencyAccrualUndiscounted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MalpracticeLossContingencyPremiumCosts": { "auth_ref": [ "r403" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of costs incurred that are associated with obtaining malpractice insurance and other risk transferring arrangements during an accounting period.", "label": "Malpractice Loss Contingency, Premium Costs", "verboseLabel": "Professional liability" } } }, "localname": "MalpracticeLossContingencyPremiumCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_MortgagesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A loan to finance the purchase of real estate where the lender has a lien on the property as collateral for the loan.", "label": "Mortgages [Member]", "verboseLabel": "Mortgage Loan" } } }, "localname": "MortgagesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r147", "r148" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "BUSINESS" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/BUSINESS" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r91" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": { "auth_ref": [ "r91" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations", "totalLabel": "Net cash used in continuing operations" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r91" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "auth_ref": [ "r91" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "totalLabel": "Net cash used in continuing operations" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r91", "r93", "r96" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "auth_ref": [ "r91", "r93", "r96" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "totalLabel": "Net cash provided by continuing operations" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r9", "r63", "r66", "r74", "r96", "r101", "r112", "r116", "r117", "r118", "r119", "r122", "r123", "r135", "r153", "r155", "r157", "r160", "r162", "r170", "r313", "r365", "r382" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "NET INCOME (LOSS)", "totalLabel": "NET INCOME (LOSS)", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r116", "r117", "r118", "r119", "r127", "r128", "r136", "r139", "r153", "r155", "r157", "r160", "r162" ], "calculation": { "http://www.dvcr.com/role/EARNINGSPERCOMMONSHAREBasicandDilutedNetIncomeLossPerCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net income (loss)" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/EARNINGSPERCOMMONSHAREBasicandDilutedNetIncomeLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r110", "r111", "r114", "r115", "r124", "r125", "r126", "r172", "r173", "r220", "r221", "r222", "r223", "r249", "r262", "r263", "r264", "r353", "r354", "r355", "r398", "r399", "r400", "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "verboseLabel": "RECENT ACCOUNTING GUIDANCE" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/RECENTACCOUNTINGGUIDANCE" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Accounting Standards Recently Issued But Not Yet Adopted by the Company" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CONSOLIDATIONANDBASISOFPRESENTATIONOFFINANCIALSTATEMENTSPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r83" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expense" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "OTHER INCOME (EXPENSE):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfStatesInWhichEntityOperates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of states the entity operates in as of the balance sheet date.", "label": "Number of States in which Entity Operates", "verboseLabel": "Number of states in which entity operates" } } }, "localname": "NumberOfStatesInWhichEntityOperates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/BUSINESSDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r153", "r155", "r157", "r160", "r162" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "OPERATING INCOME" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r334", "r341" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 }, "http://www.dvcr.com/role/LEASESLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost", "verboseLabel": "Lease and rent expense" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.dvcr.com/role/LEASESLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Operating Leases" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r326" ], "calculation": { "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "dvcr_OperatingAndFinanceLeaseLiability", "weight": 1.0 }, "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r326" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.dvcr.com/role/LEASESBalanceSheetClassificationDetails": { "order": 1.0, "parentTag": "dvcr_LeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS", "http://www.dvcr.com/role/LEASESBalanceSheetClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r326" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 }, "http://www.dvcr.com/role/LEASESBalanceSheetClassificationDetails": { "order": 3.0, "parentTag": "dvcr_LeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, less current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS", "http://www.dvcr.com/role/LEASESBalanceSheetClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r329", "r336" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows for operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESOtherLeaseInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r325" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment", "weight": 1.0 }, "http://www.dvcr.com/role/LEASESBalanceSheetClassificationDetails": { "order": 1.0, "parentTag": "dvcr_LeaseRightofUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS", "http://www.dvcr.com/role/LEASESBalanceSheetClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r338", "r341" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESOtherLeaseInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r337", "r341" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESOtherLeaseInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "verboseLabel": "Other noncurrent assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r56", "r59" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "terseLabel": "Change in fair value", "verboseLabel": "Interest rate cash flow hedge" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax": { "auth_ref": [ "r300" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from discontinuance of cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Reclassification for Discontinuance, before Tax", "terseLabel": "Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESEffectOfCashFlowHedgeAccountingOnAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": { "auth_ref": [ "r57", "r59", "r298", "r302", "r310" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax", "terseLabel": "Amount of Gain (Loss) Recognized in Other Comprehensive Income on Derivative" } } }, "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESEffectOfCashFlowHedgeAccountingOnAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r64", "r67", "r69", "r75", "r187", "r315", "r320", "r321", "r366", "r383" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Total other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "verboseLabel": "OTHER COMPREHENSIVE INCOME (LOSS):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherInsuranceIndustryDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Insurance Industry Disclosures [Abstract]", "verboseLabel": "Other Insurance" } } }, "localname": "OtherInsuranceIndustryDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r14", "r15", "r40" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other noncurrent liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r96" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other noncurrent assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other noncurrent liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncome": { "auth_ref": [ "r78" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income", "terseLabel": "Other income" } } }, "localname": "OtherNonoperatingIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other operating income (expense).", "label": "Other Operating Income (Expense) [Member]", "terseLabel": "Other operating income" } } }, "localname": "OtherOperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COVID19PANDEMICDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Receivables, Net, Current", "verboseLabel": "Other receivables" } } }, "localname": "OtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r89" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedLabel": "Financing costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r86" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r232", "r245" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r12", "r35", "r36" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "verboseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet": { "auth_ref": [ "r87" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with security instrument that either represents a creditor or an ownership relationship with the holder of the investment security with a maturity of beyond one year or normal operating cycle, if longer. Includes proceeds from (a) debt, (b) capital lease obligations, (c) mandatory redeemable capital securities, and (d) any combination of (a), (b), or (c).", "label": "Proceeds from Issuance of Long-term Debt and Capital Securities, Net", "verboseLabel": "Proceeds from issuance of debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalMalpracticeLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business insurance coverage for professionals, such as doctors, lawyers, insurance agents, accountants, real estate agents, veterinarians, and others. This liability coverage insures losses for claims arising from mistakes and errors or omissions in the course of professional activities.", "label": "Professional Malpractice Liability Insurance [Member]", "verboseLabel": "Professional malpractice liability insurance" } } }, "localname": "ProfessionalMalpracticeLiabilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r176", "r327", "r333" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "negatedLabel": "Less accumulated depreciation and amortization" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r52", "r177", "r333" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r20", "r175", "r325" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization", "verboseLabel": "PROPERTY AND EQUIPMENT, at cost" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities": { "auth_ref": [ "r88" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation.", "label": "Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security", "negatedLabel": "Repayment of debt and finance lease obligations" } } }, "localname": "RepaymentsOfLongTermDebtAndCapitalSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock", "verboseLabel": "Restricted Shares" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSU's" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r30", "r188", "r250", "r376", "r398", "r402" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r107", "r108", "r109", "r113", "r121", "r123", "r171", "r246", "r247", "r248", "r260", "r261", "r394", "r396" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r149", "r150", "r154", "r158", "r159", "r163", "r164", "r165", "r209", "r210", "r352" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "verboseLabel": "PATIENT REVENUES, NET" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r149", "r150", "r154", "r158", "r159", "r163", "r164", "r165", "r209", "r210", "r352" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r100", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r224" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/CONSOLIDATIONANDBASISOFPRESENTATIONOFFINANCIALSTATEMENTSPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r212", "r224" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLE" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueNotFromContractWithCustomer": { "auth_ref": [ "r72" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue that is not accounted for under Topic 606.", "label": "Revenue Not from Contract with Customer", "terseLabel": "OTHER OPERATING INCOME" } } }, "localname": "RevenueNotFromContractWithCustomer", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "verboseLabel": "Amended Revolver" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLESummaryofAccountsReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Schedule of Accounts Receivable" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/REVENUERECOGNITIONANDACCOUNTSRECEIVABLETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Summary of Lease Term and Discount Rate and Other Lease Information" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Schedule of Fair Value of Derivative Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r285", "r287", "r288", "r290", "r291", "r297", "r301", "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Schedule of Derivatives" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/DERIVATIVESANDHEDGINGACTIVITIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r139" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "verboseLabel": "Schedule of Basic and Diluted Net Income (Loss) Per Common Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/EARNINGSPERCOMMONSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMalpracticeInsuranceTable": { "auth_ref": [ "r403", "r404", "r405", "r406" ], "lang": { "en-us": { "role": { "documentation": "Insurance coverage used by the entity to manage the financial risk of malpractice claims (including general and professional liability).", "label": "Schedule of Malpractice Insurance [Table]", "terseLabel": "Schedule of Malpractice Insurance [Table]" } } }, "localname": "ScheduleOfMalpracticeInsuranceTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis": { "auth_ref": [ "r403", "r404", "r405", "r406" ], "lang": { "en-us": { "role": { "documentation": "Information by type of insurance coverage or layer of insurance that covers malpractice claims.", "label": "Insurance Type and Tier Identifier [Axis]", "terseLabel": "Insurance Type and Tier Identifier [Axis]" } } }, "localname": "ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r232", "r245" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofEquityCompensationPlansDetails", "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofAwardsOutstandingandExercisableDetails", "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "terseLabel": "Schedule of Stock Options and SOSAR Grants Outstanding" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of Summarized Activity of Restricted Share Units" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SelfInsuranceReserveCurrent": { "auth_ref": [], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid within one year (or the normal operating cycle, if longer).", "label": "Self Insurance Reserve, Current", "verboseLabel": "Self-insurance reserves, current portion" } } }, "localname": "SelfInsuranceReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SelfInsuranceReserveNoncurrent": { "auth_ref": [], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid after one year (or the normal operating cycle, if longer).", "label": "Self Insurance Reserve, Noncurrent", "verboseLabel": "Self-insurance reserves, less current portion" } } }, "localname": "SelfInsuranceReserveNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r94" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Cancelled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Cancelled (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)", "verboseLabel": "Grant of restricted common stock (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding, ending (in shares)", "periodStartLabel": "Outstanding, beginning (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Granted Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofEquityCompensationPlansDetails", "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofAwardsOutstandingandExercisableDetails", "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Shares authorized under the plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Common stock granted to CEO (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofEquityCompensationPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofEquityCompensationPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r229", "r235" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofEquityCompensationPlansDetails", "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofAwardsOutstandingandExercisableDetails", "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockandRestrictedStockUnitsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche One [Member]", "terseLabel": "First anniversary" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche Three [Member]", "terseLabel": "Third anniversary" } } }, "localname": "ShareBasedCompensationAwardTrancheThreeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Second anniversary" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]", "terseLabel": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofAwardsOutstandingandExercisableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]", "terseLabel": "Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofAwardsOutstandingandExercisableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "terseLabel": "Range of exercise prices, minimum (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofAwardsOutstandingandExercisableDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "terseLabel": "Range of exercise prices, maximum (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONScheduleofAwardsOutstandingandExercisableDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Vesting percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Percentage of quoted market price offering rate" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r335", "r341" ], "calculation": { "http://www.dvcr.com/role/LEASESLeaseCostDetails": { "order": 4.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r48", "r107", "r108", "r109", "r113", "r121", "r123", "r146", "r171", "r187", "r188", "r246", "r247", "r248", "r260", "r261", "r315", "r316", "r317", "r318", "r319", "r321", "r394", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r107", "r108", "r109", "r146", "r352" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r26", "r27", "r187", "r188" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of equity grants, net (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r26", "r27", "r188", "r231", "r241" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of equity grants, net" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r27", "r32", "r33", "r101", "r169", "r170", "r313" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total shareholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "SHAREHOLDERS\u2019 DEFICIT:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r101", "r107", "r108", "r109", "r113", "r121", "r170", "r171", "r188", "r246", "r247", "r248", "r260", "r261", "r274", "r275", "r283", "r313", "r315", "r316", "r321", "r395", "r396" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "verboseLabel": "SUPPLEMENTAL INFORMATION:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r47", "r189" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSDEFICIT" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r47", "r189" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "verboseLabel": "Treasury stock, shares (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r47", "r189", "r190" ], "calculation": { "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock at cost, 232 shares of common stock" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/INTERIMCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeAndTierIdentifierDomain": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Name of the type of insurance coverage or layer of insurance that covers malpractice claims.", "label": "Type and Tier Identifier [Domain]", "terseLabel": "Type and Tier Identifier [Domain]" } } }, "localname": "TypeAndTierIdentifierDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnusualOrInfrequentItemLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Unusual or Infrequent Item, or Both [Line Items]", "terseLabel": "Unusual or Infrequent Item, or Both [Line Items]" } } }, "localname": "UnusualOrInfrequentItemLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COVID19PANDEMICDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnusualOrInfrequentItemTable": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the nature and financial statement effect of an event or transaction that is unusual in nature or infrequent in occurrence, or both.", "label": "Unusual or Infrequent Item, or Both [Table]", "terseLabel": "Unusual or Infrequent Item, or Both [Table]" } } }, "localname": "UnusualOrInfrequentItemTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COVID19PANDEMICDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an event or transaction that is unusual in nature or infrequent in occurrence, or both.", "label": "Unusual or Infrequent Items, or Both, Disclosure [Text Block]", "terseLabel": "COVID-19 PANDEMIC" } } }, "localname": "UnusualOrInfrequentItemsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COVID19PANDEMIC" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeasePayment": { "auth_ref": [ "r330" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for variable lease payment excluded from lease liability.", "label": "Variable Lease, Payment", "terseLabel": "Operating cash flows for finance leases" } } }, "localname": "VariableLeasePayment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LEASESOtherLeaseInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/LONGTERMDEBTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r129", "r139" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Adjusted weighted average common shares outstanding (in shares)", "verboseLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/EARNINGSPERCOMMONSHAREBasicandDilutedNetIncomeLossPerCommonShareDetails", "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r127", "r139" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Denominator: Basic Weighted Average Common Shares Outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/EARNINGSPERCOMMONSHAREBasicandDilutedNetIncomeLossPerCommonShareDetails", "http://www.dvcr.com/role/INTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "sharesItemType" }, "us-gaap_WorkersCompensationLiabilityCurrentAndNoncurrent": { "auth_ref": [ "r22", "r25", "r358", "r373" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature.", "label": "Workers' Compensation Liability", "verboseLabel": "Liability for workers compensation claims" } } }, "localname": "WorkersCompensationLiabilityCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dvcr.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r10": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693" }, "r126": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r145": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r148": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r181": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r183": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r186": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r254": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r272": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r273": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613673-111683" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.E)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r312": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r342": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(13)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.5(c))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=d3e14931-158439" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=d3e14931-158439" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "29E", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819541-158441" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "720", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=49178521&loc=d3e9100-115647" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "720", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=49178521&loc=d3e9113-115647" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "720", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=49178521&loc=d3e9127-115647" }, "r407": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r408": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r409": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r411": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(dd)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868656-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(14))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233" }, "r85": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "220", "URI": "http://asc.fasb.org/subtopic&trid=114868817" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" } }, "version": "2.1" } ZIP 68 0000919956-21-000046-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000919956-21-000046-xbrl.zip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end